id	sid	tid	token	lemma	pos
aji-153	1	1	_	_	PUNCT
aji-153	2	1	_	_	PUNCT
aji-153	3	1	_	_	PUNCT
aji-153	4	1	_	_	PUNCT
aji-153	5	1	_	_	PUNCT
aji-153	6	1	_	_	PUNCT
aji-153	7	1	_	_	PUNCT
aji-153	8	1	_	_	PUNCT
aji-153	9	1	_	_	PUNCT
aji-153	10	1	_	_	PUNCT
aji-153	11	1	_	_	PUNCT
aji-153	12	1	_	_	PUNCT
aji-153	13	1	_	_	PUNCT
aji-153	14	1	_	_	PUNCT
aji-153	15	1	_	_	PUNCT
aji-153	16	1	_	_	PUNCT
aji-153	17	1	_	_	PUNCT
aji-153	18	1	_	_	PUNCT
aji-153	19	1	_	_	PUNCT
aji-153	20	1	_	_	PUNCT
aji-153	21	1	_	_	PUNCT
aji-153	22	1	_	_	PUNCT
aji-153	23	1	_	_	PUNCT
aji-153	24	1	_	_	PUNCT
aji-153	25	1	_	_	PUNCT
aji-153	26	1	_	_	PUNCT
aji-153	27	1	_	_	PUNCT
aji-153	28	1	_	_	PUNCT
aji-153	29	1	_	_	PUNCT
aji-153	30	1	_	_	PUNCT
aji-153	31	1	_	_	PUNCT
aji-153	32	1	_	_	PUNCT
aji-153	33	1	_	_	PUNCT
aji-153	34	1	_	_	PUNCT
aji-153	35	1	_	_	PUNCT
aji-153	36	1	_	_	PUNCT
aji-153	37	1	_	_	PUNCT
aji-153	38	1	_	_	PUNCT
aji-153	39	1	_	_	PUNCT
aji-153	40	1	_	_	PUNCT
aji-153	41	1	_	_	PUNCT
aji-153	42	1	_	_	PUNCT
aji-153	43	1	_	_	PUNCT
aji-153	44	1	_	_	PUNCT
aji-153	45	1	_	_	PUNCT
aji-153	46	1	_	_	PUNCT
aji-153	47	1	_	_	PUNCT
aji-153	48	1	_	_	PUNCT
aji-153	49	1	_	_	PUNCT
aji-153	50	1	_	_	PUNCT
aji-153	51	1	_	_	PUNCT
aji-153	52	1	_	_	PUNCT
aji-153	53	1	_	_	PUNCT
aji-153	54	1	_	_	PUNCT
aji-153	55	1	_	_	PUNCT
aji-153	56	1	_	_	PUNCT
aji-153	57	1	_	_	PUNCT
aji-153	58	1	_	_	PUNCT
aji-153	59	1	_	_	PUNCT
aji-153	60	1	_	_	PUNCT
aji-153	61	1	_	_	PUNCT
aji-153	62	1	_	_	PUNCT
aji-153	63	1	_	_	PUNCT
aji-153	64	1	_	_	PUNCT
aji-153	65	1	_	_	PUNCT
aji-153	66	1	_	_	PUNCT
aji-153	67	1	_	_	PUNCT
aji-153	68	1	_	_	PUNCT
aji-153	69	1	_	_	PUNCT
aji-153	70	1	_	_	PUNCT
aji-153	71	1	_	_	PUNCT
aji-153	72	1	_	_	PUNCT
aji-153	73	1	_	_	PUNCT
aji-153	74	1	_	_	PUNCT
aji-153	75	1	_	_	PUNCT
aji-153	76	1	_	_	PUNCT
aji-153	77	1	_	_	PUNCT
aji-153	78	1	_	_	PUNCT
aji-153	79	1	_	_	PUNCT
aji-153	80	1	_	_	PUNCT
aji-153	81	1	_	_	PUNCT
aji-153	82	1	_	_	PUNCT
aji-153	83	1	_	_	PUNCT
aji-153	84	1	_	_	PUNCT
aji-153	85	1	_	_	PUNCT
aji-153	86	1	_	_	PUNCT
aji-153	87	1	_	_	PUNCT
aji-153	88	1	_	_	PUNCT
aji-153	89	1	_	_	PUNCT
aji-153	90	1	_	_	PUNCT
aji-153	91	1	_	_	PUNCT
aji-153	92	1	_	_	PUNCT
aji-153	93	1	_	_	PUNCT
aji-153	94	1	_	_	PUNCT
aji-153	95	1	_	_	PUNCT
aji-153	96	1	_	_	PUNCT
aji-153	97	1	_	_	PUNCT
aji-153	98	1	_	_	PUNCT
aji-153	99	1	_	_	PUNCT
aji-153	100	1	_	_	PUNCT
aji-153	101	1	_	_	PUNCT
aji-153	102	1	*	*	PUNCT
aji-153	102	2	corresponding	correspond	VERB
aji-153	102	3	author	author	NOUN
aji-153	102	4	:	:	PUNCT
aji-153	102	5	e	e	NOUN
aji-153	102	6	-	-	NOUN
aji-153	102	7	mail	mail	NOUN
aji-153	102	8	:	:	PUNCT
aji-153	102	9	mohdnaveedk97@gmail.com	mohdnaveedk97@gmail.com	NOUN
aji-153	102	10	;	;	PUNCT
aji-153	102	11	cite	cite	VERB
aji-153	102	12	as	as	ADP
aji-153	102	13	:	:	PUNCT
aji-153	102	14	gupta	gupta	PROPN
aji-153	102	15	,	,	PUNCT
aji-153	102	16	nikita	nikita	PROPN
aji-153	102	17	,	,	PUNCT
aji-153	102	18	mohd	mohd	PROPN
aji-153	102	19	naveed	naveed	PROPN
aji-153	102	20	khan	khan	PROPN
aji-153	102	21	,	,	PUNCT
aji-153	102	22	varda	varda	PROPN
aji-153	102	23	farooqui	farooqui	PROPN
aji-153	102	24	,	,	PUNCT
aji-153	102	25	guntoju	guntoju	PROPN
aji-153	102	26	poojitha	poojitha	PROPN
aji-153	102	27	,	,	PUNCT
aji-153	102	28	and	and	CCONJ
aji-153	102	29	thipparam	thipparam	PROPN
aji-153	102	30	kavya	kavya	PROPN
aji-153	102	31	.	.	PROPN
aji-153	102	32	2024	2024	NUM
aji-153	102	33	.	.	PUNCT
aji-153	103	1	“	"	PUNCT
aji-153	103	2	a	a	DET
aji-153	103	3	review	review	NOUN
aji-153	103	4	on	on	ADP
aji-153	103	5	vadadustat	vadadustat	NOUN
aji-153	103	6	:	:	PUNCT
aji-153	103	7	hope	hope	NOUN
aji-153	103	8	in	in	ADP
aji-153	103	9	treatment	treatment	NOUN
aji-153	103	10	of	of	ADP
aji-153	103	11	anemia	anemia	NOUN
aji-153	103	12	patients	patient	NOUN
aji-153	103	13	having	have	VERB
aji-153	103	14	chronic	chronic	ADJ
aji-153	103	15	kidney	kidney	NOUN
aji-153	103	16	disease	disease	NOUN
aji-153	103	17	”	"	PUNCT
aji-153	103	18	.	.	PUNCT
aji-153	104	1	asian	asian	ADJ
aji-153	104	2	journal	journal	NOUN
aji-153	104	3	of	of	ADP
aji-153	104	4	immunology	immunology	NOUN
aji-153	104	5	7	7	NUM
aji-153	104	6	(	(	PUNCT
aji-153	104	7	1):30215	1):30215	NUM
aji-153	104	8	.	.	PUNCT
aji-153	105	1	https://doi.org/10.9734/aji/2024/v7i1153	https://doi.org/10.9734/aji/2024/v7i1153	X
aji-153	105	2	.	.	PUNCT
aji-153	106	1	asian	asian	ADJ
aji-153	106	2	journal	journal	PROPN
aji-153	106	3	of	of	ADP
aji-153	106	4	immunology	immunology	NOUN
aji-153	106	5	volume	volume	NOUN
aji-153	106	6	7	7	NUM
aji-153	106	7	,	,	PUNCT
aji-153	106	8	issue	issue	NOUN
aji-153	106	9	1	1	NUM
aji-153	106	10	,	,	PUNCT
aji-153	106	11	page	page	NOUN
aji-153	106	12	302	302	NUM
aji-153	106	13	-	-	SYM
aji-153	106	14	315	315	NUM
aji-153	106	15	,	,	PUNCT
aji-153	106	16	2024	2024	NUM
aji-153	106	17	;	;	PUNCT
aji-153	106	18	article	article	NOUN
aji-153	106	19	no.aji.127402	no.aji.127402	VERB
aji-153	106	20	a	a	DET
aji-153	106	21	review	review	NOUN
aji-153	106	22	on	on	ADP
aji-153	106	23	vadadustat	vadadustat	NOUN
aji-153	106	24	:	:	PUNCT
aji-153	106	25	hope	hope	NOUN
aji-153	106	26	in	in	ADP
aji-153	106	27	treatment	treatment	NOUN
aji-153	106	28	of	of	ADP
aji-153	106	29	anemia	anemia	NOUN
aji-153	106	30	patients	patient	NOUN
aji-153	106	31	having	have	VERB
aji-153	106	32	chronic	chronic	ADJ
aji-153	106	33	kidney	kidney	NOUN
aji-153	106	34	disease	disease	NOUN
aji-153	106	35	nikita	nikita	PROPN
aji-153	106	36	gupta	gupta	PROPN
aji-153	106	37	a	a	X
aji-153	106	38	,	,	PUNCT
aji-153	106	39	mohd	mohd	PROPN
aji-153	106	40	naveed	naveed	PROPN
aji-153	106	41	khan	khan	PROPN
aji-153	106	42	a	a	PROPN
aji-153	106	43	*	*	PROPN
aji-153	106	44	,	,	PUNCT
aji-153	106	45	varda	varda	X
aji-153	106	46	farooqui	farooqui	PROPN
aji-153	106	47	a	a	X
aji-153	106	48	,	,	PUNCT
aji-153	106	49	guntoju	guntoju	PROPN
aji-153	106	50	poojitha	poojitha	PROPN
aji-153	106	51	a	a	PROPN
aji-153	106	52	and	and	CCONJ
aji-153	106	53	thipparam	thipparam	PROPN
aji-153	106	54	kavya	kavya	PROPN
aji-153	106	55	a	a	DET
aji-153	106	56	a	a	DET
aji-153	106	57	department	department	NOUN
aji-153	106	58	of	of	ADP
aji-153	106	59	pharmacy	pharmacy	NOUN
aji-153	106	60	practice	practice	NOUN
aji-153	106	61	,	,	PUNCT
aji-153	106	62	st	st	PROPN
aji-153	106	63	.	.	PROPN
aji-153	106	64	pauls	pauls	PROPN
aji-153	106	65	college	college	PROPN
aji-153	106	66	of	of	ADP
aji-153	106	67	pharmacy	pharmacy	NOUN
aji-153	106	68	,	,	PUNCT
aji-153	106	69	hyderabad	hyderabad	PROPN
aji-153	106	70	,	,	PUNCT
aji-153	106	71	telangana-510	telangana-510	ADJ
aji-153	106	72	,	,	PUNCT
aji-153	106	73	india	india	PROPN
aji-153	106	74	.	.	PUNCT
aji-153	107	1	authors	author	NOUN
aji-153	107	2	’	’	PART
aji-153	107	3	contributions	contribution	NOUN
aji-153	107	4	this	this	DET
aji-153	107	5	work	work	NOUN
aji-153	107	6	was	be	AUX
aji-153	107	7	carried	carry	VERB
aji-153	107	8	out	out	ADP
aji-153	107	9	in	in	ADP
aji-153	107	10	collaboration	collaboration	NOUN
aji-153	107	11	among	among	ADP
aji-153	107	12	all	all	DET
aji-153	107	13	authors	author	NOUN
aji-153	107	14	.	.	PUNCT
aji-153	108	1	all	all	DET
aji-153	108	2	authors	author	NOUN
aji-153	108	3	read	read	VERB
aji-153	108	4	and	and	CCONJ
aji-153	108	5	approved	approve	VERB
aji-153	108	6	the	the	DET
aji-153	108	7	final	final	ADJ
aji-153	108	8	manuscript	manuscript	NOUN
aji-153	108	9	.	.	PUNCT
aji-153	109	1	article	article	NOUN
aji-153	109	2	information	information	PROPN
aji-153	109	3	doi	doi	PROPN
aji-153	109	4	:	:	PUNCT
aji-153	109	5	https://doi.org/10.9734/aji/2024/v7i1153	https://doi.org/10.9734/aji/2024/v7i1153	PROPN
aji-153	109	6	open	open	ADJ
aji-153	109	7	peer	peer	NOUN
aji-153	109	8	review	review	NOUN
aji-153	109	9	history	history	NOUN
aji-153	109	10	:	:	PUNCT
aji-153	109	11	this	this	DET
aji-153	109	12	journal	journal	NOUN
aji-153	109	13	follows	follow	VERB
aji-153	109	14	the	the	DET
aji-153	109	15	advanced	advance	VERB
aji-153	109	16	open	open	ADJ
aji-153	109	17	peer	peer	NOUN
aji-153	109	18	review	review	NOUN
aji-153	109	19	policy	policy	NOUN
aji-153	109	20	.	.	PUNCT
aji-153	110	1	identity	identity	NOUN
aji-153	110	2	of	of	ADP
aji-153	110	3	the	the	DET
aji-153	110	4	reviewers	reviewer	NOUN
aji-153	110	5	,	,	PUNCT
aji-153	110	6	editor(s	editor(s	NOUN
aji-153	110	7	)	)	PUNCT
aji-153	110	8	and	and	CCONJ
aji-153	110	9	additional	additional	ADJ
aji-153	110	10	reviewers	reviewer	NOUN
aji-153	110	11	,	,	PUNCT
aji-153	110	12	peer	peer	NOUN
aji-153	110	13	review	review	NOUN
aji-153	110	14	comments	comment	NOUN
aji-153	110	15	,	,	PUNCT
aji-153	110	16	different	different	ADJ
aji-153	110	17	versions	version	NOUN
aji-153	110	18	of	of	ADP
aji-153	110	19	the	the	DET
aji-153	110	20	manuscript	manuscript	NOUN
aji-153	110	21	,	,	PUNCT
aji-153	110	22	comments	comment	NOUN
aji-153	110	23	of	of	ADP
aji-153	110	24	the	the	DET
aji-153	110	25	editors	editor	NOUN
aji-153	110	26	,	,	PUNCT
aji-153	110	27	etc	etc	X
aji-153	110	28	are	be	AUX
aji-153	110	29	available	available	ADJ
aji-153	110	30	here	here	ADV
aji-153	110	31	:	:	PUNCT
aji-153	110	32	https://www.sdiarticle5.com/review-history/127402	https://www.sdiarticle5.com/review-history/127402	NOUN
aji-153	110	33	received	receive	VERB
aji-153	110	34	:	:	PUNCT
aji-153	110	35	09/10/2024	09/10/2024	NUM
aji-153	110	36	accepted	accept	VERB
aji-153	110	37	:	:	PUNCT
aji-153	110	38	12/12/2024	12/12/2024	NUM
aji-153	110	39	published	publish	VERB
aji-153	110	40	:	:	PUNCT
aji-153	110	41	21/12/2024	21/12/2024	NUM
aji-153	110	42	abstract	abstract	ADJ
aji-153	110	43	vadadustat	vadadustat	NOUN
aji-153	110	44	,	,	PUNCT
aji-153	110	45	a	a	DET
aji-153	110	46	hypoxia	hypoxia	NOUN
aji-153	110	47	-	-	PUNCT
aji-153	110	48	inducible	inducible	ADJ
aji-153	110	49	factor	factor	NOUN
aji-153	110	50	prolyl	prolyl	NOUN
aji-153	110	51	hydroxylase	hydroxylase	NOUN
aji-153	110	52	inhibitor	inhibitor	NOUN
aji-153	110	53	,	,	PUNCT
aji-153	110	54	may	may	AUX
aji-153	110	55	offer	offer	VERB
aji-153	110	56	an	an	DET
aji-153	110	57	oral	oral	ADJ
aji-153	110	58	alternative	alternative	NOUN
aji-153	110	59	to	to	ADP
aji-153	110	60	injectable	injectable	ADJ
aji-153	110	61	erythropoiesis	erythropoiesis	NOUN
aji-153	110	62	-	-	PUNCT
aji-153	110	63	stimulating	stimulate	VERB
aji-153	110	64	agents	agent	NOUN
aji-153	110	65	(	(	PUNCT
aji-153	110	66	esas	esa	NOUN
aji-153	110	67	)	)	PUNCT
aji-153	110	68	to	to	PART
aji-153	110	69	treat	treat	VERB
aji-153	110	70	anemia	anemia	NOUN
aji-153	110	71	in	in	ADP
aji-153	110	72	patients	patient	NOUN
aji-153	110	73	undergoing	undergo	VERB
aji-153	110	74	peritoneal	peritoneal	ADJ
aji-153	110	75	dialysis	dialysis	NOUN
aji-153	110	76	.	.	PUNCT
aji-153	111	1	current	current	ADJ
aji-153	111	2	standard	standard	NOUN
aji-153	111	3	of	of	ADP
aji-153	111	4	care	care	NOUN
aji-153	111	5	for	for	ADP
aji-153	111	6	anemia	anemia	NOUN
aji-153	111	7	linked	link	VERB
aji-153	111	8	to	to	ADP
aji-153	111	9	chronic	chronic	ADJ
aji-153	111	10	kidney	kidney	NOUN
aji-153	111	11	disease	disease	NOUN
aji-153	111	12	(	(	PUNCT
aji-153	111	13	ckd	ckd	NOUN
aji-153	111	14	)	)	PUNCT
aji-153	111	15	is	be	AUX
aji-153	111	16	the	the	DET
aji-153	111	17	use	use	NOUN
aji-153	111	18	of	of	ADP
aji-153	111	19	esas	esa	NOUN
aji-153	111	20	.	.	PUNCT
aji-153	112	1	targeting	target	VERB
aji-153	112	2	the	the	DET
aji-153	112	3	hifs	hif	NOUN
aji-153	112	4	-	-	PUNCT
aji-153	112	5	the	the	DET
aji-153	112	6	basic	basic	ADJ
aji-153	112	7	elements	element	NOUN
aji-153	112	8	of	of	ADP
aji-153	112	9	rbc	rbc	PROPN
aji-153	112	10	production	production	NOUN
aji-153	112	11	-	-	PUNCT
aji-153	112	12	presents	present	VERB
aji-153	112	13	an	an	DET
aji-153	112	14	oral	oral	ADJ
aji-153	112	15	alternative	alternative	NOUN
aji-153	112	16	to	to	ADP
aji-153	112	17	the	the	DET
aji-153	112	18	standard	standard	ADJ
aji-153	112	19	esas	esa	NOUN
aji-153	112	20	.	.	PUNCT
aji-153	113	1	due	due	ADP
aji-153	113	2	to	to	ADP
aji-153	113	3	their	their	PRON
aji-153	113	4	low	low	ADJ
aji-153	113	5	oxygen	oxygen	NOUN
aji-153	113	6	environment	environment	NOUN
aji-153	113	7	,	,	PUNCT
aji-153	113	8	hif	hif	PROPN
aji-153	113	9	transcription	transcription	NOUN
aji-153	113	10	factors	factor	NOUN
aji-153	113	11	are	be	AUX
aji-153	113	12	,	,	PUNCT
aji-153	113	13	by	by	ADP
aji-153	113	14	nature	nature	NOUN
aji-153	113	15	,	,	PUNCT
aji-153	113	16	constitutively	constitutively	ADV
aji-153	113	17	activated	activate	VERB
aji-153	113	18	at	at	ADP
aji-153	113	19	high	high	ADJ
aji-153	113	20	altitude	altitude	NOUN
aji-153	113	21	,	,	PUNCT
aji-153	113	22	which	which	PRON
aji-153	113	23	enhances	enhance	VERB
aji-153	113	24	iron	iron	NOUN
aji-153	113	25	mobilization	mobilization	NOUN
aji-153	113	26	and	and	CCONJ
aji-153	113	27	boosts	boost	VERB
aji-153	113	28	production	production	NOUN
aji-153	113	29	of	of	ADP
aji-153	113	30	endogenous	endogenous	ADJ
aji-153	113	31	erythropoietin	erythropoietin	NOUN
aji-153	113	32	(	(	PUNCT
aji-153	113	33	epo	epo	NOUN
aji-153	113	34	)	)	PUNCT
aji-153	113	35	.	.	PUNCT
aji-153	114	1	while	while	SCONJ
aji-153	114	2	clinical	clinical	ADJ
aji-153	114	3	trials	trial	NOUN
aji-153	114	4	have	have	AUX
aji-153	114	5	demonstrated	demonstrate	VERB
aji-153	114	6	safety	safety	NOUN
aji-153	114	7	and	and	CCONJ
aji-153	114	8	efficacy	efficacy	NOUN
aji-153	114	9	for	for	ADP
aji-153	114	10	vadadustat	vadadustat	NOUN
aji-153	114	11	,	,	PUNCT
aji-153	114	12	whether	whether	SCONJ
aji-153	114	13	it	it	PRON
aji-153	114	14	will	will	AUX
aji-153	114	15	promote	promote	VERB
aji-153	114	16	cancer	cancer	NOUN
aji-153	114	17	is	be	AUX
aji-153	114	18	still	still	ADV
aji-153	114	19	a	a	DET
aji-153	114	20	topic	topic	NOUN
aji-153	114	21	under	under	ADP
aji-153	114	22	investigation	investigation	NOUN
aji-153	114	23	.	.	PUNCT
aji-153	115	1	in	in	ADP
aji-153	115	2	fact	fact	NOUN
aji-153	115	3	,	,	PUNCT
aji-153	115	4	research	research	NOUN
aji-153	115	5	has	have	AUX
aji-153	115	6	suggested	suggest	VERB
aji-153	115	7	that	that	SCONJ
aji-153	115	8	activation	activation	NOUN
aji-153	115	9	of	of	ADP
aji-153	115	10	hifs	hif	NOUN
aji-153	115	11	promotes	promote	VERB
aji-153	115	12	tumor	tumor	NOUN
aji-153	115	13	growth	growth	NOUN
aji-153	115	14	due	due	ADP
aji-153	115	15	to	to	ADP
aji-153	115	16	stimulation	stimulation	NOUN
aji-153	115	17	of	of	ADP
aji-153	115	18	review	review	NOUN
aji-153	115	19	article	article	NOUN
aji-153	115	20	https://doi.org/10.9734/aji/2024/v7i1153	https://doi.org/10.9734/aji/2024/v7i1153	ADP
aji-153	115	21	https://www.sdiarticle5.com/review-history/127402	https://www.sdiarticle5.com/review-history/127402	NOUN
aji-153	115	22	gupta	gupta	NOUN
aji-153	115	23	et	et	NOUN
aji-153	115	24	al	al	PROPN
aji-153	115	25	.	.	PROPN
aji-153	115	26	;	;	PUNCT
aji-153	116	1	asian	asian	PROPN
aji-153	116	2	j.	j.	PROPN
aji-153	116	3	immunol	immunol	PROPN
aji-153	116	4	.	.	PROPN
aji-153	116	5	,	,	PUNCT
aji-153	116	6	vol	vol	NOUN
aji-153	116	7	.	.	PROPN
aji-153	116	8	7	7	NUM
aji-153	116	9	,	,	PUNCT
aji-153	116	10	no	no	INTJ
aji-153	116	11	.	.	NOUN
aji-153	116	12	1	1	NUM
aji-153	116	13	,	,	PUNCT
aji-153	116	14	pp	pp	ADJ
aji-153	116	15	.	.	PUNCT
aji-153	117	1	302	302	NUM
aji-153	117	2	-	-	SYM
aji-153	117	3	315	315	NUM
aji-153	117	4	,	,	PUNCT
aji-153	117	5	2024	2024	NUM
aji-153	117	6	;	;	PUNCT
aji-153	117	7	article	article	NOUN
aji-153	117	8	no.aji.127402	no.aji.127402	VERB
aji-153	117	9	303	303	NUM
aji-153	117	10	angiogenesis	angiogenesis	NOUN
aji-153	117	11	through	through	ADP
aji-153	117	12	vascular	vascular	ADJ
aji-153	117	13	endothelial	endothelial	ADJ
aji-153	117	14	growth	growth	NOUN
aji-153	117	15	factor	factor	NOUN
aji-153	117	16	(	(	PUNCT
aji-153	117	17	vegf	vegf	PROPN
aji-153	117	18	)	)	PUNCT
aji-153	117	19	.	.	PUNCT
aji-153	118	1	the	the	DET
aji-153	118	2	hif	hif	PROPN
aji-153	118	3	system	system	NOUN
aji-153	118	4	includes	include	VERB
aji-153	118	5	two	two	NUM
aji-153	118	6	subunits	subunit	NOUN
aji-153	118	7	,	,	PUNCT
aji-153	118	8	α	α	NOUN
aji-153	118	9	and	and	CCONJ
aji-153	118	10	β	β	NOUN
aji-153	118	11	.	.	PUNCT
aji-153	119	1	under	under	ADP
aji-153	119	2	low	low	ADJ
aji-153	119	3	-	-	PUNCT
aji-153	119	4	oxygen	oxygen	NOUN
aji-153	119	5	conditions	condition	NOUN
aji-153	119	6	,	,	PUNCT
aji-153	119	7	the	the	DET
aji-153	119	8	hif-1α	hif-1α	NOUN
aji-153	119	9	subunit	subunit	NOUN
aji-153	119	10	accumulates	accumulate	VERB
aji-153	119	11	and	and	CCONJ
aji-153	119	12	translocates	translocate	NOUN
aji-153	119	13	to	to	ADP
aji-153	119	14	the	the	DET
aji-153	119	15	cell	cell	NOUN
aji-153	120	1	nucleus	nucleus	NOUN
aji-153	120	2	,	,	PUNCT
aji-153	120	3	where	where	SCONJ
aji-153	120	4	it	it	PRON
aji-153	120	5	binds	bind	VERB
aji-153	120	6	to	to	ADP
aji-153	120	7	hif	hif	PROPN
aji-153	120	8	-	-	PUNCT
aji-153	120	9	β	β	PROPN
aji-153	120	10	to	to	PART
aji-153	120	11	form	form	VERB
aji-153	120	12	the	the	DET
aji-153	120	13	heterodimer	heterodimer	NOUN
aji-153	120	14	hif-1αβ	hif-1αβ	PROPN
aji-153	120	15	.	.	PUNCT
aji-153	121	1	this	this	DET
aji-153	121	2	complex	complex	NOUN
aji-153	121	3	initiates	initiate	VERB
aji-153	121	4	the	the	DET
aji-153	121	5	expression	expression	NOUN
aji-153	121	6	of	of	ADP
aji-153	121	7	sensitive	sensitive	ADJ
aji-153	121	8	hypoxic	hypoxic	ADJ
aji-153	121	9	genes	gene	NOUN
aji-153	121	10	,	,	PUNCT
aji-153	121	11	including	include	VERB
aji-153	121	12	the	the	DET
aji-153	121	13	epo	epo	PROPN
aji-153	121	14	gene	gene	NOUN
aji-153	121	15	,	,	PUNCT
aji-153	121	16	whose	whose	DET
aji-153	121	17	production	production	NOUN
aji-153	121	18	is	be	AUX
aji-153	121	19	increased	increase	VERB
aji-153	121	20	under	under	ADP
aji-153	121	21	such	such	ADJ
aji-153	121	22	conditions	condition	NOUN
aji-153	121	23	.	.	PUNCT
aji-153	122	1	three	three	NUM
aji-153	122	2	isoforms	isoform	NOUN
aji-153	122	3	of	of	ADP
aji-153	122	4	the	the	DET
aji-153	122	5	hif	hif	PROPN
aji-153	122	6	-	-	PUNCT
aji-153	122	7	α	α	PROPN
aji-153	122	8	subunit	subunit	NOUN
aji-153	122	9	exist	exist	VERB
aji-153	122	10	:	:	PUNCT
aji-153	122	11	hif-1α	hif-1α	NOUN
aji-153	122	12	,	,	PUNCT
aji-153	122	13	hif-2α	hif-2α	NOUN
aji-153	122	14	,	,	PUNCT
aji-153	122	15	and	and	CCONJ
aji-153	122	16	hif-3α	hif-3α	NOUN
aji-153	122	17	,	,	PUNCT
aji-153	122	18	all	all	PRON
aji-153	122	19	of	of	ADP
aji-153	122	20	which	which	PRON
aji-153	122	21	can	can	AUX
aji-153	122	22	dimerize	dimerize	VERB
aji-153	122	23	with	with	ADP
aji-153	122	24	hif	hif	PROPN
aji-153	122	25	-	-	PUNCT
aji-153	122	26	β	β	PROPN
aji-153	122	27	and	and	CCONJ
aji-153	122	28	activate	activate	VERB
aji-153	122	29	the	the	DET
aji-153	122	30	transcription	transcription	NOUN
aji-153	122	31	of	of	ADP
aji-153	122	32	other	other	ADJ
aji-153	122	33	genes	gene	NOUN
aji-153	122	34	besides	besides	SCONJ
aji-153	122	35	epo	epo	PROPN
aji-153	122	36	.	.	PUNCT
aji-153	123	1	in	in	ADP
aji-153	123	2	the	the	DET
aji-153	123	3	intestine	intestine	NOUN
aji-153	123	4	,	,	PUNCT
aji-153	123	5	duodenal	duodenal	ADJ
aji-153	123	6	cytochrome	cytochrome	NOUN
aji-153	123	7	b	b	PROPN
aji-153	123	8	(	(	PUNCT
aji-153	123	9	dcytb	dcytb	NOUN
aji-153	123	10	)	)	PUNCT
aji-153	123	11	reduces	reduce	VERB
aji-153	123	12	ferric	ferric	ADJ
aji-153	123	13	iron	iron	NOUN
aji-153	123	14	(	(	PUNCT
aji-153	123	15	fe3	fe3	NOUN
aji-153	123	16	+	+	NOUN
aji-153	123	17	)	)	PUNCT
aji-153	123	18	to	to	ADP
aji-153	123	19	ferrous	ferrous	ADJ
aji-153	123	20	iron	iron	NOUN
aji-153	123	21	(	(	PUNCT
aji-153	123	22	fe2	fe2	PROPN
aji-153	123	23	+	+	NOUN
aji-153	123	24	)	)	PUNCT
aji-153	123	25	,	,	PUNCT
aji-153	123	26	which	which	PRON
aji-153	123	27	is	be	AUX
aji-153	123	28	then	then	ADV
aji-153	123	29	taken	take	VERB
aji-153	123	30	into	into	ADP
aji-153	123	31	enterocytes	enterocyte	NOUN
aji-153	123	32	by	by	ADP
aji-153	123	33	the	the	DET
aji-153	123	34	divalent	divalent	ADJ
aji-153	123	35	metal	metal	NOUN
aji-153	123	36	transporter-1	transporter-1	NUM
aji-153	123	37	(	(	PUNCT
aji-153	123	38	dmt1	dmt1	PROPN
aji-153	123	39	)	)	PUNCT
aji-153	123	40	.	.	PUNCT
aji-153	124	1	hif-2	hif-2	PUNCT
aji-153	124	2	controls	control	VERB
aji-153	124	3	both	both	CCONJ
aji-153	124	4	dcytb	dcytb	ADJ
aji-153	124	5	and	and	CCONJ
aji-153	124	6	dmt1	dmt1	PROPN
aji-153	124	7	.	.	PUNCT
aji-153	125	1	iron	iron	NOUN
aji-153	125	2	is	be	AUX
aji-153	125	3	exported	export	VERB
aji-153	125	4	from	from	ADP
aji-153	125	5	cells	cell	NOUN
aji-153	125	6	by	by	ADP
aji-153	125	7	ferroportin	ferroportin	PROPN
aji-153	125	8	(	(	PUNCT
aji-153	125	9	fpn	fpn	PROPN
aji-153	125	10	)	)	PUNCT
aji-153	125	11	,	,	PUNCT
aji-153	125	12	and	and	CCONJ
aji-153	125	13	this	this	DET
aji-153	125	14	export	export	NOUN
aji-153	125	15	is	be	AUX
aji-153	125	16	repressed	repress	VERB
aji-153	125	17	by	by	ADP
aji-153	125	18	hepcidin	hepcidin	VERB
aji-153	125	19	but	but	CCONJ
aji-153	125	20	stimulated	stimulate	VERB
aji-153	125	21	by	by	ADP
aji-153	125	22	hif	hif	PROPN
aji-153	125	23	.	.	PROPN
aji-153	126	1	in	in	ADP
aji-153	126	2	blood	blood	NOUN
aji-153	126	3	,	,	PUNCT
aji-153	126	4	iron	iron	NOUN
aji-153	126	5	is	be	AUX
aji-153	126	6	transported	transport	VERB
aji-153	126	7	in	in	ADP
aji-153	126	8	a	a	DET
aji-153	126	9	complex	complex	NOUN
aji-153	126	10	with	with	ADP
aji-153	126	11	transferrin	transferrin	NOUN
aji-153	126	12	(	(	PUNCT
aji-153	126	13	tf	tf	INTJ
aji-153	126	14	)	)	PUNCT
aji-153	126	15	to	to	ADP
aji-153	126	16	the	the	DET
aji-153	126	17	liver	liver	NOUN
aji-153	126	18	,	,	PUNCT
aji-153	126	19	res	re	NOUN
aji-153	126	20	cells	cell	NOUN
aji-153	126	21	,	,	PUNCT
aji-153	126	22	bone	bone	NOUN
aji-153	126	23	marrow	marrow	NOUN
aji-153	126	24	,	,	PUNCT
aji-153	126	25	and	and	CCONJ
aji-153	126	26	other	other	ADJ
aji-153	126	27	tissues	tissue	NOUN
aji-153	126	28	.	.	PUNCT
aji-153	127	1	the	the	DET
aji-153	127	2	increased	increase	VERB
aji-153	127	3	erythropoietic	erythropoietic	ADJ
aji-153	127	4	activity	activity	NOUN
aji-153	127	5	in	in	ADP
aji-153	127	6	the	the	DET
aji-153	127	7	marrow	marrow	NOUN
aji-153	127	8	leads	lead	VERB
aji-153	127	9	to	to	ADP
aji-153	127	10	the	the	DET
aji-153	127	11	production	production	NOUN
aji-153	127	12	of	of	ADP
aji-153	127	13	growth	growth	NOUN
aji-153	127	14	differentiation	differentiation	NOUN
aji-153	127	15	factor	factor	NOUN
aji-153	127	16	15	15	NUM
aji-153	127	17	(	(	PUNCT
aji-153	127	18	gdf15	gdf15	NOUN
aji-153	127	19	)	)	PUNCT
aji-153	127	20	and	and	CCONJ
aji-153	127	21	erythroferrone	erythroferrone	NOUN
aji-153	127	22	,	,	PUNCT
aji-153	127	23	which	which	PRON
aji-153	127	24	are	be	AUX
aji-153	127	25	known	know	VERB
aji-153	127	26	to	to	PART
aji-153	127	27	inhibit	inhibit	VERB
aji-153	127	28	hepcidin	hepcidin	VERB
aji-153	127	29	in	in	ADP
aji-153	127	30	liver	liver	NOUN
aji-153	127	31	cells	cell	NOUN
aji-153	127	32	.	.	PUNCT
aji-153	128	1	the	the	DET
aji-153	128	2	inflammatory	inflammatory	ADJ
aji-153	128	3	cytokine	cytokine	NOUN
aji-153	128	4	relates	relate	VERB
aji-153	128	5	with	with	ADP
aji-153	128	6	increased	increase	VERB
aji-153	128	7	hepcidin	hepcidin	VERB
aji-153	128	8	production	production	NOUN
aji-153	128	9	in	in	ADP
aji-153	128	10	the	the	DET
aji-153	128	11	liver	liver	NOUN
aji-153	128	12	,	,	PUNCT
aji-153	128	13	whose	whose	DET
aji-153	128	14	action	action	NOUN
aji-153	128	15	is	be	AUX
aji-153	128	16	mediated	mediate	VERB
aji-153	128	17	by	by	ADP
aji-153	128	18	decreased	decrease	VERB
aji-153	128	19	ferroportin	ferroportin	NOUN
aji-153	128	20	expression	expression	NOUN
aji-153	128	21	on	on	ADP
aji-153	128	22	the	the	DET
aji-153	128	23	cell	cell	NOUN
aji-153	128	24	surface	surface	NOUN
aji-153	128	25	and	and	CCONJ
aji-153	128	26	lower	low	ADJ
aji-153	128	27	blood	blood	NOUN
aji-153	128	28	iron	iron	NOUN
aji-153	128	29	levels	level	NOUN
aji-153	128	30	.	.	PUNCT
aji-153	129	1	vadadustat	vadadustat	PROPN
aji-153	129	2	has	have	AUX
aji-153	129	3	hif	hif	PROPN
aji-153	129	4	stabilized	stabilize	VERB
aji-153	129	5	for	for	ADP
aji-153	129	6	the	the	DET
aji-153	129	7	promotion	promotion	NOUN
aji-153	129	8	of	of	ADP
aji-153	129	9	the	the	DET
aji-153	129	10	secretion	secretion	NOUN
aji-153	129	11	of	of	ADP
aji-153	129	12	epo	epo	PROPN
aji-153	129	13	but	but	CCONJ
aji-153	129	14	does	do	AUX
aji-153	129	15	not	not	PART
aji-153	129	16	seem	seem	VERB
aji-153	129	17	to	to	PART
aji-153	129	18	have	have	VERB
aji-153	129	19	an	an	DET
aji-153	129	20	effect	effect	NOUN
aji-153	129	21	on	on	ADP
aji-153	129	22	the	the	DET
aji-153	129	23	production	production	NOUN
aji-153	129	24	of	of	ADP
aji-153	129	25	vegf	vegf	PROPN
aji-153	129	26	.	.	PUNCT
aji-153	130	1	it	it	PRON
aji-153	130	2	is	be	AUX
aji-153	130	3	also	also	ADV
aji-153	130	4	reported	report	VERB
aji-153	130	5	that	that	SCONJ
aji-153	130	6	increased	increase	VERB
aji-153	130	7	activity	activity	NOUN
aji-153	130	8	of	of	ADP
aji-153	130	9	hif	hif	PROPN
aji-153	130	10	results	result	NOUN
aji-153	130	11	in	in	ADP
aji-153	130	12	an	an	DET
aji-153	130	13	antitumor	antitumor	PROPN
aji-153	130	14	effect	effect	NOUN
aji-153	130	15	.	.	PUNCT
aji-153	131	1	results	result	NOUN
aji-153	131	2	from	from	ADP
aji-153	131	3	clinical	clinical	ADJ
aji-153	131	4	trials	trial	NOUN
aji-153	131	5	support	support	VERB
aji-153	131	6	the	the	DET
aji-153	131	7	use	use	NOUN
aji-153	131	8	of	of	ADP
aji-153	131	9	vadadustat	vadadustat	NOUN
aji-153	131	10	without	without	ADP
aji-153	131	11	genotoxicity	genotoxicity	NOUN
aji-153	131	12	,	,	PUNCT
aji-153	131	13	facilitating	facilitate	VERB
aji-153	131	14	the	the	DET
aji-153	131	15	treatment	treatment	NOUN
aji-153	131	16	of	of	ADP
aji-153	131	17	anemia	anemia	NOUN
aji-153	131	18	in	in	ADP
aji-153	131	19	patients	patient	NOUN
aji-153	131	20	with	with	ADP
aji-153	131	21	chronic	chronic	ADJ
aji-153	131	22	kidney	kidney	NOUN
aji-153	131	23	disease	disease	NOUN
aji-153	131	24	.	.	PUNCT
aji-153	132	1	keywords	keyword	NOUN
aji-153	132	2	:	:	PUNCT
aji-153	132	3	vadadustat	vadadustat	NOUN
aji-153	132	4	;	;	PUNCT
aji-153	132	5	anaemia	anaemia	NOUN
aji-153	132	6	;	;	PUNCT
aji-153	132	7	chronic	chronic	ADJ
aji-153	132	8	kidney	kidney	NOUN
aji-153	132	9	disease	disease	NOUN
aji-153	132	10	;	;	PUNCT
aji-153	132	11	hypoxia	hypoxia	NOUN
aji-153	132	12	-	-	PUNCT
aji-153	132	13	inducible	inducible	ADJ
aji-153	132	14	factor	factor	NOUN
aji-153	132	15	;	;	PUNCT
aji-153	132	16	erythropoiesis	erythropoiesis	NOUN
aji-153	132	17	stimulating	stimulate	VERB
aji-153	132	18	agents	agent	NOUN
aji-153	132	19	.	.	PUNCT
aji-153	133	1	1	1	X
aji-153	133	2	.	.	X
aji-153	133	3	introduction	introduction	NOUN
aji-153	133	4	1.1	1.1	NUM
aji-153	133	5	vadadustat	vadadustat	NOUN
aji-153	133	6	vadadustat	vadadustat	NOUN
aji-153	133	7	is	be	AUX
aji-153	133	8	an	an	DET
aji-153	133	9	experimental	experimental	ADJ
aji-153	133	10	oral	oral	ADJ
aji-153	133	11	inhibitor	inhibitor	NOUN
aji-153	133	12	of	of	ADP
aji-153	133	13	hypoxia	hypoxia	NOUN
aji-153	133	14	-	-	PUNCT
aji-153	133	15	inducible	inducible	ADJ
aji-153	133	16	factor	factor	NOUN
aji-153	133	17	prolyl	prolyl	NOUN
aji-153	133	18	-	-	PUNCT
aji-153	133	19	hydroxylase	hydroxylase	NOUN
aji-153	133	20	,	,	PUNCT
aji-153	133	21	which	which	PRON
aji-153	133	22	stimulates	stimulate	VERB
aji-153	133	23	the	the	DET
aji-153	133	24	natural	natural	ADJ
aji-153	133	25	production	production	NOUN
aji-153	133	26	of	of	ADP
aji-153	133	27	erythropoietin	erythropoietin	NOUN
aji-153	133	28	.	.	PUNCT
aji-153	134	1	currently	currently	ADV
aji-153	134	2	,	,	PUNCT
aji-153	134	3	erythropoiesisstimulating	erythropoiesisstimulate	VERB
aji-153	134	4	agents	agent	NOUN
aji-153	134	5	are	be	AUX
aji-153	134	6	the	the	DET
aji-153	134	7	first	first	ADJ
aji-153	134	8	-	-	PUNCT
aji-153	134	9	line	line	NOUN
aji-153	134	10	treatment	treatment	NOUN
aji-153	134	11	for	for	ADP
aji-153	134	12	anemia	anemia	NOUN
aji-153	134	13	associated	associate	VERB
aji-153	134	14	with	with	ADP
aji-153	134	15	chronic	chronic	ADJ
aji-153	134	16	kidney	kidney	NOUN
aji-153	134	17	disease	disease	NOUN
aji-153	134	18	.	.	PUNCT
aji-153	135	1	all	all	DET
aji-153	135	2	esas	esa	NOUN
aji-153	135	3	effectively	effectively	ADV
aji-153	135	4	treat	treat	VERB
aji-153	135	5	anemia	anemia	NOUN
aji-153	135	6	caused	cause	VERB
aji-153	135	7	by	by	ADP
aji-153	135	8	ckd	ckd	PROPN
aji-153	135	9	as	as	SCONJ
aji-153	135	10	they	they	PRON
aji-153	135	11	compensate	compensate	VERB
aji-153	135	12	for	for	ADP
aji-153	135	13	the	the	DET
aji-153	135	14	deficit	deficit	NOUN
aji-153	135	15	of	of	ADP
aji-153	135	16	epo	epo	NOUN
aji-153	135	17	produced	produce	VERB
aji-153	135	18	by	by	ADP
aji-153	135	19	failing	fail	VERB
aji-153	135	20	kidneys	kidney	NOUN
aji-153	135	21	.	.	PUNCT
aji-153	136	1	hif	hif	PROPN
aji-153	136	2	-	-	PUNCT
aji-153	136	3	phis	phis	PROPN
aji-153	136	4	have	have	AUX
aji-153	136	5	been	be	AUX
aji-153	136	6	differentiated	differentiate	VERB
aji-153	136	7	from	from	ADP
aji-153	136	8	esas	esa	NOUN
aji-153	136	9	by	by	ADP
aji-153	136	10	the	the	DET
aji-153	136	11	fact	fact	NOUN
aji-153	136	12	that	that	SCONJ
aji-153	136	13	they	they	PRON
aji-153	136	14	activate	activate	VERB
aji-153	136	15	the	the	DET
aji-153	136	16	hif	hif	PROPN
aji-153	136	17	pathway	pathway	NOUN
aji-153	136	18	and	and	CCONJ
aji-153	136	19	result	result	VERB
aji-153	136	20	in	in	ADP
aji-153	136	21	downstream	downstream	ADJ
aji-153	136	22	effects	effect	NOUN
aji-153	136	23	on	on	ADP
aji-153	136	24	the	the	DET
aji-153	136	25	epo	epo	PROPN
aji-153	136	26	gene	gene	NOUN
aji-153	136	27	transcription	transcription	NOUN
aji-153	136	28	,	,	PUNCT
aji-153	136	29	expression	expression	NOUN
aji-153	136	30	of	of	ADP
aji-153	136	31	genes	gene	NOUN
aji-153	136	32	involved	involve	VERB
aji-153	136	33	in	in	ADP
aji-153	136	34	erythropoiesis	erythropoiesis	NOUN
aji-153	136	35	and	and	CCONJ
aji-153	136	36	iron	iron	NOUN
aji-153	136	37	metabolism	metabolism	NOUN
aji-153	136	38	.	.	PUNCT
aji-153	137	1	the	the	DET
aji-153	137	2	conventional	conventional	ADJ
aji-153	137	3	management	management	NOUN
aji-153	137	4	of	of	ADP
aji-153	137	5	anemia	anemia	NOUN
aji-153	137	6	in	in	ADP
aji-153	137	7	the	the	DET
aji-153	137	8	ckd	ckd	PROPN
aji-153	137	9	patient	patient	NOUN
aji-153	137	10	is	be	AUX
aji-153	137	11	intravenous	intravenous	ADJ
aji-153	137	12	esa	esa	PROPN
aji-153	137	13	,	,	PUNCT
aji-153	137	14	either	either	CCONJ
aji-153	137	15	as	as	ADP
aji-153	137	16	monotherapy	monotherapy	NOUN
aji-153	137	17	or	or	CCONJ
aji-153	137	18	with	with	ADP
aji-153	137	19	iv	iv	NUM
aji-153	137	20	or	or	CCONJ
aji-153	137	21	oral	oral	ADJ
aji-153	137	22	iron	iron	NOUN
aji-153	137	23	supplementation	supplementation	NOUN
aji-153	137	24	.	.	PUNCT
aji-153	138	1	although	although	SCONJ
aji-153	138	2	esas	esa	NOUN
aji-153	138	3	are	be	AUX
aji-153	138	4	highly	highly	ADV
aji-153	138	5	effective	effective	ADJ
aji-153	138	6	for	for	ADP
aji-153	138	7	many	many	ADJ
aji-153	138	8	patients	patient	NOUN
aji-153	138	9	with	with	ADP
aji-153	138	10	ckd	ckd	PROPN
aji-153	138	11	,	,	PUNCT
aji-153	138	12	they	they	PRON
aji-153	138	13	do	do	AUX
aji-153	138	14	come	come	VERB
aji-153	138	15	with	with	ADP
aji-153	138	16	significant	significant	ADJ
aji-153	138	17	limitations	limitation	NOUN
aji-153	138	18	.	.	PUNCT
aji-153	139	1	many	many	ADJ
aji-153	139	2	ckd	ckd	PROPN
aji-153	139	3	patients	patient	NOUN
aji-153	139	4	have	have	VERB
aji-153	139	5	a	a	DET
aji-153	139	6	diminished	diminished	ADJ
aji-153	139	7	ability	ability	NOUN
aji-153	139	8	to	to	PART
aji-153	139	9	produce	produce	VERB
aji-153	139	10	epo	epo	NOUN
aji-153	139	11	and	and	CCONJ
aji-153	139	12	absorb	absorb	VERB
aji-153	139	13	and	and	CCONJ
aji-153	139	14	mobilize	mobilize	VERB
aji-153	139	15	iron	iron	NOUN
aji-153	139	16	.	.	PUNCT
aji-153	140	1	the	the	DET
aji-153	140	2	production	production	NOUN
aji-153	140	3	of	of	ADP
aji-153	140	4	hb	hb	PROPN
aji-153	140	5	is	be	AUX
aji-153	140	6	largely	largely	ADV
aji-153	140	7	dependent	dependent	ADJ
aji-153	140	8	on	on	ADP
aji-153	140	9	the	the	DET
aji-153	140	10	supply	supply	NOUN
aji-153	140	11	of	of	ADP
aji-153	140	12	iron	iron	NOUN
aji-153	140	13	,	,	PUNCT
aji-153	140	14	which	which	PRON
aji-153	140	15	is	be	AUX
aji-153	140	16	controlled	control	VERB
aji-153	140	17	by	by	ADP
aji-153	140	18	both	both	CCONJ
aji-153	140	19	the	the	DET
aji-153	140	20	liver	liver	NOUN
aji-153	140	21	,	,	PUNCT
aji-153	140	22	the	the	DET
aji-153	140	23	kidneys	kidney	NOUN
aji-153	140	24	,	,	PUNCT
aji-153	140	25	and	and	CCONJ
aji-153	140	26	the	the	DET
aji-153	140	27	bone	bone	NOUN
aji-153	140	28	marrow	marrow	NOUN
aji-153	140	29	through	through	ADP
aji-153	140	30	synchronized	synchronize	VERB
aji-153	140	31	signals	signal	NOUN
aji-153	140	32	.	.	PUNCT
aji-153	141	1	normally	normally	ADV
aji-153	141	2	,	,	PUNCT
aji-153	141	3	epo	epo	PROPN
aji-153	141	4	stimulates	stimulate	VERB
aji-153	141	5	erythroblasts	erythroblast	NOUN
aji-153	141	6	to	to	PART
aji-153	141	7	produce	produce	VERB
aji-153	141	8	erythroferrone	erythroferrone	NOUN
aji-153	141	9	,	,	PUNCT
aji-153	141	10	a	a	DET
aji-153	141	11	protein	protein	NOUN
aji-153	141	12	that	that	PRON
aji-153	141	13	acts	act	VERB
aji-153	141	14	to	to	PART
aji-153	141	15	inhibit	inhibit	VERB
aji-153	141	16	the	the	DET
aji-153	141	17	production	production	NOUN
aji-153	141	18	of	of	ADP
aji-153	141	19	hepcidin	hepcidin	VERB
aji-153	141	20	in	in	ADP
aji-153	141	21	the	the	DET
aji-153	141	22	liver	liver	NOUN
aji-153	141	23	[	[	X
aji-153	141	24	1	1	NUM
aji-153	141	25	]	]	PUNCT
aji-153	141	26	.	.	PUNCT
aji-153	142	1	“	"	PUNCT
aji-153	142	2	hypoxia	hypoxia	NOUN
aji-153	142	3	-	-	PUNCT
aji-153	142	4	inducible	inducible	ADJ
aji-153	142	5	factor	factor	NOUN
aji-153	142	6	is	be	AUX
aji-153	142	7	a	a	DET
aji-153	142	8	transcription	transcription	NOUN
aji-153	142	9	factor	factor	NOUN
aji-153	142	10	that	that	PRON
aji-153	142	11	controls	control	VERB
aji-153	142	12	the	the	DET
aji-153	142	13	expression	expression	NOUN
aji-153	142	14	of	of	ADP
aji-153	142	15	many	many	ADJ
aji-153	142	16	low	low	ADJ
aji-153	142	17	oxygenregulated	oxygenregulate	VERB
aji-153	142	18	genes	gene	NOUN
aji-153	142	19	,	,	PUNCT
aji-153	142	20	including	include	VERB
aji-153	142	21	epo	epo	PROPN
aji-153	142	22	,	,	PUNCT
aji-153	142	23	which	which	PRON
aji-153	142	24	is	be	AUX
aji-153	142	25	an	an	DET
aji-153	142	26	important	important	ADJ
aji-153	142	27	stimulator	stimulator	NOUN
aji-153	142	28	of	of	ADP
aji-153	142	29	erythropoiesis	erythropoiesis	NOUN
aji-153	142	30	.	.	PUNCT
aji-153	143	1	hif	hif	PROPN
aji-153	143	2	levels	level	NOUN
aji-153	143	3	are	be	AUX
aji-153	143	4	controlled	control	VERB
aji-153	143	5	by	by	ADP
aji-153	143	6	oxygen	oxygen	NOUN
aji-153	143	7	-	-	PUNCT
aji-153	143	8	dependent	dependent	ADJ
aji-153	143	9	degradation	degradation	NOUN
aji-153	143	10	at	at	ADP
aji-153	143	11	the	the	DET
aji-153	143	12	proteasome	proteasome	NOUN
aji-153	143	13	,	,	PUNCT
aji-153	143	14	a	a	DET
aji-153	143	15	process	process	NOUN
aji-153	143	16	mediated	mediate	VERB
aji-153	143	17	by	by	ADP
aji-153	143	18	a	a	DET
aji-153	143	19	family	family	NOUN
aji-153	143	20	of	of	ADP
aji-153	143	21	prolyl	prolyl	PROPN
aji-153	143	22	hydroxylases	hydroxylase	NOUN
aji-153	143	23	that	that	PRON
aji-153	143	24	serve	serve	VERB
aji-153	143	25	as	as	ADP
aji-153	143	26	oxygen	oxygen	NOUN
aji-153	143	27	sensors	sensor	NOUN
aji-153	143	28	.	.	PUNCT
aji-153	144	1	hif	hif	PROPN
aji-153	144	2	-	-	PUNCT
aji-153	144	3	prolyl	prolyl	PROPN
aji-153	144	4	hydroxylase	hydroxylase	NOUN
aji-153	144	5	inhibitors	inhibitor	NOUN
aji-153	144	6	or	or	CCONJ
aji-153	144	7	hif	hif	PROPN
aji-153	144	8	-	-	PUNCT
aji-153	144	9	phis	phis	NOUN
aji-153	144	10	are	be	AUX
aji-153	144	11	novel	novel	ADJ
aji-153	144	12	drugs	drug	NOUN
aji-153	144	13	that	that	PRON
aji-153	144	14	stabilize	stabilize	VERB
aji-153	144	15	hif	hif	PROPN
aji-153	144	16	and	and	CCONJ
aji-153	144	17	promote	promote	VERB
aji-153	144	18	the	the	DET
aji-153	144	19	expression	expression	NOUN
aji-153	144	20	of	of	ADP
aji-153	144	21	epo	epo	PROPN
aji-153	144	22	and	and	CCONJ
aji-153	144	23	may	may	AUX
aji-153	144	24	correct	correct	VERB
aji-153	144	25	anemia	anemia	NOUN
aji-153	144	26	related	relate	VERB
aji-153	144	27	to	to	ADP
aji-153	144	28	ckd	ckd	PROPN
aji-153	144	29	.	.	PUNCT
aji-153	145	1	on	on	ADP
aji-153	145	2	the	the	DET
aji-153	145	3	other	other	ADJ
aji-153	145	4	hand	hand	NOUN
aji-153	145	5	,	,	PUNCT
aji-153	145	6	because	because	SCONJ
aji-153	145	7	initiation	initiation	NOUN
aji-153	145	8	of	of	ADP
aji-153	145	9	hif	hif	PROPN
aji-153	145	10	and	and	CCONJ
aji-153	145	11	its	its	PRON
aji-153	145	12	downstream	downstream	ADJ
aji-153	145	13	genes	gene	NOUN
aji-153	145	14	results	result	VERB
aji-153	145	15	in	in	ADP
aji-153	145	16	a	a	DET
aji-153	145	17	global	global	ADJ
aji-153	145	18	response	response	NOUN
aji-153	145	19	to	to	PART
aji-153	145	20	hypoxia	hypoxia	VERB
aji-153	145	21	,	,	PUNCT
aji-153	145	22	there	there	PRON
aji-153	145	23	is	be	VERB
aji-153	145	24	,	,	PUNCT
aji-153	145	25	in	in	ADP
aji-153	145	26	theory	theory	NOUN
aji-153	145	27	,	,	PUNCT
aji-153	145	28	a	a	DET
aji-153	145	29	potential	potential	ADJ
aji-153	145	30	risk	risk	NOUN
aji-153	145	31	for	for	ADP
aji-153	145	32	adverse	adverse	ADJ
aji-153	145	33	events	event	NOUN
aji-153	145	34	including	include	VERB
aji-153	145	35	neoplasia	neoplasia	NOUN
aji-153	145	36	due	due	ADP
aji-153	145	37	to	to	ADP
aji-153	145	38	activation	activation	NOUN
aji-153	145	39	of	of	ADP
aji-153	145	40	the	the	DET
aji-153	145	41	hif	hif	PROPN
aji-153	145	42	pathway	pathway	NOUN
aji-153	145	43	.	.	PUNCT
aji-153	146	1	the	the	DET
aji-153	146	2	oxygen	oxygen	NOUN
aji-153	146	3	dependent	dependent	ADJ
aji-153	146	4	hydroxylation	hydroxylation	NOUN
aji-153	146	5	of	of	ADP
aji-153	146	6	hif	hif	PROPN
aji-153	146	7	-	-	PUNCT
aji-153	146	8	α	α	PROPN
aji-153	146	9	is	be	AUX
aji-153	146	10	catalyzed	catalyze	VERB
aji-153	146	11	by	by	ADP
aji-153	146	12	phd1	phd1	PROPN
aji-153	146	13	,	,	PUNCT
aji-153	146	14	phd2	phd2	NOUN
aji-153	146	15	,	,	PUNCT
aji-153	146	16	and	and	CCONJ
aji-153	146	17	phd3	phd3	NOUN
aji-153	146	18	that	that	PRON
aji-153	146	19	function	function	VERB
aji-153	146	20	as	as	ADP
aji-153	146	21	oxygen	oxygen	NOUN
aji-153	146	22	sensors	sensor	NOUN
aji-153	146	23	within	within	ADP
aji-153	146	24	the	the	DET
aji-153	146	25	hif	hif	PROPN
aji-153	146	26	pathway	pathway	NOUN
aji-153	146	27	.	.	PUNCT
aji-153	147	1	phds	phds	PROPN
aji-153	147	2	are	be	AUX
aji-153	147	3	part	part	NOUN
aji-153	147	4	of	of	ADP
aji-153	147	5	a	a	DET
aji-153	147	6	large	large	ADJ
aji-153	147	7	family	family	NOUN
aji-153	147	8	of	of	ADP
aji-153	147	9	2og	2og	ADJ
aji-153	147	10	-	-	PUNCT
aji-153	147	11	dependent	dependent	ADJ
aji-153	147	12	dioxygenases	dioxygenase	NOUN
aji-153	147	13	,	,	PUNCT
aji-153	147	14	with	with	ADP
aji-153	147	15	more	more	ADJ
aji-153	147	16	than	than	ADP
aji-153	147	17	60	60	NUM
aji-153	147	18	members	member	NOUN
aji-153	147	19	.	.	PUNCT
aji-153	148	1	dioxygenases	dioxygenase	NOUN
aji-153	148	2	catalyze	catalyze	VERB
aji-153	148	3	the	the	DET
aji-153	148	4	hydroxylation	hydroxylation	NOUN
aji-153	148	5	reaction	reaction	NOUN
aji-153	148	6	by	by	ADP
aji-153	148	7	using	use	VERB
aji-153	148	8	molecular	molecular	ADJ
aji-153	148	9	oxygen	oxygen	NOUN
aji-153	148	10	,	,	PUNCT
aji-153	148	11	thereby	thereby	ADV
aji-153	148	12	linking	link	VERB
aji-153	148	13	oxygen	oxygen	NOUN
aji-153	148	14	,	,	PUNCT
aji-153	148	15	intermediary	intermediary	ADJ
aji-153	148	16	metabolism	metabolism	NOUN
aji-153	148	17	,	,	PUNCT
aji-153	148	18	and	and	CCONJ
aji-153	148	19	amino	amino	NOUN
aji-153	148	20	acid	acid	NOUN
aji-153	148	21	metabolism	metabolism	NOUN
aji-153	148	22	to	to	ADP
aji-153	148	23	a	a	DET
aji-153	148	24	variety	variety	NOUN
aji-153	148	25	of	of	ADP
aji-153	148	26	cellular	cellular	ADJ
aji-153	148	27	functions	function	NOUN
aji-153	148	28	,	,	PUNCT
aji-153	148	29	including	include	VERB
aji-153	148	30	hif	hif	PROPN
aji-153	148	31	regulation	regulation	PROPN
aji-153	148	32	,	,	PUNCT
aji-153	148	33	hypoxia	hypoxia	NOUN
aji-153	148	34	responses	response	NOUN
aji-153	148	35	,	,	PUNCT
aji-153	148	36	collagen	collagen	NOUN
aji-153	148	37	synthesis	synthesis	NOUN
aji-153	148	38	,	,	PUNCT
aji-153	148	39	epigenetic	epigenetic	ADJ
aji-153	148	40	gene	gene	NOUN
aji-153	148	41	regulation	regulation	NOUN
aji-153	148	42	,	,	PUNCT
aji-153	148	43	and	and	CCONJ
aji-153	148	44	fatty	fatty	NOUN
aji-153	148	45	acid	acid	ADJ
aji-153	148	46	metabolism	metabolism	NOUN
aji-153	148	47	.	.	PUNCT
aji-153	149	1	systemic	systemic	ADJ
aji-153	149	2	activation	activation	NOUN
aji-153	149	3	of	of	ADP
aji-153	149	4	hif	hif	PROPN
aji-153	149	5	reduces	reduce	VERB
aji-153	149	6	hepcidin	hepcidin	ADJ
aji-153	149	7	production	production	NOUN
aji-153	149	8	in	in	ADP
aji-153	149	9	the	the	DET
aji-153	149	10	liver	liver	NOUN
aji-153	149	11	,	,	PUNCT
aji-153	149	12	thereby	thereby	ADV
aji-153	149	13	improving	improve	VERB
aji-153	149	14	iron	iron	NOUN
aji-153	149	15	uptake	uptake	NOUN
aji-153	149	16	and	and	CCONJ
aji-153	149	17	mobilization	mobilization	NOUN
aji-153	149	18	.	.	PUNCT
aji-153	150	1	the	the	DET
aji-153	150	2	anemia	anemia	NOUN
aji-153	150	3	of	of	ADP
aji-153	150	4	ckd	ckd	PROPN
aji-153	150	5	is	be	AUX
aji-153	150	6	caused	cause	VERB
aji-153	150	7	by	by	ADP
aji-153	150	8	a	a	DET
aji-153	150	9	relative	relative	ADJ
aji-153	150	10	lack	lack	NOUN
aji-153	150	11	of	of	ADP
aji-153	150	12	renal	renal	ADJ
aji-153	150	13	production	production	NOUN
aji-153	150	14	of	of	ADP
aji-153	150	15	epo	epo	PROPN
aji-153	150	16	,	,	PUNCT
aji-153	150	17	together	together	ADV
aji-153	150	18	with	with	ADP
aji-153	150	19	functional	functional	ADJ
aji-153	150	20	or	or	CCONJ
aji-153	150	21	absolute	absolute	ADJ
aji-153	150	22	iron	iron	NOUN
aji-153	150	23	deficiency	deficiency	NOUN
aji-153	150	24	and	and	CCONJ
aji-153	150	25	gupta	gupta	NOUN
aji-153	150	26	et	et	PROPN
aji-153	150	27	al	al	PROPN
aji-153	150	28	.	.	PROPN
aji-153	150	29	;	;	PUNCT
aji-153	150	30	asian	asian	PROPN
aji-153	150	31	j.	j.	PROPN
aji-153	150	32	immunol	immunol	PROPN
aji-153	150	33	.	.	PROPN
aji-153	150	34	,	,	PUNCT
aji-153	150	35	vol	vol	NOUN
aji-153	150	36	.	.	PROPN
aji-153	150	37	7	7	NUM
aji-153	150	38	,	,	PUNCT
aji-153	150	39	no	no	INTJ
aji-153	150	40	.	.	NOUN
aji-153	150	41	1	1	NUM
aji-153	150	42	,	,	PUNCT
aji-153	150	43	pp	pp	ADJ
aji-153	150	44	.	.	PUNCT
aji-153	151	1	302	302	NUM
aji-153	151	2	-	-	SYM
aji-153	151	3	315	315	NUM
aji-153	151	4	,	,	PUNCT
aji-153	151	5	2024	2024	NUM
aji-153	152	1	;	;	PUNCT
aji-153	152	2	article	article	NOUN
aji-153	152	3	no.aji.127402	no.aji.127402	VERB
aji-153	152	4	304	304	NUM
aji-153	152	5	resistance	resistance	NOUN
aji-153	152	6	to	to	ADP
aji-153	152	7	epo	epo	PROPN
aji-153	152	8	signaling	signal	VERB
aji-153	152	9	,	,	PUNCT
aji-153	152	10	often	often	ADV
aji-153	152	11	in	in	ADP
aji-153	152	12	the	the	DET
aji-153	152	13	context	context	NOUN
aji-153	152	14	of	of	ADP
aji-153	152	15	inflammation	inflammation	NOUN
aji-153	152	16	.	.	PUNCT
aji-153	153	1	activation	activation	NOUN
aji-153	153	2	of	of	ADP
aji-153	153	3	hif	hif	PROPN
aji-153	153	4	signaling	signal	VERB
aji-153	153	5	by	by	ADP
aji-153	153	6	pharmacological	pharmacological	ADJ
aji-153	153	7	agonists	agonist	NOUN
aji-153	153	8	may	may	AUX
aji-153	153	9	provide	provide	VERB
aji-153	153	10	a	a	DET
aji-153	153	11	more	more	ADV
aji-153	153	12	physiologic	physiologic	ADJ
aji-153	153	13	and	and	CCONJ
aji-153	153	14	holistic	holistic	ADJ
aji-153	153	15	treatment	treatment	NOUN
aji-153	153	16	strategy	strategy	NOUN
aji-153	153	17	for	for	ADP
aji-153	153	18	renal	renal	ADJ
aji-153	153	19	anemia	anemia	NOUN
aji-153	153	20	than	than	ADP
aji-153	153	21	administration	administration	NOUN
aji-153	153	22	of	of	ADP
aji-153	153	23	recombinant	recombinant	ADJ
aji-153	153	24	epo	epo	NOUN
aji-153	153	25	alone	alone	ADV
aji-153	153	26	.	.	PUNCT
aji-153	154	1	while	while	SCONJ
aji-153	154	2	initial	initial	ADJ
aji-153	154	3	reports	report	NOUN
aji-153	154	4	suggested	suggest	VERB
aji-153	154	5	a	a	DET
aji-153	154	6	direct	direct	ADJ
aji-153	154	7	role	role	NOUN
aji-153	154	8	for	for	ADP
aji-153	154	9	hif-1	hif-1	X
aji-153	154	10	in	in	ADP
aji-153	154	11	suppressing	suppress	VERB
aji-153	154	12	the	the	DET
aji-153	154	13	transcription	transcription	NOUN
aji-153	154	14	of	of	ADP
aji-153	154	15	hepcidin	hepcidin	VERB
aji-153	154	16	,	,	PUNCT
aji-153	154	17	subsequent	subsequent	ADJ
aji-153	154	18	mouse	mouse	NOUN
aji-153	154	19	models	model	NOUN
aji-153	154	20	with	with	ADP
aji-153	154	21	global	global	ADJ
aji-153	154	22	or	or	CCONJ
aji-153	154	23	liver	liver	NOUN
aji-153	154	24	-	-	PUNCT
aji-153	154	25	specific	specific	ADJ
aji-153	154	26	hif	hif	NOUN
aji-153	154	27	activation	activation	NOUN
aji-153	154	28	showed	show	VERB
aji-153	154	29	that	that	SCONJ
aji-153	154	30	suppression	suppression	NOUN
aji-153	154	31	of	of	ADP
aji-153	154	32	hepcidin	hepcidin	NOUN
aji-153	154	33	depends	depend	VERB
aji-153	154	34	upon	upon	SCONJ
aji-153	154	35	epoinduced	epoinduce	VERB
aji-153	154	36	stimulation	stimulation	NOUN
aji-153	154	37	of	of	ADP
aji-153	154	38	erythropoiesis	erythropoiesis	NOUN
aji-153	154	39	.	.	PUNCT
aji-153	155	1	which	which	PRON
aji-153	155	2	would	would	AUX
aji-153	155	3	argue	argue	VERB
aji-153	155	4	that	that	SCONJ
aji-153	155	5	hif	hif	PROPN
aji-153	155	6	itself	itself	PRON
aji-153	155	7	does	do	AUX
aji-153	155	8	not	not	PART
aji-153	155	9	play	play	VERB
aji-153	155	10	a	a	DET
aji-153	155	11	role	role	NOUN
aji-153	155	12	in	in	ADP
aji-153	155	13	suppressing	suppress	VERB
aji-153	155	14	hepcidin	hepcidin	VERB
aji-153	155	15	transcription	transcription	NOUN
aji-153	155	16	[	[	X
aji-153	155	17	2	2	NUM
aji-153	155	18	]	]	PUNCT
aji-153	155	19	.	.	PUNCT
aji-153	156	1	1.2	1.2	NUM
aji-153	156	2	anemia	anemia	NOUN
aji-153	156	3	anemia	anemia	NOUN
aji-153	156	4	is	be	AUX
aji-153	156	5	the	the	DET
aji-153	156	6	most	most	ADV
aji-153	156	7	common	common	ADJ
aji-153	156	8	disorder	disorder	NOUN
aji-153	156	9	diagnosed	diagnose	VERB
aji-153	156	10	in	in	ADP
aji-153	156	11	most	most	ADJ
aji-153	156	12	patients	patient	NOUN
aji-153	156	13	with	with	ADP
aji-153	156	14	chronic	chronic	ADJ
aji-153	156	15	kidney	kidney	NOUN
aji-153	156	16	disease	disease	NOUN
aji-153	156	17	.	.	PUNCT
aji-153	157	1	it	it	PRON
aji-153	157	2	could	could	AUX
aji-153	157	3	significantly	significantly	ADV
aji-153	157	4	affect	affect	VERB
aji-153	157	5	a	a	DET
aji-153	157	6	patient	patient	NOUN
aji-153	157	7	's	's	PART
aji-153	157	8	quality	quality	NOUN
aji-153	157	9	of	of	ADP
aji-153	157	10	life	life	NOUN
aji-153	157	11	if	if	SCONJ
aji-153	157	12	left	leave	VERB
aji-153	157	13	unappropriately	unappropriately	ADV
aji-153	157	14	managed	manage	VERB
aji-153	157	15	.	.	PUNCT
aji-153	158	1	there	there	PRON
aji-153	158	2	are	be	VERB
aji-153	158	3	multiple	multiple	ADJ
aji-153	158	4	reasons	reason	NOUN
aji-153	158	5	for	for	ADP
aji-153	158	6	anemia	anemia	NOUN
aji-153	158	7	in	in	ADP
aji-153	158	8	this	this	DET
aji-153	158	9	patient	patient	ADJ
aji-153	158	10	population	population	NOUN
aji-153	158	11	.	.	PUNCT
aji-153	159	1	in	in	ADP
aji-153	159	2	addition	addition	NOUN
aji-153	159	3	to	to	ADP
aji-153	159	4	drugs	drug	NOUN
aji-153	159	5	and	and	CCONJ
aji-153	159	6	dietary	dietary	ADJ
aji-153	159	7	restrictions	restriction	NOUN
aji-153	159	8	,	,	PUNCT
aji-153	159	9	patients	patient	NOUN
aji-153	159	10	may	may	AUX
aji-153	159	11	develop	develop	VERB
aji-153	159	12	anemia	anemia	NOUN
aji-153	159	13	due	due	ADP
aji-153	159	14	to	to	ADP
aji-153	159	15	iron	iron	NOUN
aji-153	159	16	deficiency	deficiency	NOUN
aji-153	159	17	resulting	result	VERB
aji-153	159	18	from	from	ADP
aji-153	159	19	a	a	DET
aji-153	159	20	decrease	decrease	NOUN
aji-153	159	21	in	in	ADP
aji-153	159	22	the	the	DET
aji-153	159	23	renal	renal	ADJ
aji-153	159	24	capability	capability	NOUN
aji-153	159	25	.	.	PUNCT
aji-153	160	1	this	this	PRON
aji-153	160	2	leads	lead	VERB
aji-153	160	3	to	to	ADP
aji-153	160	4	lowering	lower	VERB
aji-153	160	5	the	the	DET
aji-153	160	6	amount	amount	NOUN
aji-153	160	7	of	of	ADP
aji-153	160	8	iron	iron	NOUN
aji-153	160	9	available	available	ADJ
aji-153	160	10	for	for	ADP
aji-153	160	11	the	the	DET
aji-153	160	12	bone	bone	NOUN
aji-153	160	13	marrow	marrow	NOUN
aji-153	160	14	to	to	PART
aji-153	160	15	produce	produce	VERB
aji-153	160	16	various	various	ADJ
aji-153	160	17	blood	blood	NOUN
aji-153	160	18	elements	element	NOUN
aji-153	160	19	.	.	PUNCT
aji-153	161	1	chronic	chronic	ADJ
aji-153	161	2	patients	patient	NOUN
aji-153	161	3	with	with	ADP
aji-153	161	4	kidney	kidney	NOUN
aji-153	161	5	diseases	disease	NOUN
aji-153	161	6	can	can	AUX
aji-153	161	7	hardly	hardly	ADV
aji-153	161	8	utilize	utilize	VERB
aji-153	161	9	their	their	PRON
aji-153	161	10	body	body	NOUN
aji-153	161	11	's	's	PART
aji-153	161	12	iron	iron	NOUN
aji-153	161	13	stores	store	NOUN
aji-153	161	14	,	,	PUNCT
aji-153	161	15	and	and	CCONJ
aji-153	161	16	many	many	ADJ
aji-153	161	17	of	of	ADP
aji-153	161	18	them	they	PRON
aji-153	161	19	,	,	PUNCT
aji-153	161	20	especially	especially	ADV
aji-153	161	21	those	those	PRON
aji-153	161	22	who	who	PRON
aji-153	161	23	are	be	AUX
aji-153	161	24	hemodialysed	hemodialyse	VERB
aji-153	161	25	,	,	PUNCT
aji-153	161	26	develop	develop	VERB
aji-153	161	27	an	an	DET
aji-153	161	28	increased	increase	VERB
aji-153	161	29	need	need	NOUN
aji-153	161	30	for	for	ADP
aji-153	161	31	additional	additional	ADJ
aji-153	161	32	iron	iron	NOUN
aji-153	161	33	therapy	therapy	NOUN
aji-153	161	34	which	which	PRON
aji-153	161	35	has	have	AUX
aji-153	161	36	been	be	AUX
aji-153	161	37	primarily	primarily	ADV
aji-153	161	38	delivered	deliver	VERB
aji-153	161	39	by	by	ADP
aji-153	161	40	infusions	infusion	NOUN
aji-153	161	41	.	.	PUNCT
aji-153	162	1	“	"	PUNCT
aji-153	162	2	the	the	DET
aji-153	162	3	erythropoietic	erythropoietic	ADJ
aji-153	162	4	system	system	NOUN
aji-153	162	5	maintains	maintain	VERB
aji-153	162	6	the	the	DET
aji-153	162	7	balance	balance	NOUN
aji-153	162	8	in	in	ADP
aji-153	162	9	the	the	DET
aji-153	162	10	supply	supply	NOUN
aji-153	162	11	of	of	ADP
aji-153	162	12	red	red	ADJ
aji-153	162	13	blood	blood	NOUN
aji-153	162	14	cells	cell	NOUN
aji-153	162	15	,	,	PUNCT
aji-153	162	16	therefore	therefore	ADV
aji-153	162	17	,	,	PUNCT
aji-153	162	18	ensuring	ensure	VERB
aji-153	162	19	an	an	DET
aji-153	162	20	adequate	adequate	ADJ
aji-153	162	21	tissue	tissue	NOUN
aji-153	162	22	oxygenation4	oxygenation4	NOUN
aji-153	162	23	.	.	PUNCT
aji-153	163	1	in	in	ADP
aji-153	163	2	order	order	NOUN
aji-153	163	3	to	to	PART
aji-153	163	4	maintain	maintain	VERB
aji-153	163	5	this	this	DET
aji-153	163	6	balance	balance	NOUN
aji-153	163	7	,	,	PUNCT
aji-153	163	8	senescent	senescent	ADJ
aji-153	163	9	erythrocytes	erythrocyte	NOUN
aji-153	163	10	are	be	AUX
aji-153	163	11	replaced	replace	VERB
aji-153	163	12	by	by	ADP
aji-153	163	13	new	new	ADJ
aji-153	163	14	cells	cell	NOUN
aji-153	163	15	.	.	PUNCT
aji-153	164	1	hypoxia	hypoxia	NOUN
aji-153	164	2	is	be	AUX
aji-153	164	3	important	important	ADJ
aji-153	164	4	in	in	ADP
aji-153	164	5	stimulating	stimulate	VERB
aji-153	164	6	erythrocyte	erythrocyte	NOUN
aji-153	164	7	production	production	NOUN
aji-153	164	8	through	through	ADP
aji-153	164	9	its	its	PRON
aji-153	164	10	interaction	interaction	NOUN
aji-153	164	11	with	with	ADP
aji-153	164	12	the	the	DET
aji-153	164	13	hif	hif	PROPN
aji-153	164	14	(	(	PUNCT
aji-153	164	15	hypoxia	hypoxia	NOUN
aji-153	164	16	-	-	PUNCT
aji-153	164	17	inducible	inducible	ADJ
aji-153	164	18	factor	factor	NOUN
aji-153	164	19	)	)	PUNCT
aji-153	164	20	system	system	NOUN
aji-153	164	21	.	.	PUNCT
aji-153	165	1	the	the	DET
aji-153	165	2	hif	hif	PROPN
aji-153	165	3	is	be	AUX
aji-153	165	4	a	a	DET
aji-153	165	5	heterodimer	heterodimer	NOUN
aji-153	165	6	,	,	PUNCT
aji-153	165	7	consisting	consist	VERB
aji-153	165	8	of	of	ADP
aji-153	165	9	two	two	NUM
aji-153	165	10	subunits	subunit	NOUN
aji-153	165	11	:	:	PUNCT
aji-153	165	12	alpha	alpha	NOUN
aji-153	165	13	and	and	CCONJ
aji-153	165	14	beta	beta	NOUN
aji-153	165	15	.	.	PUNCT
aji-153	166	1	the	the	DET
aji-153	166	2	production	production	NOUN
aji-153	166	3	of	of	ADP
aji-153	166	4	hifalpha	hifalpha	NOUN
aji-153	166	5	continues	continue	VERB
aji-153	166	6	,	,	PUNCT
aji-153	166	7	but	but	CCONJ
aji-153	166	8	its	its	PRON
aji-153	166	9	degradation	degradation	NOUN
aji-153	166	10	occurs	occur	VERB
aji-153	166	11	in	in	ADP
aji-153	166	12	the	the	DET
aji-153	166	13	absence	absence	NOUN
aji-153	166	14	of	of	ADP
aji-153	166	15	tissue	tissue	NOUN
aji-153	166	16	hypoxia	hypoxia	NOUN
aji-153	166	17	.	.	PUNCT
aji-153	167	1	on	on	ADP
aji-153	167	2	the	the	DET
aji-153	167	3	opposite	opposite	ADJ
aji-153	167	4	situation	situation	NOUN
aji-153	167	5	,	,	PUNCT
aji-153	167	6	alpha	alpha	NOUN
aji-153	167	7	and	and	CCONJ
aji-153	167	8	beta	beta	NOUN
aji-153	167	9	subunits	subunit	NOUN
aji-153	167	10	join	join	VERB
aji-153	167	11	and	and	CCONJ
aji-153	167	12	bind	bind	VERB
aji-153	167	13	in	in	ADP
aji-153	167	14	the	the	DET
aji-153	167	15	nucleus	nucleus	NOUN
aji-153	167	16	of	of	ADP
aji-153	167	17	the	the	DET
aji-153	167	18	cell	cell	NOUN
aji-153	167	19	,	,	PUNCT
aji-153	167	20	a	a	DET
aji-153	167	21	dna	dna	NOUN
aji-153	167	22	sequence	sequence	NOUN
aji-153	167	23	called	call	VERB
aji-153	167	24	hypoxia	hypoxia	NOUN
aji-153	167	25	-	-	PUNCT
aji-153	167	26	responsive	responsive	ADJ
aji-153	167	27	elements	element	NOUN
aji-153	167	28	.	.	PUNCT
aji-153	168	1	thus	thus	ADV
aji-153	168	2	,	,	PUNCT
aji-153	168	3	the	the	DET
aji-153	168	4	production	production	NOUN
aji-153	168	5	of	of	ADP
aji-153	168	6	erythropoietin	erythropoietin	NOUN
aji-153	168	7	is	be	AUX
aji-153	168	8	stimulated	stimulate	VERB
aji-153	168	9	”	"	PUNCT
aji-153	169	1	[	[	X
aji-153	169	2	3	3	NUM
aji-153	169	3	]	]	PUNCT
aji-153	169	4	.	.	PUNCT
aji-153	170	1	erythropoietin	erythropoietin	NOUN
aji-153	170	2	,	,	PUNCT
aji-153	170	3	on	on	ADP
aji-153	170	4	the	the	DET
aji-153	170	5	other	other	ADJ
aji-153	170	6	hand	hand	NOUN
aji-153	170	7	,	,	PUNCT
aji-153	170	8	is	be	AUX
aji-153	170	9	a	a	DET
aji-153	170	10	molecule	molecule	NOUN
aji-153	170	11	of	of	ADP
aji-153	170	12	165	165	NUM
aji-153	170	13	amino	amino	ADJ
aji-153	170	14	acids	acid	NOUN
aji-153	170	15	and	and	CCONJ
aji-153	170	16	4	4	NUM
aji-153	170	17	chains	chain	NOUN
aji-153	170	18	of	of	ADP
aji-153	170	19	carbohydrates	carbohydrate	NOUN
aji-153	170	20	.	.	PUNCT
aji-153	171	1	mainly	mainly	ADV
aji-153	171	2	produced	produce	VERB
aji-153	171	3	in	in	ADP
aji-153	171	4	the	the	DET
aji-153	171	5	interstitial	interstitial	ADJ
aji-153	171	6	cells	cell	NOUN
aji-153	171	7	of	of	ADP
aji-153	171	8	the	the	DET
aji-153	171	9	renal	renal	ADJ
aji-153	171	10	cortex	cortex	NOUN
aji-153	171	11	,	,	PUNCT
aji-153	171	12	the	the	DET
aji-153	171	13	production	production	NOUN
aji-153	171	14	of	of	ADP
aji-153	171	15	the	the	DET
aji-153	171	16	liver	liver	NOUN
aji-153	171	17	significantly	significantly	ADV
aji-153	171	18	increases	increase	VERB
aji-153	171	19	with	with	ADP
aji-153	171	20	reduction	reduction	NOUN
aji-153	171	21	in	in	ADP
aji-153	171	22	glomerular	glomerular	ADJ
aji-153	171	23	filtration	filtration	NOUN
aji-153	171	24	.	.	PUNCT
aji-153	172	1	the	the	DET
aji-153	172	2	half	half	ADJ
aji-153	172	3	-	-	PUNCT
aji-153	172	4	life	life	NOUN
aji-153	172	5	of	of	ADP
aji-153	172	6	erythropoietin	erythropoietin	NOUN
aji-153	172	7	is	be	AUX
aji-153	172	8	5	5	NUM
aji-153	172	9	to	to	PART
aji-153	172	10	12	12	NUM
aji-153	172	11	hours	hour	NOUN
aji-153	172	12	,	,	PUNCT
aji-153	172	13	and	and	CCONJ
aji-153	172	14	it	it	PRON
aji-153	172	15	acts	act	VERB
aji-153	172	16	like	like	ADP
aji-153	172	17	a	a	DET
aji-153	172	18	true	true	ADJ
aji-153	172	19	hormone	hormone	NOUN
aji-153	172	20	that	that	PRON
aji-153	172	21	binds	bind	VERB
aji-153	172	22	to	to	ADP
aji-153	172	23	the	the	DET
aji-153	172	24	receptors	receptor	NOUN
aji-153	172	25	of	of	ADP
aji-153	172	26	bone	bone	NOUN
aji-153	172	27	marrow	marrow	NOUN
aji-153	172	28	cells	cell	NOUN
aji-153	172	29	to	to	PART
aji-153	172	30	produce	produce	VERB
aji-153	172	31	erythrocytes	erythrocyte	NOUN
aji-153	172	32	.	.	PUNCT
aji-153	173	1	“	"	PUNCT
aji-153	173	2	although	although	SCONJ
aji-153	173	3	reduction	reduction	NOUN
aji-153	173	4	in	in	ADP
aji-153	173	5	erythropoietin	erythropoietin	NOUN
aji-153	173	6	production	production	NOUN
aji-153	173	7	is	be	AUX
aji-153	173	8	one	one	NUM
aji-153	173	9	of	of	ADP
aji-153	173	10	the	the	DET
aji-153	173	11	main	main	ADJ
aji-153	173	12	causes	cause	NOUN
aji-153	173	13	of	of	ADP
aji-153	173	14	anemia	anemia	NOUN
aji-153	173	15	in	in	ADP
aji-153	173	16	ckd	ckd	PROPN
aji-153	173	17	,	,	PUNCT
aji-153	173	18	other	other	ADJ
aji-153	173	19	causes	cause	NOUN
aji-153	173	20	include	include	VERB
aji-153	173	21	iron	iron	NOUN
aji-153	173	22	deficiency	deficiency	NOUN
aji-153	173	23	.	.	PUNCT
aji-153	174	1	it	it	PRON
aji-153	174	2	is	be	AUX
aji-153	174	3	assumed	assume	VERB
aji-153	174	4	that	that	SCONJ
aji-153	174	5	iron	iron	NOUN
aji-153	174	6	loss	loss	NOUN
aji-153	174	7	varies	vary	VERB
aji-153	174	8	between	between	ADP
aji-153	174	9	1	1	NUM
aji-153	174	10	and	and	CCONJ
aji-153	174	11	3	3	NUM
aji-153	174	12	gram	gram	NOUN
aji-153	174	13	per	per	ADP
aji-153	174	14	year	year	NOUN
aji-153	174	15	in	in	ADP
aji-153	174	16	patients	patient	NOUN
aji-153	174	17	on	on	ADP
aji-153	174	18	hemodialysis	hemodialysis	NOUN
aji-153	174	19	.	.	PUNCT
aji-153	175	1	also	also	ADV
aji-153	175	2	,	,	PUNCT
aji-153	175	3	in	in	ADP
aji-153	175	4	the	the	DET
aji-153	175	5	absence	absence	NOUN
aji-153	175	6	of	of	ADP
aji-153	175	7	dialysis	dialysis	NOUN
aji-153	175	8	,	,	PUNCT
aji-153	175	9	depletion	depletion	NOUN
aji-153	175	10	in	in	ADP
aji-153	175	11	iron	iron	NOUN
aji-153	175	12	is	be	AUX
aji-153	175	13	observed	observe	VERB
aji-153	175	14	in	in	ADP
aji-153	175	15	most	most	ADJ
aji-153	175	16	patients4	patients4	NOUN
aji-153	175	17	.	.	PUNCT
aji-153	176	1	this	this	PRON
aji-153	176	2	might	might	AUX
aji-153	176	3	be	be	AUX
aji-153	176	4	related	relate	VERB
aji-153	176	5	to	to	ADP
aji-153	176	6	frequent	frequent	ADJ
aji-153	176	7	phlebotomies	phlebotomy	NOUN
aji-153	176	8	,	,	PUNCT
aji-153	176	9	blood	blood	NOUN
aji-153	176	10	loss	loss	NOUN
aji-153	176	11	in	in	ADP
aji-153	176	12	the	the	DET
aji-153	176	13	hemodialysis	hemodialysis	NOUN
aji-153	176	14	apparatus	apparatus	NOUN
aji-153	176	15	,	,	PUNCT
aji-153	176	16	and	and	CCONJ
aji-153	176	17	impairment	impairment	NOUN
aji-153	176	18	in	in	ADP
aji-153	176	19	its	its	PRON
aji-153	176	20	absorption	absorption	NOUN
aji-153	176	21	.	.	PUNCT
aji-153	177	1	the	the	DET
aji-153	177	2	initiation	initiation	NOUN
aji-153	177	3	of	of	ADP
aji-153	177	4	treatment	treatment	NOUN
aji-153	177	5	with	with	ADP
aji-153	177	6	erythropoietin	erythropoietin	NOUN
aji-153	177	7	analogs	analog	NOUN
aji-153	177	8	demonstrated	demonstrate	VERB
aji-153	177	9	how	how	SCONJ
aji-153	177	10	frequent	frequent	ADJ
aji-153	177	11	iron	iron	NOUN
aji-153	177	12	deficiency	deficiency	NOUN
aji-153	177	13	is	be	AUX
aji-153	177	14	among	among	ADP
aji-153	177	15	ckd	ckd	PROPN
aji-153	177	16	patients	patient	NOUN
aji-153	177	17	”	"	PUNCT
aji-153	178	1	[	[	X
aji-153	178	2	4	4	NUM
aji-153	178	3	]	]	PUNCT
aji-153	178	4	.	.	PUNCT
aji-153	179	1	“	"	PUNCT
aji-153	179	2	iron	iron	NOUN
aji-153	179	3	deficiency	deficiency	NOUN
aji-153	179	4	is	be	AUX
aji-153	179	5	usually	usually	ADV
aji-153	179	6	a	a	DET
aji-153	179	7	functional	functional	ADJ
aji-153	179	8	deficiency	deficiency	NOUN
aji-153	179	9	and	and	CCONJ
aji-153	179	10	is	be	AUX
aji-153	179	11	often	often	ADV
aji-153	179	12	characterized	characterize	VERB
aji-153	179	13	by	by	ADP
aji-153	179	14	low	low	ADJ
aji-153	179	15	tsi	tsi	PROPN
aji-153	179	16	and	and	CCONJ
aji-153	179	17	normal	normal	ADJ
aji-153	179	18	or	or	CCONJ
aji-153	179	19	increased	increase	VERB
aji-153	179	20	ferritin	ferritin	NOUN
aji-153	179	21	.	.	PUNCT
aji-153	179	22	ferritin	ferritin	PROPN
aji-153	179	23	can	can	AUX
aji-153	179	24	be	be	AUX
aji-153	179	25	raised	raise	VERB
aji-153	179	26	in	in	ADP
aji-153	179	27	the	the	DET
aji-153	179	28	presence	presence	NOUN
aji-153	179	29	of	of	ADP
aji-153	179	30	inflammation	inflammation	NOUN
aji-153	179	31	,	,	PUNCT
aji-153	179	32	infection	infection	NOUN
aji-153	179	33	,	,	PUNCT
aji-153	179	34	liver	liver	NOUN
aji-153	179	35	disease	disease	NOUN
aji-153	179	36	,	,	PUNCT
aji-153	179	37	and	and	CCONJ
aji-153	179	38	malignancy	malignancy	NOUN
aji-153	179	39	.	.	PUNCT
aji-153	180	1	the	the	DET
aji-153	180	2	systemic	systemic	ADJ
aji-153	180	3	homeostasis	homeostasis	NOUN
aji-153	180	4	of	of	ADP
aji-153	180	5	iron	iron	NOUN
aji-153	180	6	,	,	PUNCT
aji-153	180	7	being	be	AUX
aji-153	180	8	regulated	regulate	VERB
aji-153	180	9	and	and	CCONJ
aji-153	180	10	managed	manage	VERB
aji-153	180	11	by	by	ADP
aji-153	180	12	hepcidin	hepcidin	VERB
aji-153	180	13	9.10	9.10	NUM
aji-153	180	14	,	,	PUNCT
aji-153	180	15	is	be	AUX
aji-153	180	16	also	also	ADV
aji-153	180	17	produced	produce	VERB
aji-153	180	18	in	in	ADP
aji-153	180	19	the	the	DET
aji-153	180	20	liver	liver	NOUN
aji-153	180	21	.	.	PUNCT
aji-153	181	1	it	it	PRON
aji-153	181	2	mediates	mediate	VERB
aji-153	181	3	degradation	degradation	NOUN
aji-153	181	4	of	of	ADP
aji-153	181	5	ferroportin	ferroportin	NOUN
aji-153	181	6	in	in	ADP
aji-153	181	7	duodenal	duodenal	ADJ
aji-153	181	8	enterocytes	enterocyte	NOUN
aji-153	181	9	,	,	PUNCT
aji-153	181	10	hepatocytes	hepatocyte	NOUN
aji-153	181	11	and	and	CCONJ
aji-153	181	12	macrophages	macrophage	NOUN
aji-153	181	13	,	,	PUNCT
aji-153	181	14	which	which	PRON
aji-153	181	15	mainly	mainly	ADV
aji-153	181	16	prevents	prevent	VERB
aji-153	181	17	proper	proper	ADJ
aji-153	181	18	absorption	absorption	NOUN
aji-153	181	19	and	and	CCONJ
aji-153	181	20	usage	usage	NOUN
aji-153	181	21	of	of	ADP
aji-153	181	22	iron	iron	NOUN
aji-153	181	23	.	.	PUNCT
aji-153	182	1	inflammatory	inflammatory	ADJ
aji-153	182	2	cytokines	cytokine	NOUN
aji-153	182	3	can	can	AUX
aji-153	182	4	induce	induce	VERB
aji-153	182	5	the	the	DET
aji-153	182	6	transcription	transcription	NOUN
aji-153	182	7	of	of	ADP
aji-153	182	8	hepcidin5.6	hepcidin5.6	NUM
aji-153	182	9	,	,	PUNCT
aji-153	182	10	and	and	CCONJ
aji-153	182	11	its	its	PRON
aji-153	182	12	increase	increase	NOUN
aji-153	182	13	has	have	AUX
aji-153	182	14	been	be	AUX
aji-153	182	15	reported	report	VERB
aji-153	182	16	in	in	ADP
aji-153	182	17	patients	patient	NOUN
aji-153	182	18	with	with	ADP
aji-153	182	19	ckd5	ckd5	PROPN
aji-153	182	20	.	.	PUNCT
aji-153	183	1	anemia	anemia	NOUN
aji-153	183	2	in	in	ADP
aji-153	183	3	ckd	ckd	PROPN
aji-153	183	4	therefore	therefore	ADV
aji-153	183	5	is	be	AUX
aji-153	183	6	a	a	DET
aji-153	183	7	multi	multi	ADJ
aji-153	183	8	-	-	ADJ
aji-153	183	9	factorial	factorial	ADJ
aji-153	183	10	process	process	NOUN
aji-153	183	11	with	with	ADP
aji-153	183	12	three	three	NUM
aji-153	183	13	major	major	ADJ
aji-153	183	14	factors	factor	NOUN
aji-153	183	15	being	be	AUX
aji-153	183	16	deficiency	deficiency	NOUN
aji-153	183	17	of	of	ADP
aji-153	183	18	erythropoietin	erythropoietin	NOUN
aji-153	183	19	,	,	PUNCT
aji-153	183	20	reduction	reduction	NOUN
aji-153	183	21	in	in	ADP
aji-153	183	22	the	the	DET
aji-153	183	23	life	life	NOUN
aji-153	183	24	span	span	NOUN
aji-153	183	25	of	of	ADP
aji-153	183	26	erythrocytes	erythrocyte	NOUN
aji-153	183	27	of	of	ADP
aji-153	183	28	poorly	poorly	ADV
aji-153	183	29	defined	define	VERB
aji-153	183	30	etiology	etiology	NOUN
aji-153	183	31	,	,	PUNCT
aji-153	183	32	and	and	CCONJ
aji-153	183	33	changes	change	NOUN
aji-153	183	34	in	in	ADP
aji-153	183	35	homeostasis	homeostasis	NOUN
aji-153	183	36	of	of	ADP
aji-153	183	37	iron	iron	NOUN
aji-153	183	38	”	"	PUNCT
aji-153	184	1	[	[	X
aji-153	184	2	5	5	NUM
aji-153	184	3	]	]	PUNCT
aji-153	184	4	.	.	PUNCT
aji-153	185	1	anemia	anemia	NOUN
aji-153	185	2	is	be	AUX
aji-153	185	3	associated	associate	VERB
aji-153	185	4	with	with	ADP
aji-153	185	5	several	several	ADJ
aji-153	185	6	symptoms	symptom	NOUN
aji-153	185	7	that	that	PRON
aji-153	185	8	lead	lead	VERB
aji-153	185	9	to	to	ADP
aji-153	185	10	reduced	reduce	VERB
aji-153	185	11	quality	quality	NOUN
aji-153	185	12	of	of	ADP
aji-153	185	13	life	life	NOUN
aji-153	185	14	,	,	PUNCT
aji-153	185	15	such	such	ADJ
aji-153	185	16	as	as	ADP
aji-153	185	17	fatigue	fatigue	NOUN
aji-153	185	18	,	,	PUNCT
aji-153	185	19	dyspnea	dyspnea	NOUN
aji-153	185	20	,	,	PUNCT
aji-153	185	21	insomnia	insomnia	NOUN
aji-153	185	22	,	,	PUNCT
aji-153	185	23	and	and	CCONJ
aji-153	185	24	headache	headache	NOUN
aji-153	185	25	.	.	PUNCT
aji-153	186	1	it	it	PRON
aji-153	186	2	is	be	AUX
aji-153	186	3	also	also	ADV
aji-153	186	4	related	relate	VERB
aji-153	186	5	to	to	ADP
aji-153	186	6	reduced	reduce	VERB
aji-153	186	7	cognitive	cognitive	ADJ
aji-153	186	8	capacity	capacity	NOUN
aji-153	186	9	.	.	PUNCT
aji-153	187	1	in	in	ADP
aji-153	187	2	addition	addition	NOUN
aji-153	187	3	,	,	PUNCT
aji-153	187	4	as	as	SCONJ
aji-153	187	5	kidneys	kidney	NOUN
aji-153	187	6	fail	fail	ADJ
aji-153	187	7	,	,	PUNCT
aji-153	187	8	patients	patient	NOUN
aji-153	187	9	may	may	AUX
aji-153	187	10	require	require	VERB
aji-153	187	11	erythropoietin	erythropoietin	VERB
aji-153	187	12	a	a	DET
aji-153	187	13	stimulus	stimulus	NOUN
aji-153	187	14	to	to	ADP
aji-153	187	15	bone	bone	NOUN
aji-153	187	16	marrow	marrow	NOUN
aji-153	187	17	to	to	PART
aji-153	187	18	produce	produce	VERB
aji-153	187	19	more	more	ADJ
aji-153	187	20	blood	blood	NOUN
aji-153	187	21	.	.	PUNCT
aji-153	188	1	this	this	DET
aji-153	188	2	hormone	hormone	NOUN
aji-153	188	3	is	be	AUX
aji-153	188	4	naturally	naturally	ADV
aji-153	188	5	produced	produce	VERB
aji-153	188	6	by	by	ADP
aji-153	188	7	the	the	DET
aji-153	188	8	kidneys	kidney	NOUN
aji-153	188	9	but	but	CCONJ
aji-153	188	10	becomes	become	VERB
aji-153	188	11	relatively	relatively	ADV
aji-153	188	12	limited	limited	ADJ
aji-153	188	13	in	in	ADP
aji-153	188	14	chronic	chronic	ADJ
aji-153	188	15	disease	disease	NOUN
aji-153	188	16	of	of	ADP
aji-153	188	17	the	the	DET
aji-153	188	18	kidneys	kidney	NOUN
aji-153	188	19	.	.	PUNCT
aji-153	189	1	most	most	ADJ
aji-153	189	2	patients	patient	NOUN
aji-153	189	3	will	will	AUX
aji-153	189	4	come	come	VERB
aji-153	189	5	to	to	PART
aji-153	189	6	require	require	VERB
aji-153	189	7	erythropoietin	erythropoietin	NOUN
aji-153	189	8	or	or	CCONJ
aji-153	189	9	equivalent	equivalent	ADJ
aji-153	189	10	injectable	injectable	ADJ
aji-153	189	11	products	product	NOUN
aji-153	189	12	.	.	PUNCT
aji-153	190	1	the	the	DET
aji-153	190	2	two	two	NUM
aji-153	190	3	main	main	ADJ
aji-153	190	4	treatments	treatment	NOUN
aji-153	190	5	for	for	ADP
aji-153	190	6	anemia	anemia	NOUN
aji-153	190	7	are	be	AUX
aji-153	190	8	erythropoiesisstimulating	erythropoiesisstimulate	VERB
aji-153	190	9	agents	agent	NOUN
aji-153	190	10	and	and	CCONJ
aji-153	190	11	iron	iron	NOUN
aji-153	190	12	replacement	replacement	NOUN
aji-153	190	13	.	.	PUNCT
aji-153	191	1	however	however	ADV
aji-153	191	2	,	,	PUNCT
aji-153	191	3	despite	despite	SCONJ
aji-153	191	4	these	these	DET
aji-153	191	5	treatments	treatment	NOUN
aji-153	191	6	,	,	PUNCT
aji-153	191	7	an	an	DET
aji-153	191	8	important	important	ADJ
aji-153	191	9	proportion	proportion	NOUN
aji-153	191	10	of	of	ADP
aji-153	191	11	children	child	NOUN
aji-153	191	12	remain	remain	VERB
aji-153	191	13	anemic	anemic	ADJ
aji-153	191	14	.	.	PUNCT
aji-153	192	1	increasing	increase	VERB
aji-153	192	2	the	the	DET
aji-153	192	3	esa	esa	PROPN
aji-153	192	4	dose	dose	NOUN
aji-153	192	5	to	to	PART
aji-153	192	6	achieve	achieve	VERB
aji-153	192	7	higher	high	ADJ
aji-153	192	8	hemoglobin	hemoglobin	NOUN
aji-153	192	9	levels	level	NOUN
aji-153	192	10	has	have	AUX
aji-153	192	11	been	be	AUX
aji-153	192	12	associated	associate	VERB
aji-153	192	13	with	with	ADP
aji-153	192	14	adverse	adverse	ADJ
aji-153	192	15	outcomes	outcome	NOUN
aji-153	192	16	in	in	ADP
aji-153	192	17	adults	adult	NOUN
aji-153	192	18	;	;	PUNCT
aji-153	192	19	this	this	DET
aji-153	192	20	association	association	NOUN
aji-153	192	21	has	have	AUX
aji-153	192	22	not	not	PART
aji-153	192	23	gupta	gupta	NOUN
aji-153	192	24	et	et	PROPN
aji-153	192	25	al	al	PROPN
aji-153	192	26	.	.	PROPN
aji-153	192	27	;	;	PUNCT
aji-153	192	28	asian	asian	PROPN
aji-153	192	29	j.	j.	PROPN
aji-153	192	30	immunol	immunol	PROPN
aji-153	192	31	.	.	PROPN
aji-153	192	32	,	,	PUNCT
aji-153	192	33	vol	vol	NOUN
aji-153	192	34	.	.	PROPN
aji-153	193	1	7	7	NUM
aji-153	193	2	,	,	PUNCT
aji-153	193	3	no	no	INTJ
aji-153	193	4	.	.	NOUN
aji-153	193	5	1	1	NUM
aji-153	193	6	,	,	PUNCT
aji-153	193	7	pp	pp	ADJ
aji-153	193	8	.	.	PUNCT
aji-153	194	1	302	302	NUM
aji-153	194	2	-	-	SYM
aji-153	194	3	315	315	NUM
aji-153	194	4	,	,	PUNCT
aji-153	194	5	2024	2024	NUM
aji-153	194	6	;	;	PUNCT
aji-153	194	7	article	article	NOUN
aji-153	194	8	no.aji.127402	no.aji.127402	VERB
aji-153	194	9	305	305	NUM
aji-153	194	10	been	be	AUX
aji-153	194	11	examined	examine	VERB
aji-153	194	12	in	in	ADP
aji-153	194	13	children	child	NOUN
aji-153	194	14	.	.	PUNCT
aji-153	195	1	hemoglobin	hemoglobin	NOUN
aji-153	195	2	may	may	AUX
aji-153	195	3	be	be	AUX
aji-153	195	4	hard	hard	ADJ
aji-153	195	5	to	to	PART
aji-153	195	6	keep	keep	VERB
aji-153	195	7	within	within	ADP
aji-153	195	8	a	a	DET
aji-153	195	9	narrow	narrow	ADJ
aji-153	195	10	range	range	NOUN
aji-153	195	11	using	use	VERB
aji-153	195	12	conservative	conservative	ADJ
aji-153	195	13	esa	esa	PROPN
aji-153	195	14	dosing	dosing	PROPN
aji-153	195	15	.	.	PUNCT
aji-153	196	1	careful	careful	ADJ
aji-153	196	2	administration	administration	NOUN
aji-153	196	3	of	of	ADP
aji-153	196	4	iron	iron	NOUN
aji-153	196	5	supplements	supplement	NOUN
aji-153	196	6	may	may	AUX
aji-153	196	7	enhance	enhance	VERB
aji-153	196	8	esa	esa	PROPN
aji-153	196	9	’s	’s	PART
aji-153	196	10	efficacy	efficacy	NOUN
aji-153	196	11	,	,	PUNCT
aji-153	196	12	yet	yet	CCONJ
aji-153	196	13	the	the	DET
aji-153	196	14	commonly	commonly	ADV
aji-153	196	15	applied	apply	VERB
aji-153	196	16	markers	marker	NOUN
aji-153	196	17	of	of	ADP
aji-153	196	18	iron	iron	NOUN
aji-153	196	19	storage	storage	NOUN
aji-153	196	20	in	in	ADP
aji-153	196	21	the	the	DET
aji-153	196	22	clinical	clinical	ADJ
aji-153	196	23	setting	setting	NOUN
aji-153	196	24	lack	lack	VERB
aji-153	196	25	the	the	DET
aji-153	196	26	sensitivity	sensitivity	NOUN
aji-153	196	27	to	to	PART
aji-153	196	28	identify	identify	VERB
aji-153	196	29	which	which	PRON
aji-153	196	30	patients	patient	NOUN
aji-153	196	31	can	can	AUX
aji-153	196	32	benefit	benefit	VERB
aji-153	196	33	the	the	DET
aji-153	196	34	most	most	ADJ
aji-153	196	35	from	from	ADP
aji-153	196	36	supplemental	supplemental	ADJ
aji-153	196	37	iron	iron	NOUN
aji-153	196	38	.	.	PUNCT
aji-153	197	1	other	other	ADJ
aji-153	197	2	agents	agent	NOUN
aji-153	197	3	that	that	PRON
aji-153	197	4	target	target	VERB
aji-153	197	5	the	the	DET
aji-153	197	6	hif	hif	PROPN
aji-153	197	7	pathway	pathway	NOUN
aji-153	197	8	,	,	PUNCT
aji-153	197	9	such	such	ADJ
aji-153	197	10	as	as	ADP
aji-153	197	11	hypoxiainducible	hypoxiainducible	ADJ
aji-153	197	12	factor	factor	NOUN
aji-153	197	13	stabilizers	stabilizer	NOUN
aji-153	197	14	and	and	CCONJ
aji-153	197	15	prolyl	prolyl	NOUN
aji-153	197	16	hydroxylase	hydroxylase	NOUN
aji-153	197	17	inhibitors	inhibitor	NOUN
aji-153	197	18	,	,	PUNCT
aji-153	197	19	and	and	CCONJ
aji-153	197	20	iron	iron	NOUN
aji-153	197	21	supplements	supplement	NOUN
aji-153	197	22	delivered	deliver	VERB
aji-153	197	23	via	via	ADP
aji-153	197	24	dialysis	dialysis	NOUN
aji-153	197	25	are	be	AUX
aji-153	197	26	,	,	PUNCT
aji-153	197	27	therefore	therefore	ADV
aji-153	197	28	under	under	ADP
aji-153	197	29	investigation	investigation	NOUN
aji-153	197	30	and	and	CCONJ
aji-153	197	31	may	may	AUX
aji-153	197	32	provide	provide	VERB
aji-153	197	33	alternative	alternative	ADJ
aji-153	197	34	management	management	NOUN
aji-153	197	35	.	.	PUNCT
aji-153	198	1	nonetheless	nonetheless	ADV
aji-153	198	2	,	,	PUNCT
aji-153	198	3	the	the	DET
aji-153	198	4	effectiveness	effectiveness	NOUN
aji-153	198	5	and	and	CCONJ
aji-153	198	6	safety	safety	NOUN
aji-153	198	7	of	of	ADP
aji-153	198	8	these	these	DET
aji-153	198	9	treatments	treatment	NOUN
aji-153	198	10	in	in	ADP
aji-153	198	11	children	child	NOUN
aji-153	198	12	with	with	ADP
aji-153	198	13	ckd	ckd	PROPN
aji-153	198	14	have	have	AUX
aji-153	198	15	not	not	PART
aji-153	198	16	been	be	AUX
aji-153	198	17	reported	report	VERB
aji-153	198	18	yet	yet	ADV
aji-153	198	19	[	[	X
aji-153	198	20	6	6	NUM
aji-153	198	21	]	]	PUNCT
aji-153	198	22	.	.	PUNCT
aji-153	199	1	for	for	ADP
aji-153	199	2	those	those	PRON
aji-153	199	3	with	with	ADP
aji-153	199	4	gfr	gfr	PROPN
aji-153	199	5	<	<	X
aji-153	199	6	30	30	NUM
aji-153	199	7	ml	ml	NOUN
aji-153	199	8	/	/	SYM
aji-153	199	9	minute	minute	NOUN
aji-153	199	10	,	,	PUNCT
aji-153	199	11	it	it	PRON
aji-153	199	12	is	be	AUX
aji-153	199	13	fair	fair	ADJ
aji-153	199	14	to	to	PART
aji-153	199	15	assume	assume	VERB
aji-153	199	16	that	that	SCONJ
aji-153	199	17	anemia	anemia	NOUN
aji-153	199	18	is	be	AUX
aji-153	199	19	secondary	secondary	ADJ
aji-153	199	20	to	to	ADP
aji-153	199	21	renal	renal	ADJ
aji-153	199	22	failure	failure	NOUN
aji-153	199	23	.	.	PUNCT
aji-153	200	1	nonetheless	nonetheless	ADV
aji-153	200	2	,	,	PUNCT
aji-153	200	3	it	it	PRON
aji-153	200	4	is	be	AUX
aji-153	200	5	important	important	ADJ
aji-153	200	6	to	to	PART
aji-153	200	7	rule	rule	VERB
aji-153	200	8	out	out	ADP
aji-153	200	9	iron	iron	NOUN
aji-153	200	10	deficiency	deficiency	NOUN
aji-153	200	11	among	among	ADP
aji-153	200	12	others	other	NOUN
aji-153	200	13	since	since	SCONJ
aji-153	200	14	the	the	DET
aji-153	200	15	disease	disease	NOUN
aji-153	200	16	can	can	AUX
aji-153	200	17	be	be	AUX
aji-153	200	18	easily	easily	ADV
aji-153	200	19	reversed	reverse	VERB
aji-153	200	20	.	.	PUNCT
aji-153	201	1	if	if	SCONJ
aji-153	201	2	anemia	anemia	NOUN
aji-153	201	3	appears	appear	VERB
aji-153	201	4	disproportionate	disproportionate	ADJ
aji-153	201	5	to	to	ADP
aji-153	201	6	the	the	DET
aji-153	201	7	level	level	NOUN
aji-153	201	8	of	of	ADP
aji-153	201	9	kidney	kidney	NOUN
aji-153	201	10	dysfunction	dysfunction	NOUN
aji-153	201	11	,	,	PUNCT
aji-153	201	12	further	further	ADJ
aji-153	201	13	investigation	investigation	NOUN
aji-153	201	14	should	should	AUX
aji-153	201	15	be	be	AUX
aji-153	201	16	made	make	VERB
aji-153	201	17	.	.	PUNCT
aji-153	202	1	in	in	ADP
aji-153	202	2	such	such	ADJ
aji-153	202	3	cases	case	NOUN
aji-153	202	4	,	,	PUNCT
aji-153	202	5	an	an	DET
aji-153	202	6	example	example	NOUN
aji-153	202	7	-	-	PUNCT
aji-153	202	8	like	like	ADJ
aji-153	202	9	hemoglobin	hemoglobin	NOUN
aji-153	202	10	at	at	ADP
aji-153	202	11	9	9	NUM
aji-153	202	12	g	g	NOUN
aji-153	202	13	/	/	SYM
aji-153	202	14	dl	dl	PROPN
aji-153	202	15	with	with	ADP
aji-153	202	16	serum	serum	NOUN
aji-153	202	17	creatinine	creatinine	NOUN
aji-153	202	18	of	of	ADP
aji-153	202	19	200	200	NUM
aji-153	202	20	μmol	μmol	NOUN
aji-153	202	21	/	/	SYM
aji-153	202	22	l	l	NOUN
aji-153	202	23	should	should	AUX
aji-153	202	24	be	be	AUX
aji-153	202	25	investigated	investigate	VERB
aji-153	202	26	.	.	PUNCT
aji-153	203	1	further	far	ADV
aji-153	203	2	.	.	PUNCT
aji-153	204	1	type	type	NOUN
aji-153	204	2	2	2	NUM
aji-153	204	3	diabetes	diabetes	NOUN
aji-153	204	4	and	and	CCONJ
aji-153	204	5	hypertension	hypertension	NOUN
aji-153	204	6	are	be	AUX
aji-153	204	7	the	the	DET
aji-153	204	8	predominant	predominant	ADJ
aji-153	204	9	causes	cause	NOUN
aji-153	204	10	of	of	ADP
aji-153	204	11	ckd	ckd	PROPN
aji-153	204	12	in	in	ADP
aji-153	204	13	the	the	DET
aji-153	204	14	developed	developed	ADJ
aji-153	204	15	world	world	NOUN
aji-153	204	16	and	and	CCONJ
aji-153	204	17	increase	increase	VERB
aji-153	204	18	the	the	DET
aji-153	204	19	risk	risk	NOUN
aji-153	204	20	of	of	ADP
aji-153	204	21	developing	develop	VERB
aji-153	204	22	cardiovascular	cardiovascular	ADJ
aji-153	204	23	disease	disease	NOUN
aji-153	204	24	,	,	PUNCT
aji-153	204	25	hyperlipidemia	hyperlipidemia	NOUN
aji-153	204	26	,	,	PUNCT
aji-153	204	27	mineral	mineral	NOUN
aji-153	204	28	and	and	CCONJ
aji-153	204	29	bone	bone	NOUN
aji-153	204	30	disorders	disorder	NOUN
aji-153	204	31	,	,	PUNCT
aji-153	204	32	and	and	CCONJ
aji-153	204	33	anemia	anemia	NOUN
aji-153	204	34	.	.	PUNCT
aji-153	205	1	anemia	anemia	NOUN
aji-153	205	2	is	be	AUX
aji-153	205	3	characterized	characterize	VERB
aji-153	205	4	by	by	ADP
aji-153	205	5	a	a	DET
aji-153	205	6	decrease	decrease	NOUN
aji-153	205	7	in	in	ADP
aji-153	205	8	red	red	ADJ
aji-153	205	9	blood	blood	NOUN
aji-153	205	10	cells	cell	NOUN
aji-153	205	11	and	and	CCONJ
aji-153	205	12	,	,	PUNCT
aji-153	205	13	consequently	consequently	ADV
aji-153	205	14	,	,	PUNCT
aji-153	205	15	hemoglobin	hemoglobin	NOUN
aji-153	205	16	(	(	PUNCT
aji-153	205	17	hb	hb	PROPN
aji-153	205	18	)	)	PUNCT
aji-153	205	19	,	,	PUNCT
aji-153	205	20	and	and	CCONJ
aji-153	205	21	typical	typical	ADJ
aji-153	205	22	symptoms	symptom	NOUN
aji-153	205	23	and	and	CCONJ
aji-153	205	24	signs	sign	NOUN
aji-153	205	25	include	include	VERB
aji-153	205	26	paleness	paleness	NOUN
aji-153	205	27	,	,	PUNCT
aji-153	205	28	fatigue	fatigue	NOUN
aji-153	205	29	,	,	PUNCT
aji-153	205	30	and	and	CCONJ
aji-153	205	31	breathlessness	breathlessness	NOUN
aji-153	205	32	.	.	PUNCT
aji-153	206	1	at	at	ADV
aji-153	206	2	least	least	ADV
aji-153	206	3	two	two	NUM
aji-153	206	4	factors	factor	NOUN
aji-153	206	5	determine	determine	VERB
aji-153	206	6	the	the	DET
aji-153	206	7	lag	lag	NOUN
aji-153	206	8	between	between	ADP
aji-153	206	9	ckd	ckd	NOUN
aji-153	206	10	onset	onset	NOUN
aji-153	206	11	and	and	CCONJ
aji-153	206	12	development	development	NOUN
aji-153	206	13	of	of	ADP
aji-153	206	14	anemia	anemia	NOUN
aji-153	206	15	.	.	PUNCT
aji-153	207	1	first	first	ADV
aji-153	207	2	,	,	PUNCT
aji-153	207	3	epo	epo	PROPN
aji-153	207	4	,	,	PUNCT
aji-153	207	5	the	the	DET
aji-153	207	6	hormone	hormone	NOUN
aji-153	207	7	that	that	PRON
aji-153	207	8	promotes	promote	VERB
aji-153	207	9	red	red	ADJ
aji-153	207	10	blood	blood	NOUN
aji-153	207	11	cell	cell	NOUN
aji-153	207	12	production	production	NOUN
aji-153	207	13	,	,	PUNCT
aji-153	207	14	is	be	AUX
aji-153	207	15	produced	produce	VERB
aji-153	207	16	in	in	ADP
aji-153	207	17	smaller	small	ADJ
aji-153	207	18	quantities	quantity	NOUN
aji-153	207	19	in	in	ADP
aji-153	207	20	ckd	ckd	PROPN
aji-153	207	21	patients	patient	NOUN
aji-153	207	22	than	than	ADP
aji-153	207	23	in	in	ADP
aji-153	207	24	non	non	ADJ
aji-153	207	25	-	-	ADJ
aji-153	207	26	ckd	ckd	ADJ
aji-153	207	27	patients	patient	NOUN
aji-153	207	28	.	.	PUNCT
aji-153	208	1	second	second	ADV
aji-153	208	2	,	,	PUNCT
aji-153	208	3	hepcidin	hepcidin	NOUN
aji-153	208	4	,	,	PUNCT
aji-153	208	5	a	a	DET
aji-153	208	6	hormone	hormone	NOUN
aji-153	208	7	that	that	PRON
aji-153	208	8	suppresses	suppress	VERB
aji-153	208	9	dietary	dietary	ADJ
aji-153	208	10	iron	iron	NOUN
aji-153	208	11	absorption	absorption	NOUN
aji-153	208	12	when	when	SCONJ
aji-153	208	13	levels	level	NOUN
aji-153	208	14	are	be	AUX
aji-153	208	15	elevated	elevate	VERB
aji-153	208	16	,	,	PUNCT
aji-153	208	17	is	be	AUX
aji-153	208	18	elevated	elevate	VERB
aji-153	208	19	in	in	ADP
aji-153	208	20	greater	great	ADJ
aji-153	208	21	concentrations	concentration	NOUN
aji-153	208	22	in	in	ADP
aji-153	208	23	ckd	ckd	PROPN
aji-153	208	24	patients	patient	NOUN
aji-153	208	25	.	.	PUNCT
aji-153	209	1	iron	iron	NOUN
aji-153	209	2	is	be	AUX
aji-153	209	3	one	one	NUM
aji-153	209	4	constituent	constituent	NOUN
aji-153	209	5	of	of	ADP
aji-153	209	6	hemoglobin	hemoglobin	NOUN
aji-153	209	7	;	;	PUNCT
aji-153	209	8	it	it	PRON
aji-153	209	9	serves	serve	VERB
aji-153	209	10	as	as	ADP
aji-153	209	11	a	a	DET
aji-153	209	12	critical	critical	ADJ
aji-153	209	13	component	component	NOUN
aji-153	209	14	in	in	ADP
aji-153	209	15	the	the	DET
aji-153	209	16	oxygen	oxygen	NOUN
aji-153	209	17	transport	transport	NOUN
aji-153	209	18	process	process	NOUN
aji-153	209	19	.	.	PUNCT
aji-153	210	1	anemia	anemia	NOUN
aji-153	210	2	in	in	ADP
aji-153	210	3	patients	patient	NOUN
aji-153	210	4	with	with	ADP
aji-153	210	5	ckd	ckd	PROPN
aji-153	210	6	is	be	AUX
aji-153	210	7	a	a	DET
aji-153	210	8	known	know	VERB
aji-153	210	9	contributor	contributor	NOUN
aji-153	210	10	to	to	ADP
aji-153	210	11	a	a	DET
aji-153	210	12	lower	low	ADJ
aji-153	210	13	quality	quality	NOUN
aji-153	210	14	of	of	ADP
aji-153	210	15	life	life	NOUN
aji-153	210	16	and	and	CCONJ
aji-153	210	17	increased	increase	VERB
aji-153	210	18	risk	risk	NOUN
aji-153	210	19	of	of	ADP
aji-153	210	20	clinical	clinical	ADJ
aji-153	210	21	outcomes	outcome	NOUN
aji-153	210	22	that	that	PRON
aji-153	210	23	are	be	AUX
aji-153	210	24	unfavorable	unfavorable	ADJ
aji-153	210	25	[	[	X
aji-153	210	26	7	7	NUM
aji-153	210	27	]	]	PUNCT
aji-153	210	28	.	.	PUNCT
aji-153	211	1	1.3	1.3	NUM
aji-153	211	2	chronic	chronic	ADJ
aji-153	211	3	kidney	kidney	NOUN
aji-153	211	4	disease	disease	NOUN
aji-153	211	5	(	(	PUNCT
aji-153	211	6	ckd	ckd	NOUN
aji-153	211	7	)	)	PUNCT
aji-153	211	8	chronic	chronic	ADJ
aji-153	211	9	kidney	kidney	NOUN
aji-153	211	10	disease	disease	NOUN
aji-153	211	11	is	be	AUX
aji-153	211	12	a	a	DET
aji-153	211	13	degenerative	degenerative	ADJ
aji-153	211	14	and	and	CCONJ
aji-153	211	15	incurable	incurable	ADJ
aji-153	211	16	illness	illness	NOUN
aji-153	211	17	with	with	ADP
aji-153	211	18	high	high	ADJ
aji-153	211	19	morbidity	morbidity	NOUN
aji-153	211	20	and	and	CCONJ
aji-153	211	21	mortality	mortality	NOUN
aji-153	211	22	rates	rate	NOUN
aji-153	211	23	and	and	CCONJ
aji-153	211	24	also	also	ADV
aji-153	211	25	the	the	DET
aji-153	211	26	most	most	ADV
aji-153	211	27	common	common	ADJ
aji-153	211	28	cause	cause	NOUN
aji-153	211	29	of	of	ADP
aji-153	211	30	morbidity	morbidity	NOUN
aji-153	211	31	in	in	ADP
aji-153	211	32	adults	adult	NOUN
aji-153	211	33	,	,	PUNCT
aji-153	211	34	especially	especially	ADV
aji-153	211	35	those	those	PRON
aji-153	211	36	with	with	ADP
aji-153	211	37	diabetes	diabetes	NOUN
aji-153	211	38	and	and	CCONJ
aji-153	211	39	hypertension	hypertension	NOUN
aji-153	211	40	.	.	PUNCT
aji-153	212	1	as	as	ADP
aji-153	212	2	such	such	ADJ
aji-153	212	3	,	,	PUNCT
aji-153	212	4	nonpharmacological	nonpharmacological	ADJ
aji-153	212	5	interventions	intervention	NOUN
aji-153	212	6	,	,	PUNCT
aji-153	212	7	for	for	ADP
aji-153	212	8	instance	instance	NOUN
aji-153	212	9	,	,	PUNCT
aji-153	212	10	dietary	dietary	ADJ
aji-153	212	11	and	and	CCONJ
aji-153	212	12	lifestyle	lifestyle	NOUN
aji-153	212	13	changes	change	NOUN
aji-153	212	14	,	,	PUNCT
aji-153	212	15	and	and	CCONJ
aji-153	212	16	renal	renal	ADJ
aji-153	212	17	diseasespecific	diseasespecific	NOUN
aji-153	212	18	pharmacological	pharmacological	ADJ
aji-153	212	19	treatments	treatment	NOUN
aji-153	212	20	,	,	PUNCT
aji-153	212	21	targeting	target	VERB
aji-153	212	22	chronic	chronic	ADJ
aji-153	212	23	kidney	kidney	NOUN
aji-153	212	24	disease	disease	NOUN
aji-153	212	25	can	can	AUX
aji-153	212	26	help	help	VERB
aji-153	212	27	preserve	preserve	VERB
aji-153	212	28	renal	renal	ADJ
aji-153	212	29	function	function	NOUN
aji-153	212	30	that	that	PRON
aji-153	212	31	otherwise	otherwise	ADV
aji-153	212	32	may	may	AUX
aji-153	212	33	otherwise	otherwise	ADV
aji-153	212	34	improve	improve	VERB
aji-153	212	35	the	the	DET
aji-153	212	36	outcomes	outcome	NOUN
aji-153	212	37	.	.	PUNCT
aji-153	213	1	a	a	DET
aji-153	213	2	plant	plant	NOUN
aji-153	213	3	-	-	PUNCT
aji-153	213	4	based	base	VERB
aji-153	213	5	diet	diet	NOUN
aji-153	213	6	low	low	ADJ
aji-153	213	7	in	in	ADP
aji-153	213	8	protein	protein	NOUN
aji-153	213	9	and	and	CCONJ
aji-153	213	10	salt	salt	NOUN
aji-153	213	11	may	may	AUX
aji-153	213	12	reduce	reduce	VERB
aji-153	213	13	glomerular	glomerular	ADJ
aji-153	213	14	hyperfiltration	hyperfiltration	NOUN
aji-153	213	15	and	and	CCONJ
aji-153	213	16	halt	halt	VERB
aji-153	213	17	or	or	CCONJ
aji-153	213	18	slow	slow	VERB
aji-153	213	19	the	the	DET
aji-153	213	20	progression	progression	NOUN
aji-153	213	21	of	of	ADP
aji-153	213	22	renal	renal	ADJ
aji-153	213	23	deterioration	deterioration	NOUN
aji-153	213	24	and	and	CCONJ
aji-153	213	25	even	even	ADV
aji-153	213	26	contribute	contribute	VERB
aji-153	213	27	to	to	ADP
aji-153	213	28	alterations	alteration	NOUN
aji-153	213	29	in	in	ADP
aji-153	213	30	acid	acid	NOUN
aji-153	213	31	-	-	PUNCT
aji-153	213	32	base	base	NOUN
aji-153	213	33	balance	balance	NOUN
aji-153	213	34	and	and	CCONJ
aji-153	213	35	in	in	ADP
aji-153	213	36	the	the	DET
aji-153	213	37	gut	gut	NOUN
aji-153	213	38	microbiome	microbiome	NOUN
aji-153	213	39	that	that	PRON
aji-153	213	40	are	be	AUX
aji-153	213	41	favorable	favorable	ADJ
aji-153	213	42	.	.	PUNCT
aji-153	214	1	alteration	alteration	NOUN
aji-153	214	2	in	in	ADP
aji-153	214	3	intrarenal	intrarenal	ADJ
aji-153	214	4	hemodynamics	hemodynamic	NOUN
aji-153	214	5	through	through	ADP
aji-153	214	6	pharmacological	pharmacological	ADJ
aji-153	214	7	therapies	therapy	NOUN
aji-153	214	8	(	(	PUNCT
aji-153	214	9	e.g.	e.g.	ADV
aji-153	214	10	,	,	PUNCT
aji-153	214	11	reninangiotensin	reninangiotensin	NOUN
aji-153	214	12	-	-	PUNCT
aji-153	214	13	aldosterone	aldosterone	NOUN
aji-153	214	14	pathway	pathway	NOUN
aji-153	214	15	regulators	regulator	NOUN
aji-153	214	16	and	and	CCONJ
aji-153	214	17	sglt2	sglt2	X
aji-153	215	1	[	[	X
aji-153	215	2	slc5a2	slc5a2	ADV
aji-153	215	3	]	]	X
aji-153	215	4	inhibitors	inhibitor	NOUN
aji-153	215	5	)	)	PUNCT
aji-153	215	6	may	may	AUX
aji-153	215	7	preserve	preserve	VERB
aji-153	215	8	renal	renal	ADJ
aji-153	215	9	function	function	NOUN
aji-153	215	10	through	through	ADP
aji-153	215	11	a	a	DET
aji-153	215	12	reduction	reduction	NOUN
aji-153	215	13	in	in	ADP
aji-153	215	14	intraglomerular	intraglomerular	ADJ
aji-153	215	15	pressure	pressure	NOUN
aji-153	215	16	that	that	PRON
aji-153	215	17	is	be	AUX
aji-153	215	18	independent	independent	ADJ
aji-153	215	19	of	of	ADP
aji-153	215	20	control	control	NOUN
aji-153	215	21	of	of	ADP
aji-153	215	22	bp	bp	PROPN
aji-153	215	23	and	and	CCONJ
aji-153	215	24	glycemia	glycemia	NOUN
aji-153	215	25	;	;	PUNCT
aji-153	215	26	other	other	ADJ
aji-153	215	27	pharmacological	pharmacological	ADJ
aji-153	215	28	therapies	therapy	NOUN
aji-153	215	29	are	be	AUX
aji-153	215	30	novel	novel	ADJ
aji-153	215	31	active	active	ADJ
aji-153	215	32	moieties	moiety	NOUN
aji-153	215	33	:	:	PUNCT
aji-153	215	34	nonpharmacologic	nonpharmacologic	ADJ
aji-153	215	35	steroidal	steroidal	NOUN
aji-153	215	36	mineralocorticoid	mineralocorticoid	NOUN
aji-153	215	37	receptor	receptor	NOUN
aji-153	215	38	antagonists	antagonist	NOUN
aji-153	215	39	which	which	PRON
aji-153	215	40	may	may	AUX
aji-153	215	41	protect	protect	VERB
aji-153	215	42	the	the	DET
aji-153	215	43	kidney	kidney	NOUN
aji-153	215	44	through	through	ADP
aji-153	215	45	antiinflammatory	antiinflammatory	NOUN
aji-153	215	46	or	or	CCONJ
aji-153	215	47	anti	anti	ADJ
aji-153	215	48	-	-	ADJ
aji-153	215	49	fibrotic	fibrotic	ADJ
aji-153	215	50	mechanisms	mechanism	NOUN
aji-153	215	51	[	[	X
aji-153	215	52	8	8	NUM
aji-153	215	53	]	]	PUNCT
aji-153	215	54	.	.	PUNCT
aji-153	216	1	some	some	DET
aji-153	216	2	glomerular	glomerular	ADJ
aji-153	216	3	and	and	CCONJ
aji-153	216	4	cystic	cystic	ADJ
aji-153	216	5	kidney	kidney	NOUN
aji-153	216	6	diseases	disease	NOUN
aji-153	216	7	may	may	AUX
aji-153	216	8	benefit	benefit	VERB
aji-153	216	9	from	from	ADP
aji-153	216	10	disease	disease	NOUN
aji-153	216	11	-	-	PUNCT
aji-153	216	12	specific	specific	ADJ
aji-153	216	13	treatment	treatment	NOUN
aji-153	216	14	.	.	PUNCT
aji-153	217	1	considering	consider	VERB
aji-153	217	2	the	the	DET
aji-153	217	3	sheer	sheer	ADJ
aji-153	217	4	number	number	NOUN
aji-153	217	5	of	of	ADP
aji-153	217	6	comorbidities	comorbiditie	NOUN
aji-153	217	7	,	,	PUNCT
aji-153	217	8	the	the	DET
aji-153	217	9	morbidity	morbidity	NOUN
aji-153	217	10	and	and	CCONJ
aji-153	217	11	mortality	mortality	NOUN
aji-153	217	12	associated	associate	VERB
aji-153	217	13	with	with	ADP
aji-153	217	14	them	they	PRON
aji-153	217	15	,	,	PUNCT
aji-153	217	16	and	and	CCONJ
aji-153	217	17	the	the	DET
aji-153	217	18	role	role	NOUN
aji-153	217	19	of	of	ADP
aji-153	217	20	non	non	ADJ
aji-153	217	21	-	-	ADJ
aji-153	217	22	traditional	traditional	ADJ
aji-153	217	23	risk	risk	NOUN
aji-153	217	24	factors	factor	NOUN
aji-153	217	25	in	in	ADP
aji-153	217	26	ckd	ckd	PROPN
aji-153	217	27	,	,	PUNCT
aji-153	217	28	managing	manage	VERB
aji-153	217	29	the	the	DET
aji-153	217	30	cardiovascular	cardiovascular	ADJ
aji-153	217	31	risk	risk	NOUN
aji-153	217	32	of	of	ADP
aji-153	217	33	ckd	ckd	PROPN
aji-153	217	34	,	,	PUNCT
aji-153	217	35	minimizing	minimize	VERB
aji-153	217	36	infection	infection	NOUN
aji-153	217	37	risk	risk	NOUN
aji-153	217	38	,	,	PUNCT
aji-153	217	39	and	and	CCONJ
aji-153	217	40	preventing	prevent	VERB
aji-153	217	41	acute	acute	ADJ
aji-153	217	42	renal	renal	ADJ
aji-153	217	43	failure	failure	NOUN
aji-153	217	44	are	be	AUX
aji-153	217	45	some	some	DET
aji-153	217	46	important	important	ADJ
aji-153	217	47	interventions	intervention	NOUN
aji-153	217	48	for	for	ADP
aji-153	217	49	these	these	DET
aji-153	217	50	patients	patient	NOUN
aji-153	217	51	.	.	PUNCT
aji-153	218	1	if	if	SCONJ
aji-153	218	2	renal	renal	ADJ
aji-153	218	3	replacement	replacement	NOUN
aji-153	218	4	therapy	therapy	NOUN
aji-153	218	5	is	be	AUX
aji-153	218	6	unavoidable	unavoidable	ADJ
aji-153	218	7	,	,	PUNCT
aji-153	218	8	then	then	ADV
aji-153	218	9	stepwise	stepwise	PROPN
aji-153	218	10	switching	switch	VERB
aji-153	218	11	to	to	ADP
aji-153	218	12	dialysis	dialysis	NOUN
aji-153	218	13	may	may	AUX
aji-153	218	14	be	be	AUX
aji-153	218	15	considered	consider	VERB
aji-153	218	16	.	.	PUNCT
aji-153	219	1	it	it	PRON
aji-153	219	2	has	have	AUX
aji-153	219	3	also	also	ADV
aji-153	219	4	been	be	AUX
aji-153	219	5	suggested	suggest	VERB
aji-153	219	6	that	that	SCONJ
aji-153	219	7	this	this	PRON
aji-153	219	8	may	may	AUX
aji-153	219	9	preserve	preserve	VERB
aji-153	219	10	residual	residual	ADJ
aji-153	219	11	renal	renal	ADJ
aji-153	219	12	function	function	NOUN
aji-153	219	13	for	for	ADP
aji-153	219	14	longer	long	ADV
aji-153	219	15	.	.	PUNCT
aji-153	220	1	ksp	ksp	PROPN
aji-153	220	2	and	and	CCONJ
aji-153	220	3	sc	sc	PROPN
aji-153	220	4	share	share	NOUN
aji-153	220	5	similarities	similarity	NOUN
aji-153	220	6	but	but	CCONJ
aji-153	220	7	are	be	AUX
aji-153	220	8	different	different	ADJ
aji-153	220	9	from	from	ADP
aji-153	220	10	one	one	NUM
aji-153	220	11	another	another	DET
aji-153	220	12	.	.	PUNCT
aji-153	221	1	more	more	ADJ
aji-153	221	2	research	research	NOUN
aji-153	221	3	is	be	AUX
aji-153	221	4	needed	need	VERB
aji-153	221	5	,	,	PUNCT
aji-153	221	6	along	along	ADP
aji-153	221	7	with	with	ADP
aji-153	221	8	the	the	DET
aji-153	221	9	development	development	NOUN
aji-153	221	10	of	of	ADP
aji-153	221	11	new	new	ADJ
aji-153	221	12	treatment	treatment	NOUN
aji-153	221	13	strategies	strategy	NOUN
aji-153	221	14	in	in	ADP
aji-153	221	15	dietary	dietary	ADJ
aji-153	221	16	and	and	CCONJ
aji-153	221	17	pharmacological	pharmacological	ADJ
aji-153	221	18	interventions	intervention	NOUN
aji-153	221	19	,	,	PUNCT
aji-153	221	20	to	to	PART
aji-153	221	21	achieve	achieve	VERB
aji-153	221	22	optimal	optimal	ADJ
aji-153	221	23	kidney	kidney	NOUN
aji-153	221	24	-	-	PUNCT
aji-153	221	25	sparing	spare	VERB
aji-153	221	26	treatment	treatment	NOUN
aji-153	221	27	in	in	ADP
aji-153	221	28	these	these	DET
aji-153	221	29	patients	patient	NOUN
aji-153	221	30	,	,	PUNCT
aji-153	221	31	increasing	increase	VERB
aji-153	221	32	their	their	PRON
aji-153	221	33	life	life	NOUN
aji-153	221	34	expectancy	expectancy	NOUN
aji-153	221	35	,	,	PUNCT
aji-153	221	36	and	and	CCONJ
aji-153	221	37	achieving	achieve	VERB
aji-153	221	38	better	well	ADJ
aji-153	221	39	hrqolid	hrqolid	ADJ
aji-153	221	40	anemia	anemia	NOUN
aji-153	221	41	is	be	AUX
aji-153	221	42	a	a	DET
aji-153	221	43	frequent	frequent	ADJ
aji-153	221	44	complication	complication	NOUN
aji-153	221	45	present	present	NOUN
aji-153	221	46	in	in	ADP
aji-153	221	47	ckd	ckd	PROPN
aji-153	221	48	.	.	PUNCT
aji-153	222	1	both	both	PRON
aji-153	222	2	absolute	absolute	ADJ
aji-153	222	3	and	and	CCONJ
aji-153	222	4	functional	functional	ADJ
aji-153	222	5	i	i	NOUN
aji-153	222	6	d	d	PROPN
aji-153	222	7	are	be	AUX
aji-153	222	8	encountered	encounter	VERB
aji-153	222	9	in	in	ADP
aji-153	222	10	ckd	ckd	NOUN
aji-153	222	11	patients	patient	NOUN
aji-153	222	12	[	[	X
aji-153	222	13	9	9	NUM
aji-153	222	14	]	]	PUNCT
aji-153	222	15	.	.	PUNCT
aji-153	223	1	absolute	absolute	ADJ
aji-153	223	2	iron	iron	NOUN
aji-153	223	3	deficiency	deficiency	NOUN
aji-153	223	4	is	be	AUX
aji-153	223	5	defined	define	VERB
aji-153	223	6	as	as	ADP
aji-153	223	7	substantially	substantially	ADV
aji-153	223	8	depleted	deplete	VERB
aji-153	223	9	or	or	CCONJ
aji-153	223	10	depleted	depleted	ADJ
aji-153	223	11	iron	iron	NOUN
aji-153	223	12	stores	store	NOUN
aji-153	223	13	.	.	PUNCT
aji-153	224	1	functional	functional	ADJ
aji-153	224	2	iron	iron	NOUN
aji-153	224	3	deficiency	deficiency	NOUN
aji-153	224	4	refers	refer	VERB
aji-153	224	5	to	to	ADP
aji-153	224	6	sufficient	sufficient	ADJ
aji-153	224	7	storage	storage	NOUN
aji-153	224	8	but	but	CCONJ
aji-153	224	9	insufficient	insufficient	ADJ
aji-153	224	10	availability	availability	NOUN
aji-153	224	11	of	of	ADP
aji-153	224	12	iron	iron	NOUN
aji-153	224	13	to	to	PART
aji-153	224	14	be	be	AUX
aji-153	224	15	absorbed	absorb	VERB
aji-153	224	16	into	into	ADP
aji-153	224	17	erythroid	erythroid	ADJ
aji-153	224	18	precursors	precursor	NOUN
aji-153	224	19	,	,	PUNCT
aji-153	224	20	primarily	primarily	ADV
aji-153	224	21	because	because	SCONJ
aji-153	224	22	of	of	ADP
aji-153	224	23	increased	increase	VERB
aji-153	224	24	hepcidin	hepcidin	NOUN
aji-153	224	25	levels	level	NOUN
aji-153	224	26	.	.	PUNCT
aji-153	225	1	anemia	anemia	NOUN
aji-153	225	2	in	in	ADP
aji-153	225	3	gupta	gupta	PROPN
aji-153	225	4	et	et	PROPN
aji-153	225	5	al	al	PROPN
aji-153	225	6	.	.	PROPN
aji-153	225	7	;	;	PUNCT
aji-153	225	8	asian	asian	PROPN
aji-153	225	9	j.	j.	PROPN
aji-153	225	10	immunol	immunol	PROPN
aji-153	225	11	.	.	PROPN
aji-153	225	12	,	,	PUNCT
aji-153	225	13	vol	vol	NOUN
aji-153	225	14	.	.	PROPN
aji-153	225	15	7	7	NUM
aji-153	225	16	,	,	PUNCT
aji-153	225	17	no	no	INTJ
aji-153	225	18	.	.	NOUN
aji-153	225	19	1	1	NUM
aji-153	225	20	,	,	PUNCT
aji-153	225	21	pp	pp	ADJ
aji-153	225	22	.	.	PUNCT
aji-153	226	1	302	302	NUM
aji-153	226	2	-	-	SYM
aji-153	226	3	315	315	NUM
aji-153	226	4	,	,	PUNCT
aji-153	226	5	2024	2024	NUM
aji-153	226	6	;	;	PUNCT
aji-153	226	7	article	article	NOUN
aji-153	226	8	no.aji.127402	no.aji.127402	VERB
aji-153	226	9	306	306	NUM
aji-153	226	10	patients	patient	NOUN
aji-153	226	11	with	with	ADP
aji-153	226	12	ckd	ckd	PROPN
aji-153	226	13	has	have	AUX
aji-153	226	14	been	be	AUX
aji-153	226	15	tied	tie	VERB
aji-153	226	16	to	to	ADP
aji-153	226	17	increased	increase	VERB
aji-153	226	18	morbidity	morbidity	NOUN
aji-153	226	19	and	and	CCONJ
aji-153	226	20	mortality	mortality	NOUN
aji-153	226	21	.	.	PUNCT
aji-153	227	1	the	the	DET
aji-153	227	2	association	association	NOUN
aji-153	227	3	of	of	ADP
aji-153	227	4	mortality	mortality	NOUN
aji-153	227	5	with	with	ADP
aji-153	227	6	anemia	anemia	NOUN
aji-153	227	7	may	may	AUX
aji-153	227	8	be	be	AUX
aji-153	227	9	related	relate	VERB
aji-153	227	10	to	to	ADP
aji-153	227	11	the	the	DET
aji-153	227	12	severity	severity	NOUN
aji-153	227	13	of	of	ADP
aji-153	227	14	anemia	anemia	NOUN
aji-153	227	15	.	.	PUNCT
aji-153	228	1	all	all	DET
aji-153	228	2	patients	patient	NOUN
aji-153	228	3	with	with	ADP
aji-153	228	4	ckd	ckd	PROPN
aji-153	228	5	should	should	AUX
aji-153	228	6	be	be	AUX
aji-153	228	7	assessed	assess	VERB
aji-153	228	8	for	for	ADP
aji-153	228	9	anemia	anemia	NOUN
aji-153	228	10	when	when	SCONJ
aji-153	228	11	first	first	ADV
aji-153	228	12	evaluated	evaluate	VERB
aji-153	228	13	.	.	PUNCT
aji-153	229	1	the	the	DET
aji-153	229	2	concept	concept	NOUN
aji-153	229	3	of	of	ADP
aji-153	229	4	iron	iron	NOUN
aji-153	229	5	deficiency	deficiency	NOUN
aji-153	229	6	in	in	ADP
aji-153	229	7	ckd	ckd	PROPN
aji-153	229	8	is	be	AUX
aji-153	229	9	much	much	ADV
aji-153	229	10	less	less	ADV
aji-153	229	11	similar	similar	ADJ
aji-153	229	12	to	to	ADP
aji-153	229	13	that	that	PRON
aji-153	229	14	in	in	ADP
aji-153	229	15	patients	patient	NOUN
aji-153	229	16	with	with	ADP
aji-153	229	17	normal	normal	ADJ
aji-153	229	18	renal	renal	ADJ
aji-153	229	19	function	function	NOUN
aji-153	229	20	.	.	PUNCT
aji-153	230	1	in	in	ADP
aji-153	230	2	the	the	DET
aji-153	230	3	case	case	NOUN
aji-153	230	4	of	of	ADP
aji-153	230	5	ckd	ckd	PROPN
aji-153	230	6	patients	patient	NOUN
aji-153	230	7	,	,	PUNCT
aji-153	230	8	absolute	absolute	ADJ
aji-153	230	9	iron	iron	NOUN
aji-153	230	10	deficiency	deficiency	NOUN
aji-153	230	11	is	be	AUX
aji-153	230	12	characterized	characterize	VERB
aji-153	230	13	by	by	ADP
aji-153	230	14	tsat	tsat	NOUN
aji-153	230	15	≤20	≤20	PROPN
aji-153	230	16	%	%	NOUN
aji-153	230	17	and	and	CCONJ
aji-153	230	18	a	a	DET
aji-153	230	19	serum	serum	NOUN
aji-153	230	20	ferritin	ferritin	ADJ
aji-153	230	21	concentration	concentration	NOUN
aji-153	230	22	≤100	≤100	PROPN
aji-153	230	23	ng	ng	PROPN
aji-153	230	24	/	/	SYM
aji-153	230	25	ml	ml	X
aji-153	230	26	in	in	ADP
aji-153	230	27	predialysis	predialysis	NOUN
aji-153	230	28	and	and	CCONJ
aji-153	230	29	peritoneal	peritoneal	ADJ
aji-153	230	30	dialysis	dialysis	NOUN
aji-153	230	31	patients	patient	NOUN
aji-153	230	32	and	and	CCONJ
aji-153	230	33	≤200	≤200	PROPN
aji-153	230	34	ng	ng	PROPN
aji-153	230	35	/	/	SYM
aji-153	230	36	ml	ml	X
aji-153	230	37	in	in	ADP
aji-153	230	38	hemodialysis	hemodialysis	NOUN
aji-153	230	39	patients	patient	NOUN
aji-153	231	1	[	[	X
aji-153	231	2	11	11	NUM
aji-153	231	3	]	]	PUNCT
aji-153	231	4	.	.	PUNCT
aji-153	232	1	iron	iron	NOUN
aji-153	232	2	-	-	PUNCT
aji-153	232	3	restricted	restrict	VERB
aji-153	232	4	erythropoiesis	erythropoiesis	NOUN
aji-153	232	5	,	,	PUNCT
aji-153	232	6	or	or	CCONJ
aji-153	232	7	functional	functional	ADJ
aji-153	232	8	iron	iron	NOUN
aji-153	232	9	deficiency	deficiency	NOUN
aji-153	232	10	,	,	PUNCT
aji-153	232	11	is	be	AUX
aji-153	232	12	characterized	characterize	VERB
aji-153	232	13	by	by	ADP
aji-153	232	14	tsat	tsat	NOUN
aji-153	232	15	≤20	≤20	PROPN
aji-153	232	16	%	%	NOUN
aji-153	232	17	and	and	CCONJ
aji-153	232	18	elevated	elevated	ADJ
aji-153	232	19	ferritin	ferritin	ADJ
aji-153	232	20	.	.	PUNCT
aji-153	233	1	iron	iron	NOUN
aji-153	233	2	supplementation	supplementation	NOUN
aji-153	233	3	is	be	AUX
aji-153	233	4	provided	provide	VERB
aji-153	233	5	to	to	ADP
aji-153	233	6	all	all	DET
aji-153	233	7	ckd	ckd	NOUN
aji-153	233	8	patients	patient	NOUN
aji-153	233	9	who	who	PRON
aji-153	233	10	have	have	VERB
aji-153	233	11	anemia	anemia	NOUN
aji-153	233	12	.	.	PUNCT
aji-153	234	1	furthermore	furthermore	ADV
aji-153	234	2	,	,	PUNCT
aji-153	234	3	the	the	DET
aji-153	234	4	overwhelming	overwhelming	ADJ
aji-153	234	5	majority	majority	NOUN
aji-153	234	6	of	of	ADP
aji-153	234	7	patients	patient	NOUN
aji-153	234	8	do	do	AUX
aji-153	234	9	not	not	PART
aji-153	234	10	attain	attain	VERB
aji-153	234	11	optimal	optimal	ADJ
aji-153	234	12	responses	response	NOUN
aji-153	234	13	to	to	ADP
aji-153	234	14	esas	esa	NOUN
aji-153	234	15	.	.	PUNCT
aji-153	235	1	to	to	PART
aji-153	235	2	overcome	overcome	VERB
aji-153	235	3	these	these	DET
aji-153	235	4	barriers	barrier	NOUN
aji-153	235	5	,	,	PUNCT
aji-153	235	6	hif	hif	PROPN
aji-153	235	7	-	-	PUNCT
aji-153	235	8	phis	phis	PROPN
aji-153	235	9	have	have	AUX
aji-153	235	10	been	be	AUX
aji-153	235	11	created	create	VERB
aji-153	235	12	as	as	ADP
aji-153	235	13	oral	oral	ADJ
aji-153	235	14	agents	agent	NOUN
aji-153	235	15	in	in	ADP
aji-153	235	16	the	the	DET
aji-153	235	17	treatment	treatment	NOUN
aji-153	235	18	of	of	ADP
aji-153	235	19	anemia	anemia	NOUN
aji-153	235	20	in	in	ADP
aji-153	235	21	ckd.they	ckd.they	X
aji-153	235	22	mimic	mimic	VERB
aji-153	235	23	the	the	DET
aji-153	235	24	body	body	NOUN
aji-153	235	25	's	's	PART
aji-153	235	26	exposure	exposure	NOUN
aji-153	235	27	to	to	ADP
aji-153	235	28	moderate	moderate	ADJ
aji-153	235	29	hypoxia	hypoxia	NOUN
aji-153	235	30	,	,	PUNCT
aji-153	235	31	thereby	thereby	ADV
aji-153	235	32	stimulating	stimulate	VERB
aji-153	235	33	endogenous	endogenous	ADJ
aji-153	235	34	erythropoietin	erythropoietin	NOUN
aji-153	235	35	production	production	NOUN
aji-153	235	36	.	.	PUNCT
aji-153	236	1	some	some	PRON
aji-153	236	2	of	of	ADP
aji-153	236	3	these	these	DET
aji-153	236	4	agents	agent	NOUN
aji-153	236	5	are	be	AUX
aji-153	236	6	already	already	ADV
aji-153	236	7	approved	approve	VERB
aji-153	236	8	for	for	ADP
aji-153	236	9	clinical	clinical	ADJ
aji-153	236	10	use	use	NOUN
aji-153	236	11	in	in	ADP
aji-153	236	12	specific	specific	ADJ
aji-153	236	13	countries	country	NOUN
aji-153	236	14	.	.	PUNCT
aji-153	237	1	clinical	clinical	ADJ
aji-153	237	2	trial	trial	NOUN
aji-153	237	3	data	datum	NOUN
aji-153	237	4	show	show	VERB
aji-153	237	5	noninferiority	noninferiority	NOUN
aji-153	237	6	compared	compare	VERB
aji-153	237	7	with	with	ADP
aji-153	237	8	esas	esa	NOUN
aji-153	237	9	and	and	CCONJ
aji-153	237	10	superiority	superiority	NOUN
aji-153	237	11	to	to	PART
aji-153	237	12	placebo	placebo	NOUN
aji-153	237	13	for	for	ADP
aji-153	237	14	the	the	DET
aji-153	237	15	correction	correction	NOUN
aji-153	237	16	of	of	ADP
aji-153	237	17	anemia	anemia	NOUN
aji-153	237	18	.	.	PUNCT
aji-153	238	1	hif	hif	PROPN
aji-153	238	2	prolyl	prolyl	PROPN
aji-153	238	3	hydroxylase	hydroxylase	PROPN
aji-153	238	4	domain	domain	NOUN
aji-153	238	5	inhibitors	inhibitor	NOUN
aji-153	238	6	could	could	AUX
aji-153	238	7	offer	offer	VERB
aji-153	238	8	patients	patient	NOUN
aji-153	238	9	with	with	ADP
aji-153	238	10	inflammation	inflammation	NOUN
aji-153	238	11	another	another	DET
aji-153	238	12	advantage	advantage	NOUN
aji-153	238	13	:	:	PUNCT
aji-153	238	14	enhancing	enhance	VERB
aji-153	238	15	iron	iron	NOUN
aji-153	238	16	use	use	NOUN
aji-153	238	17	and	and	CCONJ
aji-153	238	18	mobilization	mobilization	NOUN
aji-153	238	19	as	as	ADV
aji-153	238	20	well	well	ADV
aji-153	238	21	as	as	ADP
aji-153	238	22	reducing	reduce	VERB
aji-153	238	23	ldl	ldl	NOUN
aji-153	238	24	cholesterol	cholesterol	NOUN
aji-153	238	25	levels	level	NOUN
aji-153	238	26	.	.	PUNCT
aji-153	239	1	overall	overall	ADJ
aji-153	239	2	,	,	PUNCT
aji-153	239	3	non	non	ADJ
aji-153	239	4	-	-	ADJ
aji-153	239	5	inferiority	inferiority	NOUN
aji-153	239	6	was	be	AUX
aji-153	239	7	also	also	ADV
aji-153	239	8	established	establish	VERB
aji-153	239	9	for	for	ADP
aji-153	239	10	major	major	ADJ
aji-153	239	11	cardiovascular	cardiovascular	ADJ
aji-153	239	12	events	event	NOUN
aji-153	239	13	except	except	SCONJ
aji-153	239	14	in	in	ADP
aji-153	239	15	one	one	NUM
aji-153	239	16	molecule	molecule	NOUN
aji-153	239	17	in	in	ADP
aji-153	239	18	the	the	DET
aji-153	239	19	population	population	NOUN
aji-153	239	20	of	of	ADP
aji-153	239	21	non	non	ADJ
aji-153	239	22	-	-	NOUN
aji-153	239	23	dialysis	dialysis	NOUN
aji-153	239	24	.	.	PUNCT
aji-153	240	1	such	such	DET
aji-153	240	2	a	a	DET
aji-153	240	3	finding	finding	NOUN
aji-153	240	4	is	be	AUX
aji-153	240	5	rather	rather	ADV
aji-153	240	6	an	an	DET
aji-153	240	7	unexpected	unexpected	ADJ
aji-153	240	8	given	give	VERB
aji-153	240	9	that	that	SCONJ
aji-153	240	10	,	,	PUNCT
aji-153	240	11	based	base	VERB
aji-153	240	12	on	on	ADP
aji-153	240	13	their	their	PRON
aji-153	240	14	mechanism	mechanism	NOUN
aji-153	240	15	of	of	ADP
aji-153	240	16	action	action	NOUN
aji-153	240	17	,	,	PUNCT
aji-153	240	18	these	these	DET
aji-153	240	19	drugs	drug	NOUN
aji-153	240	20	have	have	VERB
aji-153	240	21	low	low	ADJ
aji-153	240	22	levels	level	NOUN
aji-153	240	23	of	of	ADP
aji-153	240	24	erythropoietin	erythropoietin	NOUN
aji-153	240	25	.	.	PUNCT
aji-153	241	1	more	more	ADJ
aji-153	241	2	data	datum	NOUN
aji-153	241	3	and	and	CCONJ
aji-153	241	4	longer	long	ADV
aji-153	241	5	follow	follow	VERB
aji-153	241	6	-	-	PUNCT
aji-153	241	7	up	up	NOUN
aji-153	241	8	are	be	AUX
aji-153	241	9	needed	need	VERB
aji-153	241	10	to	to	PART
aji-153	241	11	clarify	clarify	VERB
aji-153	241	12	safety	safety	NOUN
aji-153	241	13	issues	issue	NOUN
aji-153	241	14	and	and	CCONJ
aji-153	241	15	further	far	ADV
aji-153	241	16	explore	explore	VERB
aji-153	241	17	the	the	DET
aji-153	241	18	diversity	diversity	NOUN
aji-153	241	19	of	of	ADP
aji-153	241	20	signaling	signal	VERB
aji-153	241	21	pathways	pathway	NOUN
aji-153	241	22	activated	activate	VERB
aji-153	241	23	by	by	ADP
aji-153	241	24	hif	hif	PROPN
aji-153	241	25	that	that	PRON
aji-153	241	26	may	may	AUX
aji-153	241	27	have	have	VERB
aji-153	241	28	positive	positive	ADJ
aji-153	241	29	or	or	CCONJ
aji-153	241	30	negative	negative	ADJ
aji-153	241	31	effects	effect	NOUN
aji-153	241	32	and	and	CCONJ
aji-153	241	33	distinguish	distinguish	VERB
aji-153	241	34	hif	hif	PROPN
aji-153	241	35	-	-	PUNCT
aji-153	241	36	phis	phis	NOUN
aji-153	241	37	from	from	ADP
aji-153	241	38	esas	esa	NOUN
aji-153	241	39	[	[	X
aji-153	241	40	12	12	NUM
aji-153	241	41	]	]	PUNCT
aji-153	241	42	.	.	PUNCT
aji-153	242	1	2	2	X
aji-153	242	2	.	.	X
aji-153	242	3	mechanism	mechanism	NOUN
aji-153	242	4	of	of	ADP
aji-153	242	5	action	action	NOUN
aji-153	242	6	of	of	ADP
aji-153	242	7	vadadustat	vadadustat	NOUN
aji-153	242	8	2.1	2.1	NUM
aji-153	242	9	hif	hif	NOUN
aji-153	242	10	-	-	PUNCT
aji-153	242	11	ph	ph	ADJ
aji-153	242	12	inhibition	inhibition	NOUN
aji-153	242	13	“	"	PUNCT
aji-153	242	14	the	the	DET
aji-153	242	15	hif	hif	PROPN
aji-153	242	16	system	system	NOUN
aji-153	242	17	elicits	elicit	VERB
aji-153	242	18	an	an	DET
aji-153	242	19	adaptive	adaptive	ADJ
aji-153	242	20	response	response	NOUN
aji-153	242	21	to	to	ADP
aji-153	242	22	tissue	tissue	NOUN
aji-153	242	23	hypoxia	hypoxia	NOUN
aji-153	242	24	in	in	ADP
aji-153	242	25	order	order	NOUN
aji-153	242	26	to	to	PART
aji-153	242	27	prevent	prevent	VERB
aji-153	242	28	cell	cell	NOUN
aji-153	242	29	damage	damage	NOUN
aji-153	242	30	by	by	ADP
aji-153	242	31	optimizing	optimize	VERB
aji-153	242	32	oxygen	oxygen	NOUN
aji-153	242	33	delivery	delivery	NOUN
aji-153	242	34	and	and	CCONJ
aji-153	242	35	reducing	reduce	VERB
aji-153	242	36	tissue	tissue	NOUN
aji-153	242	37	oxygen	oxygen	NOUN
aji-153	242	38	utilization	utilization	NOUN
aji-153	242	39	which	which	PRON
aji-153	242	40	causes	cause	VERB
aji-153	242	41	the	the	DET
aji-153	242	42	production	production	NOUN
aji-153	242	43	of	of	ADP
aji-153	242	44	epo	epo	NOUN
aji-153	242	45	,	,	PUNCT
aji-153	242	46	primarily	primarily	ADV
aji-153	242	47	by	by	ADP
aji-153	242	48	interstitial	interstitial	ADJ
aji-153	242	49	perinephric	perinephric	ADJ
aji-153	242	50	cells	cell	NOUN
aji-153	242	51	of	of	ADP
aji-153	242	52	the	the	DET
aji-153	242	53	kidney	kidney	NOUN
aji-153	242	54	and	and	CCONJ
aji-153	242	55	by	by	ADP
aji-153	242	56	cells	cell	NOUN
aji-153	242	57	in	in	ADP
aji-153	242	58	the	the	DET
aji-153	242	59	liver	liver	NOUN
aji-153	242	60	.	.	PUNCT
aji-153	243	1	epo	epo	PROPN
aji-153	243	2	binds	bind	VERB
aji-153	243	3	to	to	ADP
aji-153	243	4	its	its	PRON
aji-153	243	5	receptor	receptor	NOUN
aji-153	243	6	on	on	ADP
aji-153	243	7	the	the	DET
aji-153	243	8	surface	surface	NOUN
aji-153	243	9	of	of	ADP
aji-153	243	10	erythroid	erythroid	ADJ
aji-153	243	11	progenitor	progenitor	NOUN
aji-153	243	12	cells	cell	NOUN
aji-153	243	13	in	in	ADP
aji-153	243	14	the	the	DET
aji-153	243	15	bone	bone	NOUN
aji-153	243	16	marrow	marrow	NOUN
aji-153	243	17	,	,	PUNCT
aji-153	243	18	thus	thus	ADV
aji-153	243	19	enhancing	enhance	VERB
aji-153	243	20	the	the	DET
aji-153	243	21	survival	survival	NOUN
aji-153	243	22	,	,	PUNCT
aji-153	243	23	maturation	maturation	NOUN
aji-153	243	24	,	,	PUNCT
aji-153	243	25	and	and	CCONJ
aji-153	243	26	proliferation	proliferation	NOUN
aji-153	243	27	of	of	ADP
aji-153	243	28	red	red	ADJ
aji-153	243	29	blood	blood	NOUN
aji-153	243	30	cells	cell	NOUN
aji-153	243	31	.	.	PUNCT
aji-153	244	1	the	the	DET
aji-153	244	2	activity	activity	NOUN
aji-153	244	3	of	of	ADP
aji-153	244	4	the	the	DET
aji-153	244	5	hif	hif	PROPN
aji-153	244	6	system	system	NOUN
aji-153	244	7	varies	vary	VERB
aji-153	244	8	according	accord	VERB
aji-153	244	9	to	to	ADP
aji-153	244	10	tissue	tissue	NOUN
aji-153	244	11	oxygenation	oxygenation	NOUN
aji-153	244	12	”	"	PUNCT
aji-153	244	13	.	.	PUNCT
aji-153	245	1	fig	fig	NOUN
aji-153	245	2	.	.	PUNCT
aji-153	246	1	1	1	NUM
aji-153	246	2	.	.	X
aji-153	246	3	hypoxia	hypoxia	NOUN
aji-153	246	4	-	-	PUNCT
aji-153	246	5	inducible	inducible	ADJ
aji-153	246	6	factor	factor	NOUN
aji-153	246	7	(	(	PUNCT
aji-153	246	8	hif	hif	PROPN
aji-153	246	9	)	)	PUNCT
aji-153	246	10	system	system	NOUN
aji-153	246	11	.	.	PUNCT
aji-153	247	1	ph	ph	VERB
aji-153	247	2	—	—	PUNCT
aji-153	247	3	prolyl	prolyl	ADJ
aji-153	247	4	hydroxylase	hydroxylase	NOUN
aji-153	247	5	,	,	PUNCT
aji-153	247	6	pvhl	pvhl	PROPN
aji-153	247	7	—	—	PUNCT
aji-153	247	8	von	von	PROPN
aji-153	247	9	hippel−lindau	hippel−lindau	NOUN
aji-153	247	10	protein	protein	NOUN
aji-153	247	11	,	,	PUNCT
aji-153	247	12	hre	hre	ADJ
aji-153	247	13	—	—	PUNCT
aji-153	247	14	hypoxia	hypoxia	NOUN
aji-153	247	15	-	-	PUNCT
aji-153	247	16	responsive	responsive	ADJ
aji-153	247	17	element	element	NOUN
aji-153	247	18	,	,	PUNCT
aji-153	247	19	epo	epo	NOUN
aji-153	247	20	—	—	PUNCT
aji-153	247	21	erythropoietin	erythropoietin	PROPN
aji-153	247	22	,	,	PUNCT
aji-153	247	23	vegf	vegf	NOUN
aji-153	247	24	—	—	PUNCT
aji-153	247	25	vascular	vascular	ADJ
aji-153	247	26	endothelial	endothelial	ADJ
aji-153	247	27	growth	growth	NOUN
aji-153	247	28	factor	factor	NOUN
aji-153	247	29	gupta	gupta	PROPN
aji-153	247	30	et	et	PROPN
aji-153	247	31	al	al	PROPN
aji-153	247	32	.	.	PROPN
aji-153	247	33	;	;	PUNCT
aji-153	247	34	asian	asian	PROPN
aji-153	247	35	j.	j.	PROPN
aji-153	247	36	immunol	immunol	PROPN
aji-153	247	37	.	.	PROPN
aji-153	247	38	,	,	PUNCT
aji-153	247	39	vol	vol	NOUN
aji-153	247	40	.	.	PROPN
aji-153	247	41	7	7	NUM
aji-153	247	42	,	,	PUNCT
aji-153	247	43	no	no	INTJ
aji-153	247	44	.	.	NOUN
aji-153	247	45	1	1	NUM
aji-153	247	46	,	,	PUNCT
aji-153	247	47	pp	pp	ADJ
aji-153	247	48	.	.	PUNCT
aji-153	248	1	302	302	NUM
aji-153	248	2	-	-	SYM
aji-153	248	3	315	315	NUM
aji-153	248	4	,	,	PUNCT
aji-153	248	5	2024	2024	NUM
aji-153	248	6	;	;	PUNCT
aji-153	248	7	article	article	NOUN
aji-153	248	8	no.aji.127402	no.aji.127402	VERB
aji-153	248	9	307	307	NUM
aji-153	248	10	fig	fig	NOUN
aji-153	248	11	.	.	PUNCT
aji-153	249	1	2	2	NUM
aji-153	249	2	.	.	X
aji-153	249	3	schematic	schematic	ADJ
aji-153	249	4	overview	overview	NOUN
aji-153	249	5	of	of	ADP
aji-153	249	6	the	the	DET
aji-153	249	7	phd	phd	NOUN
aji-153	249	8	/	/	SYM
aji-153	249	9	hypoxia	hypoxia	NOUN
aji-153	249	10	-	-	PUNCT
aji-153	249	11	inducible	inducible	ADJ
aji-153	249	12	factor	factor	NOUN
aji-153	249	13	(	(	PUNCT
aji-153	249	14	hif	hif	PROPN
aji-153	249	15	)	)	PUNCT
aji-153	249	16	pathway	pathway	NOUN
aji-153	249	17	“	"	PUNCT
aji-153	249	18	the	the	DET
aji-153	249	19	hif	hif	PROPN
aji-153	249	20	system	system	NOUN
aji-153	249	21	consists	consist	VERB
aji-153	249	22	of	of	ADP
aji-153	249	23	subunits	subunit	NOUN
aji-153	249	24	α	α	NOUN
aji-153	249	25	and	and	CCONJ
aji-153	249	26	β	β	X
aji-153	249	27	.	.	PUNCT
aji-153	250	1	hif-1α	hif-1α	NOUN
aji-153	250	2	accumulates	accumulate	VERB
aji-153	250	3	and	and	CCONJ
aji-153	250	4	translocates	translocate	NOUN
aji-153	250	5	to	to	ADP
aji-153	250	6	the	the	DET
aji-153	250	7	nucleus	nucleus	NOUN
aji-153	250	8	of	of	ADP
aji-153	250	9	a	a	DET
aji-153	250	10	cell	cell	NOUN
aji-153	250	11	where	where	SCONJ
aji-153	250	12	it	it	PRON
aji-153	250	13	binds	bind	VERB
aji-153	250	14	to	to	ADP
aji-153	250	15	hif	hif	PROPN
aji-153	250	16	-	-	PUNCT
aji-153	250	17	β	β	PROPN
aji-153	250	18	and	and	CCONJ
aji-153	250	19	leads	lead	VERB
aji-153	250	20	to	to	ADP
aji-153	250	21	the	the	DET
aji-153	250	22	synthesis	synthesis	NOUN
aji-153	250	23	of	of	ADP
aji-153	250	24	the	the	DET
aji-153	250	25	heterodimer	heterodimer	NOUN
aji-153	250	26	hif1αβ	hif1αβ	PROPN
aji-153	250	27	.	.	PUNCT
aji-153	251	1	the	the	DET
aji-153	251	2	heterodimer	heterodimer	PROPN
aji-153	251	3	hif-1αβ	hif-1αβ	PROPN
aji-153	251	4	leads	lead	VERB
aji-153	251	5	to	to	ADP
aji-153	251	6	the	the	DET
aji-153	251	7	expression	expression	NOUN
aji-153	251	8	of	of	ADP
aji-153	251	9	various	various	ADJ
aji-153	251	10	hypoxia	hypoxia	NOUN
aji-153	251	11	-	-	PUNCT
aji-153	251	12	inducible	inducible	ADJ
aji-153	251	13	genes	gene	NOUN
aji-153	251	14	,	,	PUNCT
aji-153	251	15	such	such	ADJ
aji-153	251	16	as	as	ADP
aji-153	251	17	the	the	DET
aji-153	251	18	gene	gene	NOUN
aji-153	251	19	for	for	ADP
aji-153	251	20	epo	epo	NOUN
aji-153	251	21	,	,	PUNCT
aji-153	251	22	thereby	thereby	ADV
aji-153	251	23	enhancing	enhance	VERB
aji-153	251	24	its	its	PRON
aji-153	251	25	rate	rate	NOUN
aji-153	251	26	of	of	ADP
aji-153	251	27	production	production	NOUN
aji-153	251	28	.	.	PUNCT
aji-153	252	1	there	there	PRON
aji-153	252	2	are	be	VERB
aji-153	252	3	three	three	NUM
aji-153	252	4	isoforms	isoform	NOUN
aji-153	252	5	of	of	ADP
aji-153	252	6	the	the	DET
aji-153	252	7	subunit	subunit	NOUN
aji-153	252	8	hif	hif	PROPN
aji-153	252	9	-	-	PUNCT
aji-153	252	10	α	α	PROPN
aji-153	252	11	:	:	PUNCT
aji-153	252	12	hif-1α	hif-1α	NOUN
aji-153	252	13	,	,	PUNCT
aji-153	252	14	hif-2α	hif-2α	NOUN
aji-153	252	15	,	,	PUNCT
aji-153	252	16	and	and	CCONJ
aji-153	252	17	hif-3α	hif-3α	NOUN
aji-153	252	18	,	,	PUNCT
aji-153	252	19	which	which	PRON
aji-153	252	20	all	all	PRON
aji-153	252	21	can	can	AUX
aji-153	252	22	dimerize	dimerize	VERB
aji-153	252	23	with	with	ADP
aji-153	252	24	hif	hif	PROPN
aji-153	252	25	-	-	PUNCT
aji-153	252	26	β	β	PROPN
aji-153	252	27	and	and	CCONJ
aji-153	252	28	stimulate	stimulate	VERB
aji-153	252	29	the	the	DET
aji-153	252	30	expression	expression	NOUN
aji-153	252	31	of	of	ADP
aji-153	252	32	many	many	ADJ
aji-153	252	33	genes	gene	NOUN
aji-153	252	34	other	other	ADJ
aji-153	252	35	than	than	ADP
aji-153	252	36	the	the	DET
aji-153	252	37	epo	epo	NOUN
aji-153	252	38	gene	gene	NOUN
aji-153	252	39	.	.	PUNCT
aji-153	253	1	thus	thus	ADV
aji-153	253	2	,	,	PUNCT
aji-153	253	3	the	the	DET
aji-153	253	4	dimer	dimer	NOUN
aji-153	253	5	composed	compose	VERB
aji-153	253	6	of	of	ADP
aji-153	253	7	the	the	DET
aji-153	253	8	hif	hif	PROPN
aji-153	253	9	-	-	PUNCT
aji-153	253	10	α	α	PROPN
aji-153	253	11	and	and	CCONJ
aji-153	253	12	hif	hif	PROPN
aji-153	253	13	-	-	PUNCT
aji-153	253	14	β	β	PROPN
aji-153	253	15	subunits	subunit	NOUN
aji-153	253	16	controls	control	VERB
aji-153	253	17	the	the	DET
aji-153	253	18	expression	expression	NOUN
aji-153	253	19	of	of	ADP
aji-153	253	20	transferrin	transferrin	NOUN
aji-153	253	21	receptors	receptor	NOUN
aji-153	253	22	,	,	PUNCT
aji-153	253	23	vegf	vegf	PROPN
aji-153	253	24	,	,	PUNCT
aji-153	253	25	and	and	CCONJ
aji-153	253	26	endothelin-1	endothelin-1	NUM
aji-153	253	27	receptors	receptor	NOUN
aji-153	253	28	”	"	PUNCT
aji-153	254	1	[	[	X
aji-153	254	2	13	13	NUM
aji-153	254	3	]	]	PUNCT
aji-153	254	4	.	.	PUNCT
aji-153	255	1	in	in	ADP
aji-153	255	2	addition	addition	NOUN
aji-153	255	3	,	,	PUNCT
aji-153	255	4	it	it	PRON
aji-153	255	5	has	have	AUX
aji-153	255	6	been	be	AUX
aji-153	255	7	postulated	postulate	VERB
aji-153	255	8	that	that	SCONJ
aji-153	255	9	the	the	DET
aji-153	255	10	hif	hif	PROPN
aji-153	255	11	system	system	NOUN
aji-153	255	12	is	be	AUX
aji-153	255	13	somehow	somehow	ADV
aji-153	255	14	involved	involve	VERB
aji-153	255	15	in	in	ADP
aji-153	255	16	the	the	DET
aji-153	255	17	control	control	NOUN
aji-153	255	18	of	of	ADP
aji-153	255	19	cell	cell	NOUN
aji-153	255	20	metabolism	metabolism	NOUN
aji-153	255	21	and	and	CCONJ
aji-153	255	22	activity	activity	NOUN
aji-153	255	23	,	,	PUNCT
aji-153	255	24	including	include	VERB
aji-153	255	25	immune	immune	ADJ
aji-153	255	26	cells	cell	NOUN
aji-153	255	27	,	,	PUNCT
aji-153	255	28	and	and	CCONJ
aji-153	255	29	affects	affect	VERB
aji-153	255	30	the	the	DET
aji-153	255	31	total	total	ADJ
aji-153	255	32	cholesterol	cholesterol	NOUN
aji-153	255	33	and	and	CCONJ
aji-153	255	34	ldl	ldl	NOUN
aji-153	255	35	fraction	fraction	NOUN
aji-153	255	36	.	.	PUNCT
aji-153	256	1	the	the	DET
aji-153	256	2	hif	hif	PROPN
aji-153	256	3	system	system	NOUN
aji-153	256	4	is	be	AUX
aji-153	256	5	nearly	nearly	ADV
aji-153	256	6	ubiquitous	ubiquitous	ADJ
aji-153	256	7	:	:	PUNCT
aji-153	256	8	the	the	DET
aji-153	256	9	transcription	transcription	NOUN
aji-153	256	10	factor	factor	NOUN
aji-153	256	11	hif-1α	hif-1α	NOUN
aji-153	256	12	is	be	AUX
aji-153	256	13	induced	induce	VERB
aji-153	256	14	in	in	ADP
aji-153	256	15	virtually	virtually	ADV
aji-153	256	16	all	all	PRON
aji-153	256	17	cell	cell	NOUN
aji-153	256	18	types	type	NOUN
aji-153	256	19	whereas	whereas	SCONJ
aji-153	256	20	hif-2α	hif-2α	NOUN
aji-153	256	21	is	be	AUX
aji-153	256	22	expressed	express	VERB
aji-153	256	23	in	in	ADP
aji-153	256	24	a	a	DET
aji-153	256	25	more	more	ADV
aji-153	256	26	tissue	tissue	NOUN
aji-153	256	27	-	-	PUNCT
aji-153	256	28	restricted	restrict	VERB
aji-153	256	29	manner	manner	NOUN
aji-153	256	30	.	.	PUNCT
aji-153	257	1	“	"	PUNCT
aji-153	257	2	mrna	mrna	PROPN
aji-153	257	3	expression	expression	NOUN
aji-153	257	4	of	of	ADP
aji-153	257	5	hif-2α	hif-2α	NOUN
aji-153	257	6	is	be	AUX
aji-153	257	7	mainly	mainly	ADV
aji-153	257	8	detected	detect	VERB
aji-153	257	9	in	in	ADP
aji-153	257	10	the	the	DET
aji-153	257	11	brain	brain	NOUN
aji-153	257	12	,	,	PUNCT
aji-153	257	13	heart	heart	NOUN
aji-153	257	14	,	,	PUNCT
aji-153	257	15	lung	lung	NOUN
aji-153	257	16	,	,	PUNCT
aji-153	257	17	kidney	kidney	NOUN
aji-153	257	18	,	,	PUNCT
aji-153	257	19	pancreas	pancrea	NOUN
aji-153	257	20	,	,	PUNCT
aji-153	257	21	and	and	CCONJ
aji-153	257	22	intestine	intestine	NOUN
aji-153	257	23	.	.	PUNCT
aji-153	258	1	hif-3α	hif-3α	NOUN
aji-153	258	2	tissue	tissue	NOUN
aji-153	258	3	expression	expression	NOUN
aji-153	258	4	was	be	AUX
aji-153	258	5	observed	observe	VERB
aji-153	258	6	in	in	ADP
aji-153	258	7	the	the	DET
aji-153	258	8	heart	heart	NOUN
aji-153	258	9	,	,	PUNCT
aji-153	258	10	lungs	lung	NOUN
aji-153	258	11	,	,	PUNCT
aji-153	258	12	and	and	CCONJ
aji-153	258	13	kidneys	kidney	NOUN
aji-153	258	14	.	.	PUNCT
aji-153	259	1	normoxic	normoxic	ADJ
aji-153	259	2	tissue	tissue	NOUN
aji-153	259	3	oxygenation	oxygenation	NOUN
aji-153	259	4	leads	lead	VERB
aji-153	259	5	to	to	ADP
aji-153	259	6	the	the	DET
aji-153	259	7	degradation	degradation	NOUN
aji-153	259	8	of	of	ADP
aji-153	259	9	hif-1α	hif-1α	NOUN
aji-153	259	10	through	through	ADP
aji-153	259	11	its	its	PRON
aji-153	259	12	hydroxylation	hydroxylation	NOUN
aji-153	259	13	via	via	ADP
aji-153	259	14	prolyl	prolyl	PROPN
aji-153	259	15	hydroxylase	hydroxylase	PROPN
aji-153	259	16	(	(	PUNCT
aji-153	259	17	ph	ph	PROPN
aji-153	259	18	)	)	PUNCT
aji-153	259	19	with	with	ADP
aji-153	259	20	the	the	DET
aji-153	259	21	von	von	PROPN
aji-153	259	22	hippellindau	hippellindau	NOUN
aji-153	259	23	protein	protein	NOUN
aji-153	259	24	(	(	PUNCT
aji-153	259	25	pvhl	pvhl	NOUN
aji-153	259	26	)	)	PUNCT
aji-153	259	27	thereby	thereby	ADV
aji-153	259	28	preventing	prevent	VERB
aji-153	259	29	dimerization	dimerization	NOUN
aji-153	259	30	between	between	ADP
aji-153	259	31	hif-1α	hif-1α	NOUN
aji-153	259	32	and	and	CCONJ
aji-153	259	33	hif	hif	PROPN
aji-153	259	34	-	-	PROPN
aji-153	259	35	β	β	PROPN
aji-153	259	36	at	at	ADP
aji-153	259	37	a	a	DET
aji-153	259	38	lower	low	ADJ
aji-153	259	39	level	level	NOUN
aji-153	259	40	of	of	ADP
aji-153	259	41	gene	gene	NOUN
aji-153	259	42	expression	expression	NOUN
aji-153	259	43	that	that	PRON
aji-153	259	44	encodes	encode	VERB
aji-153	259	45	epo	epo	NOUN
aji-153	259	46	.	.	PUNCT
aji-153	260	1	under	under	ADP
aji-153	260	2	hypoxia	hypoxia	NOUN
aji-153	260	3	,	,	PUNCT
aji-153	260	4	ph	ph	NOUN
aji-153	260	5	is	be	AUX
aji-153	260	6	inhibited	inhibit	VERB
aji-153	260	7	and	and	CCONJ
aji-153	260	8	hif-1α	hif-1α	NOUN
aji-153	260	9	does	do	AUX
aji-153	260	10	not	not	PART
aji-153	260	11	undergo	undergo	VERB
aji-153	260	12	degradation	degradation	NOUN
aji-153	260	13	,	,	PUNCT
aji-153	260	14	and	and	CCONJ
aji-153	260	15	there	there	PRON
aji-153	260	16	is	be	VERB
aji-153	260	17	possibility	possibility	NOUN
aji-153	260	18	of	of	ADP
aji-153	260	19	combination	combination	NOUN
aji-153	260	20	to	to	PART
aji-153	260	21	produce	produce	VERB
aji-153	260	22	the	the	DET
aji-153	260	23	heterodimer	heterodimer	NOUN
aji-153	260	24	hif-1αβ	hif-1αβ	PROPN
aji-153	260	25	,	,	PUNCT
aji-153	260	26	which	which	PRON
aji-153	260	27	activates	activate	VERB
aji-153	260	28	the	the	DET
aji-153	260	29	gene	gene	NOUN
aji-153	260	30	in	in	ADP
aji-153	260	31	charge	charge	NOUN
aji-153	260	32	of	of	ADP
aji-153	260	33	epo	epo	NOUN
aji-153	260	34	synthesis	synthesis	NOUN
aji-153	260	35	.	.	PUNCT
aji-153	261	1	inhibition	inhibition	NOUN
aji-153	261	2	of	of	ADP
aji-153	261	3	ph	ph	ADJ
aji-153	261	4	corresponds	correspond	NOUN
aji-153	261	5	to	to	ADP
aji-153	261	6	the	the	DET
aji-153	261	7	site	site	NOUN
aji-153	261	8	of	of	ADP
aji-153	261	9	action	action	NOUN
aji-153	261	10	for	for	ADP
aji-153	261	11	a	a	DET
aji-153	261	12	class	class	NOUN
aji-153	261	13	of	of	ADP
aji-153	261	14	drugs	drug	NOUN
aji-153	261	15	hif	hif	PROPN
aji-153	261	16	-	-	PUNCT
aji-153	261	17	phis	phis	NOUN
aji-153	261	18	,	,	PUNCT
aji-153	261	19	used	use	VERB
aji-153	261	20	to	to	PART
aji-153	261	21	treat	treat	VERB
aji-153	261	22	anemia	anemia	NOUN
aji-153	261	23	in	in	ADP
aji-153	261	24	patients	patient	NOUN
aji-153	261	25	with	with	ADP
aji-153	261	26	ckd	ckd	PROPN
aji-153	261	27	”	"	PUNCT
aji-153	262	1	[	[	X
aji-153	262	2	14	14	NUM
aji-153	262	3	]	]	PUNCT
aji-153	262	4	.	.	PUNCT
aji-153	263	1	2.2	2.2	NUM
aji-153	263	2	the	the	DET
aji-153	263	3	phd	phd	PROPN
aji-153	263	4	/	/	SYM
aji-153	263	5	hif	hif	PROPN
aji-153	263	6	oxygen	oxygen	NOUN
aji-153	263	7	-	-	PUNCT
aji-153	263	8	sensing	sense	VERB
aji-153	263	9	pathway	pathway	NOUN
aji-153	263	10	“	"	PUNCT
aji-153	263	11	hif	hif	PROPN
aji-153	263	12	-	-	PUNCT
aji-153	263	13	α	α	PROPN
aji-153	263	14	is	be	AUX
aji-153	263	15	rapidly	rapidly	ADV
aji-153	263	16	degraded	degrade	VERB
aji-153	263	17	under	under	ADP
aji-153	263	18	normoxic	normoxic	ADJ
aji-153	263	19	conditions	condition	NOUN
aji-153	263	20	through	through	ADP
aji-153	263	21	the	the	DET
aji-153	263	22	hydroxylation	hydroxylation	NOUN
aji-153	263	23	of	of	ADP
aji-153	263	24	certain	certain	ADJ
aji-153	263	25	proline	proline	NOUN
aji-153	263	26	residues	residue	NOUN
aji-153	263	27	.	.	PUNCT
aji-153	264	1	hydroxylated	hydroxylate	VERB
aji-153	264	2	hif	hif	PROPN
aji-153	264	3	-	-	PUNCT
aji-153	264	4	α	α	PROPN
aji-153	264	5	is	be	AUX
aji-153	264	6	tagged	tag	VERB
aji-153	264	7	for	for	ADP
aji-153	264	8	proteasomal	proteasomal	ADJ
aji-153	264	9	degradation	degradation	NOUN
aji-153	264	10	by	by	ADP
aji-153	264	11	the	the	DET
aji-153	264	12	von	von	PROPN
aji-153	264	13	hippellindau	hippellindau	PROPN
aji-153	264	14	(	(	PUNCT
aji-153	264	15	vhl	vhl	NOUN
aji-153	264	16	)	)	PUNCT
aji-153	264	17	tumor	tumor	NOUN
aji-153	264	18	hifs	hif	NOUN
aji-153	264	19	are	be	AUX
aji-153	264	20	basic	basic	ADJ
aji-153	264	21	pleiotropic	pleiotropic	ADJ
aji-153	264	22	helix	helix	NOUN
aji-153	264	23	-	-	PUNCT
aji-153	264	24	loop	loop	NOUN
aji-153	264	25	-	-	PUNCT
aji-153	264	26	helix	helix	NOUN
aji-153	264	27	transcription	transcription	NOUN
aji-153	264	28	factors	factor	NOUN
aji-153	264	29	that	that	PRON
aji-153	264	30	belong	belong	VERB
aji-153	264	31	to	to	ADP
aji-153	264	32	the	the	DET
aji-153	264	33	pas	pas	NOUN
aji-153	264	34	(	(	PUNCT
aji-153	264	35	per	per	ADP
aji-153	264	36	/	/	SYM
aji-153	264	37	aryl	aryl	NOUN
aji-153	264	38	hydrocarbon	hydrocarbon	NOUN
aji-153	264	39	receptor	receptor	NOUN
aji-153	264	40	nuclear	nuclear	ADJ
aji-153	264	41	translocator	translocator	NOUN
aji-153	264	42	[	[	X
aji-153	264	43	arnt]/single	arnt]/single	ADV
aji-153	264	44	minded	minded	ADJ
aji-153	264	45	)	)	PUNCT
aji-153	264	46	family	family	NOUN
aji-153	264	47	of	of	ADP
aji-153	264	48	transcription	transcription	NOUN
aji-153	264	49	factors	factor	NOUN
aji-153	264	50	.	.	PUNCT
aji-153	265	1	they	they	PRON
aji-153	265	2	consist	consist	VERB
aji-153	265	3	of	of	ADP
aji-153	265	4	two	two	NUM
aji-153	265	5	subunits	subunit	NOUN
aji-153	265	6	,	,	PUNCT
aji-153	265	7	an	an	DET
aji-153	265	8	oxygen	oxygen	NOUN
aji-153	265	9	-	-	PUNCT
aji-153	265	10	sensitive	sensitive	ADJ
aji-153	265	11	α	α	NOUN
aji-153	265	12	-	-	NOUN
aji-153	265	13	subunit	subunit	NOUN
aji-153	265	14	and	and	CCONJ
aji-153	265	15	a	a	DET
aji-153	265	16	constitutively	constitutively	ADV
aji-153	265	17	expressed	express	VERB
aji-153	265	18	β	β	NOUN
aji-153	265	19	-	-	NOUN
aji-153	265	20	subunit	subunit	NOUN
aji-153	265	21	,	,	PUNCT
aji-153	265	22	which	which	PRON
aji-153	265	23	is	be	AUX
aji-153	265	24	often	often	ADV
aji-153	265	25	referred	refer	VERB
aji-153	265	26	to	to	ADP
aji-153	265	27	as	as	ADP
aji-153	265	28	the	the	DET
aji-153	265	29	arnt	arnt	PROPN
aji-153	265	30	.	.	PUNCT
aji-153	266	1	the	the	DET
aji-153	266	2	hif	hif	PROPN
aji-153	266	3	-	-	PUNCT
aji-153	266	4	α	α	PROPN
aji-153	266	5	subunit	subunit	NOUN
aji-153	266	6	is	be	AUX
aji-153	266	7	continuously	continuously	ADV
aji-153	266	8	synthesized	synthesize	VERB
aji-153	266	9	but	but	CCONJ
aji-153	266	10	is	be	AUX
aji-153	266	11	rapidly	rapidly	ADV
aji-153	266	12	degraded	degrade	VERB
aji-153	266	13	in	in	ADP
aji-153	266	14	the	the	DET
aji-153	266	15	presence	presence	NOUN
aji-153	266	16	of	of	ADP
aji-153	266	17	molecular	molecular	ADJ
aji-153	266	18	oxygen	oxygen	NOUN
aji-153	266	19	.	.	PUNCT
aji-153	267	1	three	three	NUM
aji-153	267	2	hif	hif	PROPN
aji-153	267	3	-	-	PUNCT
aji-153	267	4	α	α	NOUN
aji-153	267	5	-	-	PUNCT
aji-153	267	6	subunits	subunit	NOUN
aji-153	267	7	have	have	AUX
aji-153	267	8	been	be	AUX
aji-153	267	9	identified	identify	VERB
aji-153	267	10	,	,	PUNCT
aji-153	267	11	hif1α	hif1α	PROPN
aji-153	267	12	,	,	PUNCT
aji-153	267	13	hif-2α	hif-2α	NOUN
aji-153	267	14	(	(	PUNCT
aji-153	267	15	also	also	ADV
aji-153	267	16	known	know	VERB
aji-153	267	17	as	as	ADP
aji-153	267	18	epas1	epas1	NOUN
aji-153	267	19	)	)	PUNCT
aji-153	267	20	,	,	PUNCT
aji-153	267	21	and	and	CCONJ
aji-153	267	22	hif-3α	hif-3α	NOUN
aji-153	267	23	.	.	PUNCT
aji-153	268	1	under	under	ADP
aji-153	268	2	hypoxic	hypoxic	ADJ
aji-153	268	3	conditions	condition	NOUN
aji-153	268	4	,	,	PUNCT
aji-153	268	5	hif	hif	PROPN
aji-153	268	6	-	-	PUNCT
aji-153	268	7	α	α	PROPN
aji-153	268	8	no	no	ADV
aji-153	268	9	longer	long	ADV
aji-153	268	10	gets	get	VERB
aji-153	268	11	degraded	degrade	VERB
aji-153	268	12	,	,	PUNCT
aji-153	268	13	but	but	CCONJ
aji-153	268	14	translocates	translocate	NOUN
aji-153	268	15	to	to	ADP
aji-153	268	16	the	the	DET
aji-153	268	17	nucleus	nucleus	NOUN
aji-153	268	18	,	,	PUNCT
aji-153	268	19	forms	form	VERB
aji-153	268	20	a	a	DET
aji-153	268	21	heterodimer	heterodimer	NOUN
aji-153	268	22	with	with	ADP
aji-153	268	23	hif	hif	PROPN
aji-153	268	24	-	-	PUNCT
aji-153	268	25	β	β	PROPN
aji-153	268	26	,	,	PUNCT
aji-153	268	27	and	and	CCONJ
aji-153	268	28	activates	activate	VERB
aji-153	268	29	gene	gene	NOUN
aji-153	268	30	transcription.hif-1	transcription.hif-1	NOUN
aji-153	268	31	and	and	CCONJ
aji-153	268	32	hif-2	hif-2	NUM
aji-153	268	33	,	,	PUNCT
aji-153	268	34	the	the	DET
aji-153	268	35	most	most	ADV
aji-153	268	36	intensively	intensively	ADV
aji-153	268	37	studied	study	VERB
aji-153	268	38	hif	hif	PROPN
aji-153	268	39	transcription	transcription	NOUN
aji-153	268	40	factors	factor	NOUN
aji-153	268	41	,	,	PUNCT
aji-153	268	42	control	control	VERB
aji-153	268	43	a	a	DET
aji-153	268	44	very	very	ADV
aji-153	268	45	wide	wide	ADJ
aji-153	268	46	range	range	NOUN
aji-153	268	47	of	of	ADP
aji-153	268	48	hypoxia	hypoxia	NOUN
aji-153	268	49	responses	response	NOUN
aji-153	268	50	,	,	PUNCT
aji-153	268	51	such	such	ADJ
aji-153	268	52	as	as	ADP
aji-153	268	53	angiogenesis	angiogenesis	NOUN
aji-153	268	54	,	,	PUNCT
aji-153	268	55	anaerobic	anaerobic	NOUN
aji-153	268	56	glucose	glucose	NOUN
aji-153	268	57	metabolism	metabolism	NOUN
aji-153	268	58	,	,	PUNCT
aji-153	268	59	mitochondrial	mitochondrial	ADJ
aji-153	268	60	biogenesis	biogenesis	NOUN
aji-153	268	61	,	,	PUNCT
aji-153	268	62	and	and	CCONJ
aji-153	268	63	many	many	ADJ
aji-153	268	64	others	other	NOUN
aji-153	268	65	,	,	PUNCT
aji-153	268	66	thus	thus	ADV
aji-153	268	67	ensuring	ensure	VERB
aji-153	268	68	oxygen	oxygen	NOUN
aji-153	268	69	delivery	delivery	NOUN
aji-153	268	70	and	and	CCONJ
aji-153	268	71	adaptation	adaptation	NOUN
aji-153	268	72	of	of	ADP
aji-153	268	73	cells	cell	NOUN
aji-153	268	74	to	to	PART
aji-153	268	75	hypoxia	hypoxia	VERB
aji-153	268	76	[	[	X
aji-153	268	77	15	15	NUM
aji-153	268	78	]	]	PUNCT
aji-153	268	79	.	.	PUNCT
aji-153	269	1	the	the	DET
aji-153	269	2	list	list	NOUN
aji-153	269	3	of	of	ADP
aji-153	269	4	genes	gene	NOUN
aji-153	269	5	directly	directly	ADV
aji-153	269	6	hif	hif	PROPN
aji-153	269	7	-	-	PUNCT
aji-153	269	8	regulated	regulate	VERB
aji-153	269	9	is	be	AUX
aji-153	269	10	vast	vast	ADJ
aji-153	269	11	and	and	CCONJ
aji-153	269	12	several	several	ADJ
aji-153	269	13	gupta	gupta	NOUN
aji-153	269	14	et	et	PROPN
aji-153	269	15	al	al	PROPN
aji-153	269	16	.	.	PROPN
aji-153	269	17	;	;	PUNCT
aji-153	269	18	asian	asian	PROPN
aji-153	269	19	j.	j.	PROPN
aji-153	269	20	immunol	immunol	PROPN
aji-153	269	21	.	.	PROPN
aji-153	269	22	,	,	PUNCT
aji-153	269	23	vol	vol	NOUN
aji-153	269	24	.	.	PROPN
aji-153	270	1	7	7	NUM
aji-153	270	2	,	,	PUNCT
aji-153	270	3	no	no	INTJ
aji-153	270	4	.	.	NOUN
aji-153	270	5	1	1	NUM
aji-153	270	6	,	,	PUNCT
aji-153	270	7	pp	pp	ADJ
aji-153	270	8	.	.	PUNCT
aji-153	271	1	302	302	NUM
aji-153	271	2	-	-	SYM
aji-153	271	3	315	315	NUM
aji-153	271	4	,	,	PUNCT
aji-153	271	5	2024	2024	NUM
aji-153	272	1	;	;	PUNCT
aji-153	272	2	article	article	NOUN
aji-153	272	3	no.aji.127402	no.aji.127402	VERB
aji-153	272	4	308	308	NUM
aji-153	272	5	hundred	hundred	NUM
aji-153	272	6	high	high	ADJ
aji-153	272	7	stringency	stringency	NOUN
aji-153	272	8	hif	hif	PROPN
aji-153	272	9	binding	bind	VERB
aji-153	272	10	sites	site	NOUN
aji-153	272	11	have	have	AUX
aji-153	272	12	been	be	AUX
aji-153	272	13	identified	identify	VERB
aji-153	272	14	in	in	ADP
aji-153	272	15	the	the	DET
aji-153	272	16	genome	genome	NOUN
aji-153	272	17	.	.	PUNCT
aji-153	273	1	although	although	SCONJ
aji-153	273	2	hif-1	hif-1	NUM
aji-153	273	3	and	and	CCONJ
aji-153	273	4	hif-2	hif-2	PRON
aji-153	273	5	share	share	VERB
aji-153	273	6	many	many	ADJ
aji-153	273	7	transcriptional	transcriptional	ADJ
aji-153	273	8	targets	target	NOUN
aji-153	273	9	,	,	PUNCT
aji-153	273	10	some	some	DET
aji-153	273	11	genes	gene	NOUN
aji-153	273	12	are	be	AUX
aji-153	273	13	not	not	PART
aji-153	273	14	co	co	VERB
aji-153	273	15	-	-	VERB
aji-153	273	16	regulated	regulated	ADJ
aji-153	273	17	.	.	PUNCT
aji-153	274	1	for	for	ADP
aji-153	274	2	example	example	NOUN
aji-153	274	3	,	,	PUNCT
aji-153	274	4	the	the	DET
aji-153	274	5	glucose	glucose	NOUN
aji-153	274	6	metabolism	metabolism	NOUN
aji-153	274	7	through	through	ADP
aji-153	274	8	glycolysis	glycolysis	NOUN
aji-153	274	9	is	be	AUX
aji-153	274	10	under	under	ADP
aji-153	274	11	the	the	DET
aji-153	274	12	control	control	NOUN
aji-153	274	13	of	of	ADP
aji-153	274	14	hif-1	hif-1	NUM
aji-153	274	15	,	,	PUNCT
aji-153	274	16	whereas	whereas	SCONJ
aji-153	274	17	epo	epo	NOUN
aji-153	274	18	production	production	NOUN
aji-153	274	19	and	and	CCONJ
aji-153	274	20	some	some	DET
aji-153	274	21	iron	iron	NOUN
aji-153	274	22	genes	gene	NOUN
aji-153	274	23	are	be	AUX
aji-153	274	24	under	under	ADP
aji-153	274	25	the	the	DET
aji-153	274	26	regulation	regulation	NOUN
aji-153	274	27	of	of	ADP
aji-153	274	28	hifsuppressor	hifsuppressor	NOUN
aji-153	274	29	protein	protein	NOUN
aji-153	274	30	,	,	PUNCT
aji-153	274	31	which	which	PRON
aji-153	274	32	acts	act	VERB
aji-153	274	33	as	as	ADP
aji-153	274	34	the	the	DET
aji-153	274	35	substrate	substrate	NOUN
aji-153	274	36	recognition	recognition	NOUN
aji-153	274	37	”	"	PUNCT
aji-153	274	38	“	"	PUNCT
aji-153	274	39	under	under	ADP
aji-153	274	40	hypoxic	hypoxic	ADJ
aji-153	274	41	conditions	condition	NOUN
aji-153	274	42	,	,	PUNCT
aji-153	274	43	hif	hif	PROPN
aji-153	274	44	-	-	PUNCT
aji-153	274	45	prolyl	prolyl	PROPN
aji-153	274	46	hydroxylation	hydroxylation	NOUN
aji-153	274	47	is	be	AUX
aji-153	274	48	decreased	decrease	VERB
aji-153	274	49	,	,	PUNCT
aji-153	274	50	hif	hif	PROPN
aji-153	274	51	-	-	PUNCT
aji-153	274	52	α	α	PROPN
aji-153	274	53	is	be	AUX
aji-153	274	54	no	no	ADV
aji-153	274	55	longer	long	ADV
aji-153	274	56	degraded	degrade	VERB
aji-153	274	57	and	and	CCONJ
aji-153	274	58	translocates	translocate	NOUN
aji-153	274	59	to	to	ADP
aji-153	274	60	the	the	DET
aji-153	274	61	nucleus	nucleus	NOUN
aji-153	274	62	where	where	SCONJ
aji-153	274	63	it	it	PRON
aji-153	274	64	heterodimerizes	heterodimerize	VERB
aji-153	274	65	with	with	ADP
aji-153	274	66	hif	hif	PROPN
aji-153	274	67	-	-	PUNCT
aji-153	274	68	β	β	X
aji-153	274	69	and	and	CCONJ
aji-153	274	70	initiates	initiate	VERB
aji-153	274	71	gene	gene	NOUN
aji-153	274	72	transcription	transcription	NOUN
aji-153	274	73	.	.	PUNCT
aji-153	275	1	any	any	DET
aji-153	275	2	decrease	decrease	NOUN
aji-153	275	3	in	in	ADP
aji-153	275	4	hif	hif	PROPN
aji-153	275	5	-	-	PUNCT
aji-153	275	6	proline	proline	NOUN
aji-153	275	7	hydroxylation	hydroxylation	NOUN
aji-153	275	8	or	or	CCONJ
aji-153	275	9	inactivation	inactivation	NOUN
aji-153	275	10	of	of	ADP
aji-153	275	11	vhl	vhl	PROPN
aji-153	275	12	function	function	NOUN
aji-153	275	13	decreases	decrease	VERB
aji-153	275	14	hif	hif	PROPN
aji-153	275	15	degradation	degradation	NOUN
aji-153	275	16	and	and	CCONJ
aji-153	275	17	leads	lead	VERB
aji-153	275	18	to	to	ADP
aji-153	275	19	greater	great	ADJ
aji-153	275	20	expression	expression	NOUN
aji-153	275	21	of	of	ADP
aji-153	275	22	hif	hif	PROPN
aji-153	275	23	target	target	PROPN
aji-153	275	24	gene	gene	NOUN
aji-153	275	25	[	[	X
aji-153	275	26	16	16	NUM
aji-153	275	27	]	]	PUNCT
aji-153	275	28	.	.	PUNCT
aji-153	276	1	for	for	ADP
aji-153	276	2	example	example	NOUN
aji-153	276	3	,	,	PUNCT
aji-153	276	4	patients	patient	NOUN
aji-153	276	5	carrying	carry	VERB
aji-153	276	6	particular	particular	ADJ
aji-153	276	7	inactivating	inactivating	NOUN
aji-153	276	8	vhl	vhl	PROPN
aji-153	276	9	mutations	mutation	NOUN
aji-153	276	10	are	be	AUX
aji-153	276	11	susceptible	susceptible	ADJ
aji-153	276	12	to	to	ADP
aji-153	276	13	cns	cns	PROPN
aji-153	276	14	hemangioblastomas	hemangioblastoma	NOUN
aji-153	276	15	,	,	PUNCT
aji-153	276	16	clear	clear	ADJ
aji-153	276	17	cell	cell	NOUN
aji-153	276	18	renal	renal	ADJ
aji-153	276	19	cancer	cancer	NOUN
aji-153	276	20	,	,	PUNCT
aji-153	276	21	and	and	CCONJ
aji-153	276	22	pheochromocytomas	pheochromocytoma	NOUN
aji-153	276	23	,	,	PUNCT
aji-153	276	24	cancers	cancer	NOUN
aji-153	276	25	that	that	PRON
aji-153	276	26	are	be	AUX
aji-153	276	27	described	describe	VERB
aji-153	276	28	by	by	ADP
aji-153	276	29	upregulated	upregulate	VERB
aji-153	276	30	hif	hif	PROPN
aji-153	276	31	-	-	PUNCT
aji-153	276	32	regulated	regulate	VERB
aji-153	276	33	gene	gene	NOUN
aji-153	276	34	expression	expression	NOUN
aji-153	276	35	.	.	PUNCT
aji-153	277	1	in	in	ADP
aji-153	277	2	addition	addition	NOUN
aji-153	277	3	,	,	PUNCT
aji-153	277	4	particular	particular	ADJ
aji-153	277	5	mutations	mutation	NOUN
aji-153	277	6	that	that	PRON
aji-153	277	7	compromise	compromise	VERB
aji-153	277	8	the	the	DET
aji-153	277	9	ability	ability	NOUN
aji-153	277	10	of	of	ADP
aji-153	277	11	cells	cell	NOUN
aji-153	277	12	to	to	PART
aji-153	277	13	faithfully	faithfully	ADV
aji-153	277	14	hydroxylate	hydroxylate	VERB
aji-153	277	15	hif	hif	PROPN
aji-153	277	16	-	-	PUNCT
aji-153	277	17	α	α	PROPN
aji-153	277	18	lead	lead	NOUN
aji-153	277	19	to	to	ADP
aji-153	277	20	abnormal	abnormal	ADJ
aji-153	277	21	regulation	regulation	NOUN
aji-153	277	22	of	of	ADP
aji-153	277	23	hif	hif	PROPN
aji-153	277	24	activity	activity	NOUN
aji-153	277	25	and	and	CCONJ
aji-153	277	26	predispose	predispose	VERB
aji-153	277	27	to	to	ADP
aji-153	277	28	polycythemia	polycythemia	NOUN
aji-153	277	29	”	"	PUNCT
aji-153	277	30	.	.	PUNCT
aji-153	278	1	“	"	PUNCT
aji-153	278	2	although	although	SCONJ
aji-153	278	3	the	the	DET
aji-153	278	4	oxygen	oxygen	NOUN
aji-153	278	5	-	-	PUNCT
aji-153	278	6	sensitive	sensitive	ADJ
aji-153	278	7	α	α	NOUN
aji-153	278	8	-	-	NOUN
aji-153	278	9	subunit	subunit	NOUN
aji-153	278	10	of	of	ADP
aji-153	278	11	hif	hif	PROPN
aji-153	278	12	is	be	AUX
aji-153	278	13	ubiquitously	ubiquitously	ADV
aji-153	278	14	expressed	express	VERB
aji-153	278	15	and	and	CCONJ
aji-153	278	16	continuously	continuously	ADV
aji-153	278	17	produced	produce	VERB
aji-153	278	18	,	,	PUNCT
aji-153	278	19	it	it	PRON
aji-153	278	20	is	be	AUX
aji-153	278	21	degraded	degrade	VERB
aji-153	278	22	rapidly	rapidly	ADV
aji-153	278	23	in	in	ADP
aji-153	278	24	normoxic	normoxic	ADJ
aji-153	278	25	conditions	condition	NOUN
aji-153	278	26	[	[	X
aji-153	278	27	17	17	NUM
aji-153	278	28	]	]	PUNCT
aji-153	278	29	.	.	PUNCT
aji-153	279	1	on	on	ADP
aji-153	279	2	the	the	DET
aji-153	279	3	contrary	contrary	NOUN
aji-153	279	4	,	,	PUNCT
aji-153	279	5	in	in	ADP
aji-153	279	6	hypoxia	hypoxia	NOUN
aji-153	279	7	,	,	PUNCT
aji-153	279	8	the	the	DET
aji-153	279	9	levels	level	NOUN
aji-153	279	10	of	of	ADP
aji-153	279	11	cellular	cellular	ADJ
aji-153	279	12	hif	hif	PROPN
aji-153	279	13	-	-	PUNCT
aji-153	279	14	α	α	PROPN
aji-153	279	15	accumulate	accumulate	NOUN
aji-153	279	16	and	and	CCONJ
aji-153	279	17	hif	hif	PROPN
aji-153	279	18	-	-	PUNCT
aji-153	279	19	α	α	PROPN
aji-153	279	20	moves	move	NOUN
aji-153	279	21	to	to	ADP
aji-153	279	22	the	the	DET
aji-153	279	23	nucleus	nucleus	NOUN
aji-153	279	24	,	,	PUNCT
aji-153	279	25	where	where	SCONJ
aji-153	279	26	it	it	PRON
aji-153	279	27	dimerizes	dimerize	VERB
aji-153	279	28	with	with	ADP
aji-153	279	29	hif	hif	PROPN
aji-153	279	30	-	-	PUNCT
aji-153	279	31	β	β	PROPN
aji-153	279	32	.	.	PUNCT
aji-153	280	1	hif	hif	PROPN
aji-153	280	2	-	-	PUNCT
aji-153	280	3	α	α	PROPN
aji-153	280	4	degradation	degradation	NOUN
aji-153	280	5	is	be	AUX
aji-153	280	6	orchestrated	orchestrate	VERB
aji-153	280	7	by	by	ADP
aji-153	280	8	the	the	DET
aji-153	280	9	pvhl	pvhl	NOUN
aji-153	280	10	-	-	PUNCT
aji-153	280	11	e3	e3	NOUN
aji-153	280	12	-	-	PUNCT
aji-153	280	13	ubiquitin	ubiquitin	ADJ
aji-153	280	14	ligase	ligase	NOUN
aji-153	280	15	complex	complex	NOUN
aji-153	280	16	,	,	PUNCT
aji-153	280	17	but	but	CCONJ
aji-153	280	18	this	this	PRON
aji-153	280	19	is	be	AUX
aji-153	280	20	only	only	ADV
aji-153	280	21	possible	possible	ADJ
aji-153	280	22	in	in	ADP
aji-153	280	23	the	the	DET
aji-153	280	24	presence	presence	NOUN
aji-153	280	25	of	of	ADP
aji-153	280	26	oxygenand	oxygenand	ADJ
aji-153	280	27	iron	iron	NOUN
aji-153	280	28	-	-	PUNCT
aji-153	280	29	dependent	dependent	ADJ
aji-153	280	30	phd	phd	NOUN
aji-153	280	31	dioxygenases	dioxygenase	NOUN
aji-153	280	32	(	(	PUNCT
aji-153	280	33	phd1	phd1	NOUN
aji-153	280	34	-	-	PUNCT
aji-153	280	35	3	3	NUM
aji-153	280	36	)	)	PUNCT
aji-153	280	37	that	that	PRON
aji-153	280	38	hydroxylate	hydroxylate	VERB
aji-153	280	39	prolyl	prolyl	ADJ
aji-153	280	40	residues	residue	NOUN
aji-153	280	41	of	of	ADP
aji-153	280	42	hif	hif	PROPN
aji-153	280	43	-	-	PUNCT
aji-153	280	44	α	α	PROPN
aji-153	280	45	.	.	PUNCT
aji-153	280	46	decarboxylation	decarboxylation	NOUN
aji-153	280	47	of	of	ADP
aji-153	280	48	2	2	NUM
aji-153	280	49	-	-	PUNCT
aji-153	280	50	oxoglurate	oxoglurate	ADJ
aji-153	280	51	(	(	PUNCT
aji-153	280	52	2og	2og	ADJ
aji-153	280	53	produces	produce	VERB
aji-153	280	54	hydroxylated	hydroxylate	VERB
aji-153	280	55	hif	hif	PROPN
aji-153	280	56	-	-	PUNCT
aji-153	280	57	α	α	PROPN
aji-153	280	58	,	,	PUNCT
aji-153	280	59	succinate	succinate	NOUN
aji-153	280	60	and	and	CCONJ
aji-153	280	61	co2	co2	NOUN
aji-153	280	62	.	.	PUNCT
aji-153	281	1	inhibition	inhibition	NOUN
aji-153	281	2	of	of	ADP
aji-153	281	3	phd	phd	NOUN
aji-153	281	4	or	or	CCONJ
aji-153	281	5	von	von	PROPN
aji-153	281	6	hippel	hippel	PROPN
aji-153	281	7	-	-	PUNCT
aji-153	281	8	lindau	lindau	NOUN
aji-153	281	9	leads	lead	VERB
aji-153	281	10	to	to	ADP
aji-153	281	11	increased	increase	VERB
aji-153	281	12	transcription	transcription	NOUN
aji-153	281	13	of	of	ADP
aji-153	281	14	hif	hif	PROPN
aji-153	281	15	-	-	PUNCT
aji-153	281	16	regulated	regulate	VERB
aji-153	281	17	genes	gene	NOUN
aji-153	281	18	such	such	ADJ
aji-153	281	19	as	as	ADP
aji-153	281	20	vegf	vegf	PROPN
aji-153	281	21	,	,	PUNCT
aji-153	281	22	epo	epo	PROPN
aji-153	281	23	,	,	PUNCT
aji-153	281	24	pgk1	pgk1	ADJ
aji-153	281	25	,	,	PUNCT
aji-153	281	26	ldh	ldh	PROPN
aji-153	281	27	,	,	PUNCT
aji-153	281	28	and	and	CCONJ
aji-153	281	29	other	other	ADJ
aji-153	281	30	genes	gene	NOUN
aji-153	281	31	implicated	implicate	VERB
aji-153	281	32	in	in	ADP
aji-153	281	33	hypoxia	hypoxia	NOUN
aji-153	281	34	response	response	NOUN
aji-153	281	35	regulation	regulation	NOUN
aji-153	281	36	,	,	PUNCT
aji-153	281	37	including	include	VERB
aji-153	281	38	cellular	cellular	ADJ
aji-153	281	39	metabolism	metabolism	NOUN
aji-153	281	40	,	,	PUNCT
aji-153	281	41	mitochondrial	mitochondrial	ADJ
aji-153	281	42	function	function	NOUN
aji-153	281	43	,	,	PUNCT
aji-153	281	44	inflammation	inflammation	NOUN
aji-153	281	45	,	,	PUNCT
aji-153	281	46	vascular	vascular	ADJ
aji-153	281	47	function	function	NOUN
aji-153	281	48	,	,	PUNCT
aji-153	281	49	oxidative	oxidative	ADJ
aji-153	281	50	stress	stress	NOUN
aji-153	281	51	,	,	PUNCT
aji-153	281	52	and	and	CCONJ
aji-153	281	53	other	other	ADJ
aji-153	281	54	responses	response	NOUN
aji-153	281	55	.	.	PUNCT
aji-153	282	1	here	here	ADV
aji-153	282	2	is	be	AUX
aji-153	282	3	the	the	DET
aji-153	282	4	structure	structure	NOUN
aji-153	282	5	of	of	ADP
aji-153	282	6	a	a	DET
aji-153	282	7	hif	hif	PROPN
aji-153	282	8	-	-	PUNCT
aji-153	282	9	phd	phd	NOUN
aji-153	282	10	inhibitor	inhibitor	NOUN
aji-153	282	11	(	(	PUNCT
aji-153	282	12	phi	phi	NOUN
aji-153	282	13	)	)	PUNCT
aji-153	282	14	,	,	PUNCT
aji-153	282	15	which	which	PRON
aji-153	282	16	has	have	AUX
aji-153	282	17	been	be	AUX
aji-153	282	18	found	find	VERB
aji-153	282	19	to	to	PART
aji-153	282	20	hold	hold	VERB
aji-153	282	21	promise	promise	NOUN
aji-153	282	22	in	in	ADP
aji-153	282	23	potently	potently	ADV
aji-153	282	24	inducing	induce	VERB
aji-153	282	25	endogenous	endogenous	ADJ
aji-153	282	26	epo	epo	NOUN
aji-153	282	27	in	in	ADP
aji-153	282	28	dialysis	dialysis	NOUN
aji-153	282	29	patients	patient	NOUN
aji-153	282	30	[	[	X
aji-153	282	31	18	18	NUM
aji-153	282	32	]	]	PUNCT
aji-153	282	33	.	.	PUNCT
aji-153	283	1	hif	hif	PROPN
aji-153	283	2	-	-	PUNCT
aji-153	283	3	α	α	PROPN
aji-153	283	4	is	be	AUX
aji-153	283	5	hydroxylated	hydroxylate	VERB
aji-153	283	6	in	in	ADP
aji-153	283	7	an	an	DET
aji-153	283	8	oxygendependent	oxygendependent	NOUN
aji-153	283	9	reaction	reaction	NOUN
aji-153	283	10	by	by	ADP
aji-153	283	11	phd1	phd1	PROPN
aji-153	283	12	,	,	PUNCT
aji-153	283	13	phd2	phd2	NOUN
aji-153	283	14	,	,	PUNCT
aji-153	283	15	and	and	CCONJ
aji-153	283	16	phd3	phd3	PROPN
aji-153	283	17	”	"	PUNCT
aji-153	284	1	[	[	X
aji-153	284	2	18	18	NUM
aji-153	284	3	]	]	PUNCT
aji-153	284	4	.	.	PUNCT
aji-153	285	1	“	"	PUNCT
aji-153	285	2	phds	phds	NOUN
aji-153	285	3	represent	represent	VERB
aji-153	285	4	a	a	DET
aji-153	285	5	large	large	ADJ
aji-153	285	6	family	family	NOUN
aji-153	285	7	of	of	ADP
aji-153	285	8	2ogdependent	2ogdependent	NUM
aji-153	285	9	dioxygenases	dioxygenase	NOUN
aji-153	285	10	comprising	comprise	VERB
aji-153	285	11	over	over	ADP
aji-153	285	12	60	60	NUM
aji-153	285	13	members	member	NOUN
aji-153	285	14	.	.	PUNCT
aji-153	286	1	since	since	SCONJ
aji-153	286	2	these	these	DET
aji-153	286	3	dioxygenases	dioxygenase	NOUN
aji-153	286	4	catalyze	catalyze	VERB
aji-153	286	5	the	the	DET
aji-153	286	6	hydroxylation	hydroxylation	NOUN
aji-153	286	7	requiring	require	VERB
aji-153	286	8	the	the	DET
aji-153	286	9	use	use	NOUN
aji-153	286	10	of	of	ADP
aji-153	286	11	molecular	molecular	ADJ
aji-153	286	12	oxygen	oxygen	NOUN
aji-153	286	13	,	,	PUNCT
aji-153	286	14	they	they	PRON
aji-153	286	15	constitute	constitute	VERB
aji-153	286	16	a	a	DET
aji-153	286	17	point	point	NOUN
aji-153	286	18	of	of	ADP
aji-153	286	19	intersection	intersection	NOUN
aji-153	286	20	between	between	ADP
aji-153	286	21	oxygen	oxygen	NOUN
aji-153	286	22	,	,	PUNCT
aji-153	286	23	intermediary	intermediary	NOUN
aji-153	286	24	,	,	PUNCT
aji-153	286	25	and	and	CCONJ
aji-153	286	26	amino	amino	NOUN
aji-153	286	27	acid	acid	NOUN
aji-153	286	28	metabolism	metabolism	NOUN
aji-153	286	29	and	and	CCONJ
aji-153	286	30	a	a	DET
aji-153	286	31	variety	variety	NOUN
aji-153	286	32	of	of	ADP
aji-153	286	33	cellular	cellular	ADJ
aji-153	286	34	processes	process	NOUN
aji-153	286	35	including	include	VERB
aji-153	286	36	hif	hif	PROPN
aji-153	286	37	regulation	regulation	NOUN
aji-153	286	38	/	/	SYM
aji-153	286	39	hypoxia	hypoxia	NOUN
aji-153	286	40	responses	response	NOUN
aji-153	286	41	,	,	PUNCT
aji-153	286	42	collagen	collagen	NOUN
aji-153	286	43	synthesis	synthesis	NOUN
aji-153	286	44	,	,	PUNCT
aji-153	286	45	epigenetic	epigenetic	ADJ
aji-153	286	46	gene	gene	NOUN
aji-153	286	47	regulation	regulation	NOUN
aji-153	286	48	,	,	PUNCT
aji-153	286	49	and	and	CCONJ
aji-153	286	50	fatty	fatty	NOUN
aji-153	286	51	acid	acid	ADJ
aji-153	286	52	metabolism	metabolism	NOUN
aji-153	286	53	.	.	PUNCT
aji-153	287	1	other	other	ADJ
aji-153	287	2	small	small	ADJ
aji-153	287	3	molecules	molecule	NOUN
aji-153	287	4	,	,	PUNCT
aji-153	287	5	including	include	VERB
aji-153	287	6	reactive	reactive	ADJ
aji-153	287	7	oxygen	oxygen	NOUN
aji-153	287	8	species	specie	NOUN
aji-153	287	9	,	,	PUNCT
aji-153	287	10	nitric	nitric	ADJ
aji-153	287	11	oxide	oxide	NOUN
aji-153	287	12	,	,	PUNCT
aji-153	287	13	and	and	CCONJ
aji-153	287	14	the	the	DET
aji-153	287	15	krebs	krebs	NOUN
aji-153	287	16	cycle	cycle	NOUN
aji-153	287	17	intermediates	intermediate	VERB
aji-153	287	18	succinate	succinate	NOUN
aji-153	287	19	and	and	CCONJ
aji-153	287	20	fumarate	fumarate	NOUN
aji-153	287	21	,	,	PUNCT
aji-153	287	22	have	have	VERB
aji-153	287	23	inhibitory	inhibitory	ADJ
aji-153	287	24	effects	effect	NOUN
aji-153	287	25	on	on	ADP
aji-153	287	26	phd	phd	NOUN
aji-153	287	27	catalytic	catalytic	ADJ
aji-153	287	28	activity	activity	NOUN
aji-153	287	29	and	and	CCONJ
aji-153	287	30	stabilize	stabilize	VERB
aji-153	287	31	and	and	CCONJ
aji-153	287	32	activate	activate	VERB
aji-153	287	33	hifα	hifα	ADJ
aji-153	287	34	,	,	PUNCT
aji-153	287	35	leading	lead	VERB
aji-153	287	36	to	to	ADP
aji-153	287	37	associated	associated	ADJ
aji-153	287	38	transcriptional	transcriptional	ADJ
aji-153	287	39	programs	program	NOUN
aji-153	287	40	.	.	PUNCT
aji-153	288	1	the	the	DET
aji-153	288	2	latter	latter	ADJ
aji-153	288	3	is	be	AUX
aji-153	288	4	clinically	clinically	ADV
aji-153	288	5	relevant	relevant	ADJ
aji-153	288	6	in	in	ADP
aji-153	288	7	patients	patient	NOUN
aji-153	288	8	with	with	ADP
aji-153	288	9	deficiency	deficiency	NOUN
aji-153	288	10	of	of	ADP
aji-153	288	11	fumarate	fumarate	ADJ
aji-153	288	12	hydratase	hydratase	NOUN
aji-153	288	13	,	,	PUNCT
aji-153	288	14	who	who	PRON
aji-153	288	15	are	be	AUX
aji-153	288	16	at	at	ADP
aji-153	288	17	risk	risk	NOUN
aji-153	288	18	of	of	ADP
aji-153	288	19	developing	develop	VERB
aji-153	288	20	the	the	DET
aji-153	288	21	hereditary	hereditary	ADJ
aji-153	288	22	leiomyomatosis	leiomyomatosis	NOUN
aji-153	288	23	renal	renal	ADJ
aji-153	288	24	cell	cell	NOUN
aji-153	288	25	cancer	cancer	NOUN
aji-153	288	26	syndrome	syndrome	NOUN
aji-153	288	27	associated	associate	VERB
aji-153	288	28	with	with	ADP
aji-153	288	29	increased	increase	VERB
aji-153	288	30	hif	hif	PROPN
aji-153	288	31	activity	activity	NOUN
aji-153	288	32	within	within	ADP
aji-153	288	33	affected	affected	ADJ
aji-153	288	34	tissues	tissue	NOUN
aji-153	288	35	.	.	PUNCT
aji-153	289	1	structural	structural	ADJ
aji-153	289	2	analogues	analogue	NOUN
aji-153	289	3	of	of	ADP
aji-153	289	4	2og	2og	NOUN
aji-153	289	5	that	that	PRON
aji-153	289	6	inhibit	inhibit	VERB
aji-153	289	7	the	the	DET
aji-153	289	8	access	access	NOUN
aji-153	289	9	of	of	ADP
aji-153	289	10	2og	2og	ADJ
aji-153	289	11	and	and	CCONJ
aji-153	289	12	hifα	hifα	ADJ
aji-153	289	13	to	to	ADP
aji-153	289	14	the	the	DET
aji-153	289	15	catalytic	catalytic	ADJ
aji-153	289	16	center	center	NOUN
aji-153	289	17	of	of	ADP
aji-153	289	18	the	the	DET
aji-153	289	19	phd	phd	NOUN
aji-153	289	20	and	and	CCONJ
aji-153	289	21	thus	thus	ADV
aji-153	289	22	reversibly	reversibly	ADV
aji-153	289	23	inhibit	inhibit	VERB
aji-153	289	24	hifα	hifα	ADJ
aji-153	289	25	hydroxylation	hydroxylation	NOUN
aji-153	289	26	are	be	AUX
aji-153	289	27	now	now	ADV
aji-153	289	28	under	under	ADP
aji-153	289	29	clinical	clinical	ADJ
aji-153	289	30	development	development	NOUN
aji-153	289	31	for	for	ADP
aji-153	289	32	treatment	treatment	NOUN
aji-153	289	33	of	of	ADP
aji-153	289	34	renal	renal	ADJ
aji-153	289	35	anemia	anemia	NOUN
aji-153	289	36	and	and	CCONJ
aji-153	289	37	other	other	ADJ
aji-153	289	38	indications	indication	NOUN
aji-153	289	39	”	"	PUNCT
aji-153	290	1	[	[	X
aji-153	290	2	19	19	NUM
aji-153	290	3	]	]	PUNCT
aji-153	290	4	.	.	PUNCT
aji-153	291	1	2.3	2.3	NUM
aji-153	291	2	the	the	DET
aji-153	291	3	phd	phd	PROPN
aji-153	291	4	/	/	SYM
aji-153	291	5	hif	hif	PROPN
aji-153	291	6	axis	axis	NOUN
aji-153	291	7	in	in	ADP
aji-153	291	8	erythropoiesis	erythropoiesis	NOUN
aji-153	291	9	and	and	CCONJ
aji-153	291	10	iron	iron	NOUN
aji-153	291	11	metabolism	metabolism	NOUN
aji-153	291	12	“	"	PUNCT
aji-153	291	13	hif	hif	PROPN
aji-153	291	14	-	-	PUNCT
aji-153	291	15	dependent	dependent	ADJ
aji-153	291	16	regulation	regulation	NOUN
aji-153	291	17	of	of	ADP
aji-153	291	18	iron	iron	NOUN
aji-153	291	19	metabolism	metabolism	NOUN
aji-153	291	20	.	.	PUNCT
aji-153	292	1	overview	overview	VERB
aji-153	292	2	schematic	schematic	ADJ
aji-153	292	3	overview	overview	NOUN
aji-153	292	4	of	of	ADP
aji-153	292	5	hif	hif	PROPN
aji-153	292	6	-	-	PUNCT
aji-153	292	7	regulated	regulate	VERB
aji-153	292	8	genes	gene	NOUN
aji-153	292	9	in	in	ADP
aji-153	292	10	iron	iron	NOUN
aji-153	292	11	metabolism	metabolism	NOUN
aji-153	292	12	shown	show	VERB
aji-153	292	13	in	in	ADP
aji-153	292	14	red	red	PROPN
aji-153	292	15	.	.	PUNCT
aji-153	293	1	in	in	ADP
aji-153	293	2	the	the	DET
aji-153	293	3	intestine	intestine	NOUN
aji-153	293	4	,	,	PUNCT
aji-153	293	5	duodenal	duodenal	ADJ
aji-153	293	6	cytochrome	cytochrome	NOUN
aji-153	293	7	b	b	PROPN
aji-153	293	8	(	(	PUNCT
aji-153	293	9	dcytb	dcytb	NOUN
aji-153	293	10	)	)	PUNCT
aji-153	293	11	reduces	reduce	VERB
aji-153	293	12	ferric	ferric	ADJ
aji-153	293	13	iron	iron	NOUN
aji-153	293	14	(	(	PUNCT
aji-153	293	15	fe3	fe3	NOUN
aji-153	293	16	+	+	NOUN
aji-153	293	17	)	)	PUNCT
aji-153	293	18	to	to	ADP
aji-153	293	19	fe2	fe2	PROPN
aji-153	293	20	+	+	PROPN
aji-153	293	21	,	,	PUNCT
aji-153	293	22	which	which	PRON
aji-153	293	23	enters	enter	VERB
aji-153	293	24	via	via	ADP
aji-153	293	25	the	the	DET
aji-153	293	26	enterocytes	enterocyte	NOUN
aji-153	293	27	.	.	PUNCT
aji-153	294	1	dcytb	dcytb	NOUN
aji-153	294	2	and	and	CCONJ
aji-153	294	3	dmt1	dmt1	PROPN
aji-153	294	4	are	be	AUX
aji-153	294	5	both	both	ADV
aji-153	294	6	bonafide	bonafide	ADJ
aji-153	294	7	hif-2	hif-2	ADV
aji-153	294	8	-	-	PUNCT
aji-153	294	9	regulated	regulate	VERB
aji-153	294	10	genes	gene	NOUN
aji-153	294	11	.	.	PUNCT
aji-153	295	1	there	there	PRON
aji-153	295	2	is	be	VERB
aji-153	295	3	a	a	DET
aji-153	295	4	release	release	NOUN
aji-153	295	5	of	of	ADP
aji-153	295	6	iron	iron	NOUN
aji-153	295	7	into	into	ADP
aji-153	295	8	the	the	DET
aji-153	295	9	circulation	circulation	NOUN
aji-153	295	10	via	via	ADP
aji-153	295	11	ferroportin	ferroportin	PROPN
aji-153	295	12	(	(	PUNCT
aji-153	295	13	fpn	fpn	PROPN
aji-153	295	14	)	)	PUNCT
aji-153	295	15	that	that	PRON
aji-153	295	16	is	be	AUX
aji-153	295	17	hepcidin	hepcidin	VERB
aji-153	295	18	-	-	PUNCT
aji-153	295	19	regulated	regulated	ADJ
aji-153	295	20	but	but	CCONJ
aji-153	295	21	also	also	ADV
aji-153	295	22	hifinducible	hifinducible	ADJ
aji-153	295	23	.	.	PUNCT
aji-153	296	1	in	in	ADP
aji-153	296	2	blood	blood	NOUN
aji-153	296	3	,	,	PUNCT
aji-153	296	4	iron	iron	NOUN
aji-153	296	5	is	be	AUX
aji-153	296	6	transported	transport	VERB
aji-153	296	7	in	in	ADP
aji-153	296	8	complex	complex	NOUN
aji-153	296	9	with	with	ADP
aji-153	296	10	transferrin	transferrin	NOUN
aji-153	296	11	(	(	PUNCT
aji-153	296	12	tf	tf	INTJ
aji-153	296	13	)	)	PUNCT
aji-153	296	14	to	to	ADP
aji-153	296	15	the	the	DET
aji-153	296	16	liver	liver	NOUN
aji-153	296	17	,	,	PUNCT
aji-153	296	18	cells	cell	NOUN
aji-153	296	19	of	of	ADP
aji-153	296	20	the	the	DET
aji-153	296	21	reticulo	reticulo	NOUN
aji-153	296	22	-	-	PUNCT
aji-153	296	23	endothelial	endothelial	NOUN
aji-153	296	24	system	system	NOUN
aji-153	296	25	(	(	PUNCT
aji-153	296	26	res	re	NOUN
aji-153	296	27	)	)	PUNCT
aji-153	296	28	,	,	PUNCT
aji-153	296	29	bone	bone	NOUN
aji-153	296	30	marrow	marrow	NOUN
aji-153	296	31	,	,	PUNCT
aji-153	296	32	and	and	CCONJ
aji-153	296	33	other	other	ADJ
aji-153	296	34	organs	organ	NOUN
aji-153	296	35	.	.	PUNCT
aji-153	297	1	it	it	PRON
aji-153	297	2	has	have	AUX
aji-153	297	3	been	be	AUX
aji-153	297	4	demonstrated	demonstrate	VERB
aji-153	297	5	that	that	SCONJ
aji-153	297	6	increased	increase	VERB
aji-153	297	7	erythropoietic	erythropoietic	ADJ
aji-153	297	8	activity	activity	NOUN
aji-153	297	9	in	in	ADP
aji-153	297	10	the	the	DET
aji-153	297	11	bone	bone	NOUN
aji-153	297	12	marrow	marrow	NOUN
aji-153	297	13	produces	produce	VERB
aji-153	297	14	growth	growth	NOUN
aji-153	297	15	differentiation	differentiation	NOUN
aji-153	297	16	factor	factor	NOUN
aji-153	297	17	15	15	NUM
aji-153	297	18	(	(	PUNCT
aji-153	297	19	gdf15	gdf15	NOUN
aji-153	297	20	)	)	PUNCT
aji-153	297	21	and	and	CCONJ
aji-153	297	22	erythroferrone	erythroferrone	NOUN
aji-153	297	23	that	that	PRON
aji-153	297	24	suppress	suppress	VERB
aji-153	297	25	hepcidin	hepcidin	VERB
aji-153	297	26	in	in	ADP
aji-153	297	27	hepatocytes	hepatocyte	NOUN
aji-153	297	28	.	.	PUNCT
aji-153	298	1	inflammatory	inflammatory	ADJ
aji-153	298	2	cytokines	cytokine	NOUN
aji-153	298	3	stimulate	stimulate	VERB
aji-153	298	4	hepcidin	hepcidin	ADJ
aji-153	298	5	production	production	NOUN
aji-153	298	6	in	in	ADP
aji-153	298	7	the	the	DET
aji-153	298	8	liver	liver	NOUN
aji-153	298	9	and	and	CCONJ
aji-153	298	10	lead	lead	VERB
aji-153	298	11	to	to	ADP
aji-153	298	12	reduced	reduce	VERB
aji-153	298	13	ferroportin	ferroportin	NOUN
aji-153	298	14	surface	surface	NOUN
aji-153	298	15	expression	expression	NOUN
aji-153	298	16	and	and	CCONJ
aji-153	298	17	hypoferremia	hypoferremia	NOUN
aji-153	298	18	.	.	PUNCT
aji-153	299	1	the	the	DET
aji-153	299	2	small	small	ADJ
aji-153	299	3	25	25	NUM
aji-153	299	4	-	-	PUNCT
aji-153	299	5	amino	amino	NOUN
aji-153	299	6	-	-	PUNCT
aji-153	299	7	acid	acid	NOUN
aji-153	299	8	peptide	peptide	NOUN
aji-153	299	9	produced	produce	VERB
aji-153	299	10	by	by	ADP
aji-153	299	11	hepatocytes	hepatocyte	NOUN
aji-153	299	12	,	,	PUNCT
aji-153	299	13	hepcidin	hepcidin	ADJ
aji-153	299	14	,	,	PUNCT
aji-153	299	15	targets	target	NOUN
aji-153	299	16	fpn	fpn	VERB
aji-153	299	17	for	for	ADP
aji-153	299	18	degradation	degradation	NOUN
aji-153	299	19	”	"	PUNCT
aji-153	300	1	[	[	X
aji-153	300	2	20	20	NUM
aji-153	300	3	]	]	PUNCT
aji-153	300	4	.	.	PUNCT
aji-153	301	1	“	"	PUNCT
aji-153	301	2	its	its	PRON
aji-153	301	3	production	production	NOUN
aji-153	301	4	increases	increase	VERB
aji-153	301	5	with	with	ADP
aji-153	301	6	iron	iron	NOUN
aji-153	301	7	and	and	CCONJ
aji-153	301	8	inflammatory	inflammatory	ADJ
aji-153	301	9	cytokines	cytokine	NOUN
aji-153	301	10	,	,	PUNCT
aji-153	301	11	including	include	VERB
aji-153	301	12	interleukin	interleukin	NOUN
aji-153	301	13	6	6	NUM
aji-153	301	14	.	.	PUNCT
aji-153	301	15	as	as	ADP
aji-153	301	16	hepcidin	hepcidin	ADJ
aji-153	301	17	decreases	decrease	NOUN
aji-153	301	18	the	the	DET
aji-153	301	19	expression	expression	NOUN
aji-153	301	20	of	of	ADP
aji-153	301	21	fpn	fpn	NOUN
aji-153	301	22	on	on	ADP
aji-153	301	23	the	the	DET
aji-153	301	24	cell	cell	NOUN
aji-153	301	25	surface	surface	NOUN
aji-153	301	26	,	,	PUNCT
aji-153	301	27	high	high	ADJ
aji-153	301	28	plasma	plasma	NOUN
aji-153	301	29	hepcidin	hepcidin	NOUN
aji-153	301	30	levels	level	NOUN
aji-153	301	31	have	have	AUX
aji-153	301	32	led	lead	VERB
aji-153	301	33	to	to	ADP
aji-153	301	34	reduced	reduce	VERB
aji-153	301	35	intestinal	intestinal	ADJ
aji-153	301	36	iron	iron	NOUN
aji-153	301	37	uptake	uptake	NOUN
aji-153	301	38	and	and	CCONJ
aji-153	301	39	impaired	impaired	ADJ
aji-153	301	40	release	release	NOUN
aji-153	301	41	of	of	ADP
aji-153	301	42	iron	iron	NOUN
aji-153	301	43	from	from	ADP
aji-153	301	44	internal	internal	ADJ
aji-153	301	45	stores	store	NOUN
aji-153	301	46	.	.	PUNCT
aji-153	302	1	gupta	gupta	PROPN
aji-153	302	2	et	et	PROPN
aji-153	302	3	al	al	PROPN
aji-153	302	4	.	.	PROPN
aji-153	302	5	;	;	PUNCT
aji-153	302	6	asian	asian	PROPN
aji-153	302	7	j.	j.	PROPN
aji-153	302	8	immunol	immunol	PROPN
aji-153	302	9	.	.	PROPN
aji-153	302	10	,	,	PUNCT
aji-153	302	11	vol	vol	NOUN
aji-153	302	12	.	.	PROPN
aji-153	303	1	7	7	NUM
aji-153	303	2	,	,	PUNCT
aji-153	303	3	no	no	INTJ
aji-153	303	4	.	.	NOUN
aji-153	303	5	1	1	NUM
aji-153	303	6	,	,	PUNCT
aji-153	303	7	pp	pp	ADJ
aji-153	303	8	.	.	PUNCT
aji-153	304	1	302	302	NUM
aji-153	304	2	-	-	SYM
aji-153	304	3	315	315	NUM
aji-153	304	4	,	,	PUNCT
aji-153	304	5	2024	2024	NUM
aji-153	304	6	;	;	PUNCT
aji-153	304	7	article	article	NOUN
aji-153	304	8	no.aji.127402	no.aji.127402	VERB
aji-153	304	9	309	309	NUM
aji-153	304	10	fig	fig	NOUN
aji-153	304	11	.	.	PUNCT
aji-153	305	1	3	3	X
aji-153	305	2	.	.	X
aji-153	305	3	schematic	schematic	ADJ
aji-153	305	4	overview	overview	NOUN
aji-153	305	5	of	of	ADP
aji-153	305	6	hif	hif	PROPN
aji-153	305	7	-	-	PUNCT
aji-153	305	8	dependent	dependent	ADJ
aji-153	305	9	regulation	regulation	NOUN
aji-153	305	10	of	of	ADP
aji-153	305	11	iron	iron	NOUN
aji-153	305	12	metabolism	metabolism	NOUN
aji-153	305	13	plasma	plasma	NOUN
aji-153	305	14	hepcidin	hepcidin	NOUN
aji-153	305	15	levels	level	NOUN
aji-153	305	16	are	be	AUX
aji-153	305	17	generally	generally	ADV
aji-153	305	18	increased	increase	VERB
aji-153	305	19	in	in	ADP
aji-153	305	20	more	more	ADV
aji-153	305	21	advanced	advanced	ADJ
aji-153	305	22	stages	stage	NOUN
aji-153	305	23	of	of	ADP
aji-153	305	24	ckd	ckd	NOUN
aji-153	305	25	and	and	CCONJ
aji-153	305	26	enhance	enhance	VERB
aji-153	305	27	the	the	DET
aji-153	305	28	pathogenesis	pathogenesis	NOUN
aji-153	305	29	of	of	ADP
aji-153	305	30	renal	renal	ADJ
aji-153	305	31	anemia	anemia	NOUN
aji-153	305	32	by	by	ADP
aji-153	305	33	causing	cause	VERB
aji-153	305	34	functional	functional	ADJ
aji-153	305	35	iron	iron	NOUN
aji-153	305	36	-	-	PUNCT
aji-153	305	37	deficiency	deficiency	NOUN
aji-153	305	38	,	,	PUNCT
aji-153	305	39	due	due	ADJ
aji-153	305	40	to	to	ADP
aji-153	305	41	increased	increase	VERB
aji-153	305	42	hepcidin	hepcidin	NOUN
aji-153	305	43	levels	level	NOUN
aji-153	305	44	.	.	PUNCT
aji-153	306	1	this	this	PRON
aji-153	306	2	involves	involve	VERB
aji-153	306	3	systemic	systemic	ADJ
aji-153	306	4	activation	activation	NOUN
aji-153	306	5	of	of	ADP
aji-153	306	6	hif	hif	PROPN
aji-153	306	7	,	,	PUNCT
aji-153	306	8	suppressing	suppress	VERB
aji-153	306	9	hepcidin	hepcidin	ADJ
aji-153	306	10	production	production	NOUN
aji-153	306	11	in	in	ADP
aji-153	306	12	the	the	DET
aji-153	306	13	liver	liver	NOUN
aji-153	306	14	and	and	CCONJ
aji-153	306	15	thus	thus	ADV
aji-153	306	16	enhancing	enhance	VERB
aji-153	306	17	iron	iron	NOUN
aji-153	306	18	uptake	uptake	NOUN
aji-153	306	19	and	and	CCONJ
aji-153	306	20	mobilization	mobilization	NOUN
aji-153	306	21	[	[	X
aji-153	306	22	21	21	NUM
aji-153	306	23	]	]	PUNCT
aji-153	306	24	.	.	PUNCT
aji-153	307	1	the	the	DET
aji-153	307	2	first	first	ADJ
aji-153	307	3	studies	study	NOUN
aji-153	307	4	implicated	implicate	VERB
aji-153	307	5	hif-1	hif-1	ADV
aji-153	307	6	directly	directly	ADV
aji-153	307	7	in	in	ADP
aji-153	307	8	the	the	DET
aji-153	307	9	suppression	suppression	NOUN
aji-153	307	10	of	of	ADP
aji-153	307	11	hepcidin	hepcidin	VERB
aji-153	307	12	transcription	transcription	NOUN
aji-153	307	13	;	;	PUNCT
aji-153	307	14	however	however	ADV
aji-153	307	15	,	,	PUNCT
aji-153	307	16	more	more	ADV
aji-153	307	17	detailed	detailed	ADJ
aji-153	307	18	analysis	analysis	NOUN
aji-153	307	19	of	of	ADP
aji-153	307	20	mouse	mouse	NOUN
aji-153	307	21	models	model	NOUN
aji-153	307	22	with	with	ADP
aji-153	307	23	either	either	CCONJ
aji-153	307	24	global	global	ADJ
aji-153	307	25	or	or	CCONJ
aji-153	307	26	liver	liver	NOUN
aji-153	307	27	-	-	PUNCT
aji-153	307	28	specific	specific	ADJ
aji-153	307	29	hif	hif	NOUN
aji-153	307	30	activation	activation	NOUN
aji-153	307	31	suggests	suggest	VERB
aji-153	307	32	that	that	SCONJ
aji-153	307	33	suppression	suppression	NOUN
aji-153	307	34	of	of	ADP
aji-153	307	35	hepcidin	hepcidin	NOUN
aji-153	307	36	is	be	AUX
aji-153	307	37	epo	epo	NOUN
aji-153	307	38	-	-	PUNCT
aji-153	307	39	mediated	mediate	VERB
aji-153	307	40	stimulation	stimulation	NOUN
aji-153	307	41	of	of	ADP
aji-153	307	42	erythropoiesis	erythropoiesis	NOUN
aji-153	307	43	.	.	PUNCT
aji-153	308	1	hif	hif	PROPN
aji-153	308	2	does	do	AUX
aji-153	308	3	not	not	PART
aji-153	308	4	have	have	VERB
aji-153	308	5	a	a	DET
aji-153	308	6	direct	direct	ADJ
aji-153	308	7	repressor	repressor	NOUN
aji-153	308	8	role	role	NOUN
aji-153	308	9	on	on	ADP
aji-153	308	10	hepcidin	hepcidin	VERB
aji-153	308	11	transcription	transcription	NOUN
aji-153	308	12	in	in	ADP
aji-153	308	13	the	the	DET
aji-153	308	14	liver	liver	NOUN
aji-153	308	15	.	.	PUNCT
aji-153	309	1	the	the	DET
aji-153	309	2	interaction	interaction	NOUN
aji-153	309	3	between	between	ADP
aji-153	309	4	hif	hif	PROPN
aji-153	309	5	and	and	CCONJ
aji-153	309	6	iron	iron	NOUN
aji-153	309	7	metabolism	metabolism	NOUN
aji-153	309	8	is	be	AUX
aji-153	309	9	a	a	DET
aji-153	309	10	bi	bi	ADJ
aji-153	309	11	-	-	ADJ
aji-153	309	12	directional	directional	ADJ
aji-153	309	13	one	one	NOUN
aji-153	309	14	”	"	PUNCT
aji-153	309	15	.	.	PUNCT
aji-153	310	1	“	"	PUNCT
aji-153	310	2	the	the	DET
aji-153	310	3	5′	5′	NUM
aji-153	310	4	utr	utr	NOUN
aji-153	310	5	of	of	ADP
aji-153	310	6	the	the	DET
aji-153	310	7	gene	gene	NOUN
aji-153	310	8	encoding	encode	VERB
aji-153	310	9	hif-2α	hif-2α	NOUN
aji-153	310	10	bears	bear	VERB
aji-153	310	11	an	an	DET
aji-153	310	12	iron	iron	NOUN
aji-153	310	13	response	response	NOUN
aji-153	310	14	element	element	NOUN
aji-153	310	15	that	that	PRON
aji-153	310	16	interacts	interact	VERB
aji-153	310	17	with	with	ADP
aji-153	310	18	irps	irps	NOUN
aji-153	310	19	.	.	PUNCT
aji-153	311	1	in	in	ADP
aji-153	311	2	analogy	analogy	NOUN
aji-153	311	3	to	to	ADP
aji-153	311	4	the	the	DET
aji-153	311	5	inhibition	inhibition	NOUN
aji-153	311	6	of	of	ADP
aji-153	311	7	ferritin	ferritin	ADJ
aji-153	311	8	translation	translation	NOUN
aji-153	311	9	,	,	PUNCT
aji-153	311	10	irp	irp	NOUN
aji-153	311	11	binding	bind	VERB
aji-153	311	12	to	to	ADP
aji-153	311	13	the	the	DET
aji-153	311	14	hif2a	hif2a	NOUN
aji-153	311	15	5′	5′	NUM
aji-153	311	16	utr	utr	NOUN
aji-153	311	17	will	will	AUX
aji-153	311	18	block	block	VERB
aji-153	311	19	hif-2α	hif-2α	NOUN
aji-153	311	20	translation	translation	NOUN
aji-153	311	21	and	and	CCONJ
aji-153	311	22	therefore	therefore	ADV
aji-153	311	23	diminish	diminish	VERB
aji-153	311	24	the	the	DET
aji-153	311	25	level	level	NOUN
aji-153	311	26	of	of	ADP
aji-153	311	27	hif-2α	hif-2α	ADJ
aji-153	311	28	protein	protein	NOUN
aji-153	311	29	in	in	ADP
aji-153	311	30	the	the	DET
aji-153	311	31	cell	cell	NOUN
aji-153	311	32	in	in	ADP
aji-153	311	33	response	response	NOUN
aji-153	311	34	to	to	ADP
aji-153	311	35	low	low	ADJ
aji-153	311	36	intracellular	intracellular	ADJ
aji-153	311	37	iron	iron	NOUN
aji-153	312	1	[	[	X
aji-153	312	2	22	22	NUM
aji-153	312	3	]	]	PUNCT
aji-153	312	4	.	.	PUNCT
aji-153	313	1	from	from	ADP
aji-153	313	2	this	this	DET
aji-153	313	3	mechanism	mechanism	NOUN
aji-153	313	4	,	,	PUNCT
aji-153	313	5	one	one	PRON
aji-153	313	6	would	would	AUX
aji-153	313	7	anticipate	anticipate	VERB
aji-153	313	8	that	that	SCONJ
aji-153	313	9	renal	renal	ADJ
aji-153	313	10	epo	epo	NOUN
aji-153	313	11	production	production	NOUN
aji-153	313	12	would	would	AUX
aji-153	313	13	be	be	AUX
aji-153	313	14	only	only	ADV
aji-153	313	15	mildly	mildly	ADV
aji-153	313	16	suppressed	suppress	VERB
aji-153	313	17	in	in	ADP
aji-153	313	18	iron	iron	NOUN
aji-153	313	19	deficiency	deficiency	NOUN
aji-153	313	20	anemia	anemia	NOUN
aji-153	313	21	compared	compare	VERB
aji-153	313	22	with	with	ADP
aji-153	313	23	other	other	ADJ
aji-153	313	24	forms	form	NOUN
aji-153	313	25	of	of	ADP
aji-153	313	26	anemia	anemia	NOUN
aji-153	313	27	that	that	PRON
aji-153	313	28	are	be	AUX
aji-153	313	29	associated	associate	VERB
aji-153	313	30	with	with	ADP
aji-153	313	31	either	either	CCONJ
aji-153	313	32	maintenance	maintenance	NOUN
aji-153	313	33	or	or	CCONJ
aji-153	313	34	even	even	ADV
aji-153	313	35	elevation	elevation	NOUN
aji-153	313	36	of	of	ADP
aji-153	313	37	plasma	plasma	NOUN
aji-153	313	38	iron	iron	NOUN
aji-153	313	39	.	.	PUNCT
aji-153	314	1	hypoxia	hypoxia	NOUN
aji-153	314	2	and	and	CCONJ
aji-153	314	3	the	the	DET
aji-153	314	4	phd	phd	NOUN
aji-153	314	5	/	/	SYM
aji-153	314	6	hif	hif	PROPN
aji-153	314	7	pathway	pathway	NOUN
aji-153	314	8	play	play	VERB
aji-153	314	9	an	an	DET
aji-153	314	10	important	important	ADJ
aji-153	314	11	role	role	NOUN
aji-153	314	12	in	in	ADP
aji-153	314	13	regulating	regulate	VERB
aji-153	314	14	iron	iron	NOUN
aji-153	314	15	metabolism	metabolism	NOUN
aji-153	314	16	;	;	PUNCT
aji-153	314	17	in	in	ADP
aji-153	314	18	addition	addition	NOUN
aji-153	314	19	,	,	PUNCT
aji-153	314	20	it	it	PRON
aji-153	314	21	promotes	promote	VERB
aji-153	314	22	erythropoiesis	erythropoiesis	NOUN
aji-153	314	23	through	through	ADP
aji-153	314	24	direct	direct	ADJ
aji-153	314	25	effects	effect	NOUN
aji-153	314	26	on	on	ADP
aji-153	314	27	the	the	DET
aji-153	314	28	bone	bone	NOUN
aji-153	314	29	marrow	marrow	NOUN
aji-153	314	30	,	,	PUNCT
aji-153	314	31	including	include	VERB
aji-153	314	32	stimulating	stimulate	VERB
aji-153	314	33	the	the	DET
aji-153	314	34	expression	expression	NOUN
aji-153	314	35	of	of	ADP
aji-153	314	36	the	the	DET
aji-153	314	37	epo	epo	NOUN
aji-153	314	38	receptor	receptor	NOUN
aji-153	314	39	and	and	CCONJ
aji-153	314	40	enhancing	enhance	VERB
aji-153	314	41	the	the	DET
aji-153	314	42	synthesis	synthesis	NOUN
aji-153	314	43	of	of	ADP
aji-153	314	44	hemoglobin	hemoglobin	NOUN
aji-153	314	45	,	,	PUNCT
aji-153	314	46	as	as	ADV
aji-153	314	47	well	well	ADV
aji-153	314	48	as	as	ADP
aji-153	314	49	modulating	modulate	VERB
aji-153	314	50	the	the	DET
aji-153	314	51	maintenance	maintenance	NOUN
aji-153	314	52	and	and	CCONJ
aji-153	314	53	lineage	lineage	NOUN
aji-153	314	54	differentiation	differentiation	NOUN
aji-153	314	55	of	of	ADP
aji-153	314	56	stem	stem	NOUN
aji-153	314	57	cells	cell	NOUN
aji-153	314	58	and	and	CCONJ
aji-153	314	59	their	their	PRON
aji-153	314	60	maturation	maturation	NOUN
aji-153	314	61	”	"	PUNCT
aji-153	314	62	.	.	PUNCT
aji-153	315	1	anemia	anemia	NOUN
aji-153	315	2	associated	associate	VERB
aji-153	315	3	with	with	ADP
aji-153	315	4	ckd	ckd	PROPN
aji-153	315	5	results	result	NOUN
aji-153	315	6	from	from	ADP
aji-153	315	7	relative	relative	ADJ
aji-153	315	8	deficiency	deficiency	NOUN
aji-153	315	9	of	of	ADP
aji-153	315	10	renal	renal	ADJ
aji-153	315	11	epo	epo	NOUN
aji-153	315	12	production	production	NOUN
aji-153	315	13	,	,	PUNCT
aji-153	315	14	combined	combined	ADJ
aji-153	315	15	functional	functional	ADJ
aji-153	315	16	and/or	and/or	CCONJ
aji-153	315	17	absolute	absolute	ADJ
aji-153	315	18	iron	iron	NOUN
aji-153	315	19	deficiency	deficiency	NOUN
aji-153	315	20	and	and	CCONJ
aji-153	315	21	resistance	resistance	NOUN
aji-153	315	22	to	to	ADP
aji-153	315	23	epo	epo	PROPN
aji-153	315	24	signaling	signal	VERB
aji-153	315	25	,	,	PUNCT
aji-153	315	26	a	a	DET
aji-153	315	27	condition	condition	NOUN
aji-153	315	28	often	often	ADV
aji-153	315	29	seen	see	VERB
aji-153	315	30	in	in	ADP
aji-153	315	31	the	the	DET
aji-153	315	32	context	context	NOUN
aji-153	315	33	of	of	ADP
aji-153	315	34	inflammation	inflammation	NOUN
aji-153	315	35	.	.	PUNCT
aji-153	316	1	pharmacologic	pharmacologic	ADJ
aji-153	316	2	activation	activation	NOUN
aji-153	316	3	of	of	ADP
aji-153	316	4	hif	hif	PROPN
aji-153	316	5	signaling	signal	VERB
aji-153	316	6	may	may	AUX
aji-153	316	7	offer	offer	VERB
aji-153	316	8	a	a	DET
aji-153	316	9	more	more	ADV
aji-153	316	10	holistic	holistic	ADJ
aji-153	316	11	and	and	CCONJ
aji-153	316	12	physiologic	physiologic	ADJ
aji-153	316	13	therapeutic	therapeutic	ADJ
aji-153	316	14	option	option	NOUN
aji-153	316	15	for	for	ADP
aji-153	316	16	treating	treat	VERB
aji-153	316	17	renal	renal	ADJ
aji-153	316	18	anemia	anemia	NOUN
aji-153	316	19	than	than	ADP
aji-153	316	20	therapy	therapy	NOUN
aji-153	316	21	with	with	ADP
aji-153	316	22	recombinant	recombinant	ADJ
aji-153	316	23	preparations	preparation	NOUN
aji-153	316	24	of	of	ADP
aji-153	316	25	epo	epo	PROPN
aji-153	317	1	[	[	X
aji-153	317	2	23	23	NUM
aji-153	317	3	]	]	PUNCT
aji-153	317	4	.	.	PUNCT
aji-153	318	1	3	3	X
aji-153	318	2	.	.	X
aji-153	318	3	progress	progress	NOUN
aji-153	318	4	in	in	ADP
aji-153	318	5	clinical	clinical	ADJ
aji-153	318	6	research	research	NOUN
aji-153	318	7	in	in	ADP
aji-153	318	8	clinical	clinical	ADJ
aji-153	318	9	trials	trial	NOUN
aji-153	318	10	of	of	ADP
aji-153	318	11	a	a	DET
aji-153	318	12	20	20	NUM
aji-153	318	13	-	-	PUNCT
aji-153	318	14	week	week	NOUN
aji-153	318	15	,	,	PUNCT
aji-153	318	16	phase	phase	NOUN
aji-153	318	17	2b	2b	NUM
aji-153	318	18	multicenter	multicenter	NOUN
aji-153	318	19	,	,	PUNCT
aji-153	318	20	randomized	randomize	VERB
aji-153	318	21	,	,	PUNCT
aji-153	318	22	double	double	ADJ
aji-153	318	23	-	-	PUNCT
aji-153	318	24	blind	blind	ADJ
aji-153	318	25	,	,	PUNCT
aji-153	318	26	placebocontrolled	placebocontrolle	VERB
aji-153	318	27	study	study	NOUN
aji-153	318	28	to	to	PART
aji-153	318	29	assess	assess	VERB
aji-153	318	30	the	the	DET
aji-153	318	31	oral	oral	ADJ
aji-153	318	32	,	,	PUNCT
aji-153	318	33	once	once	ADV
aji-153	318	34	-	-	PUNCT
aji-153	318	35	daily	daily	ADJ
aji-153	318	36	vadadustat	vadadustat	NOUN
aji-153	318	37	ability	ability	NOUN
aji-153	318	38	to	to	PART
aji-153	318	39	correct	correct	VERB
aji-153	318	40	anemia	anemia	NOUN
aji-153	318	41	in	in	ADP
aji-153	318	42	patients	patient	NOUN
aji-153	318	43	with	with	ADP
aji-153	318	44	ndd	ndd	PROPN
aji-153	318	45	-	-	PROPN
aji-153	318	46	ckd	ckd	PROPN
aji-153	318	47	.	.	PUNCT
aji-153	319	1	a	a	DET
aji-153	319	2	total	total	NOUN
aji-153	319	3	of	of	ADP
aji-153	319	4	1,929	1,929	NUM
aji-153	319	5	patients	patient	NOUN
aji-153	319	6	at	at	ADP
aji-153	319	7	nddckd	nddckd	NOUN
aji-153	319	8	stage	stage	NOUN
aji-153	319	9	3a	3a	NUM
aji-153	319	10	/	/	SYM
aji-153	319	11	b	b	PROPN
aji-153	319	12	,	,	PUNCT
aji-153	319	13	4	4	NUM
aji-153	319	14	,	,	PUNCT
aji-153	319	15	and	and	CCONJ
aji-153	319	16	5	5	NUM
aji-153	319	17	stages	stage	NOUN
aji-153	319	18	from	from	ADP
aji-153	319	19	61	61	NUM
aji-153	319	20	centers	center	NOUN
aji-153	319	21	were	be	AUX
aji-153	319	22	stratified	stratify	VERB
aji-153	319	23	by	by	ADP
aji-153	319	24	esa	esa	PROPN
aji-153	319	25	therapy	therapy	NOUN
aji-153	319	26	use	use	NOUN
aji-153	319	27	and	and	CCONJ
aji-153	319	28	hb	hb	NOUN
aji-153	319	29	level	level	NOUN
aji-153	319	30	.	.	PUNCT
aji-153	320	1	group	group	NOUN
aji-153	320	2	1	1	NUM
aji-153	320	3	:	:	PUNCT
aji-153	320	4	esa	esa	PROPN
aji-153	320	5	treatment	treatment	PROPN
aji-153	320	6	naïve	naïve	PROPN
aji-153	320	7	and	and	CCONJ
aji-153	320	8	hb	hb	X
aji-153	320	9	≤10.5	≤10.5	PRON
aji-153	320	10	g	g	PROPN
aji-153	320	11	/	/	SYM
aji-153	320	12	dl	dl	PROPN
aji-153	320	13	;	;	PUNCT
aji-153	320	14	group	group	NOUN
aji-153	320	15	2	2	NUM
aji-153	320	16	:	:	PUNCT
aji-153	320	17	previously	previously	ADV
aji-153	320	18	treated	treat	VERB
aji-153	320	19	with	with	ADP
aji-153	320	20	esa	esa	PROPN
aji-153	320	21	and	and	CCONJ
aji-153	320	22	hb	hb	PROPN
aji-153	320	23	≤10.5	≤10.5	PRON
aji-153	320	24	g	g	PROPN
aji-153	320	25	/	/	SYM
aji-153	320	26	dl	dl	PROPN
aji-153	320	27	;	;	PUNCT
aji-153	320	28	group	group	NOUN
aji-153	320	29	3	3	NUM
aji-153	320	30	:	:	PUNCT
aji-153	320	31	actively	actively	ADV
aji-153	320	32	treated	treat	VERB
aji-153	320	33	with	with	ADP
aji-153	320	34	esa	esa	PROPN
aji-153	320	35	,	,	PUNCT
aji-153	320	36	hb	hb	X
aji-153	320	37	≥9.5	≥9.5	NOUN
aji-153	320	38	g	g	PROPN
aji-153	320	39	/	/	SYM
aji-153	320	40	dl	dl	NOUN
aji-153	320	41	to	to	ADP
aji-153	320	42	≤12.0	≤12.0	PROPN
aji-153	320	43	g	g	PROPN
aji-153	320	44	/	/	SYM
aji-153	320	45	dl	dl	PROPN
aji-153	321	1	[	[	X
aji-153	321	2	24	24	NUM
aji-153	321	3	]	]	PUNCT
aji-153	321	4	.	.	PUNCT
aji-153	322	1	patients	patient	NOUN
aji-153	322	2	in	in	ADP
aji-153	322	3	each	each	DET
aji-153	322	4	group	group	NOUN
aji-153	322	5	received	receive	VERB
aji-153	322	6	double	double	ADJ
aji-153	322	7	blinded	blind	VERB
aji-153	322	8	randomization	randomization	NOUN
aji-153	322	9	2:1	2:1	NUM
aji-153	322	10	for	for	ADP
aji-153	322	11	vadadustat	vadadustat	NOUN
aji-153	322	12	versus	versus	ADP
aji-153	322	13	placebo	placebo	NOUN
aji-153	322	14	,	,	PUNCT
aji-153	322	15	stratified	stratify	VERB
aji-153	322	16	by	by	ADP
aji-153	322	17	ckd	ckd	PROPN
aji-153	322	18	stage	stage	NOUN
aji-153	322	19	and	and	CCONJ
aji-153	322	20	the	the	DET
aji-153	322	21	presence	presence	NOUN
aji-153	322	22	or	or	CCONJ
aji-153	322	23	absence	absence	NOUN
aji-153	322	24	of	of	ADP
aji-153	322	25	diabetes	diabetes	NOUN
aji-153	322	26	mellitus	mellitus	NOUN
aji-153	322	27	.	.	PUNCT
aji-153	323	1	two	two	NUM
aji-153	323	2	hundred	hundred	NUM
aji-153	323	3	ten	ten	NUM
aji-153	323	4	patients	patient	NOUN
aji-153	323	5	were	be	AUX
aji-153	323	6	included	include	VERB
aji-153	323	7	in	in	ADP
aji-153	323	8	the	the	DET
aji-153	323	9	safety	safety	NOUN
aji-153	323	10	analyses	analysis	NOUN
aji-153	323	11	:	:	PUNCT
aji-153	323	12	those	those	DET
aji-153	323	13	patients	patient	NOUN
aji-153	323	14	who	who	PRON
aji-153	323	15	received	receive	VERB
aji-153	323	16	the	the	DET
aji-153	323	17	study	study	NOUN
aji-153	323	18	drug	drug	NOUN
aji-153	323	19	were	be	AUX
aji-153	323	20	treated	treat	VERB
aji-153	323	21	with	with	ADP
aji-153	323	22	either	either	DET
aji-153	323	23	vadadustat	vadadustat	NOUN
aji-153	323	24	(	(	PUNCT
aji-153	323	25	n	n	NOUN
aji-153	323	26	=	=	PUNCT
aji-153	323	27	gupta	gupta	PROPN
aji-153	323	28	et	et	PROPN
aji-153	323	29	al	al	PROPN
aji-153	323	30	.	.	PROPN
aji-153	323	31	;	;	PUNCT
aji-153	323	32	asian	asian	PROPN
aji-153	323	33	j.	j.	PROPN
aji-153	323	34	immunol	immunol	PROPN
aji-153	323	35	.	.	PROPN
aji-153	323	36	,	,	PUNCT
aji-153	323	37	vol	vol	NOUN
aji-153	323	38	.	.	PROPN
aji-153	324	1	7	7	NUM
aji-153	324	2	,	,	PUNCT
aji-153	324	3	no	no	INTJ
aji-153	324	4	.	.	NOUN
aji-153	324	5	1	1	NUM
aji-153	324	6	,	,	PUNCT
aji-153	324	7	pp	pp	ADJ
aji-153	324	8	.	.	PUNCT
aji-153	325	1	302	302	NUM
aji-153	325	2	-	-	SYM
aji-153	325	3	315	315	NUM
aji-153	325	4	,	,	PUNCT
aji-153	325	5	2024	2024	NUM
aji-153	326	1	;	;	PUNCT
aji-153	326	2	article	article	NOUN
aji-153	326	3	no.aji.127402	no.aji.127402	VERB
aji-153	326	4	310	310	NUM
aji-153	326	5	138	138	NUM
aji-153	326	6	)	)	PUNCT
aji-153	326	7	or	or	CCONJ
aji-153	326	8	placebo	placebo	NOUN
aji-153	326	9	(	(	PUNCT
aji-153	326	10	n	n	NOUN
aji-153	326	11	=	=	NOUN
aji-153	326	12	72	72	NUM
aji-153	326	13	)	)	PUNCT
aji-153	326	14	.	.	PUNCT
aji-153	327	1	for	for	ADP
aji-153	327	2	all	all	DET
aji-153	327	3	efficacy	efficacy	NOUN
aji-153	327	4	analyses	analysis	NOUN
aji-153	327	5	,	,	PUNCT
aji-153	327	6	the	the	DET
aji-153	327	7	modified	modify	VERB
aji-153	327	8	intent	intent	NOUN
aji-153	327	9	-	-	PUNCT
aji-153	327	10	to	to	ADP
aji-153	327	11	-	-	PUNCT
aji-153	327	12	treat	treat	VERB
aji-153	327	13	population	population	NOUN
aji-153	327	14	of	of	ADP
aji-153	327	15	208	208	NUM
aji-153	327	16	patients	patient	NOUN
aji-153	327	17	was	be	AUX
aji-153	327	18	used	use	VERB
aji-153	327	19	,	,	PUNCT
aji-153	327	20	those	those	DET
aji-153	327	21	patients	patient	NOUN
aji-153	327	22	who	who	PRON
aji-153	327	23	had	have	VERB
aji-153	327	24	a	a	DET
aji-153	327	25	baseline	baseline	NOUN
aji-153	327	26	and	and	CCONJ
aji-153	327	27	≥1	≥1	NUM
aji-153	327	28	postbaseline	postbaseline	NOUN
aji-153	327	29	measurement	measurement	NOUN
aji-153	327	30	of	of	ADP
aji-153	327	31	hb	hb	PROPN
aji-153	327	32	and	and	CCONJ
aji-153	327	33	red	red	ADJ
aji-153	327	34	blood	blood	NOUN
aji-153	327	35	cells	cell	NOUN
aji-153	327	36	[	[	X
aji-153	327	37	24	24	NUM
aji-153	327	38	]	]	PUNCT
aji-153	327	39	.	.	PUNCT
aji-153	328	1	the	the	DET
aji-153	328	2	former	former	ADJ
aji-153	328	3	group	group	NOUN
aji-153	328	4	included	include	VERB
aji-153	328	5	136	136	NUM
aji-153	328	6	patients	patient	NOUN
aji-153	328	7	randomized	randomize	VERB
aji-153	328	8	to	to	ADP
aji-153	328	9	vadadustat	vadadustat	NOUN
aji-153	328	10	and	and	CCONJ
aji-153	328	11	72	72	NUM
aji-153	328	12	to	to	ADP
aji-153	328	13	placebo	placebo	NOUN
aji-153	328	14	.	.	PUNCT
aji-153	329	1	the	the	DET
aji-153	329	2	per	per	ADP
aji-153	329	3	-	-	PUNCT
aji-153	329	4	protocol	protocol	NOUN
aji-153	329	5	population	population	NOUN
aji-153	329	6	was	be	AUX
aji-153	329	7	defined	define	VERB
aji-153	329	8	a	a	DET
aji-153	329	9	priori	priori	NOUN
aji-153	329	10	as	as	ADP
aji-153	329	11	the	the	DET
aji-153	329	12	primary	primary	ADJ
aji-153	329	13	population	population	NOUN
aji-153	329	14	for	for	ADP
aji-153	329	15	use	use	NOUN
aji-153	329	16	in	in	ADP
aji-153	329	17	analysis	analysis	NOUN
aji-153	329	18	of	of	ADP
aji-153	329	19	the	the	DET
aji-153	329	20	primary	primary	ADJ
aji-153	329	21	endpoint	endpoint	NOUN
aji-153	329	22	and	and	CCONJ
aji-153	329	23	consisted	consist	VERB
aji-153	329	24	of	of	ADP
aji-153	329	25	all	all	DET
aji-153	329	26	modified	modified	ADJ
aji-153	329	27	intent	intent	NOUN
aji-153	329	28	-	-	PUNCT
aji-153	329	29	to	to	ADP
aji-153	329	30	-	-	PUNCT
aji-153	329	31	treat	treat	VERB
aji-153	329	32	patients	patient	NOUN
aji-153	329	33	who	who	PRON
aji-153	329	34	completed	complete	VERB
aji-153	329	35	the	the	DET
aji-153	329	36	study	study	NOUN
aji-153	329	37	,	,	PUNCT
aji-153	329	38	had	have	VERB
aji-153	329	39	efficacy	efficacy	NOUN
aji-153	329	40	data	datum	NOUN
aji-153	329	41	through	through	ADP
aji-153	329	42	week	week	NOUN
aji-153	329	43	20	20	NUM
aji-153	329	44	,	,	PUNCT
aji-153	329	45	were	be	AUX
aji-153	329	46	≥80	≥80	NUM
aji-153	329	47	%	%	NOUN
aji-153	329	48	compliant	compliant	ADJ
aji-153	329	49	with	with	ADP
aji-153	329	50	study	study	NOUN
aji-153	329	51	medication	medication	NOUN
aji-153	329	52	,	,	PUNCT
aji-153	329	53	and	and	CCONJ
aji-153	329	54	did	do	AUX
aji-153	329	55	not	not	PART
aji-153	329	56	have	have	VERB
aji-153	329	57	a	a	DET
aji-153	329	58	major	major	ADJ
aji-153	329	59	protocol	protocol	NOUN
aji-153	329	60	deviation	deviation	NOUN
aji-153	329	61	[	[	X
aji-153	329	62	25	25	NUM
aji-153	329	63	]	]	PUNCT
aji-153	329	64	.	.	PUNCT
aji-153	330	1	a	a	DET
aji-153	330	2	total	total	NOUN
aji-153	330	3	of	of	ADP
aji-153	330	4	160	160	NUM
aji-153	330	5	patients	patient	NOUN
aji-153	330	6	qualified	qualify	VERB
aji-153	330	7	for	for	ADP
aji-153	330	8	the	the	DET
aji-153	330	9	perprotocol	perprotocol	ADJ
aji-153	330	10	population	population	NOUN
aji-153	330	11	.	.	PUNCT
aji-153	331	1	of	of	ADP
aji-153	331	2	the	the	DET
aji-153	331	3	210	210	NUM
aji-153	331	4	patients	patient	NOUN
aji-153	331	5	who	who	PRON
aji-153	331	6	were	be	AUX
aji-153	331	7	treated	treat	VERB
aji-153	331	8	with	with	ADP
aji-153	331	9	the	the	DET
aji-153	331	10	study	study	NOUN
aji-153	331	11	medication	medication	NOUN
aji-153	331	12	,	,	PUNCT
aji-153	331	13	81	81	NUM
aji-153	331	14	%	%	NOUN
aji-153	331	15	(	(	PUNCT
aji-153	331	16	n	n	NOUN
aji-153	331	17	=	=	SYM
aji-153	331	18	112	112	NUM
aji-153	331	19	)	)	PUNCT
aji-153	331	20	in	in	ADP
aji-153	331	21	the	the	DET
aji-153	331	22	vadadustat	vadadustat	NOUN
aji-153	331	23	group	group	NOUN
aji-153	331	24	and	and	CCONJ
aji-153	331	25	88	88	NUM
aji-153	331	26	%	%	NOUN
aji-153	331	27	(	(	PUNCT
aji-153	331	28	n	n	NOUN
aji-153	331	29	=	=	SYM
aji-153	331	30	63	63	NUM
aji-153	331	31	)	)	PUNCT
aji-153	331	32	in	in	ADP
aji-153	331	33	the	the	DET
aji-153	331	34	placebo	placebo	NOUN
aji-153	331	35	group	group	NOUN
aji-153	331	36	completed	complete	VERB
aji-153	331	37	treatment	treatment	NOUN
aji-153	331	38	through	through	ADP
aji-153	331	39	to	to	ADP
aji-153	331	40	week	week	NOUN
aji-153	331	41	20	20	NUM
aji-153	331	42	of	of	ADP
aji-153	331	43	the	the	DET
aji-153	331	44	study	study	NOUN
aji-153	331	45	.	.	PUNCT
aji-153	332	1	in	in	ADP
aji-153	332	2	terms	term	NOUN
aji-153	332	3	of	of	ADP
aji-153	332	4	demographic	demographic	ADJ
aji-153	332	5	and	and	CCONJ
aji-153	332	6	disease	disease	NOUN
aji-153	332	7	-	-	PUNCT
aji-153	332	8	related	relate	VERB
aji-153	332	9	characteristics	characteristic	NOUN
aji-153	332	10	,	,	PUNCT
aji-153	332	11	hb	hb	PROPN
aji-153	332	12	,	,	PUNCT
aji-153	332	13	hemoglobin	hemoglobin	NOUN
aji-153	332	14	;	;	PUNCT
aji-153	332	15	itt	itt	ADJ
aji-153	332	16	,	,	PUNCT
aji-153	332	17	intent	intent	NOUN
aji-153	332	18	-	-	PUNCT
aji-153	332	19	totreat	totreat	NOUN
aji-153	332	20	population	population	NOUN
aji-153	332	21	,	,	PUNCT
aji-153	332	22	i.e.	i.e.	ADV
aji-153	332	23	all	all	PRON
aji-153	332	24	randomized	randomize	VERB
aji-153	332	25	patients	patient	NOUN
aji-153	332	26	who	who	PRON
aji-153	332	27	received	receive	VERB
aji-153	332	28	≥1	≥1	PROPN
aji-153	332	29	dose	dose	NOUN
aji-153	332	30	of	of	ADP
aji-153	332	31	study	study	NOUN
aji-153	332	32	medication	medication	NOUN
aji-153	332	33	;	;	PUNCT
aji-153	332	34	tsat	tsat	VERB
aji-153	332	35	,	,	PUNCT
aji-153	332	36	transferrin	transferrin	NOUN
aji-153	332	37	saturation	saturation	NOUN
aji-153	332	38	;	;	PUNCT
aji-153	332	39	uacr	uacr	PRON
aji-153	332	40	,	,	PUNCT
aji-153	332	41	urine	urine	ADJ
aji-153	332	42	albumin	albumin	ADJ
aji-153	332	43	-	-	PUNCT
aji-153	332	44	tocreatinine	tocreatinine	NOUN
aji-153	332	45	ratio	ratio	NOUN
aji-153	332	46	.	.	PUNCT
aji-153	333	1	values	value	NOUN
aji-153	333	2	are	be	AUX
aji-153	333	3	n	n	PRON
aji-153	333	4	(	(	PUNCT
aji-153	333	5	%	%	INTJ
aji-153	333	6	)	)	PUNCT
aji-153	333	7	or	or	CCONJ
aji-153	333	8	mean	mean	VERB
aji-153	333	9	±	±	NUM
aji-153	333	10	sd	sd	NOUN
aji-153	333	11	.	.	PUNCT
aji-153	334	1	if	if	SCONJ
aji-153	334	2	a	a	DET
aji-153	334	3	subject	subject	NOUN
aji-153	334	4	had	have	VERB
aji-153	334	5	>	>	SYM
aji-153	334	6	1	1	NUM
aji-153	334	7	reason	reason	NOUN
aji-153	334	8	checked	check	VERB
aji-153	334	9	for	for	ADP
aji-153	334	10	etiology	etiology	NOUN
aji-153	334	11	of	of	ADP
aji-153	334	12	ckd	ckd	PROPN
aji-153	334	13	,	,	PUNCT
aji-153	334	14	all	all	DET
aji-153	334	15	reasons	reason	NOUN
aji-153	334	16	were	be	AUX
aji-153	334	17	counted	count	VERB
aji-153	334	18	.	.	PUNCT
aji-153	335	1	the	the	DET
aji-153	335	2	most	most	ADV
aji-153	335	3	important	important	ADJ
aji-153	335	4	endpoint	endpoint	NOUN
aji-153	335	5	of	of	ADP
aji-153	335	6	the	the	DET
aji-153	335	7	investigation	investigation	NOUN
aji-153	335	8	was	be	AUX
aji-153	335	9	the	the	DET
aji-153	335	10	percentage	percentage	NOUN
aji-153	335	11	of	of	ADP
aji-153	335	12	patients	patient	NOUN
aji-153	335	13	reaching	reach	VERB
aji-153	335	14	or	or	CCONJ
aji-153	335	15	maintaining	maintain	VERB
aji-153	335	16	a	a	DET
aji-153	335	17	mean	mean	NOUN
aji-153	335	18	hb	hb	X
aji-153	335	19	≥11.0	≥11.0	X
aji-153	335	20	g	g	PROPN
aji-153	335	21	/	/	SYM
aji-153	335	22	dl	dl	PROPN
aji-153	335	23	at	at	ADP
aji-153	335	24	the	the	DET
aji-153	335	25	end	end	NOUN
aji-153	335	26	of	of	ADP
aji-153	335	27	the	the	DET
aji-153	335	28	last	last	ADJ
aji-153	335	29	2	2	NUM
aji-153	335	30	weeks	week	NOUN
aji-153	335	31	of	of	ADP
aji-153	335	32	treatment	treatment	NOUN
aji-153	335	33	or	or	CCONJ
aji-153	335	34	showing	show	VERB
aji-153	335	35	an	an	DET
aji-153	335	36	increase	increase	NOUN
aji-153	335	37	in	in	ADP
aji-153	335	38	hb	hb	X
aji-153	335	39	≥1.2	≥1.2	NOUN
aji-153	335	40	g	g	PROPN
aji-153	335	41	/	/	SYM
aji-153	335	42	dl	dl	PROPN
aji-153	335	43	above	above	ADP
aji-153	335	44	the	the	DET
aji-153	335	45	per	per	X
aji-153	335	46	dose	dose	NOUN
aji-153	335	47	average	average	NOUN
aji-153	335	48	[	[	X
aji-153	335	49	26	26	NUM
aji-153	335	50	]	]	PUNCT
aji-153	335	51	.	.	PUNCT
aji-153	336	1	vadadustat	vadadustat	PROPN
aji-153	336	2	treatment	treatment	NOUN
aji-153	336	3	raised	raise	VERB
aji-153	336	4	and	and	CCONJ
aji-153	336	5	maintained	maintain	VERB
aji-153	336	6	hb	hb	PROPN
aji-153	336	7	levels	level	NOUN
aji-153	336	8	in	in	ADP
aji-153	336	9	the	the	DET
aji-153	336	10	patients	patient	NOUN
aji-153	336	11	with	with	ADP
aji-153	336	12	anemia	anemia	NOUN
aji-153	336	13	secondary	secondary	ADJ
aji-153	336	14	to	to	ADP
aji-153	336	15	ckd	ckd	PROPN
aji-153	336	16	.	.	PUNCT
aji-153	337	1	in	in	ADP
aji-153	337	2	the	the	DET
aji-153	337	3	per	per	ADP
aji-153	337	4	-	-	PUNCT
aji-153	337	5	protocol	protocol	NOUN
aji-153	337	6	population	population	NOUN
aji-153	337	7	,	,	PUNCT
aji-153	337	8	54.9	54.9	NUM
aji-153	337	9	%	%	NOUN
aji-153	337	10	of	of	ADP
aji-153	337	11	patients	patient	NOUN
aji-153	337	12	treated	treat	VERB
aji-153	337	13	with	with	ADP
aji-153	337	14	vadadustat	vadadustat	NOUN
aji-153	337	15	achieved	achieve	VERB
aji-153	337	16	the	the	DET
aji-153	337	17	primary	primary	ADJ
aji-153	337	18	endpoint	endpoint	NOUN
aji-153	337	19	compared	compare	VERB
aji-153	337	20	with	with	ADP
aji-153	337	21	10.3	10.3	NUM
aji-153	337	22	%	%	NOUN
aji-153	337	23	of	of	ADP
aji-153	337	24	patients	patient	NOUN
aji-153	337	25	treated	treat	VERB
aji-153	337	26	with	with	ADP
aji-153	337	27	the	the	DET
aji-153	337	28	placebo	placebo	NOUN
aji-153	337	29	(	(	PUNCT
aji-153	337	30	p	p	X
aji-153	337	31	<	<	X
aji-153	337	32	0.0001	0.0001	NUM
aji-153	337	33	)	)	PUNCT
aji-153	337	34	.	.	PUNCT
aji-153	338	1	at	at	ADP
aji-153	338	2	an	an	DET
aji-153	338	3	estimated	estimate	VERB
aji-153	338	4	odds	odd	NOUN
aji-153	338	5	ratio	ratio	NOUN
aji-153	338	6	,	,	PUNCT
aji-153	338	7	patients	patient	NOUN
aji-153	338	8	receiving	receive	VERB
aji-153	338	9	vadadustat	vadadustat	NOUN
aji-153	338	10	were	be	AUX
aji-153	338	11	approximately	approximately	ADV
aji-153	338	12	11.5	11.5	NUM
aji-153	338	13	times	time	NOUN
aji-153	338	14	more	more	ADV
aji-153	338	15	likely	likely	ADJ
aji-153	338	16	than	than	ADP
aji-153	338	17	patients	patient	NOUN
aji-153	338	18	receiving	receive	VERB
aji-153	338	19	a	a	DET
aji-153	338	20	placebo	placebo	NOUN
aji-153	338	21	to	to	PART
aji-153	338	22	attain	attain	VERB
aji-153	338	23	a	a	DET
aji-153	338	24	successful	successful	ADJ
aji-153	338	25	hb	hb	X
aji-153	338	26	response	response	NOUN
aji-153	338	27	(	(	PUNCT
aji-153	338	28	p	p	NOUN
aji-153	338	29	=	=	NOUN
aji-153	338	30	0.0001	0.0001	NUM
aji-153	338	31	)	)	PUNCT
aji-153	338	32	success	success	NOUN
aji-153	338	33	:	:	PUNCT
aji-153	338	34	hb	hb	PROPN
aji-153	338	35	average	average	NOUN
aji-153	338	36	of	of	ADP
aji-153	338	37	weeks	week	NOUN
aji-153	338	38	19	19	NUM
aji-153	338	39	and	and	CCONJ
aji-153	338	40	20	20	NUM
aji-153	338	41	≥11.0	≥11.0	NOUN
aji-153	338	42	g	g	PROPN
aji-153	338	43	/	/	SYM
aji-153	338	44	dl	dl	PROPN
aji-153	338	45	or	or	CCONJ
aji-153	338	46	hb	hb	X
aji-153	338	47	average	average	NOUN
aji-153	338	48	of	of	ADP
aji-153	338	49	weeks	week	NOUN
aji-153	338	50	19	19	NUM
aji-153	338	51	and	and	CCONJ
aji-153	338	52	20	20	NUM
aji-153	338	53	≥1.2	≥1.2	NOUN
aji-153	338	54	g	g	PROPN
aji-153	338	55	/	/	SYM
aji-153	338	56	dl	dl	NOUN
aji-153	338	57	higher	high	ADJ
aji-153	338	58	than	than	ADP
aji-153	338	59	predose	predose	NOUN
aji-153	338	60	mean	mean	NOUN
aji-153	338	61	.	.	PUNCT
aji-153	339	1	for	for	ADP
aji-153	339	2	a	a	DET
aji-153	339	3	missing	miss	VERB
aji-153	339	4	value	value	NOUN
aji-153	339	5	,	,	PUNCT
aji-153	339	6	a	a	DET
aji-153	339	7	single	single	ADJ
aji-153	339	8	value	value	NOUN
aji-153	339	9	was	be	AUX
aji-153	339	10	used	use	VERB
aji-153	339	11	p	p	NOUN
aji-153	339	12	-	-	PUNCT
aji-153	339	13	value	value	NOUN
aji-153	339	14	for	for	ADP
aji-153	339	15	vadadustat	vadadustat	NOUN
aji-153	339	16	versus	versus	ADP
aji-153	339	17	placebo	placebo	NOUN
aji-153	339	18	is	be	AUX
aji-153	339	19	from	from	ADP
aji-153	339	20	a	a	DET
aji-153	339	21	logistic	logistic	ADJ
aji-153	339	22	regression	regression	NOUN
aji-153	339	23	analysis	analysis	NOUN
aji-153	340	1	[	[	X
aji-153	340	2	27	27	NUM
aji-153	340	3	]	]	SYM
aji-153	340	4	.	.	PUNCT
aji-153	340	5	vadadustat	vadadustat	PROPN
aji-153	340	6	dose	dose	NOUN
aji-153	340	7	-	-	PUNCT
aji-153	340	8	robustly	robustly	ADV
aji-153	340	9	increased	increase	VERB
aji-153	340	10	and	and	CCONJ
aji-153	340	11	maintained	maintain	VERB
aji-153	340	12	hb	hb	PROPN
aji-153	340	13	levels	level	NOUN
aji-153	340	14	in	in	ADP
aji-153	340	15	patients	patient	NOUN
aji-153	340	16	throughout	throughout	ADP
aji-153	340	17	the	the	DET
aji-153	340	18	20	20	NUM
aji-153	340	19	-	-	PUNCT
aji-153	340	20	week	week	NOUN
aji-153	340	21	study	study	NOUN
aji-153	340	22	.	.	PUNCT
aji-153	341	1	by	by	ADP
aji-153	341	2	week	week	NOUN
aji-153	341	3	2	2	NUM
aji-153	341	4	,	,	PUNCT
aji-153	341	5	mean	mean	VERB
aji-153	341	6	hb	hb	NOUN
aji-153	341	7	levels	level	NOUN
aji-153	341	8	in	in	ADP
aji-153	341	9	the	the	DET
aji-153	341	10	vadadustat	vadadustat	NOUN
aji-153	341	11	group	group	NOUN
aji-153	341	12	had	have	AUX
aji-153	341	13	increased	increase	VERB
aji-153	341	14	substantially	substantially	ADV
aji-153	341	15	from	from	ADP
aji-153	341	16	baseline	baseline	NOUN
aji-153	341	17	;	;	PUNCT
aji-153	341	18	hb	hb	PROPN
aji-153	341	19	levels	level	NOUN
aji-153	341	20	plateaued	plateaue	VERB
aji-153	341	21	between	between	ADP
aji-153	341	22	weeks	week	NOUN
aji-153	341	23	6	6	NUM
aji-153	341	24	to	to	PART
aji-153	341	25	8	8	NUM
aji-153	341	26	and	and	CCONJ
aji-153	341	27	were	be	AUX
aji-153	341	28	maintained	maintain	VERB
aji-153	341	29	throughout	throughout	ADP
aji-153	341	30	the	the	DET
aji-153	341	31	20	20	NUM
aji-153	341	32	weeks	week	NOUN
aji-153	341	33	of	of	ADP
aji-153	341	34	treatment	treatment	NOUN
aji-153	341	35	hb	hb	X
aji-153	341	36	response	response	NOUN
aji-153	341	37	versus	versus	ADP
aji-153	341	38	time	time	NOUN
aji-153	341	39	in	in	ADP
aji-153	341	40	each	each	PRON
aji-153	341	41	of	of	ADP
aji-153	341	42	the	the	DET
aji-153	341	43	3	3	NUM
aji-153	341	44	study	study	NOUN
aji-153	341	45	groups	group	NOUN
aji-153	341	46	based	base	VERB
aji-153	341	47	on	on	ADP
aji-153	341	48	esa	esa	PROPN
aji-153	341	49	treatment	treatment	NOUN
aji-153	341	50	status	status	NOUN
aji-153	341	51	is	be	AUX
aji-153	341	52	shown	show	VERB
aji-153	341	53	in	in	ADP
aji-153	341	54	hb	hb	PROPN
aji-153	341	55	excursions	excursion	NOUN
aji-153	341	56	≥13	≥13	PUNCT
aji-153	341	57	g	g	NOUN
aji-153	341	58	/	/	SYM
aji-153	341	59	dl	dl	PROPN
aji-153	341	60	occurred	occur	VERB
aji-153	341	61	in	in	ADP
aji-153	341	62	only	only	ADV
aji-153	341	63	4.3	4.3	NUM
aji-153	341	64	%	%	NOUN
aji-153	341	65	(	(	PUNCT
aji-153	341	66	6	6	NUM
aji-153	341	67	of	of	ADP
aji-153	341	68	138	138	NUM
aji-153	341	69	)	)	PUNCT
aji-153	341	70	of	of	ADP
aji-153	341	71	patients	patient	NOUN
aji-153	341	72	in	in	ADP
aji-153	341	73	the	the	DET
aji-153	341	74	vadadustat	vadadustat	NOUN
aji-153	341	75	group	group	NOUN
aji-153	341	76	.	.	PUNCT
aji-153	342	1	post	post	VERB
aji-153	342	2	hoc	hoc	X
aji-153	342	3	analysis	analysis	NOUN
aji-153	342	4	of	of	ADP
aji-153	342	5	hb	hb	NOUN
aji-153	342	6	values	value	NOUN
aji-153	342	7	for	for	ADP
aji-153	342	8	all	all	DET
aji-153	342	9	weeks	week	NOUN
aji-153	342	10	between	between	ADP
aji-153	342	11	8	8	NUM
aji-153	342	12	and	and	CCONJ
aji-153	342	13	20	20	NUM
aji-153	342	14	:	:	PUNCT
aji-153	342	15	for	for	ADP
aji-153	342	16	vadadustat	vadadustat	NOUN
aji-153	342	17	71.2	71.2	NUM
aji-153	342	18	%	%	NOUN
aji-153	342	19	and	and	CCONJ
aji-153	342	20	for	for	ADP
aji-153	342	21	placebo	placebo	NOUN
aji-153	342	22	42.7	42.7	NUM
aji-153	342	23	%	%	NOUN
aji-153	342	24	were	be	AUX
aji-153	342	25	between	between	ADP
aji-153	342	26	10	10	NUM
aji-153	342	27	and	and	CCONJ
aji-153	342	28	<	<	X
aji-153	342	29	12	12	NUM
aji-153	342	30	g	g	NOUN
aji-153	342	31	/	/	SYM
aji-153	342	32	dl	dl	PROPN
aji-153	342	33	;	;	PUNCT
aji-153	342	34	and	and	CCONJ
aji-153	342	35	for	for	ADP
aji-153	342	36	vadadustat	vadadustat	NOUN
aji-153	342	37	8.9	8.9	NUM
aji-153	342	38	%	%	NOUN
aji-153	342	39	were	be	AUX
aji-153	342	40	between	between	ADP
aji-153	342	41	12.0	12.0	NUM
aji-153	342	42	and	and	CCONJ
aji-153	342	43	12.9	12.9	NUM
aji-153	342	44	g	g	NOUN
aji-153	342	45	/	/	SYM
aji-153	342	46	dl	dl	PROPN
aji-153	342	47	,	,	PUNCT
aji-153	342	48	1	1	NUM
aji-153	342	49	%	%	NOUN
aji-153	342	50	were	be	AUX
aji-153	342	51	≥13.0	≥13.0	PUNCT
aji-153	342	52	g	g	PROPN
aji-153	342	53	/	/	SYM
aji-153	342	54	dl	dl	NOUN
aji-153	342	55	,	,	PUNCT
aji-153	342	56	while	while	SCONJ
aji-153	342	57	none	none	NOUN
aji-153	342	58	for	for	ADP
aji-153	342	59	the	the	DET
aji-153	342	60	placebo	placebo	NOUN
aji-153	342	61	group	group	NOUN
aji-153	342	62	were≥12.0	were≥12.0	PROPN
aji-153	342	63	g	g	PROPN
aji-153	342	64	/	/	SYM
aji-153	342	65	dl	dl	PROPN
aji-153	343	1	[	[	X
aji-153	343	2	28	28	NUM
aji-153	343	3	]	]	PUNCT
aji-153	343	4	.	.	PUNCT
aji-153	344	1	fewer	few	ADJ
aji-153	344	2	vadadustat	vadadustat	NOUN
aji-153	344	3	-	-	PUNCT
aji-153	344	4	treated	treat	VERB
aji-153	344	5	patients	patient	NOUN
aji-153	344	6	required	require	VERB
aji-153	344	7	esa	esa	PROPN
aji-153	344	8	rescue	rescue	NOUN
aji-153	344	9	therapy	therapy	NOUN
aji-153	344	10	compared	compare	VERB
aji-153	344	11	with	with	ADP
aji-153	344	12	placebo	placebo	NOUN
aji-153	344	13	(	(	PUNCT
aji-153	344	14	4.4	4.4	NUM
aji-153	344	15	%	%	NOUN
aji-153	344	16	vs	vs	ADP
aji-153	344	17	16.7	16.7	NUM
aji-153	344	18	%	%	NOUN
aji-153	344	19	,	,	PUNCT
aji-153	344	20	p	p	X
aji-153	344	21	=	=	NOUN
aji-153	344	22	0.045	0.045	NUM
aji-153	344	23	)	)	PUNCT
aji-153	344	24	.	.	PUNCT
aji-153	345	1	of	of	ADP
aji-153	345	2	the	the	DET
aji-153	345	3	6	6	NUM
aji-153	345	4	vadadustat	vadadustat	NOUN
aji-153	345	5	-	-	PUNCT
aji-153	345	6	treated	treat	VERB
aji-153	345	7	patients	patient	NOUN
aji-153	345	8	who	who	PRON
aji-153	345	9	received	receive	VERB
aji-153	345	10	esa	esa	NOUN
aji-153	345	11	during	during	ADP
aji-153	345	12	the	the	DET
aji-153	345	13	study	study	NOUN
aji-153	345	14	,	,	PUNCT
aji-153	345	15	4	4	NUM
aji-153	345	16	did	do	AUX
aji-153	345	17	not	not	PART
aji-153	345	18	meet	meet	VERB
aji-153	345	19	the	the	DET
aji-153	345	20	protocol	protocol	NOUN
aji-153	345	21	-	-	PUNCT
aji-153	345	22	prespecified	prespecifie	VERB
aji-153	345	23	criteria	criterion	NOUN
aji-153	345	24	for	for	ADP
aji-153	345	25	esa	esa	NOUN
aji-153	345	26	rescue	rescue	NOUN
aji-153	345	27	;	;	PUNCT
aji-153	345	28	of	of	ADP
aji-153	345	29	the	the	DET
aji-153	345	30	remaining	remain	VERB
aji-153	345	31	2	2	NUM
aji-153	345	32	,	,	PUNCT
aji-153	345	33	1	1	NUM
aji-153	345	34	was	be	AUX
aji-153	345	35	in	in	ADP
aji-153	345	36	the	the	DET
aji-153	345	37	previously	previously	ADV
aji-153	345	38	treated	treat	VERB
aji-153	345	39	group	group	NOUN
aji-153	345	40	,	,	PUNCT
aji-153	345	41	and	and	CCONJ
aji-153	345	42	1	1	NUM
aji-153	345	43	in	in	ADP
aji-153	345	44	the	the	DET
aji-153	345	45	actively	actively	ADV
aji-153	345	46	treated	treat	VERB
aji-153	345	47	group	group	NOUN
aji-153	345	48	.	.	PUNCT
aji-153	346	1	out	out	ADP
aji-153	346	2	of	of	ADP
aji-153	346	3	the	the	DET
aji-153	346	4	12	12	NUM
aji-153	346	5	placebo	placebo	NOUN
aji-153	346	6	patients	patient	NOUN
aji-153	346	7	treated	treat	VERB
aji-153	346	8	with	with	ADP
aji-153	346	9	esa	esa	PROPN
aji-153	346	10	rescue	rescue	NOUN
aji-153	346	11	,	,	PUNCT
aji-153	346	12	2	2	NUM
aji-153	346	13	did	do	AUX
aji-153	346	14	not	not	PART
aji-153	346	15	meet	meet	VERB
aji-153	346	16	protocol	protocol	NOUN
aji-153	346	17	-	-	PUNCT
aji-153	346	18	specified	specify	VERB
aji-153	346	19	criteria	criterion	NOUN
aji-153	346	20	;	;	PUNCT
aji-153	346	21	of	of	ADP
aji-153	346	22	the	the	DET
aji-153	346	23	remaining	remain	VERB
aji-153	346	24	10	10	NUM
aji-153	346	25	,	,	PUNCT
aji-153	346	26	1	1	NUM
aji-153	346	27	was	be	AUX
aji-153	346	28	in	in	ADP
aji-153	346	29	the	the	DET
aji-153	346	30	treatment	treatment	NOUN
aji-153	346	31	naïve	naïve	ADJ
aji-153	346	32	group	group	NOUN
aji-153	346	33	,	,	PUNCT
aji-153	346	34	3	3	NUM
aji-153	346	35	were	be	AUX
aji-153	346	36	in	in	ADP
aji-153	346	37	the	the	DET
aji-153	346	38	previously	previously	ADV
aji-153	346	39	treated	treat	VERB
aji-153	346	40	group	group	NOUN
aji-153	346	41	,	,	PUNCT
aji-153	346	42	and	and	CCONJ
aji-153	346	43	6	6	NUM
aji-153	346	44	were	be	AUX
aji-153	346	45	in	in	ADP
aji-153	346	46	the	the	DET
aji-153	346	47	actively	actively	ADV
aji-153	346	48	treated	treat	VERB
aji-153	346	49	group	group	NOUN
aji-153	346	50	.	.	PUNCT
aji-153	347	1	no	no	DET
aji-153	347	2	patient	patient	NOUN
aji-153	347	3	receiving	receiving	NOUN
aji-153	347	4	vadadustat	vadadustat	NOUN
aji-153	347	5	and	and	CCONJ
aji-153	347	6	1	1	NUM
aji-153	347	7	placebo	placebo	NOUN
aji-153	347	8	-	-	PUNCT
aji-153	347	9	treated	treat	VERB
aji-153	347	10	patient	patient	NOUN
aji-153	347	11	required	require	VERB
aji-153	347	12	transfusion	transfusion	NOUN
aji-153	347	13	rescue	rescue	NOUN
aji-153	347	14	at	at	ADP
aji-153	347	15	any	any	DET
aji-153	347	16	time	time	NOUN
aji-153	347	17	during	during	ADP
aji-153	347	18	the	the	DET
aji-153	347	19	trial	trial	NOUN
aji-153	347	20	[	[	X
aji-153	347	21	29	29	NUM
aji-153	347	22	]	]	PUNCT
aji-153	347	23	.	.	PUNCT
aji-153	348	1	baseline	baseline	PROPN
aji-153	348	2	increase	increase	NOUN
aji-153	348	3	in	in	ADP
aji-153	348	4	mean	mean	ADJ
aji-153	348	5	absolute	absolute	ADJ
aji-153	348	6	reticulocyte	reticulocyte	NOUN
aji-153	348	7	count	count	NOUN
aji-153	348	8	occurred	occur	VERB
aji-153	348	9	in	in	ADP
aji-153	348	10	the	the	DET
aji-153	348	11	vadadustat	vadadustat	NOUN
aji-153	348	12	group	group	NOUN
aji-153	348	13	at	at	ADP
aji-153	348	14	week	week	NOUN
aji-153	348	15	2	2	NUM
aji-153	348	16	(	(	PUNCT
aji-153	348	17	+0.022	+0.022	NOUN
aji-153	348	18	×	×	PROPN
aji-153	348	19	10	10	NUM
aji-153	348	20	6	6	NUM
aji-153	348	21	/μl	/μl	ADV
aji-153	348	22	)	)	PUNCT
aji-153	348	23	compared	compare	VERB
aji-153	348	24	with	with	ADP
aji-153	348	25	a	a	DET
aji-153	348	26	slight	slight	ADJ
aji-153	348	27	decrease	decrease	NOUN
aji-153	348	28	in	in	ADP
aji-153	348	29	the	the	DET
aji-153	348	30	placebo	placebo	NOUN
aji-153	348	31	group	group	NOUN
aji-153	348	32	(	(	PUNCT
aji-153	348	33	–	–	PUNCT
aji-153	348	34	0.005	0.005	NUM
aji-153	348	35	×	×	NOUN
aji-153	348	36	10	10	NUM
aji-153	348	37	6	6	NUM
aji-153	348	38	/μl	/μl	PRON
aji-153	348	39	;	;	PUNCT
aji-153	348	40	p	p	X
aji-153	348	41	=	=	NOUN
aji-153	348	42	0.0001	0.0001	NUM
aji-153	348	43	)	)	PUNCT
aji-153	349	1	[	[	X
aji-153	349	2	30	30	NUM
aji-153	349	3	]	]	PUNCT
aji-153	349	4	.	.	PUNCT
aji-153	350	1	the	the	DET
aji-153	350	2	mean	mean	ADJ
aji-153	350	3	reticulocyte	reticulocyte	NOUN
aji-153	350	4	count	count	NOUN
aji-153	350	5	in	in	ADP
aji-153	350	6	the	the	DET
aji-153	350	7	vadadustat	vadadustat	NOUN
aji-153	350	8	group	group	NOUN
aji-153	350	9	continued	continue	VERB
aji-153	350	10	to	to	PART
aji-153	350	11	decrease	decrease	VERB
aji-153	350	12	and	and	CCONJ
aji-153	350	13	reached	reach	VERB
aji-153	350	14	plateau	plateau	NOUN
aji-153	350	15	during	during	ADP
aji-153	350	16	weeks	week	NOUN
aji-153	350	17	6	6	NUM
aji-153	350	18	to	to	PART
aji-153	350	19	8	8	NUM
aji-153	350	20	at	at	ADP
aji-153	350	21	a	a	DET
aji-153	350	22	level	level	NOUN
aji-153	350	23	significantly	significantly	ADV
aji-153	350	24	above	above	ADP
aji-153	350	25	that	that	PRON
aji-153	350	26	of	of	ADP
aji-153	350	27	the	the	DET
aji-153	350	28	placebo	placebo	NOUN
aji-153	350	29	group	group	NOUN
aji-153	350	30	,	,	PUNCT
aji-153	350	31	reflecting	reflect	VERB
aji-153	350	32	the	the	DET
aji-153	350	33	new	new	ADJ
aji-153	350	34	hb	hb	PROPN
aji-153	350	35	baseline	baseline	PROPN
aji-153	350	36	.	.	PUNCT
aji-153	351	1	markedly	markedly	ADV
aji-153	351	2	lower	lower	ADV
aji-153	351	3	hepcidin	hepcidin	ADJ
aji-153	351	4	and	and	CCONJ
aji-153	351	5	ferritin	ferritin	ADJ
aji-153	351	6	levels	level	NOUN
aji-153	351	7	and	and	CCONJ
aji-153	351	8	significantly	significantly	ADV
aji-153	351	9	higher	high	ADJ
aji-153	351	10	total	total	ADJ
aji-153	351	11	ironbinding	ironbinding	NOUN
aji-153	351	12	capacity	capacity	NOUN
aji-153	351	13	were	be	AUX
aji-153	351	14	noted	note	VERB
aji-153	351	15	in	in	ADP
aji-153	351	16	the	the	DET
aji-153	351	17	vadadustat	vadadustat	NOUN
aji-153	351	18	group	group	NOUN
aji-153	351	19	,	,	PUNCT
aji-153	351	20	compared	compare	VERB
aji-153	351	21	with	with	ADP
aji-153	351	22	the	the	DET
aji-153	351	23	placebo	placebo	NOUN
aji-153	351	24	group	group	NOUN
aji-153	351	25	,	,	PUNCT
aji-153	351	26	at	at	ADP
aji-153	351	27	each	each	DET
aji-153	351	28	postbaseline	postbaseline	NOUN
aji-153	351	29	evaluation	evaluation	NOUN
aji-153	351	30	.	.	PUNCT
aji-153	352	1	serum	serum	NOUN
aji-153	352	2	iron	iron	NOUN
aji-153	352	3	and	and	CCONJ
aji-153	352	4	transferrin	transferrin	NOUN
aji-153	352	5	saturation	saturation	NOUN
aji-153	352	6	did	do	AUX
aji-153	352	7	not	not	PART
aji-153	352	8	differ	differ	VERB
aji-153	352	9	between	between	ADP
aji-153	352	10	the	the	DET
aji-153	352	11	2	2	NUM
aji-153	352	12	treatment	treatment	NOUN
aji-153	352	13	groups	group	NOUN
aji-153	352	14	over	over	ADP
aji-153	352	15	the	the	DET
aji-153	352	16	course	course	NOUN
aji-153	352	17	of	of	ADP
aji-153	352	18	the	the	DET
aji-153	352	19	study	study	NOUN
aji-153	352	20	[	[	X
aji-153	352	21	31	31	NUM
aji-153	352	22	]	]	PUNCT
aji-153	352	23	.	.	PUNCT
aji-153	353	1	at	at	ADP
aji-153	353	2	the	the	DET
aji-153	353	3	end	end	NOUN
aji-153	353	4	of	of	ADP
aji-153	353	5	20	20	NUM
aji-153	353	6	weeks	week	NOUN
aji-153	353	7	,	,	PUNCT
aji-153	353	8	45.8	45.8	NUM
aji-153	353	9	%	%	NOUN
aji-153	353	10	of	of	ADP
aji-153	353	11	patients	patient	NOUN
aji-153	353	12	in	in	ADP
aji-153	353	13	the	the	DET
aji-153	353	14	vadadustat	vadadustat	NOUN
aji-153	353	15	group	group	NOUN
aji-153	353	16	were	be	AUX
aji-153	353	17	also	also	ADV
aji-153	353	18	receiving	receive	VERB
aji-153	353	19	iron	iron	NOUN
aji-153	353	20	supplementation	supplementation	NOUN
aji-153	353	21	,	,	PUNCT
aji-153	353	22	whereas	whereas	SCONJ
aji-153	353	23	52.8	52.8	NUM
aji-153	353	24	%	%	NOUN
aji-153	353	25	of	of	ADP
aji-153	353	26	those	those	PRON
aji-153	353	27	in	in	ADP
aji-153	353	28	the	the	DET
aji-153	353	29	placebo	placebo	NOUN
aji-153	353	30	group	group	NOUN
aji-153	353	31	were	be	AUX
aji-153	353	32	receiving	receive	VERB
aji-153	353	33	iron	iron	NOUN
aji-153	353	34	supplementation	supplementation	NOUN
aji-153	353	35	at	at	ADP
aji-153	353	36	this	this	DET
aji-153	353	37	point	point	NOUN
aji-153	353	38	.	.	PUNCT
aji-153	354	1	furthermore	furthermore	ADV
aji-153	354	2	,	,	PUNCT
aji-153	354	3	2.9	2.9	NUM
aji-153	354	4	%	%	NOUN
aji-153	354	5	of	of	ADP
aji-153	354	6	the	the	DET
aji-153	354	7	patients	patient	NOUN
aji-153	354	8	(	(	PUNCT
aji-153	354	9	4	4	NUM
aji-153	354	10	of	of	ADP
aji-153	354	11	136	136	NUM
aji-153	354	12	)	)	PUNCT
aji-153	354	13	receiving	receive	VERB
aji-153	354	14	vadadustat	vadadustat	NOUN
aji-153	354	15	,	,	PUNCT
aji-153	354	16	but	but	CCONJ
aji-153	354	17	none	none	NOUN
aji-153	354	18	in	in	ADP
aji-153	354	19	the	the	DET
aji-153	354	20	placebo	placebo	NOUN
aji-153	354	21	group	group	NOUN
aji-153	354	22	received	receive	VERB
aji-153	354	23	i.v	i.v	PRON
aji-153	354	24	.	.	PUNCT
aji-153	355	1	iron.initial	iron.initial	ADJ
aji-153	355	2	drug	drug	NOUN
aji-153	355	3	dosage	dosage	NOUN
aji-153	355	4	at	at	ADP
aji-153	355	5	treatment	treatment	NOUN
aji-153	355	6	initiation	initiation	NOUN
aji-153	355	7	was	be	AUX
aji-153	355	8	450	450	NUM
aji-153	355	9	mg	mg	NOUN
aji-153	355	10	once	once	ADV
aji-153	355	11	daily	daily	ADV
aji-153	355	12	;	;	PUNCT
aji-153	355	13	mean	mean	VERB
aji-153	355	14	drug	drug	NOUN
aji-153	355	15	dosage	dosage	NOUN
aji-153	355	16	at	at	ADP
aji-153	355	17	gupta	gupta	PROPN
aji-153	355	18	et	et	PROPN
aji-153	355	19	al	al	PROPN
aji-153	355	20	.	.	PROPN
aji-153	355	21	;	;	PUNCT
aji-153	356	1	asian	asian	PROPN
aji-153	356	2	j.	j.	PROPN
aji-153	356	3	immunol	immunol	PROPN
aji-153	356	4	.	.	PROPN
aji-153	356	5	,	,	PUNCT
aji-153	356	6	vol	vol	NOUN
aji-153	356	7	.	.	PROPN
aji-153	356	8	7	7	NUM
aji-153	356	9	,	,	PUNCT
aji-153	356	10	no	no	INTJ
aji-153	356	11	.	.	NOUN
aji-153	356	12	1	1	NUM
aji-153	356	13	,	,	PUNCT
aji-153	356	14	pp	pp	ADJ
aji-153	356	15	.	.	PUNCT
aji-153	357	1	302	302	NUM
aji-153	357	2	-	-	SYM
aji-153	357	3	315	315	NUM
aji-153	357	4	,	,	PUNCT
aji-153	357	5	2024	2024	NUM
aji-153	358	1	;	;	PUNCT
aji-153	358	2	article	article	NOUN
aji-153	358	3	no.aji.127402	no.aji.127402	VERB
aji-153	358	4	311	311	NUM
aji-153	358	5	week	week	NOUN
aji-153	358	6	19	19	NUM
aji-153	358	7	:	:	SYM
aji-153	358	8	450	450	NUM
aji-153	358	9	mg	mg	NOUN
aji-153	358	10	once	once	ADV
aji-153	358	11	daily	daily	ADV
aji-153	358	12	[	[	X
aji-153	358	13	32	32	NUM
aji-153	358	14	]	]	PUNCT
aji-153	358	15	.	.	PUNCT
aji-153	359	1	for	for	ADP
aji-153	359	2	the	the	DET
aji-153	359	3	majority	majority	NOUN
aji-153	359	4	of	of	ADP
aji-153	359	5	patients	patient	NOUN
aji-153	359	6	:	:	PUNCT
aji-153	359	7	89	89	NUM
aji-153	359	8	%	%	NOUN
aji-153	359	9	,	,	PUNCT
aji-153	359	10	120	120	NUM
aji-153	359	11	of	of	ADP
aji-153	359	12	135	135	NUM
aji-153	359	13	who	who	PRON
aji-153	359	14	received	receive	VERB
aji-153	359	15	vadadustat	vadadustat	NOUN
aji-153	359	16	,	,	PUNCT
aji-153	359	17	a	a	DET
aji-153	359	18	stable	stable	ADJ
aji-153	359	19	hb	hb	NOUN
aji-153	359	20	level	level	NOUN
aji-153	359	21	was	be	AUX
aji-153	359	22	achieved	achieve	VERB
aji-153	359	23	and	and	CCONJ
aji-153	359	24	maintained	maintain	VERB
aji-153	359	25	with	with	ADP
aji-153	359	26	≤2	≤2	NOUN
aji-153	359	27	dose	dose	NOUN
aji-153	359	28	adjustments	adjustment	NOUN
aji-153	359	29	over	over	ADP
aji-153	359	30	the	the	DET
aji-153	359	31	20	20	NUM
aji-153	359	32	-	-	PUNCT
aji-153	359	33	week	week	NOUN
aji-153	359	34	treatment	treatment	NOUN
aji-153	359	35	period	period	NOUN
aji-153	359	36	,	,	PUNCT
aji-153	359	37	and	and	CCONJ
aji-153	359	38	no	no	DET
aji-153	359	39	dose	dose	NOUN
aji-153	359	40	adjustment	adjustment	NOUN
aji-153	359	41	was	be	AUX
aji-153	359	42	required	require	VERB
aji-153	359	43	in	in	ADP
aji-153	359	44	24	24	NUM
aji-153	359	45	%	%	NOUN
aji-153	359	46	of	of	ADP
aji-153	359	47	patients	patient	NOUN
aji-153	359	48	(	(	PUNCT
aji-153	359	49	33	33	NUM
aji-153	359	50	of	of	ADP
aji-153	359	51	135	135	NUM
aji-153	359	52	)	)	PUNCT
aji-153	360	1	[	[	X
aji-153	360	2	33	33	NUM
aji-153	360	3	]	]	PUNCT
aji-153	360	4	.	.	PUNCT
aji-153	361	1	patients	patient	NOUN
aji-153	361	2	who	who	PRON
aji-153	361	3	were	be	AUX
aji-153	361	4	≥80	≥80	NUM
aji-153	361	5	%	%	NOUN
aji-153	361	6	compliant	compliant	ADJ
aji-153	361	7	with	with	ADP
aji-153	361	8	the	the	DET
aji-153	361	9	allocated	allocate	VERB
aji-153	361	10	treatment	treatment	NOUN
aji-153	361	11	had	have	VERB
aji-153	361	12	92.8	92.8	NUM
aji-153	361	13	%	%	NOUN
aji-153	361	14	(	(	PUNCT
aji-153	361	15	128/138	128/138	PROPN
aji-153	361	16	)	)	PUNCT
aji-153	361	17	in	in	ADP
aji-153	361	18	the	the	DET
aji-153	361	19	vadadustat	vadadustat	NOUN
aji-153	361	20	group	group	NOUN
aji-153	361	21	versus	versus	ADP
aji-153	361	22	94.4	94.4	NUM
aji-153	361	23	%	%	NOUN
aji-153	361	24	(	(	PUNCT
aji-153	361	25	68/72	68/72	NUM
aji-153	361	26	)	)	PUNCT
aji-153	361	27	in	in	ADP
aji-153	361	28	the	the	DET
aji-153	361	29	placebo	placebo	NOUN
aji-153	361	30	group	group	NOUN
aji-153	361	31	.	.	PUNCT
aji-153	362	1	a	a	DET
aji-153	362	2	higher	high	ADJ
aji-153	362	3	percentage	percentage	NOUN
aji-153	362	4	of	of	ADP
aji-153	362	5	the	the	DET
aji-153	362	6	vadadustat	vadadustat	NOUN
aji-153	362	7	-	-	PUNCT
aji-153	362	8	treated	treat	VERB
aji-153	362	9	patients	patient	NOUN
aji-153	362	10	experienced	experience	VERB
aji-153	362	11	≥1	≥1	NUM
aji-153	362	12	adverse	adverse	ADJ
aji-153	362	13	event	event	NOUN
aji-153	362	14	(	(	PUNCT
aji-153	362	15	ae	ae	PROPN
aji-153	362	16	)	)	PUNCT
aji-153	362	17	compared	compare	VERB
aji-153	362	18	to	to	ADP
aji-153	362	19	the	the	DET
aji-153	362	20	placebotreated	placebotreate	VERB
aji-153	362	21	patients	patient	NOUN
aji-153	362	22	(	(	PUNCT
aji-153	362	23	74.6	74.6	NUM
aji-153	362	24	%	%	NOUN
aji-153	362	25	vs	vs	ADP
aji-153	362	26	73.6	73.6	NUM
aji-153	362	27	)	)	PUNCT
aji-153	363	1	[	[	X
aji-153	363	2	34	34	NUM
aji-153	363	3	]	]	PUNCT
aji-153	363	4	.	.	PUNCT
aji-153	364	1	the	the	DET
aji-153	364	2	incidence	incidence	NOUN
aji-153	364	3	of	of	ADP
aji-153	364	4	≥1	≥1	NUM
aji-153	364	5	drug	drug	NOUN
aji-153	364	6	-	-	PUNCT
aji-153	364	7	related	relate	VERB
aji-153	364	8	ae	ae	PROPN
aji-153	364	9	was	be	AUX
aji-153	364	10	reported	report	VERB
aji-153	364	11	in	in	ADP
aji-153	364	12	25.4	25.4	NUM
aji-153	364	13	%	%	NOUN
aji-153	364	14	of	of	ADP
aji-153	364	15	the	the	DET
aji-153	364	16	vadadustat	vadadustat	NOUN
aji-153	364	17	-	-	PUNCT
aji-153	364	18	treated	treat	VERB
aji-153	364	19	patients	patient	NOUN
aji-153	364	20	(	(	PUNCT
aji-153	364	21	35	35	NUM
aji-153	364	22	of	of	ADP
aji-153	364	23	138	138	NUM
aji-153	364	24	)	)	PUNCT
aji-153	364	25	and	and	CCONJ
aji-153	364	26	in	in	ADP
aji-153	364	27	11.1	11.1	NUM
aji-153	364	28	%	%	NOUN
aji-153	364	29	of	of	ADP
aji-153	364	30	placebo	placebo	NOUN
aji-153	364	31	-	-	PUNCT
aji-153	364	32	treated	treat	VERB
aji-153	364	33	patients	patient	NOUN
aji-153	364	34	(	(	PUNCT
aji-153	364	35	8	8	NUM
aji-153	364	36	of	of	ADP
aji-153	364	37	72	72	NUM
aji-153	364	38	)	)	PUNCT
aji-153	364	39	.	.	PUNCT
aji-153	365	1	in	in	ADP
aji-153	365	2	both	both	DET
aji-153	365	3	treatment	treatment	NOUN
aji-153	365	4	arms	arm	NOUN
aji-153	365	5	,	,	PUNCT
aji-153	365	6	most	most	ADJ
aji-153	365	7	of	of	ADP
aji-153	365	8	the	the	DET
aji-153	365	9	aes	aes	NOUN
aji-153	365	10	reported	report	VERB
aji-153	365	11	were	be	AUX
aji-153	365	12	mild	mild	ADJ
aji-153	365	13	or	or	CCONJ
aji-153	365	14	moderate	moderate	ADJ
aji-153	365	15	in	in	ADP
aji-153	365	16	intensity	intensity	NOUN
aji-153	365	17	[	[	X
aji-153	365	18	35	35	NUM
aji-153	365	19	]	]	PUNCT
aji-153	365	20	.	.	PUNCT
aji-153	366	1	commonly	commonly	ADV
aji-153	366	2	reported	report	VERB
aji-153	366	3	drug	drug	NOUN
aji-153	366	4	-	-	PUNCT
aji-153	366	5	related	relate	VERB
aji-153	366	6	aes	aes	NOUN
aji-153	366	7	in	in	ADP
aji-153	366	8	the	the	DET
aji-153	366	9	vadadustat	vadadustat	NOUN
aji-153	366	10	group	group	NOUN
aji-153	366	11	were	be	AUX
aji-153	366	12	diarrhea	diarrhea	NOUN
aji-153	366	13	(	(	PUNCT
aji-153	366	14	4.3	4.3	NUM
aji-153	366	15	%	%	NOUN
aji-153	366	16	)	)	PUNCT
aji-153	366	17	,	,	PUNCT
aji-153	366	18	nausea	nausea	NOUN
aji-153	366	19	(	(	PUNCT
aji-153	366	20	4.3	4.3	NUM
aji-153	366	21	%	%	NOUN
aji-153	366	22	)	)	PUNCT
aji-153	366	23	,	,	PUNCT
aji-153	366	24	whereas	whereas	SCONJ
aji-153	366	25	most	most	ADJ
aji-153	366	26	commonly	commonly	ADV
aji-153	366	27	reported	report	VERB
aji-153	366	28	drugrelated	drugrelate	VERB
aji-153	366	29	ae	ae	PROPN
aji-153	366	30	in	in	ADP
aji-153	366	31	the	the	DET
aji-153	366	32	placebo	placebo	NOUN
aji-153	366	33	group	group	NOUN
aji-153	366	34	was	be	AUX
aji-153	366	35	diarrhoea	diarrhoea	NOUN
aji-153	366	36	(	(	PUNCT
aji-153	366	37	2.8	2.8	NUM
aji-153	366	38	%	%	NOUN
aji-153	366	39	)	)	PUNCT
aji-153	367	1	[	[	X
aji-153	367	2	36	36	NUM
aji-153	367	3	]	]	PUNCT
aji-153	367	4	.	.	PUNCT
aji-153	368	1	10	10	NUM
aji-153	368	2	patients	patient	NOUN
aji-153	368	3	treated	treat	VERB
aji-153	368	4	with	with	ADP
aji-153	368	5	vadadustat	vadadustat	NOUN
aji-153	368	6	(	(	PUNCT
aji-153	368	7	7.2	7.2	NUM
aji-153	368	8	%	%	NOUN
aji-153	368	9	)	)	PUNCT
aji-153	368	10	and	and	CCONJ
aji-153	368	11	three	three	NUM
aji-153	368	12	patients	patient	NOUN
aji-153	368	13	treated	treat	VERB
aji-153	368	14	with	with	ADP
aji-153	368	15	placebo	placebo	NOUN
aji-153	368	16	(	(	PUNCT
aji-153	368	17	4.2	4.2	NUM
aji-153	368	18	%	%	NOUN
aji-153	368	19	)	)	PUNCT
aji-153	368	20	discontinued	discontinue	VERB
aji-153	368	21	the	the	DET
aji-153	368	22	study	study	NOUN
aji-153	368	23	due	due	ADP
aji-153	368	24	to	to	ADP
aji-153	368	25	aes.not	aes.not	PROPN
aji-153	368	26	listed	list	VERB
aji-153	368	27	in	in	ADP
aji-153	368	28	the	the	DET
aji-153	368	29	table	table	NOUN
aji-153	368	30	below	below	ADV
aji-153	368	31	is	be	AUX
aji-153	368	32	one	one	NUM
aji-153	368	33	of	of	ADP
aji-153	368	34	the	the	DET
aji-153	368	35	14	14	NUM
aji-153	368	36	vadadustat	vadadustat	NOUN
aji-153	368	37	-	-	PUNCT
aji-153	368	38	treated	treat	VERB
aji-153	368	39	patients	patient	NOUN
aji-153	368	40	who	who	PRON
aji-153	368	41	were	be	AUX
aji-153	368	42	reported	report	VERB
aji-153	368	43	to	to	PART
aji-153	368	44	have	have	AUX
aji-153	368	45	had	have	VERB
aji-153	368	46	a	a	DET
aji-153	368	47	renal	renal	ADV
aji-153	368	48	-	-	PUNCT
aji-153	368	49	related	relate	VERB
aji-153	368	50	saeone	saeone	NOUN
aji-153	368	51	of	of	ADP
aji-153	368	52	whom	whom	PRON
aji-153	368	53	was	be	AUX
aji-153	368	54	subject	subject	ADJ
aji-153	368	55	1490001	1490001	NUM
aji-153	368	56	,	,	PUNCT
aji-153	368	57	previously	previously	ADV
aji-153	368	58	study	study	NOUN
aji-153	368	59	group	group	NOUN
aji-153	368	60	treated	treat	VERB
aji-153	368	61	[	[	PUNCT
aji-153	368	62	37	37	NUM
aji-153	368	63	]	]	PUNCT
aji-153	368	64	.	.	PUNCT
aji-153	369	1	the	the	DET
aji-153	369	2	patient	patient	NOUN
aji-153	369	3	was	be	AUX
aji-153	369	4	hospitalized	hospitalize	VERB
aji-153	369	5	for	for	ADP
aji-153	369	6	goodpasture	goodpasture	NOUN
aji-153	369	7	syndrome	syndrome	NOUN
aji-153	369	8	worsening	worsen	VERB
aji-153	369	9	that	that	PRON
aji-153	369	10	occurred	occur	VERB
aji-153	369	11	following	follow	VERB
aji-153	369	12	1	1	NUM
aji-153	369	13	dose	dose	NOUN
aji-153	369	14	of	of	ADP
aji-153	369	15	study	study	NOUN
aji-153	369	16	medication	medication	NOUN
aji-153	369	17	;	;	PUNCT
aji-153	369	18	other	other	ADJ
aji-153	369	19	than	than	ADP
aji-153	369	20	hospitalization	hospitalization	NOUN
aji-153	369	21	for	for	ADP
aji-153	369	22	worsening	worsen	VERB
aji-153	369	23	goodpasture	goodpasture	NOUN
aji-153	369	24	syndrome	syndrome	NOUN
aji-153	369	25	,	,	PUNCT
aji-153	369	26	no	no	DET
aji-153	369	27	other	other	ADJ
aji-153	369	28	renalrelated	renalrelate	VERB
aji-153	369	29	adverse	adverse	ADJ
aji-153	369	30	events	event	NOUN
aji-153	369	31	were	be	AUX
aji-153	369	32	reported	report	VERB
aji-153	369	33	[	[	X
aji-153	369	34	38	38	NUM
aji-153	369	35	]	]	PUNCT
aji-153	369	36	.	.	PUNCT
aji-153	370	1	there	there	PRON
aji-153	370	2	were	be	VERB
aji-153	370	3	no	no	DET
aji-153	370	4	trends	trend	NOUN
aji-153	370	5	observed	observe	VERB
aji-153	370	6	(	(	PUNCT
aji-153	370	7	either	either	CCONJ
aji-153	370	8	increases	increase	NOUN
aji-153	370	9	or	or	CCONJ
aji-153	370	10	decreases	decrease	NOUN
aji-153	370	11	)	)	PUNCT
aji-153	370	12	in	in	ADP
aji-153	370	13	the	the	DET
aji-153	370	14	systolic	systolic	ADJ
aji-153	370	15	values	value	NOUN
aji-153	370	16	of	of	ADP
aji-153	370	17	blood	blood	NOUN
aji-153	370	18	pressure	pressure	NOUN
aji-153	370	19	or	or	CCONJ
aji-153	370	20	diastolic	diastolic	ADJ
aji-153	370	21	values	value	NOUN
aji-153	370	22	of	of	ADP
aji-153	370	23	blood	blood	NOUN
aji-153	370	24	pressure	pressure	NOUN
aji-153	370	25	over	over	ADP
aji-153	370	26	time	time	NOUN
aji-153	370	27	,	,	PUNCT
aji-153	370	28	and	and	CCONJ
aji-153	370	29	the	the	DET
aji-153	370	30	distribution	distribution	NOUN
aji-153	370	31	in	in	ADP
aji-153	370	32	the	the	DET
aji-153	370	33	systolic	systolic	ADJ
aji-153	370	34	values	value	NOUN
aji-153	370	35	of	of	ADP
aji-153	370	36	blood	blood	NOUN
aji-153	370	37	pressure	pressure	NOUN
aji-153	370	38	among	among	ADP
aji-153	370	39	patients	patient	NOUN
aji-153	370	40	receiving	receive	VERB
aji-153	370	41	vadadustat	vadadustat	NOUN
aji-153	370	42	was	be	AUX
aji-153	370	43	comparable	comparable	ADJ
aji-153	370	44	to	to	ADP
aji-153	370	45	that	that	PRON
aji-153	370	46	in	in	ADP
aji-153	370	47	patients	patient	NOUN
aji-153	370	48	receiving	receive	VERB
aji-153	370	49	placebo	placebo	NOUN
aji-153	370	50	[	[	X
aji-153	370	51	39	39	NUM
aji-153	370	52	]	]	PUNCT
aji-153	370	53	.	.	PUNCT
aji-153	371	1	hypertension	hypertension	NOUN
aji-153	371	2	was	be	AUX
aji-153	371	3	an	an	DET
aji-153	371	4	ae	ae	PROPN
aji-153	371	5	in	in	ADP
aji-153	371	6	8.0	8.0	NUM
aji-153	371	7	%	%	NOUN
aji-153	371	8	of	of	ADP
aji-153	371	9	patients	patient	NOUN
aji-153	371	10	treated	treat	VERB
aji-153	371	11	with	with	ADP
aji-153	371	12	vadadustat	vadadustat	NOUN
aji-153	371	13	(	(	PUNCT
aji-153	371	14	11	11	NUM
aji-153	371	15	of	of	ADP
aji-153	371	16	138	138	NUM
aji-153	371	17	)	)	PUNCT
aji-153	371	18	and	and	CCONJ
aji-153	371	19	in	in	ADP
aji-153	371	20	2.8	2.8	NUM
aji-153	371	21	%	%	NOUN
aji-153	371	22	of	of	ADP
aji-153	371	23	patients	patient	NOUN
aji-153	371	24	treated	treat	VERB
aji-153	371	25	with	with	ADP
aji-153	371	26	placebo	placebo	NOUN
aji-153	371	27	(	(	PUNCT
aji-153	371	28	2	2	NUM
aji-153	371	29	of	of	ADP
aji-153	371	30	72	72	NUM
aji-153	371	31	)	)	PUNCT
aji-153	371	32	,	,	PUNCT
aji-153	371	33	and	and	CCONJ
aji-153	371	34	all	all	DET
aji-153	371	35	patients	patient	NOUN
aji-153	371	36	had	have	VERB
aji-153	371	37	a	a	DET
aji-153	371	38	pre	pre	ADJ
aji-153	371	39	-	-	ADJ
aji-153	371	40	existing	exist	VERB
aji-153	371	41	history	history	NOUN
aji-153	371	42	of	of	ADP
aji-153	371	43	hypertension	hypertension	NOUN
aji-153	371	44	.	.	PUNCT
aji-153	372	1	one	one	NUM
aji-153	372	2	of	of	ADP
aji-153	372	3	the	the	DET
aji-153	372	4	11	11	NUM
aji-153	372	5	patients	patient	NOUN
aji-153	372	6	on	on	ADP
aji-153	372	7	vadadustat	vadadustat	NOUN
aji-153	372	8	who	who	PRON
aji-153	372	9	experienced	experience	VERB
aji-153	372	10	an	an	DET
aji-153	372	11	ae	ae	PROPN
aji-153	372	12	of	of	ADP
aji-153	372	13	hypertension	hypertension	NOUN
aji-153	372	14	during	during	ADP
aji-153	372	15	the	the	DET
aji-153	372	16	study	study	NOUN
aji-153	372	17	had	have	AUX
aji-153	372	18	furosemide	furosemide	ADV
aji-153	372	19	discontinued	discontinue	VERB
aji-153	372	20	about	about	ADV
aji-153	372	21	1	1	NUM
aji-153	372	22	month	month	NOUN
aji-153	372	23	prior	prior	ADV
aji-153	372	24	to	to	ADP
aji-153	372	25	the	the	DET
aji-153	372	26	event	event	NOUN
aji-153	372	27	.	.	PUNCT
aji-153	373	1	otherwise	otherwise	ADV
aji-153	373	2	,	,	PUNCT
aji-153	373	3	no	no	DET
aji-153	373	4	participant	participant	NOUN
aji-153	373	5	experienced	experience	VERB
aji-153	373	6	withdrawal	withdrawal	NOUN
aji-153	373	7	or	or	CCONJ
aji-153	373	8	dose	dose	NOUN
aji-153	373	9	reduction	reduction	NOUN
aji-153	373	10	of	of	ADP
aji-153	373	11	antihypertensive	antihypertensive	ADJ
aji-153	373	12	drugs	drug	NOUN
aji-153	373	13	before	before	ADP
aji-153	373	14	development	development	NOUN
aji-153	373	15	of	of	ADP
aji-153	373	16	the	the	DET
aji-153	373	17	ae	ae	PROPN
aji-153	373	18	of	of	ADP
aji-153	373	19	hypertension	hypertension	NOUN
aji-153	373	20	;	;	PUNCT
aji-153	373	21	no	no	DET
aji-153	373	22	participant	participant	NOUN
aji-153	373	23	stopped	stop	VERB
aji-153	373	24	vadadustat	vadadustat	NOUN
aji-153	373	25	due	due	ADP
aji-153	373	26	to	to	ADP
aji-153	373	27	hypertension	hypertension	NOUN
aji-153	373	28	[	[	X
aji-153	373	29	40	40	NUM
aji-153	373	30	]	]	PUNCT
aji-153	373	31	.	.	PUNCT
aji-153	374	1	out	out	ADP
aji-153	374	2	of	of	ADP
aji-153	374	3	these	these	PRON
aji-153	374	4	,	,	PUNCT
aji-153	374	5	33	33	NUM
aji-153	374	6	patients	patient	NOUN
aji-153	374	7	treated	treat	VERB
aji-153	374	8	with	with	ADP
aji-153	374	9	vadadustat	vadadustat	NOUN
aji-153	374	10	experienced	experience	VERB
aji-153	374	11	≥1	≥1	PROPN
aji-153	374	12	sae	sae	PROPN
aji-153	374	13	(	(	PUNCT
aji-153	374	14	23.9	23.9	NUM
aji-153	374	15	%	%	NOUN
aji-153	374	16	)	)	PUNCT
aji-153	374	17	,	,	PUNCT
aji-153	374	18	compared	compare	VERB
aji-153	374	19	with	with	ADP
aji-153	374	20	11	11	NUM
aji-153	374	21	placebo	placebo	NOUN
aji-153	374	22	-	-	PUNCT
aji-153	374	23	treated	treat	VERB
aji-153	374	24	patients	patient	NOUN
aji-153	374	25	(	(	PUNCT
aji-153	374	26	15.3	15.3	NUM
aji-153	374	27	%	%	NOUN
aji-153	374	28	)	)	PUNCT
aji-153	374	29	;	;	PUNCT
aji-153	374	30	the	the	DET
aji-153	374	31	higher	high	ADJ
aji-153	374	32	proportion	proportion	NOUN
aji-153	374	33	of	of	ADP
aji-153	374	34	saes	saes	PROPN
aji-153	374	35	was	be	AUX
aji-153	374	36	mainly	mainly	ADV
aji-153	374	37	due	due	ADJ
aji-153	374	38	to	to	ADP
aji-153	374	39	a	a	DET
aji-153	374	40	higher	high	ADJ
aji-153	374	41	proportion	proportion	NOUN
aji-153	374	42	of	of	ADP
aji-153	374	43	renal	renal	ADJ
aji-153	374	44	-	-	PUNCT
aji-153	374	45	related	relate	VERB
aji-153	374	46	saes	sae	NOUN
aji-153	374	47	in	in	ADP
aji-153	374	48	the	the	DET
aji-153	374	49	vadadustat	vadadustat	NOUN
aji-153	374	50	arm	arm	NOUN
aji-153	374	51	(	(	PUNCT
aji-153	374	52	10.1	10.1	NUM
aji-153	374	53	%	%	NOUN
aji-153	374	54	)	)	PUNCT
aji-153	374	55	than	than	ADP
aji-153	374	56	in	in	ADP
aji-153	374	57	the	the	DET
aji-153	374	58	placebo	placebo	NOUN
aji-153	374	59	arm	arm	NOUN
aji-153	374	60	(	(	PUNCT
aji-153	374	61	2.8	2.8	NUM
aji-153	374	62	%	%	NOUN
aji-153	374	63	)	)	PUNCT
aji-153	375	1	[	[	X
aji-153	375	2	41	41	NUM
aji-153	375	3	]	]	PUNCT
aji-153	375	4	.	.	PUNCT
aji-153	376	1	the	the	DET
aji-153	376	2	proportion	proportion	NOUN
aji-153	376	3	of	of	ADP
aji-153	376	4	patients	patient	NOUN
aji-153	376	5	who	who	PRON
aji-153	376	6	received	receive	VERB
aji-153	376	7	a	a	DET
aji-153	376	8	baseline	baseline	ADJ
aji-153	376	9	requirement	requirement	NOUN
aji-153	376	10	for	for	ADP
aji-153	376	11	initiation	initiation	NOUN
aji-153	376	12	of	of	ADP
aji-153	376	13	dialysis	dialysis	NOUN
aji-153	376	14	,	,	PUNCT
aji-153	376	15	an	an	DET
aji-153	376	16	inorganic	inorganic	ADJ
aji-153	376	17	marker	marker	NOUN
aji-153	376	18	of	of	ADP
aji-153	376	19	the	the	DET
aji-153	376	20	seriousness	seriousness	NOUN
aji-153	376	21	of	of	ADP
aji-153	376	22	renal	renal	ADJ
aji-153	376	23	saes	saes	PROPN
aji-153	376	24	,	,	PUNCT
aji-153	376	25	was	be	AUX
aji-153	376	26	similar	similar	ADJ
aji-153	376	27	between	between	ADP
aji-153	376	28	the	the	DET
aji-153	376	29	vadadustat	vadadustat	NOUN
aji-153	376	30	(	(	PUNCT
aji-153	376	31	11	11	NUM
aji-153	376	32	of	of	ADP
aji-153	376	33	138	138	NUM
aji-153	376	34	,	,	PUNCT
aji-153	376	35	8.0	8.0	NUM
aji-153	376	36	%	%	NOUN
aji-153	376	37	)	)	PUNCT
aji-153	376	38	and	and	CCONJ
aji-153	376	39	placebo	placebo	NOUN
aji-153	376	40	(	(	PUNCT
aji-153	376	41	7	7	NUM
aji-153	376	42	of	of	ADP
aji-153	376	43	72	72	NUM
aji-153	376	44	,	,	PUNCT
aji-153	376	45	9.7	9.7	NUM
aji-153	376	46	%	%	NOUN
aji-153	376	47	)	)	PUNCT
aji-153	376	48	treatment	treatment	NOUN
aji-153	376	49	groups	group	NOUN
aji-153	376	50	[	[	X
aji-153	376	51	42	42	NUM
aji-153	376	52	]	]	PUNCT
aji-153	376	53	.	.	PUNCT
aji-153	377	1	the	the	DET
aji-153	377	2	incidences	incidence	NOUN
aji-153	377	3	of	of	ADP
aji-153	377	4	investigation	investigation	NOUN
aji-153	377	5	-	-	PUNCT
aji-153	377	6	reported	report	VERB
aji-153	377	7	renal	renal	ADJ
aji-153	377	8	-	-	PUNCT
aji-153	377	9	related	relate	VERB
aji-153	377	10	saes	sae	NOUN
aji-153	377	11	were	be	AUX
aji-153	377	12	not	not	PART
aji-153	377	13	related	relate	VERB
aji-153	377	14	to	to	ADP
aji-153	377	15	the	the	DET
aji-153	377	16	study	study	NOUN
aji-153	377	17	drug	drug	NOUN
aji-153	377	18	,	,	PUNCT
aji-153	377	19	according	accord	VERB
aji-153	377	20	to	to	ADP
aji-153	377	21	the	the	DET
aji-153	377	22	investigator	investigator	NOUN
aji-153	377	23	.	.	PUNCT
aji-153	378	1	the	the	DET
aji-153	378	2	clinical	clinical	ADJ
aji-153	378	3	studies	study	NOUN
aji-153	378	4	mentioned	mention	VERB
aji-153	378	5	above	above	ADV
aji-153	378	6	have	have	AUX
aji-153	378	7	proven	prove	VERB
aji-153	378	8	vadadustat	vadadustat	NOUN
aji-153	378	9	as	as	ADP
aji-153	378	10	a	a	DET
aji-153	378	11	worthwhile	worthwhile	ADJ
aji-153	378	12	option	option	NOUN
aji-153	378	13	as	as	ADP
aji-153	378	14	an	an	DET
aji-153	378	15	induction	induction	NOUN
aji-153	378	16	treatment	treatment	NOUN
aji-153	378	17	for	for	ADP
aji-153	378	18	patients	patient	NOUN
aji-153	378	19	with	with	ADP
aji-153	378	20	anemia	anemia	NOUN
aji-153	378	21	who	who	PRON
aji-153	378	22	have	have	VERB
aji-153	378	23	chronic	chronic	ADJ
aji-153	378	24	kidney	kidney	NOUN
aji-153	378	25	disease	disease	NOUN
aji-153	378	26	[	[	X
aji-153	378	27	43	43	NUM
aji-153	378	28	]	]	PUNCT
aji-153	378	29	.	.	PUNCT
aji-153	379	1	4	4	X
aji-153	379	2	.	.	X
aji-153	379	3	conclusion	conclusion	NOUN
aji-153	379	4	anemia	anemia	NOUN
aji-153	379	5	is	be	AUX
aji-153	379	6	an	an	DET
aji-153	379	7	inadequacy	inadequacy	NOUN
aji-153	379	8	in	in	ADP
aji-153	379	9	the	the	DET
aji-153	379	10	number	number	NOUN
aji-153	379	11	or	or	CCONJ
aji-153	379	12	quality	quality	NOUN
aji-153	379	13	of	of	ADP
aji-153	379	14	red	red	ADJ
aji-153	379	15	blood	blood	NOUN
aji-153	379	16	cells	cell	NOUN
aji-153	379	17	(	(	PUNCT
aji-153	379	18	rbcs	rbc	NOUN
aji-153	379	19	)	)	PUNCT
aji-153	379	20	or	or	CCONJ
aji-153	379	21	a	a	DET
aji-153	379	22	reduction	reduction	NOUN
aji-153	379	23	in	in	ADP
aji-153	379	24	the	the	DET
aji-153	379	25	amount	amount	NOUN
aji-153	379	26	of	of	ADP
aji-153	379	27	hemoglobin	hemoglobin	NOUN
aji-153	379	28	,	,	PUNCT
aji-153	379	29	which	which	PRON
aji-153	379	30	is	be	AUX
aji-153	379	31	the	the	DET
aji-153	379	32	oxygen	oxygen	NOUN
aji-153	379	33	-	-	PUNCT
aji-153	379	34	carrying	carry	VERB
aji-153	379	35	protein	protein	NOUN
aji-153	379	36	in	in	ADP
aji-153	379	37	rbcs	rbc	NOUN
aji-153	379	38	in	in	ADP
aji-153	379	39	the	the	DET
aji-153	379	40	blood	blood	NOUN
aji-153	379	41	[	[	X
aji-153	379	42	44	44	NUM
aji-153	379	43	]	]	PUNCT
aji-153	379	44	.	.	PUNCT
aji-153	380	1	it	it	PRON
aji-153	380	2	is	be	AUX
aji-153	380	3	associated	associate	VERB
aji-153	380	4	with	with	ADP
aji-153	380	5	poorly	poorly	ADV
aji-153	380	6	oxygenated	oxygenate	VERB
aji-153	380	7	tissues	tissue	NOUN
aji-153	380	8	and	and	CCONJ
aji-153	380	9	organs	organ	NOUN
aji-153	380	10	within	within	ADP
aji-153	380	11	the	the	DET
aji-153	380	12	body	body	NOUN
aji-153	380	13	,	,	PUNCT
aji-153	380	14	resulting	result	VERB
aji-153	380	15	in	in	ADP
aji-153	380	16	a	a	DET
aji-153	380	17	variety	variety	NOUN
aji-153	380	18	of	of	ADP
aji-153	380	19	symptoms	symptom	NOUN
aji-153	380	20	such	such	ADJ
aji-153	380	21	as	as	ADP
aji-153	380	22	fatigue	fatigue	NOUN
aji-153	380	23	and	and	CCONJ
aji-153	380	24	weakness	weakness	NOUN
aji-153	380	25	and	and	CCONJ
aji-153	380	26	paleness	paleness	NOUN
aji-153	380	27	[	[	X
aji-153	380	28	45	45	NUM
aji-153	380	29	]	]	PUNCT
aji-153	380	30	.	.	PUNCT
aji-153	381	1	esas	esa	NOUN
aji-153	381	2	or	or	CCONJ
aji-153	381	3	new	new	ADJ
aji-153	381	4	hifph	hifph	ADJ
aji-153	381	5	inhibitors	inhibitor	NOUN
aji-153	381	6	like	like	ADP
aji-153	381	7	vadadustat	vadadustat	NOUN
aji-153	381	8	,	,	PUNCT
aji-153	381	9	which	which	PRON
aji-153	381	10	act	act	VERB
aji-153	381	11	through	through	ADP
aji-153	381	12	mimicking	mimic	VERB
aji-153	381	13	hypoxia	hypoxia	NOUN
aji-153	381	14	by	by	ADP
aji-153	381	15	stabilizing	stabilize	VERB
aji-153	381	16	the	the	DET
aji-153	381	17	hypoxiainducible	hypoxiainducible	ADJ
aji-153	381	18	factor	factor	NOUN
aji-153	381	19	pathway	pathway	NOUN
aji-153	381	20	and	and	CCONJ
aji-153	381	21	activates	activate	VERB
aji-153	381	22	erythropoiesis	erythropoiesis	NOUN
aji-153	381	23	and	and	CCONJ
aji-153	381	24	epo	epo	NOUN
aji-153	381	25	production	production	NOUN
aji-153	381	26	,	,	PUNCT
aji-153	381	27	should	should	AUX
aji-153	381	28	be	be	AUX
aji-153	381	29	considered	consider	VERB
aji-153	381	30	for	for	ADP
aji-153	381	31	achieving	achieve	VERB
aji-153	381	32	treatment	treatment	NOUN
aji-153	381	33	goals	goal	NOUN
aji-153	381	34	[	[	X
aji-153	381	35	46	46	NUM
aji-153	381	36	]	]	PUNCT
aji-153	381	37	.	.	PUNCT
aji-153	382	1	vadadustat	vadadustat	PROPN
aji-153	382	2	is	be	AUX
aji-153	382	3	an	an	DET
aji-153	382	4	investigational	investigational	ADJ
aji-153	382	5	oral	oral	ADJ
aji-153	382	6	hypoxiainducible	hypoxiainducible	ADJ
aji-153	382	7	factor	factor	NOUN
aji-153	382	8	prolyl	prolyl	NOUN
aji-153	382	9	-	-	PUNCT
aji-153	382	10	hydroxylase	hydroxylase	NOUN
aji-153	382	11	inhibitor	inhibitor	NOUN
aji-153	382	12	that	that	PRON
aji-153	382	13	stimulates	stimulate	VERB
aji-153	382	14	endogenous	endogenous	ADJ
aji-153	382	15	erythropoietin	erythropoietin	NOUN
aji-153	382	16	formation	formation	NOUN
aji-153	382	17	.	.	PUNCT
aji-153	383	1	at	at	ADP
aji-153	383	2	present	present	ADJ
aji-153	383	3	,	,	PUNCT
aji-153	383	4	erythropoiesis	erythropoiesis	NOUN
aji-153	383	5	-	-	PUNCT
aji-153	383	6	stimulating	stimulate	VERB
aji-153	383	7	agents	agent	NOUN
aji-153	383	8	(	(	PUNCT
aji-153	383	9	esas	esa	NOUN
aji-153	383	10	)	)	PUNCT
aji-153	383	11	are	be	AUX
aji-153	383	12	still	still	ADV
aji-153	383	13	the	the	DET
aji-153	383	14	treatment	treatment	NOUN
aji-153	383	15	mainstay	mainstay	NOUN
aji-153	383	16	for	for	ADP
aji-153	383	17	anaemia	anaemia	NOUN
aji-153	383	18	of	of	ADP
aji-153	383	19	chronic	chronic	ADJ
aji-153	383	20	kidney	kidney	NOUN
aji-153	383	21	disease	disease	NOUN
aji-153	383	22	(	(	PUNCT
aji-153	383	23	ckd	ckd	NOUN
aji-153	383	24	)	)	PUNCT
aji-153	384	1	[	[	X
aji-153	384	2	47	47	NUM
aji-153	384	3	]	]	PUNCT
aji-153	384	4	.	.	PUNCT
aji-153	385	1	all	all	DET
aji-153	385	2	esas	esa	NOUN
aji-153	385	3	function	function	VERB
aji-153	385	4	effectively	effectively	ADV
aji-153	385	5	to	to	PART
aji-153	385	6	correct	correct	VERB
aji-153	385	7	anemia	anemia	NOUN
aji-153	385	8	in	in	ADP
aji-153	385	9	ckd	ckd	PROPN
aji-153	385	10	by	by	ADP
aji-153	385	11	countering	counter	VERB
aji-153	385	12	the	the	DET
aji-153	385	13	epo	epo	NOUN
aji-153	385	14	deficiency	deficiency	NOUN
aji-153	385	15	resulting	result	VERB
aji-153	385	16	from	from	ADP
aji-153	385	17	failing	fail	VERB
aji-153	385	18	kidneys	kidney	NOUN
aji-153	385	19	.	.	PUNCT
aji-153	386	1	in	in	ADP
aji-153	386	2	contrast	contrast	NOUN
aji-153	386	3	,	,	PUNCT
aji-153	386	4	whereas	whereas	SCONJ
aji-153	386	5	esas	esa	NOUN
aji-153	386	6	function	function	VERB
aji-153	386	7	by	by	ADP
aji-153	386	8	antagonizing	antagonize	VERB
aji-153	386	9	the	the	DET
aji-153	386	10	activity	activity	NOUN
aji-153	386	11	of	of	ADP
aji-153	386	12	the	the	DET
aji-153	386	13	hif	hif	PROPN
aji-153	386	14	pathway	pathway	NOUN
aji-153	386	15	,	,	PUNCT
aji-153	386	16	hif	hif	PROPN
aji-153	386	17	-	-	PUNCT
aji-153	386	18	phis	phis	NOUN
aji-153	386	19	activate	activate	VERB
aji-153	386	20	it	it	PRON
aji-153	386	21	,	,	PUNCT
aji-153	386	22	thereby	thereby	ADV
aji-153	386	23	stimulating	stimulate	VERB
aji-153	386	24	the	the	DET
aji-153	386	25	transcription	transcription	NOUN
aji-153	386	26	of	of	ADP
aji-153	386	27	the	the	DET
aji-153	386	28	epo	epo	PROPN
aji-153	386	29	gene	gene	NOUN
aji-153	386	30	and	and	CCONJ
aji-153	386	31	upregulating	upregulate	VERB
aji-153	386	32	the	the	DET
aji-153	386	33	expression	expression	NOUN
aji-153	386	34	of	of	ADP
aji-153	386	35	genes	gene	NOUN
aji-153	386	36	participating	participate	VERB
aji-153	386	37	in	in	ADP
aji-153	386	38	erythropoiesis	erythropoiesis	NOUN
aji-153	386	39	and	and	CCONJ
aji-153	386	40	in	in	ADP
aji-153	386	41	iron	iron	NOUN
aji-153	386	42	metabolism	metabolism	NOUN
aji-153	387	1	[	[	X
aji-153	387	2	48	48	NUM
aji-153	387	3	]	]	PUNCT
aji-153	387	4	.	.	PUNCT
aji-153	388	1	this	this	DET
aji-153	388	2	unusual	unusual	ADJ
aji-153	388	3	mechanism	mechanism	NOUN
aji-153	388	4	of	of	ADP
aji-153	388	5	action	action	NOUN
aji-153	388	6	was	be	AUX
aji-153	388	7	believed	believe	VERB
aji-153	388	8	to	to	PART
aji-153	388	9	have	have	VERB
aji-153	388	10	an	an	DET
aji-153	388	11	excellent	excellent	ADJ
aji-153	388	12	anemic	anemic	ADJ
aji-153	388	13	correction	correction	NOUN
aji-153	388	14	by	by	ADP
aji-153	388	15	promoting	promote	VERB
aji-153	388	16	endogenous	endogenous	ADJ
aji-153	388	17	production	production	NOUN
aji-153	388	18	of	of	ADP
aji-153	388	19	epo	epo	NOUN
aji-153	388	20	and	and	CCONJ
aji-153	388	21	concomitantly	concomitantly	ADV
aji-153	388	22	boosting	boost	VERB
aji-153	388	23	enteric	enteric	ADJ
aji-153	388	24	iron	iron	NOUN
aji-153	388	25	gupta	gupta	NOUN
aji-153	388	26	et	et	PROPN
aji-153	388	27	al	al	PROPN
aji-153	388	28	.	.	PROPN
aji-153	388	29	;	;	PUNCT
aji-153	388	30	asian	asian	PROPN
aji-153	388	31	j.	j.	PROPN
aji-153	388	32	immunol	immunol	PROPN
aji-153	388	33	.	.	PROPN
aji-153	388	34	,	,	PUNCT
aji-153	388	35	vol	vol	NOUN
aji-153	388	36	.	.	PROPN
aji-153	388	37	7	7	NUM
aji-153	388	38	,	,	PUNCT
aji-153	388	39	no	no	INTJ
aji-153	388	40	.	.	NOUN
aji-153	388	41	1	1	NUM
aji-153	388	42	,	,	PUNCT
aji-153	388	43	pp	pp	ADJ
aji-153	388	44	.	.	PUNCT
aji-153	389	1	302	302	NUM
aji-153	389	2	-	-	SYM
aji-153	389	3	315	315	NUM
aji-153	389	4	,	,	PUNCT
aji-153	389	5	2024	2024	NUM
aji-153	390	1	;	;	PUNCT
aji-153	390	2	article	article	NOUN
aji-153	390	3	no.aji.127402	no.aji.127402	VERB
aji-153	390	4	312	312	NUM
aji-153	390	5	absorption	absorption	NOUN
aji-153	390	6	and	and	CCONJ
aji-153	390	7	mobilization	mobilization	NOUN
aji-153	390	8	of	of	ADP
aji-153	390	9	iron	iron	NOUN
aji-153	390	10	(	(	PUNCT
aji-153	390	11	in	in	ADP
aji-153	390	12	contrast	contrast	NOUN
aji-153	390	13	to	to	ADP
aji-153	390	14	esa	esa	PROPN
aji-153	390	15	)	)	PUNCT
aji-153	390	16	.	.	PUNCT
aji-153	391	1	in	in	ADP
aji-153	391	2	addition	addition	NOUN
aji-153	391	3	,	,	PUNCT
aji-153	391	4	the	the	DET
aji-153	391	5	peak	peak	NOUN
aji-153	391	6	serum	serum	NOUN
aji-153	391	7	epo	epo	PROPN
aji-153	391	8	level	level	NOUN
aji-153	391	9	is	be	AUX
aji-153	391	10	reportedly	reportedly	ADV
aji-153	391	11	a	a	DET
aji-153	391	12	few	few	ADJ
aji-153	391	13	folds	fold	NOUN
aji-153	391	14	less	less	ADV
aji-153	391	15	in	in	ADP
aji-153	391	16	hif	hif	PROPN
aji-153	391	17	-	-	PUNCT
aji-153	391	18	phis	phis	NOUN
aji-153	391	19	as	as	SCONJ
aji-153	391	20	compared	compare	VERB
aji-153	391	21	to	to	ADP
aji-153	391	22	esa	esa	PROPN
aji-153	391	23	treatment	treatment	NOUN
aji-153	391	24	[	[	X
aji-153	391	25	49	49	NUM
aji-153	391	26	]	]	PUNCT
aji-153	391	27	.	.	PUNCT
aji-153	392	1	the	the	DET
aji-153	392	2	vast	vast	ADJ
aji-153	392	3	majority	majority	NOUN
aji-153	392	4	of	of	ADP
aji-153	392	5	rcts	rct	NOUN
aji-153	392	6	with	with	ADP
aji-153	392	7	hif	hif	PROPN
aji-153	392	8	-	-	PUNCT
aji-153	392	9	phis	phis	PROPN
aji-153	392	10	established	establish	VERB
aji-153	392	11	their	their	PRON
aji-153	392	12	non	non	ADJ
aji-153	392	13	-	-	NOUN
aji-153	392	14	inferiority	inferiority	NOUN
aji-153	392	15	as	as	ADP
aji-153	392	16	compared	compare	VERB
aji-153	392	17	to	to	ADP
aji-153	392	18	esas	esas	PROPN
aji-153	392	19	.	.	PUNCT
aji-153	393	1	vadadustat	vadadustat	PROPN
aji-153	393	2	is	be	AUX
aji-153	393	3	a	a	DET
aji-153	393	4	potent	potent	ADJ
aji-153	393	5	inhibitor	inhibitor	NOUN
aji-153	393	6	of	of	ADP
aji-153	393	7	the	the	DET
aji-153	393	8	catalytic	catalytic	ADJ
aji-153	393	9	activity	activity	NOUN
aji-153	393	10	of	of	ADP
aji-153	393	11	all	all	DET
aji-153	393	12	three	three	NUM
aji-153	393	13	human	human	ADJ
aji-153	393	14	phd	phd	NOUN
aji-153	393	15	isozymes	isozyme	NOUN
aji-153	393	16	:	:	PUNCT
aji-153	393	17	phd1	phd1	NOUN
aji-153	393	18	,	,	PUNCT
aji-153	393	19	phd2	phd2	NOUN
aji-153	393	20	,	,	PUNCT
aji-153	393	21	and	and	CCONJ
aji-153	393	22	phd3	phd3	PROPN
aji-153	393	23	;	;	PUNCT
aji-153	393	24	all	all	DET
aji-153	393	25	three	three	NUM
aji-153	393	26	endozymes	endozyme	NOUN
aji-153	393	27	have	have	VERB
aji-153	393	28	nanomolar	nanomolar	ADJ
aji-153	393	29	inhibitory	inhibitory	ADJ
aji-153	393	30	constant	constant	ADJ
aji-153	393	31	values	value	NOUN
aji-153	393	32	and	and	CCONJ
aji-153	393	33	are	be	AUX
aji-153	393	34	similar	similar	ADJ
aji-153	393	35	[	[	X
aji-153	393	36	50	50	NUM
aji-153	393	37	]	]	PUNCT
aji-153	393	38	.	.	PUNCT
aji-153	394	1	vadadustat	vadadustat	PROPN
aji-153	394	2	inhibits	inhibit	VERB
aji-153	394	3	phd	phd	NOUN
aji-153	394	4	with	with	ADP
aji-153	394	5	competition	competition	NOUN
aji-153	394	6	against	against	ADP
aji-153	394	7	the	the	DET
aji-153	394	8	cellular	cellular	ADJ
aji-153	394	9	endogenous	endogenous	ADJ
aji-153	394	10	cofactor	cofactor	NOUN
aji-153	394	11	2oxoglutarate	2oxoglutarate	NUM
aji-153	394	12	and	and	CCONJ
aji-153	394	13	is	be	AUX
aji-153	394	14	not	not	PART
aji-153	394	15	dependent	dependent	ADJ
aji-153	394	16	on	on	ADP
aji-153	394	17	free	free	ADJ
aji-153	394	18	iron	iron	NOUN
aji-153	394	19	concentration	concentration	NOUN
aji-153	394	20	.	.	PUNCT
aji-153	395	1	in	in	ADP
aji-153	395	2	the	the	DET
aji-153	395	3	human	human	ADJ
aji-153	395	4	hepatocellular	hepatocellular	ADJ
aji-153	395	5	carcinoma	carcinoma	NOUN
aji-153	395	6	cell	cell	NOUN
aji-153	395	7	line	line	NOUN
aji-153	395	8	(	(	PUNCT
aji-153	395	9	hep	hep	NOUN
aji-153	395	10	3b	3b	NUM
aji-153	395	11	)	)	PUNCT
aji-153	395	12	and	and	CCONJ
aji-153	395	13	human	human	ADJ
aji-153	395	14	umbilical	umbilical	ADJ
aji-153	395	15	vein	vein	ADJ
aji-153	395	16	endothelial	endothelial	ADJ
aji-153	395	17	cells	cell	NOUN
aji-153	395	18	,	,	PUNCT
aji-153	395	19	phd	phd	NOUN
aji-153	395	20	inhibition	inhibition	NOUN
aji-153	395	21	by	by	ADP
aji-153	395	22	vadadustat	vadadustat	NOUN
aji-153	395	23	leads	lead	VERB
aji-153	395	24	to	to	ADP
aji-153	395	25	timeand	timeand	NOUN
aji-153	395	26	concentrationdependent	concentrationdependent	NOUN
aji-153	395	27	stabilization	stabilization	NOUN
aji-153	395	28	of	of	ADP
aji-153	395	29	hif-1α	hif-1α	NOUN
aji-153	395	30	and	and	CCONJ
aji-153	395	31	hif-2α	hif-2α	NOUN
aji-153	395	32	.	.	PUNCT
aji-153	396	1	this	this	DET
aji-153	396	2	results	result	VERB
aji-153	396	3	in	in	ADP
aji-153	396	4	synthesis	synthesis	NOUN
aji-153	396	5	and	and	CCONJ
aji-153	396	6	secretion	secretion	NOUN
aji-153	396	7	of	of	ADP
aji-153	396	8	epo	epo	PROPN
aji-153	396	9	in	in	ADP
aji-153	396	10	hep	hep	NOUN
aji-153	396	11	3b	3b	NUM
aji-153	396	12	cells	cell	NOUN
aji-153	396	13	,	,	PUNCT
aji-153	396	14	whereas	whereas	SCONJ
aji-153	396	15	vascular	vascular	ADJ
aji-153	396	16	endothelial	endothelial	ADJ
aji-153	396	17	growth	growth	NOUN
aji-153	396	18	factor	factor	NOUN
aji-153	396	19	is	be	AUX
aji-153	396	20	not	not	PART
aji-153	396	21	measured	measure	VERB
aji-153	396	22	at	at	ADP
aji-153	396	23	detectable	detectable	ADJ
aji-153	396	24	levels	level	NOUN
aji-153	396	25	.	.	PUNCT
aji-153	397	1	a	a	DET
aji-153	397	2	single	single	ADJ
aji-153	397	3	oral	oral	ADJ
aji-153	397	4	dose	dose	NOUN
aji-153	397	5	of	of	ADP
aji-153	397	6	vadadustat	vadadustat	NOUN
aji-153	397	7	in	in	ADP
aji-153	397	8	rats	rat	NOUN
aji-153	397	9	potently	potently	ADV
aji-153	397	10	increases	increase	VERB
aji-153	397	11	circulating	circulate	VERB
aji-153	397	12	levels	level	NOUN
aji-153	397	13	of	of	ADP
aji-153	397	14	epo	epo	PROPN
aji-153	397	15	[	[	X
aji-153	397	16	51	51	NUM
aji-153	397	17	]	]	PUNCT
aji-153	397	18	.	.	PUNCT
aji-153	398	1	consent	consent	NOUN
aji-153	398	2	and	and	CCONJ
aji-153	398	3	ethical	ethical	ADJ
aji-153	398	4	approval	approval	NOUN
aji-153	398	5	it	it	PRON
aji-153	398	6	is	be	AUX
aji-153	398	7	not	not	PART
aji-153	398	8	applicable	applicable	ADJ
aji-153	398	9	.	.	PUNCT
aji-153	399	1	disclaimer	disclaimer	NOUN
aji-153	399	2	(	(	PUNCT
aji-153	399	3	artificial	artificial	ADJ
aji-153	399	4	intelligence	intelligence	NOUN
aji-153	399	5	)	)	PUNCT
aji-153	399	6	author(s	author(s	NOUN
aji-153	399	7	)	)	PUNCT
aji-153	399	8	hereby	hereby	ADV
aji-153	399	9	declares	declare	VERB
aji-153	399	10	that	that	SCONJ
aji-153	399	11	no	no	PRON
aji-153	399	12	generative	generative	NOUN
aji-153	399	13	ai	ai	VERB
aji-153	399	14	technologies	technology	NOUN
aji-153	399	15	such	such	ADJ
aji-153	399	16	as	as	ADP
aji-153	399	17	large	large	ADJ
aji-153	399	18	language	language	NOUN
aji-153	399	19	models	model	NOUN
aji-153	399	20	(	(	PUNCT
aji-153	399	21	chatgpt	chatgpt	NOUN
aji-153	399	22	,	,	PUNCT
aji-153	399	23	copilot	copilot	NOUN
aji-153	399	24	,	,	PUNCT
aji-153	399	25	etc	etc	X
aji-153	399	26	)	)	PUNCT
aji-153	399	27	and	and	CCONJ
aji-153	399	28	text	text	NOUN
aji-153	399	29	-	-	PUNCT
aji-153	399	30	to	to	ADP
aji-153	399	31	-	-	PUNCT
aji-153	399	32	image	image	NOUN
aji-153	399	33	generators	generator	NOUN
aji-153	399	34	have	have	AUX
aji-153	399	35	been	be	AUX
aji-153	399	36	used	use	VERB
aji-153	399	37	during	during	ADP
aji-153	399	38	writing	writing	NOUN
aji-153	399	39	or	or	CCONJ
aji-153	399	40	editing	editing	NOUN
aji-153	399	41	of	of	ADP
aji-153	399	42	this	this	DET
aji-153	399	43	manuscript	manuscript	NOUN
aji-153	399	44	.	.	PUNCT
aji-153	400	1	competing	compete	VERB
aji-153	400	2	interests	interest	NOUN
aji-153	400	3	authors	author	NOUN
aji-153	400	4	have	have	AUX
aji-153	400	5	declared	declare	VERB
aji-153	400	6	that	that	SCONJ
aji-153	400	7	no	no	DET
aji-153	400	8	competing	compete	VERB
aji-153	400	9	interests	interest	NOUN
aji-153	400	10	exist	exist	VERB
aji-153	400	11	.	.	PUNCT
aji-153	401	1	references	reference	NOUN
aji-153	401	2	1	1	NUM
aji-153	401	3	.	.	PUNCT
aji-153	401	4	mimura	mimura	PROPN
aji-153	401	5	,	,	PUNCT
aji-153	401	6	imari	imari	NOUN
aji-153	401	7	,	,	PUNCT
aji-153	401	8	tetsuhiro	tetsuhiro	VERB
aji-153	401	9	tanaka	tanaka	PROPN
aji-153	401	10	,	,	PUNCT
aji-153	401	11	and	and	CCONJ
aji-153	401	12	masaomi	masaomi	NOUN
aji-153	401	13	nangaku	nangaku	PROPN
aji-153	401	14	.	.	PUNCT
aji-153	402	1	evaluating	evaluate	VERB
aji-153	402	2	the	the	DET
aji-153	402	3	safety	safety	NOUN
aji-153	402	4	and	and	CCONJ
aji-153	402	5	efficacy	efficacy	NOUN
aji-153	402	6	of	of	ADP
aji-153	402	7	vadadustat	vadadustat	NOUN
aji-153	402	8	for	for	ADP
aji-153	402	9	the	the	DET
aji-153	402	10	treatment	treatment	NOUN
aji-153	402	11	of	of	ADP
aji-153	402	12	anemia	anemia	NOUN
aji-153	402	13	associated	associate	VERB
aji-153	402	14	with	with	ADP
aji-153	402	15	chronic	chronic	ADJ
aji-153	402	16	kidney	kidney	NOUN
aji-153	402	17	disease	disease	NOUN
aji-153	402	18	.	.	PUNCT
aji-153	403	1	expert	expert	ADJ
aji-153	403	2	opinion	opinion	NOUN
aji-153	403	3	on	on	ADP
aji-153	403	4	pharmacotherapy	pharmacotherapy	NOUN
aji-153	403	5	just	just	ADV
aji-153	403	6	-	-	PUNCT
aji-153	403	7	accepted	accept	VERB
aji-153	403	8	;	;	PUNCT
aji-153	403	9	2024	2024	NUM
aji-153	403	10	.	.	X
aji-153	404	1	2	2	NUM
aji-153	404	2	.	.	X
aji-153	404	3	kai	kai	PROPN
aji-153	404	4	-	-	PUNCT
aji-153	404	5	uwe	uwe	PROPN
aji-153	404	6	eckardt	eckardt	NOUN
aji-153	404	7	,	,	PUNCT
aji-153	404	8	rajiv	rajiv	PROPN
aji-153	404	9	agarwal	agarwal	PROPN
aji-153	404	10	,	,	PUNCT
aji-153	404	11	youssef	youssef	PROPN
aji-153	404	12	mk	mk	PROPN
aji-153	404	13	farag	farag	PROPN
aji-153	404	14	,	,	PUNCT
aji-153	404	15	alan	alan	PROPN
aji-153	404	16	g	g	PROPN
aji-153	404	17	jardine	jardine	PROPN
aji-153	404	18	,	,	PUNCT
aji-153	404	19	zeeshan	zeeshan	PROPN
aji-153	404	20	khawaja	khawaja	PROPN
aji-153	404	21	,	,	PUNCT
aji-153	404	22	mark	mark	PROPN
aji-153	404	23	j	j	PROPN
aji-153	404	24	koury	koury	PROPN
aji-153	404	25	,	,	PUNCT
aji-153	404	26	wenli	wenli	PROPN
aji-153	404	27	luo	luo	PROPN
aji-153	404	28	,	,	PUNCT
aji-153	404	29	kunihiro	kunihiro	PROPN
aji-153	404	30	matsushita	matsushita	PROPN
aji-153	404	31	,	,	PUNCT
aji-153	404	32	peter	peter	PROPN
aji-153	404	33	a	a	DET
aji-153	404	34	mccullough	mccullough	PROPN
aji-153	404	35	,	,	PUNCT
aji-153	404	36	patrick	patrick	PROPN
aji-153	404	37	parfrey	parfrey	PROPN
aji-153	404	38	,	,	PUNCT
aji-153	404	39	geoffrey	geoffrey	PROPN
aji-153	404	40	ross	ross	PROPN
aji-153	404	41	,	,	PUNCT
aji-153	404	42	mark	mark	PROPN
aji-153	404	43	j	j	PROPN
aji-153	404	44	sarnak	sarnak	PROPN
aji-153	404	45	,	,	PUNCT
aji-153	404	46	dennis	dennis	PROPN
aji-153	404	47	vargo	vargo	PROPN
aji-153	404	48	,	,	PUNCT
aji-153	404	49	wolfgang	wolfgang	PROPN
aji-153	404	50	c	c	PROPN
aji-153	404	51	winkelmayer	winkelmayer	PROPN
aji-153	404	52	,	,	PUNCT
aji-153	404	53	glenn	glenn	PROPN
aji-153	404	54	m	m	PROPN
aji-153	404	55	chertow	chertow	ADJ
aji-153	404	56	,	,	PUNCT
aji-153	404	57	global	global	ADJ
aji-153	404	58	phase	phase	NOUN
aji-153	404	59	3	3	NUM
aji-153	404	60	programme	programme	NOUN
aji-153	404	61	of	of	ADP
aji-153	404	62	vadadustat	vadadustat	NOUN
aji-153	404	63	for	for	ADP
aji-153	404	64	treatment	treatment	NOUN
aji-153	404	65	of	of	ADP
aji-153	404	66	anaemia	anaemia	NOUN
aji-153	404	67	of	of	ADP
aji-153	404	68	chronic	chronic	ADJ
aji-153	404	69	kidney	kidney	NOUN
aji-153	404	70	disease	disease	NOUN
aji-153	404	71	:	:	PUNCT
aji-153	404	72	rationale	rationale	NOUN
aji-153	404	73	,	,	PUNCT
aji-153	404	74	study	study	NOUN
aji-153	404	75	design	design	NOUN
aji-153	404	76	and	and	CCONJ
aji-153	404	77	baseline	baseline	ADJ
aji-153	404	78	characteristics	characteristic	NOUN
aji-153	404	79	of	of	ADP
aji-153	404	80	dialysisdependent	dialysisdependent	NOUN
aji-153	404	81	patients	patient	NOUN
aji-153	404	82	in	in	ADP
aji-153	404	83	the	the	DET
aji-153	404	84	inno2vate	inno2vate	NOUN
aji-153	404	85	trials	trial	NOUN
aji-153	404	86	,	,	PUNCT
aji-153	404	87	nephrology	nephrology	NOUN
aji-153	404	88	dialysis	dialysis	NOUN
aji-153	404	89	transplantation	transplantation	NOUN
aji-153	404	90	.	.	PUNCT
aji-153	405	1	november	november	PROPN
aji-153	405	2	2021;36(11):2039–2048	2021;36(11):2039–2048	NUM
aji-153	405	3	.	.	PROPN
aji-153	406	1	3	3	NUM
aji-153	406	2	.	.	PUNCT
aji-153	407	1	navarro‐gonzales	navarro‐gonzale	NOUN
aji-153	407	2	p	p	X
aji-153	407	3	,	,	PUNCT
aji-153	407	4	ganz	ganz	PROPN
aji-153	407	5	t	t	PROPN
aji-153	407	6	,	,	PUNCT
aji-153	407	7	pergola	pergola	PROPN
aji-153	407	8	pe	pe	PROPN
aji-153	407	9	,	,	PUNCT
aji-153	407	10	zuk	zuk	PROPN
aji-153	407	11	a	a	PROPN
aji-153	407	12	,	,	PUNCT
aji-153	407	13	dykstra	dykstra	PROPN
aji-153	407	14	k.	k.	PROPN
aji-153	407	15	pharmacokinetics	pharmacokinetics	PROPN
aji-153	407	16	,	,	PUNCT
aji-153	407	17	pharmacodynamics	pharmacodynamic	NOUN
aji-153	407	18	,	,	PUNCT
aji-153	407	19	and	and	CCONJ
aji-153	407	20	safety	safety	NOUN
aji-153	407	21	of	of	ADP
aji-153	407	22	vadadustat	vadadustat	NOUN
aji-153	407	23	in	in	ADP
aji-153	407	24	healthy	healthy	ADJ
aji-153	407	25	volunteers	volunteer	NOUN
aji-153	407	26	and	and	CCONJ
aji-153	407	27	patients	patient	NOUN
aji-153	407	28	with	with	ADP
aji-153	407	29	chronic	chronic	ADJ
aji-153	407	30	kidney	kidney	NOUN
aji-153	407	31	disease	disease	NOUN
aji-153	407	32	.	.	PUNCT
aji-153	408	1	clinical	clinical	ADJ
aji-153	408	2	pharmacology	pharmacology	NOUN
aji-153	408	3	&	&	CCONJ
aji-153	408	4	therapeutics	therapeutic	NOUN
aji-153	408	5	;	;	PUNCT
aji-153	408	6	2024	2024	NUM
aji-153	408	7	jun	jun	PROPN
aji-153	408	8	25	25	NUM
aji-153	408	9	.	.	NOUN
aji-153	408	10	4	4	NUM
aji-153	408	11	.	.	PUNCT
aji-153	408	12	kowalski	kowalski	PROPN
aji-153	408	13	h	h	PROPN
aji-153	408	14	,	,	PUNCT
aji-153	408	15	hoivik	hoivik	PROPN
aji-153	408	16	d	d	NOUN
aji-153	408	17	,	,	PUNCT
aji-153	408	18	rabinowitz	rabinowitz	NOUN
aji-153	408	19	m.	m.	NOUN
aji-153	408	20	assessing	assess	VERB
aji-153	408	21	the	the	DET
aji-153	408	22	carcinogenicity	carcinogenicity	NOUN
aji-153	408	23	of	of	ADP
aji-153	408	24	vadadustat	vadadustat	NOUN
aji-153	408	25	,	,	PUNCT
aji-153	408	26	an	an	DET
aji-153	408	27	oral	oral	ADJ
aji-153	408	28	hypoxia	hypoxia	NOUN
aji-153	408	29	-	-	PUNCT
aji-153	408	30	inducible	inducible	ADJ
aji-153	408	31	factor	factor	NOUN
aji-153	408	32	prolyl-4	prolyl-4	NOUN
aji-153	408	33	-	-	PUNCT
aji-153	408	34	hydroxylase	hydroxylase	NOUN
aji-153	408	35	inhibitor	inhibitor	NOUN
aji-153	408	36	,	,	PUNCT
aji-153	408	37	in	in	ADP
aji-153	408	38	rodents	rodent	NOUN
aji-153	408	39	.	.	PUNCT
aji-153	409	1	toxicologic	toxicologic	ADJ
aji-153	409	2	pathology	pathology	NOUN
aji-153	409	3	.	.	PUNCT
aji-153	410	1	2023	2023	NUM
aji-153	410	2	jan;51(1	jan;51(1	ADV
aji-153	410	3	-	-	PUNCT
aji-153	410	4	2):56	2):56	NUM
aji-153	410	5	-	-	SYM
aji-153	410	6	60	60	NUM
aji-153	410	7	.	.	PUNCT
aji-153	411	1	5	5	NUM
aji-153	411	2	.	.	X
aji-153	411	3	eckardt	eckardt	PROPN
aji-153	411	4	ku	ku	PROPN
aji-153	411	5	,	,	PUNCT
aji-153	411	6	agarwal	agarwal	PROPN
aji-153	411	7	r	r	PROPN
aji-153	411	8	,	,	PUNCT
aji-153	411	9	farag	farag	PROPN
aji-153	411	10	ym	ym	PROPN
aji-153	411	11	,	,	PUNCT
aji-153	411	12	jardine	jardine	PROPN
aji-153	411	13	ag	ag	PROPN
aji-153	411	14	,	,	PUNCT
aji-153	411	15	khawaja	khawaja	PROPN
aji-153	411	16	z	z	PROPN
aji-153	411	17	,	,	PUNCT
aji-153	411	18	koury	koury	PROPN
aji-153	411	19	mj	mj	PROPN
aji-153	411	20	,	,	PUNCT
aji-153	411	21	luo	luo	PROPN
aji-153	411	22	w	w	PROPN
aji-153	411	23	,	,	PUNCT
aji-153	411	24	matsushita	matsushita	PROPN
aji-153	411	25	k	k	PROPN
aji-153	411	26	,	,	PUNCT
aji-153	411	27	mccullough	mccullough	PROPN
aji-153	411	28	pa	pa	PROPN
aji-153	411	29	,	,	PUNCT
aji-153	411	30	parfrey	parfrey	NOUN
aji-153	411	31	p	p	NOUN
aji-153	411	32	,	,	PUNCT
aji-153	411	33	ross	ross	PROPN
aji-153	411	34	g.	g.	PROPN
aji-153	411	35	global	global	PROPN
aji-153	411	36	phase	phase	NOUN
aji-153	411	37	3	3	NUM
aji-153	411	38	programme	programme	NOUN
aji-153	411	39	of	of	ADP
aji-153	411	40	vadadustat	vadadustat	NOUN
aji-153	411	41	for	for	ADP
aji-153	411	42	treatment	treatment	NOUN
aji-153	411	43	of	of	ADP
aji-153	411	44	anaemia	anaemia	NOUN
aji-153	411	45	of	of	ADP
aji-153	411	46	chronic	chronic	ADJ
aji-153	411	47	kidney	kidney	NOUN
aji-153	411	48	disease	disease	NOUN
aji-153	411	49	:	:	PUNCT
aji-153	411	50	rationale	rationale	NOUN
aji-153	411	51	,	,	PUNCT
aji-153	411	52	study	study	NOUN
aji-153	411	53	design	design	NOUN
aji-153	411	54	and	and	CCONJ
aji-153	411	55	baseline	baseline	ADJ
aji-153	411	56	characteristics	characteristic	NOUN
aji-153	411	57	of	of	ADP
aji-153	411	58	dialysis	dialysis	NOUN
aji-153	411	59	-	-	PUNCT
aji-153	411	60	dependent	dependent	ADJ
aji-153	411	61	patients	patient	NOUN
aji-153	411	62	in	in	ADP
aji-153	411	63	the	the	DET
aji-153	411	64	inno2vate	inno2vate	NOUN
aji-153	411	65	trials	trial	NOUN
aji-153	411	66	.	.	PUNCT
aji-153	412	1	nephrology	nephrology	NOUN
aji-153	412	2	dialysis	dialysis	NOUN
aji-153	412	3	transplantation	transplantation	NOUN
aji-153	412	4	.	.	PUNCT
aji-153	413	1	2021	2021	NUM
aji-153	413	2	nov;36(11):203948	nov;36(11):203948	PROPN
aji-153	413	3	.	.	PUNCT
aji-153	414	1	6	6	NUM
aji-153	414	2	.	.	X
aji-153	414	3	locatelli	locatelli	PROPN
aji-153	414	4	f	f	PROPN
aji-153	414	5	,	,	PUNCT
aji-153	414	6	del	del	PROPN
aji-153	414	7	vecchio	vecchio	PROPN
aji-153	414	8	l	l	PROPN
aji-153	414	9	,	,	PUNCT
aji-153	414	10	esposito	esposito	PROPN
aji-153	414	11	c	c	PROPN
aji-153	414	12	,	,	PUNCT
aji-153	414	13	gesualdo	gesualdo	NOUN
aji-153	414	14	l	l	NOUN
aji-153	414	15	,	,	PUNCT
aji-153	414	16	grandaliano	grandaliano	VERB
aji-153	414	17	g	g	NOUN
aji-153	414	18	,	,	PUNCT
aji-153	414	19	ravera	ravera	PROPN
aji-153	414	20	m	m	PROPN
aji-153	414	21	,	,	PUNCT
aji-153	414	22	collaborative	collaborative	ADJ
aji-153	414	23	study	study	NOUN
aji-153	414	24	group	group	NOUN
aji-153	414	25	on	on	ADP
aji-153	414	26	the	the	DET
aji-153	414	27	conservative	conservative	ADJ
aji-153	414	28	treatment	treatment	NOUN
aji-153	414	29	of	of	ADP
aji-153	414	30	ckd	ckd	PROPN
aji-153	414	31	of	of	ADP
aji-153	414	32	the	the	DET
aji-153	414	33	italian	italian	ADJ
aji-153	414	34	society	society	NOUN
aji-153	414	35	of	of	ADP
aji-153	414	36	nephrology	nephrology	NOUN
aji-153	414	37	,	,	PUNCT
aji-153	414	38	minutolo	minutolo	PROPN
aji-153	414	39	r.	r.	PROPN
aji-153	414	40	consensus	consensus	PROPN
aji-153	414	41	commentary	commentary	NOUN
aji-153	414	42	and	and	CCONJ
aji-153	414	43	position	position	NOUN
aji-153	414	44	of	of	ADP
aji-153	414	45	the	the	DET
aji-153	414	46	italian	italian	ADJ
aji-153	414	47	society	society	NOUN
aji-153	414	48	of	of	ADP
aji-153	414	49	nephrology	nephrology	NOUN
aji-153	414	50	on	on	ADP
aji-153	414	51	kdigo	kdigo	PROPN
aji-153	414	52	controversies	controversy	NOUN
aji-153	414	53	conference	conference	NOUN
aji-153	414	54	on	on	ADP
aji-153	414	55	novel	novel	ADJ
aji-153	414	56	anemia	anemia	NOUN
aji-153	414	57	therapies	therapy	NOUN
aji-153	414	58	in	in	ADP
aji-153	414	59	chronic	chronic	ADJ
aji-153	414	60	kidney	kidney	NOUN
aji-153	414	61	disease	disease	NOUN
aji-153	414	62	.	.	PUNCT
aji-153	415	1	journal	journal	PROPN
aji-153	415	2	of	of	ADP
aji-153	415	3	nephrology	nephrology	NOUN
aji-153	415	4	.	.	PUNCT
aji-153	416	1	2024	2024	NUM
aji-153	416	2	may	may	AUX
aji-153	416	3	6:1	6:1	NUM
aji-153	416	4	-	-	SYM
aji-153	416	5	5	5	NUM
aji-153	416	6	.	.	NOUN
aji-153	416	7	7	7	NUM
aji-153	416	8	.	.	X
aji-153	416	9	zuk	zuk	PROPN
aji-153	416	10	a	a	X
aji-153	416	11	,	,	PUNCT
aji-153	416	12	si	si	PROPN
aji-153	416	13	z	z	PROPN
aji-153	416	14	,	,	PUNCT
aji-153	416	15	loi	loi	PROPN
aji-153	416	16	s	s	PROPN
aji-153	416	17	,	,	PUNCT
aji-153	416	18	bommegowda	bommegowda	PROPN
aji-153	416	19	s	s	PART
aji-153	416	20	,	,	PUNCT
aji-153	416	21	hoivik	hoivik	NOUN
aji-153	416	22	d	d	NOUN
aji-153	416	23	,	,	PUNCT
aji-153	416	24	danthi	danthi	PROPN
aji-153	416	25	s	s	PROPN
aji-153	416	26	,	,	PUNCT
aji-153	416	27	molnar	molnar	PROPN
aji-153	416	28	g	g	PROPN
aji-153	416	29	,	,	PUNCT
aji-153	416	30	csizmadia	csizmadia	PROPN
aji-153	416	31	v	v	PROPN
aji-153	416	32	,	,	PUNCT
aji-153	416	33	rabinowitz	rabinowitz	NOUN
aji-153	416	34	m.	m.	NOUN
aji-153	416	35	preclinical	preclinical	ADJ
aji-153	416	36	characterization	characterization	NOUN
aji-153	416	37	of	of	ADP
aji-153	416	38	vadadustat	vadadustat	NOUN
aji-153	416	39	(	(	PUNCT
aji-153	416	40	akb-6548	akb-6548	NOUN
aji-153	416	41	)	)	PUNCT
aji-153	416	42	,	,	PUNCT
aji-153	416	43	an	an	DET
aji-153	416	44	oral	oral	ADJ
aji-153	416	45	small	small	ADJ
aji-153	416	46	molecule	molecule	NOUN
aji-153	416	47	hypoxia	hypoxia	NOUN
aji-153	416	48	-	-	PUNCT
aji-153	416	49	inducible	inducible	ADJ
aji-153	416	50	factor	factor	NOUN
aji-153	416	51	prolyl-4hydroxylase	prolyl-4hydroxylase	PROPN
aji-153	416	52	inhibitor	inhibitor	NOUN
aji-153	416	53	,	,	PUNCT
aji-153	416	54	for	for	ADP
aji-153	416	55	the	the	DET
aji-153	416	56	potential	potential	ADJ
aji-153	416	57	treatment	treatment	NOUN
aji-153	416	58	of	of	ADP
aji-153	416	59	renal	renal	ADJ
aji-153	416	60	anemia	anemia	NOUN
aji-153	416	61	.	.	PUNCT
aji-153	417	1	journal	journal	PROPN
aji-153	417	2	of	of	ADP
aji-153	417	3	pharmacology	pharmacology	NOUN
aji-153	417	4	and	and	CCONJ
aji-153	417	5	experimental	experimental	ADJ
aji-153	417	6	therapeutics	therapeutic	NOUN
aji-153	417	7	.	.	PUNCT
aji-153	418	1	2022	2022	NUM
aji-153	418	2	oct	oct	NOUN
aji-153	418	3	1;383(1	1;383(1	NUM
aji-153	418	4	):	):	PUNCT
aji-153	418	5	11	11	NUM
aji-153	418	6	-	-	SYM
aji-153	418	7	24	24	NUM
aji-153	418	8	.	.	NOUN
aji-153	419	1	8	8	NUM
aji-153	419	2	.	.	PUNCT
aji-153	420	1	mikhail	mikhail	PROPN
aji-153	420	2	a	a	DET
aji-153	420	3	,	,	PUNCT
aji-153	420	4	brown	brown	ADJ
aji-153	420	5	c	c	NOUN
aji-153	420	6	,	,	PUNCT
aji-153	420	7	williams	williams	PROPN
aji-153	420	8	ja	ja	PROPN
aji-153	420	9	,	,	PUNCT
aji-153	420	10	mathrani	mathrani	PROPN
aji-153	420	11	v	v	NOUN
aji-153	420	12	,	,	PUNCT
aji-153	420	13	shrivastava	shrivastava	PROPN
aji-153	420	14	r	r	PROPN
aji-153	420	15	,	,	PUNCT
aji-153	420	16	evans	evans	PROPN
aji-153	420	17	j	j	PROPN
aji-153	420	18	,	,	PUNCT
aji-153	420	19	isaac	isaac	PROPN
aji-153	420	20	h	h	PROPN
aji-153	420	21	,	,	PUNCT
aji-153	420	22	bhandari	bhandari	PROPN
aji-153	420	23	s.	s.	PROPN
aji-153	420	24	renal	renal	PROPN
aji-153	420	25	association	association	PROPN
aji-153	420	26	clinical	clinical	ADJ
aji-153	420	27	practice	practice	NOUN
aji-153	420	28	guideline	guideline	NOUN
aji-153	420	29	on	on	ADP
aji-153	420	30	anaemia	anaemia	NOUN
aji-153	420	31	of	of	ADP
aji-153	420	32	chronic	chronic	ADJ
aji-153	420	33	gupta	gupta	PROPN
aji-153	420	34	et	et	PROPN
aji-153	420	35	al	al	PROPN
aji-153	420	36	.	.	PROPN
aji-153	420	37	;	;	PUNCT
aji-153	420	38	asian	asian	PROPN
aji-153	420	39	j.	j.	PROPN
aji-153	420	40	immunol	immunol	PROPN
aji-153	420	41	.	.	PROPN
aji-153	420	42	,	,	PUNCT
aji-153	420	43	vol	vol	NOUN
aji-153	420	44	.	.	PROPN
aji-153	421	1	7	7	NUM
aji-153	421	2	,	,	PUNCT
aji-153	421	3	no	no	INTJ
aji-153	421	4	.	.	NOUN
aji-153	421	5	1	1	NUM
aji-153	421	6	,	,	PUNCT
aji-153	421	7	pp	pp	ADJ
aji-153	421	8	.	.	PUNCT
aji-153	422	1	302	302	NUM
aji-153	422	2	-	-	SYM
aji-153	422	3	315	315	NUM
aji-153	422	4	,	,	PUNCT
aji-153	422	5	2024	2024	NUM
aji-153	422	6	;	;	PUNCT
aji-153	422	7	article	article	NOUN
aji-153	422	8	no.aji.127402	no.aji.127402	VERB
aji-153	422	9	313	313	NUM
aji-153	422	10	kid0ney	kid0ney	NOUN
aji-153	422	11	disease	disease	NOUN
aji-153	422	12	.	.	PUNCT
aji-153	423	1	bmc	bmc	ADJ
aji-153	423	2	nephrology	nephrology	NOUN
aji-153	423	3	.	.	PUNCT
aji-153	424	1	2017	2017	NUM
aji-153	424	2	dec;18:1	dec;18:1	NOUN
aji-153	424	3	-	-	PUNCT
aji-153	424	4	29	29	NUM
aji-153	424	5	.	.	PUNCT
aji-153	425	1	9	9	NUM
aji-153	425	2	.	.	X
aji-153	425	3	atkinson	atkinson	PROPN
aji-153	425	4	ma	ma	PROPN
aji-153	425	5	,	,	PUNCT
aji-153	425	6	warady	warady	PROPN
aji-153	425	7	ba	ba	PROPN
aji-153	425	8	.	.	PUNCT
aji-153	426	1	anemia	anemia	NOUN
aji-153	426	2	in	in	ADP
aji-153	426	3	chronic	chronic	ADJ
aji-153	426	4	kidney	kidney	NOUN
aji-153	426	5	disease	disease	NOUN
aji-153	426	6	.	.	PUNCT
aji-153	427	1	pediatric	pediatric	ADJ
aji-153	427	2	nephrology	nephrology	NOUN
aji-153	427	3	.	.	PUNCT
aji-153	428	1	2018	2018	NUM
aji-153	428	2	feb;33:227	feb;33:227	PROPN
aji-153	428	3	-	-	SYM
aji-153	428	4	38	38	NUM
aji-153	428	5	.	.	PUNCT
aji-153	429	1	10	10	NUM
aji-153	429	2	.	.	PUNCT
aji-153	430	1	macdougall	macdougall	PROPN
aji-153	430	2	ic	ic	PROPN
aji-153	430	3	.	.	PROPN
aji-153	430	4	anaemia	anaemia	NOUN
aji-153	430	5	of	of	ADP
aji-153	430	6	chronic	chronic	ADJ
aji-153	430	7	kidney	kidney	NOUN
aji-153	430	8	disease	disease	NOUN
aji-153	430	9	.	.	PUNCT
aji-153	431	1	medicine	medicine	NOUN
aji-153	431	2	.	.	PUNCT
aji-153	432	1	2007	2007	NUM
aji-153	432	2	aug	aug	PROPN
aji-153	432	3	1;35(8):45760	1;35(8):45760	NUM
aji-153	432	4	.	.	PUNCT
aji-153	433	1	11	11	NUM
aji-153	433	2	.	.	PUNCT
aji-153	434	1	palaka	palaka	PROPN
aji-153	434	2	e	e	PROPN
aji-153	434	3	,	,	PUNCT
aji-153	434	4	grandy	grandy	PROPN
aji-153	434	5	s	s	PROPN
aji-153	434	6	,	,	PUNCT
aji-153	434	7	van	van	PROPN
aji-153	434	8	haalen	haalen	PROPN
aji-153	434	9	h	h	PROPN
aji-153	434	10	,	,	PUNCT
aji-153	434	11	mcewan	mcewan	NOUN
aji-153	434	12	p	p	NOUN
aji-153	434	13	,	,	PUNCT
aji-153	434	14	darlington	darlington	PROPN
aji-153	434	15	o.	o.	NOUN
aji-153	435	1	the	the	DET
aji-153	435	2	impact	impact	NOUN
aji-153	435	3	of	of	ADP
aji-153	435	4	ckd	ckd	PROPN
aji-153	435	5	anaemia	anaemia	NOUN
aji-153	435	6	on	on	ADP
aji-153	435	7	patients	patient	NOUN
aji-153	435	8	:	:	PUNCT
aji-153	435	9	incidence	incidence	NOUN
aji-153	435	10	,	,	PUNCT
aji-153	435	11	risk	risk	NOUN
aji-153	435	12	factors	factor	NOUN
aji-153	435	13	,	,	PUNCT
aji-153	435	14	and	and	CCONJ
aji-153	435	15	clinical	clinical	ADJ
aji-153	435	16	outcomes	outcome	NOUN
aji-153	435	17	—	—	PUNCT
aji-153	435	18	a	a	DET
aji-153	435	19	systematic	systematic	ADJ
aji-153	435	20	literature	literature	NOUN
aji-153	435	21	review	review	NOUN
aji-153	435	22	.	.	PUNCT
aji-153	436	1	international	international	ADJ
aji-153	436	2	journal	journal	PROPN
aji-153	436	3	of	of	ADP
aji-153	436	4	nephrology	nephrology	NOUN
aji-153	436	5	.	.	PUNCT
aji-153	437	1	2020;2020	2020;2020	NUM
aji-153	437	2	(	(	PUNCT
aji-153	437	3	1):7692376	1):7692376	NUM
aji-153	437	4	.	.	NOUN
aji-153	437	5	12	12	NUM
aji-153	437	6	.	.	PUNCT
aji-153	438	1	kalantar	kalantar	NOUN
aji-153	438	2	-	-	PUNCT
aji-153	438	3	zadeh	zadeh	PROPN
aji-153	438	4	k	k	PROPN
aji-153	438	5	,	,	PUNCT
aji-153	438	6	jafar	jafar	PROPN
aji-153	438	7	th	th	PROPN
aji-153	438	8	,	,	PUNCT
aji-153	438	9	nitsch	nitsch	PROPN
aji-153	438	10	d	d	PROPN
aji-153	438	11	,	,	PUNCT
aji-153	438	12	neuen	neuen	PROPN
aji-153	438	13	bl	bl	PROPN
aji-153	438	14	,	,	PUNCT
aji-153	438	15	perkovic	perkovic	ADJ
aji-153	438	16	v.	v.	ADP
aji-153	438	17	chronic	chronic	ADJ
aji-153	438	18	kidney	kidney	NOUN
aji-153	438	19	disease	disease	NOUN
aji-153	438	20	.	.	PUNCT
aji-153	439	1	the	the	DET
aji-153	439	2	lancet	lancet	PROPN
aji-153	439	3	.	.	PUNCT
aji-153	440	1	2021	2021	NUM
aji-153	440	2	aug	aug	PROPN
aji-153	440	3	28;398(10302):786	28;398(10302):786	NUM
aji-153	440	4	-	-	SYM
aji-153	440	5	802	802	NUM
aji-153	440	6	.	.	NOUN
aji-153	440	7	13	13	NUM
aji-153	440	8	.	.	PUNCT
aji-153	440	9	gafter	gafter	ADJ
aji-153	440	10	-	-	PUNCT
aji-153	440	11	gvili	gvili	NOUN
aji-153	440	12	a	a	PRON
aji-153	440	13	,	,	PUNCT
aji-153	440	14	schechter	schechter	NOUN
aji-153	440	15	a	a	NOUN
aji-153	440	16	,	,	PUNCT
aji-153	440	17	rozen	rozen	PROPN
aji-153	440	18	-	-	PUNCT
aji-153	440	19	zvi	zvi	PROPN
aji-153	440	20	b.	b.	PROPN
aji-153	440	21	iron	iron	NOUN
aji-153	440	22	deficiency	deficiency	NOUN
aji-153	440	23	anemia	anemia	NOUN
aji-153	440	24	in	in	ADP
aji-153	440	25	chronic	chronic	ADJ
aji-153	440	26	kidney	kidney	NOUN
aji-153	440	27	disease	disease	NOUN
aji-153	440	28	.	.	PUNCT
aji-153	441	1	acta	acta	PROPN
aji-153	441	2	haematologica	haematologica	PROPN
aji-153	441	3	.	.	PUNCT
aji-153	442	1	2019	2019	NUM
aji-153	442	2	may	may	AUX
aji-153	442	3	15;142(1):44	15;142(1):44	NUM
aji-153	442	4	-	-	SYM
aji-153	442	5	50	50	NUM
aji-153	442	6	.	.	PUNCT
aji-153	442	7	14	14	NUM
aji-153	442	8	.	.	PUNCT
aji-153	443	1	locatelli	locatelli	PROPN
aji-153	443	2	f	f	PROPN
aji-153	443	3	,	,	PUNCT
aji-153	443	4	minutolo	minutolo	ADJ
aji-153	443	5	r	r	NOUN
aji-153	443	6	,	,	PUNCT
aji-153	443	7	de	de	X
aji-153	443	8	nicola	nicola	PROPN
aji-153	443	9	l	l	PROPN
aji-153	443	10	,	,	PUNCT
aji-153	443	11	del	del	PROPN
aji-153	443	12	vecchio	vecchio	PROPN
aji-153	443	13	l.	l.	NOUN
aji-153	443	14	evolving	evolve	VERB
aji-153	443	15	strategies	strategy	NOUN
aji-153	443	16	in	in	ADP
aji-153	443	17	the	the	DET
aji-153	443	18	treatment	treatment	NOUN
aji-153	443	19	of	of	ADP
aji-153	443	20	anaemia	anaemia	NOUN
aji-153	443	21	in	in	ADP
aji-153	443	22	chronic	chronic	ADJ
aji-153	443	23	kidney	kidney	NOUN
aji-153	443	24	disease	disease	NOUN
aji-153	443	25	:	:	PUNCT
aji-153	443	26	the	the	DET
aji-153	443	27	hif	hif	PROPN
aji-153	443	28	-	-	PUNCT
aji-153	443	29	prolyl	prolyl	PROPN
aji-153	443	30	hydroxylase	hydroxylase	NOUN
aji-153	443	31	inhibitors	inhibitor	NOUN
aji-153	443	32	.	.	PUNCT
aji-153	444	1	drugs	drug	NOUN
aji-153	444	2	.	.	PUNCT
aji-153	445	1	2022	2022	NUM
aji-153	445	2	nov;82(16):156589	nov;82(16):156589	NOUN
aji-153	445	3	.	.	PUNCT
aji-153	446	1	15	15	NUM
aji-153	446	2	.	.	PUNCT
aji-153	446	3	bartnicki	bartnicki	PROPN
aji-153	446	4	p.	p.	PROPN
aji-153	446	5	hypoxia	hypoxia	NOUN
aji-153	446	6	-	-	PUNCT
aji-153	446	7	inducible	inducible	ADJ
aji-153	446	8	factor	factor	NOUN
aji-153	446	9	prolyl	prolyl	NOUN
aji-153	446	10	hydroxylase	hydroxylase	NOUN
aji-153	446	11	inhibitors	inhibitor	NOUN
aji-153	446	12	as	as	ADP
aji-153	446	13	a	a	DET
aji-153	446	14	new	new	ADJ
aji-153	446	15	treatment	treatment	NOUN
aji-153	446	16	option	option	NOUN
aji-153	446	17	for	for	ADP
aji-153	446	18	anemia	anemia	NOUN
aji-153	446	19	in	in	ADP
aji-153	446	20	chronic	chronic	ADJ
aji-153	446	21	kidney	kidney	NOUN
aji-153	446	22	disease	disease	NOUN
aji-153	446	23	.	.	PUNCT
aji-153	447	1	biomedicines	biomedicine	NOUN
aji-153	447	2	.	.	PUNCT
aji-153	448	1	2024	2024	NUM
aji-153	448	2	aug	aug	PROPN
aji-153	448	3	18;12(8):1884	18;12(8):1884	NUM
aji-153	448	4	.	.	PUNCT
aji-153	448	5	16	16	NUM
aji-153	448	6	.	.	PUNCT
aji-153	449	1	haase	haase	PROPN
aji-153	449	2	vh	vh	PROPN
aji-153	449	3	.	.	PUNCT
aji-153	450	1	hif‐prolyl	hif‐prolyl	ADJ
aji-153	450	2	hydroxylases	hydroxylase	NOUN
aji-153	450	3	as	as	ADP
aji-153	450	4	therapeutic	therapeutic	ADJ
aji-153	450	5	targets	target	NOUN
aji-153	450	6	in	in	ADP
aji-153	450	7	erythropoiesis	erythropoiesis	NOUN
aji-153	450	8	and	and	CCONJ
aji-153	450	9	iron	iron	NOUN
aji-153	450	10	metabolism	metabolism	NOUN
aji-153	450	11	.	.	PUNCT
aji-153	451	1	hemodialysis	hemodialysis	NOUN
aji-153	451	2	international	international	ADJ
aji-153	451	3	.	.	PUNCT
aji-153	451	4	2017	2017	NUM
aji-153	451	5	apr;21	apr;21	NOUN
aji-153	451	6	:	:	PUNCT
aji-153	451	7	s110	s110	PROPN
aji-153	451	8	-	-	SYM
aji-153	451	9	24	24	NUM
aji-153	451	10	.	.	PUNCT
aji-153	451	11	17	17	NUM
aji-153	451	12	.	.	PUNCT
aji-153	452	1	pergola	pergola	PROPN
aji-153	452	2	pe	pe	PROPN
aji-153	452	3	,	,	PUNCT
aji-153	452	4	spinowitz	spinowitz	NOUN
aji-153	452	5	bs	bs	PROPN
aji-153	452	6	,	,	PUNCT
aji-153	452	7	hartman	hartman	PROPN
aji-153	452	8	cs	cs	PROPN
aji-153	452	9	,	,	PUNCT
aji-153	452	10	maroni	maroni	PROPN
aji-153	452	11	bj	bj	NOUN
aji-153	452	12	,	,	PUNCT
aji-153	452	13	haase	haase	PROPN
aji-153	452	14	vh	vh	PROPN
aji-153	452	15	.	.	PROPN
aji-153	452	16	vadadustat	vadadustat	PROPN
aji-153	452	17	,	,	PUNCT
aji-153	452	18	a	a	DET
aji-153	452	19	novel	novel	ADJ
aji-153	452	20	oral	oral	ADJ
aji-153	452	21	hif	hif	PROPN
aji-153	452	22	stabilizer	stabilizer	NOUN
aji-153	452	23	,	,	PUNCT
aji-153	452	24	provides	provide	VERB
aji-153	452	25	effective	effective	ADJ
aji-153	452	26	anemia	anemia	NOUN
aji-153	452	27	treatment	treatment	NOUN
aji-153	452	28	in	in	ADP
aji-153	452	29	nondialysisdependent	nondialysisdependent	ADJ
aji-153	452	30	chronic	chronic	ADJ
aji-153	452	31	kidney	kidney	NOUN
aji-153	452	32	disease	disease	NOUN
aji-153	452	33	.	.	PUNCT
aji-153	453	1	kidney	kidney	PROPN
aji-153	453	2	international	international	PROPN
aji-153	453	3	.	.	PUNCT
aji-153	454	1	2016	2016	NUM
aji-153	454	2	nov	nov	NOUN
aji-153	454	3	1;90(5	1;90(5	NUM
aji-153	454	4	):	):	PUNCT
aji-153	454	5	1115	1115	NUM
aji-153	454	6	-	-	SYM
aji-153	454	7	22	22	NUM
aji-153	454	8	.	.	PUNCT
aji-153	455	1	18	18	NUM
aji-153	455	2	.	.	PUNCT
aji-153	456	1	kowalski	kowalski	PROPN
aji-153	456	2	h	h	PROPN
aji-153	456	3	,	,	PUNCT
aji-153	456	4	hoivik	hoivik	PROPN
aji-153	456	5	d	d	NOUN
aji-153	456	6	,	,	PUNCT
aji-153	456	7	rabinowitz	rabinowitz	NOUN
aji-153	456	8	m.	m.	NOUN
aji-153	456	9	assessing	assess	VERB
aji-153	456	10	the	the	DET
aji-153	456	11	carcinogenicity	carcinogenicity	NOUN
aji-153	456	12	of	of	ADP
aji-153	456	13	vadadustat	vadadustat	NOUN
aji-153	456	14	,	,	PUNCT
aji-153	456	15	an	an	DET
aji-153	456	16	oral	oral	ADJ
aji-153	456	17	hypoxia	hypoxia	NOUN
aji-153	456	18	-	-	PUNCT
aji-153	456	19	inducible	inducible	ADJ
aji-153	456	20	factor	factor	NOUN
aji-153	456	21	prolyl-4	prolyl-4	NOUN
aji-153	456	22	-	-	PUNCT
aji-153	456	23	hydroxylase	hydroxylase	NOUN
aji-153	456	24	inhibitor	inhibitor	NOUN
aji-153	456	25	,	,	PUNCT
aji-153	456	26	in	in	ADP
aji-153	456	27	rodents	rodent	NOUN
aji-153	456	28	.	.	PUNCT
aji-153	457	1	toxicologic	toxicologic	ADJ
aji-153	457	2	pathology	pathology	NOUN
aji-153	457	3	.	.	PUNCT
aji-153	458	1	2023	2023	NUM
aji-153	458	2	jan;51(1	jan;51(1	ADV
aji-153	458	3	-	-	PUNCT
aji-153	458	4	2):56	2):56	NUM
aji-153	458	5	-	-	SYM
aji-153	458	6	60	60	NUM
aji-153	458	7	.	.	PUNCT
aji-153	459	1	19	19	NUM
aji-153	459	2	.	.	PUNCT
aji-153	459	3	mimura	mimura	PROPN
aji-153	459	4	i	i	PROPN
aji-153	459	5	,	,	PUNCT
aji-153	459	6	tanaka	tanaka	PROPN
aji-153	459	7	t	t	PROPN
aji-153	459	8	,	,	PUNCT
aji-153	459	9	nangaku	nangaku	PROPN
aji-153	459	10	m.	m.	NOUN
aji-153	459	11	evaluating	evaluate	VERB
aji-153	459	12	the	the	DET
aji-153	459	13	safety	safety	NOUN
aji-153	459	14	and	and	CCONJ
aji-153	459	15	efficacy	efficacy	NOUN
aji-153	459	16	of	of	ADP
aji-153	459	17	vadadustat	vadadustat	NOUN
aji-153	459	18	for	for	ADP
aji-153	459	19	the	the	DET
aji-153	459	20	treatment	treatment	NOUN
aji-153	459	21	of	of	ADP
aji-153	459	22	anemia	anemia	NOUN
aji-153	459	23	associated	associate	VERB
aji-153	459	24	with	with	ADP
aji-153	459	25	chronic	chronic	ADJ
aji-153	459	26	kidney	kidney	NOUN
aji-153	459	27	disease	disease	NOUN
aji-153	459	28	.	.	PUNCT
aji-153	460	1	expert	expert	ADJ
aji-153	460	2	opinion	opinion	NOUN
aji-153	460	3	on	on	ADP
aji-153	460	4	pharmacotherapy	pharmacotherapy	NOUN
aji-153	460	5	.	.	PUNCT
aji-153	461	1	2024	2024	NUM
aji-153	461	2	jun	jun	PROPN
aji-153	461	3	21(just	21(just	NUM
aji-153	461	4	-	-	PUNCT
aji-153	461	5	accepted	accept	VERB
aji-153	461	6	)	)	PUNCT
aji-153	461	7	.	.	PUNCT
aji-153	462	1	20	20	NUM
aji-153	462	2	.	.	X
aji-153	463	1	nangaku	nangaku	PROPN
aji-153	463	2	m	m	PROPN
aji-153	463	3	,	,	PUNCT
aji-153	463	4	ueta	ueta	PROPN
aji-153	463	5	k	k	PROPN
aji-153	463	6	,	,	PUNCT
aji-153	463	7	nishimura	nishimura	PROPN
aji-153	463	8	k	k	PROPN
aji-153	463	9	,	,	PUNCT
aji-153	463	10	sasaki	sasaki	PROPN
aji-153	463	11	k	k	PROPN
aji-153	463	12	,	,	PUNCT
aji-153	463	13	hashimoto	hashimoto	NOUN
aji-153	463	14	t.	t.	NOUN
aji-153	463	15	factors	factor	NOUN
aji-153	463	16	affecting	affect	VERB
aji-153	463	17	responsiveness	responsiveness	NOUN
aji-153	463	18	of	of	ADP
aji-153	463	19	vadadustat	vadadustat	NOUN
aji-153	463	20	in	in	ADP
aji-153	463	21	patients	patient	NOUN
aji-153	463	22	with	with	ADP
aji-153	463	23	anemia	anemia	NOUN
aji-153	463	24	associated	associate	VERB
aji-153	463	25	with	with	ADP
aji-153	463	26	chronic	chronic	ADJ
aji-153	463	27	kidney	kidney	NOUN
aji-153	463	28	disease	disease	NOUN
aji-153	463	29	:	:	PUNCT
aji-153	463	30	a	a	DET
aji-153	463	31	post	post	ADJ
aji-153	463	32	-	-	ADJ
aji-153	463	33	hoc	hoc	ADJ
aji-153	463	34	subgroup	subgroup	NOUN
aji-153	463	35	analysis	analysis	NOUN
aji-153	463	36	of	of	ADP
aji-153	463	37	japanese	japanese	ADJ
aji-153	463	38	phase	phase	NOUN
aji-153	463	39	3	3	NUM
aji-153	463	40	randomized	randomize	VERB
aji-153	463	41	studies	study	NOUN
aji-153	463	42	.	.	PUNCT
aji-153	464	1	clinical	clinical	ADJ
aji-153	464	2	and	and	CCONJ
aji-153	464	3	experimental	experimental	ADJ
aji-153	464	4	nephrology	nephrology	NOUN
aji-153	464	5	.	.	PUNCT
aji-153	465	1	2024	2024	NUM
aji-153	465	2	may;28(5):391	may;28(5):391	NOUN
aji-153	465	3	-	-	SYM
aji-153	465	4	403	403	NUM
aji-153	465	5	.	.	PUNCT
aji-153	466	1	21	21	NUM
aji-153	466	2	.	.	PUNCT
aji-153	467	1	agarwal	agarwal	PROPN
aji-153	467	2	r	r	PROPN
aji-153	467	3	,	,	PUNCT
aji-153	467	4	anand	anand	PROPN
aji-153	467	5	s	s	PROPN
aji-153	467	6	,	,	PUNCT
aji-153	467	7	eckardt	eckardt	PROPN
aji-153	467	8	ku	ku	PROPN
aji-153	467	9	,	,	PUNCT
aji-153	467	10	luo	luo	PROPN
aji-153	467	11	w	w	PROPN
aji-153	467	12	,	,	PUNCT
aji-153	467	13	parfrey	parfrey	PROPN
aji-153	467	14	ps	ps	PROPN
aji-153	467	15	,	,	PUNCT
aji-153	467	16	sarnak	sarnak	PROPN
aji-153	467	17	mj	mj	PROPN
aji-153	467	18	,	,	PUNCT
aji-153	467	19	solinsky	solinsky	PROPN
aji-153	467	20	cm	cm	PROPN
aji-153	467	21	,	,	PUNCT
aji-153	467	22	vargo	vargo	PROPN
aji-153	467	23	dl	dl	PROPN
aji-153	467	24	,	,	PUNCT
aji-153	467	25	winkelmayer	winkelmayer	PROPN
aji-153	467	26	wc	wc	PROPN
aji-153	467	27	,	,	PUNCT
aji-153	467	28	chertow	chertow	VERB
aji-153	467	29	gm	gm	PROPN
aji-153	467	30	.	.	PUNCT
aji-153	468	1	overall	overall	ADJ
aji-153	468	2	adverse	adverse	ADJ
aji-153	468	3	event	event	NOUN
aji-153	468	4	profile	profile	NOUN
aji-153	468	5	of	of	ADP
aji-153	468	6	vadadustat	vadadustat	NOUN
aji-153	468	7	versus	versus	ADP
aji-153	468	8	darbepoetin	darbepoetin	PROPN
aji-153	468	9	alfa	alfa	PROPN
aji-153	468	10	for	for	ADP
aji-153	468	11	the	the	DET
aji-153	468	12	treatment	treatment	NOUN
aji-153	468	13	of	of	ADP
aji-153	468	14	anemia	anemia	NOUN
aji-153	468	15	associated	associate	VERB
aji-153	468	16	with	with	ADP
aji-153	468	17	chronic	chronic	ADJ
aji-153	468	18	kidney	kidney	NOUN
aji-153	468	19	disease	disease	NOUN
aji-153	468	20	in	in	ADP
aji-153	468	21	phase	phase	NOUN
aji-153	468	22	3	3	NUM
aji-153	468	23	trials	trial	NOUN
aji-153	468	24	.	.	PUNCT
aji-153	469	1	american	american	PROPN
aji-153	469	2	journal	journal	PROPN
aji-153	469	3	of	of	ADP
aji-153	469	4	nephrology	nephrology	NOUN
aji-153	469	5	.	.	PUNCT
aji-153	470	1	2023	2023	NUM
aji-153	470	2	jan	jan	NOUN
aji-153	470	3	31;53(10):701	31;53(10):701	NUM
aji-153	470	4	-	-	SYM
aji-153	470	5	10	10	NUM
aji-153	470	6	.	.	PUNCT
aji-153	470	7	22	22	NUM
aji-153	470	8	.	.	PUNCT
aji-153	471	1	levin	levin	PROPN
aji-153	471	2	a.	a.	PROPN
aji-153	471	3	therapy	therapy	NOUN
aji-153	471	4	for	for	ADP
aji-153	471	5	anemia	anemia	NOUN
aji-153	471	6	in	in	ADP
aji-153	471	7	chronic	chronic	ADJ
aji-153	471	8	kidney	kidney	NOUN
aji-153	471	9	disease	disease	NOUN
aji-153	471	10	-	-	PUNCT
aji-153	471	11	new	new	ADJ
aji-153	471	12	interventions	intervention	NOUN
aji-153	471	13	and	and	CCONJ
aji-153	471	14	new	new	ADJ
aji-153	471	15	questions	question	NOUN
aji-153	471	16	.	.	PUNCT
aji-153	472	1	n	n	PROPN
aji-153	472	2	engl	engl	PROPN
aji-153	472	3	j	j	PROPN
aji-153	472	4	med	med	PROPN
aji-153	472	5	.	.	PUNCT
aji-153	473	1	2021	2021	NUM
aji-153	473	2	apr	apr	NOUN
aji-153	473	3	29;384(17):1657	29;384(17):1657	NUM
aji-153	473	4	-	-	SYM
aji-153	473	5	8	8	NUM
aji-153	473	6	.	.	X
aji-153	473	7	23	23	NUM
aji-153	473	8	.	.	PUNCT
aji-153	474	1	bartnicki	bartnicki	PROPN
aji-153	474	2	p.	p.	PROPN
aji-153	474	3	hypoxia	hypoxia	NOUN
aji-153	474	4	-	-	PUNCT
aji-153	474	5	inducible	inducible	ADJ
aji-153	474	6	factor	factor	NOUN
aji-153	474	7	prolyl	prolyl	NOUN
aji-153	474	8	hydroxylase	hydroxylase	NOUN
aji-153	474	9	inhibitors	inhibitor	NOUN
aji-153	474	10	as	as	ADP
aji-153	474	11	a	a	DET
aji-153	474	12	new	new	ADJ
aji-153	474	13	treatment	treatment	NOUN
aji-153	474	14	option	option	NOUN
aji-153	474	15	for	for	ADP
aji-153	474	16	anemia	anemia	NOUN
aji-153	474	17	in	in	ADP
aji-153	474	18	chronic	chronic	ADJ
aji-153	474	19	kidney	kidney	NOUN
aji-153	474	20	disease	disease	NOUN
aji-153	474	21	.	.	PUNCT
aji-153	475	1	biomedicines	biomedicine	NOUN
aji-153	475	2	.	.	PUNCT
aji-153	476	1	2024	2024	NUM
aji-153	476	2	aug	aug	PROPN
aji-153	476	3	18;12(8):1884	18;12(8):1884	NUM
aji-153	476	4	.	.	PUNCT
aji-153	476	5	24	24	NUM
aji-153	476	6	.	.	PUNCT
aji-153	476	7	kooienga	kooienga	PROPN
aji-153	476	8	l	l	PROPN
aji-153	476	9	,	,	PUNCT
aji-153	476	10	burke	burke	PROPN
aji-153	476	11	s	s	PROPN
aji-153	476	12	,	,	PUNCT
aji-153	476	13	kathresal	kathresal	PROPN
aji-153	476	14	a	a	PROPN
aji-153	476	15	,	,	PUNCT
aji-153	476	16	luo	luo	PROPN
aji-153	476	17	w	w	PROPN
aji-153	476	18	,	,	PUNCT
aji-153	476	19	yang	yang	PROPN
aji-153	476	20	z	z	PROPN
aji-153	476	21	,	,	PUNCT
aji-153	476	22	zhang	zhang	PROPN
aji-153	476	23	z	z	PROPN
aji-153	476	24	,	,	PUNCT
aji-153	476	25	zwiech	zwiech	NOUN
aji-153	476	26	r	r	NOUN
aji-153	476	27	,	,	PUNCT
aji-153	476	28	hernandez	hernandez	PROPN
aji-153	476	29	gt	gt	PROPN
aji-153	476	30	.	.	PUNCT
aji-153	476	31	safety	safety	PROPN
aji-153	476	32	and	and	CCONJ
aji-153	476	33	efficacy	efficacy	NOUN
aji-153	476	34	of	of	ADP
aji-153	476	35	vadadustat	vadadustat	NOUN
aji-153	476	36	once	once	ADV
aji-153	476	37	-	-	PUNCT
aji-153	476	38	daily	daily	ADJ
aji-153	476	39	and	and	CCONJ
aji-153	476	40	3	3	NUM
aji-153	476	41	-	-	PUNCT
aji-153	476	42	times	time	NOUN
aji-153	476	43	-	-	PUNCT
aji-153	476	44	weekly	weekly	NOUN
aji-153	476	45	in	in	ADP
aji-153	476	46	dialysis	dialysis	NOUN
aji-153	476	47	-	-	PUNCT
aji-153	476	48	dependent	dependent	ADJ
aji-153	476	49	chronic	chronic	ADJ
aji-153	476	50	kidney	kidney	NOUN
aji-153	476	51	disease	disease	NOUN
aji-153	476	52	patients	patient	NOUN
aji-153	476	53	with	with	ADP
aji-153	476	54	anemia	anemia	NOUN
aji-153	476	55	.	.	PUNCT
aji-153	477	1	kidney	kidney	NOUN
aji-153	477	2	360	360	NUM
aji-153	477	3	.	.	PUNCT
aji-153	478	1	2024	2024	NUM
aji-153	478	2	apr	apr	NOUN
aji-153	478	3	3:10	3:10	NUM
aji-153	478	4	-	-	SYM
aji-153	478	5	34067	34067	NUM
aji-153	478	6	.	.	PUNCT
aji-153	479	1	25	25	NUM
aji-153	479	2	.	.	PUNCT
aji-153	480	1	toka	toka	PROPN
aji-153	480	2	hr	hr	PROPN
aji-153	480	3	,	,	PUNCT
aji-153	480	4	bernardo	bernardo	PROPN
aji-153	480	5	m	m	PROPN
aji-153	480	6	,	,	PUNCT
aji-153	480	7	burke	burke	PROPN
aji-153	480	8	sk	sk	PROPN
aji-153	480	9	,	,	PUNCT
aji-153	480	10	luo	luo	PROPN
aji-153	480	11	w	w	PROPN
aji-153	480	12	,	,	PUNCT
aji-153	480	13	manllo	manllo	PROPN
aji-153	480	14	-	-	PUNCT
aji-153	480	15	karim	karim	PROPN
aji-153	480	16	r	r	PROPN
aji-153	480	17	,	,	PUNCT
aji-153	480	18	ullah	ullah	PROPN
aji-153	480	19	i	i	PROPN
aji-153	480	20	,	,	PUNCT
aji-153	480	21	yang	yang	PROPN
aji-153	480	22	z	z	PROPN
aji-153	480	23	,	,	PUNCT
aji-153	481	1	zhang	zhang	PROPN
aji-153	481	2	z	z	PROPN
aji-153	481	3	,	,	PUNCT
aji-153	481	4	tumlin	tumlin	PROPN
aji-153	481	5	j.	j.	PROPN
aji-153	481	6	vadadustat	vadadustat	PROPN
aji-153	481	7	three	three	NUM
aji-153	481	8	times	time	NOUN
aji-153	481	9	weekly	weekly	ADJ
aji-153	481	10	in	in	ADP
aji-153	481	11	patients	patient	NOUN
aji-153	481	12	with	with	ADP
aji-153	481	13	anemia	anemia	NOUN
aji-153	481	14	due	due	ADP
aji-153	481	15	to	to	ADP
aji-153	481	16	dialysisdependent	dialysisdependent	PROPN
aji-153	481	17	ckd	ckd	PROPN
aji-153	481	18	.	.	PUNCT
aji-153	481	19	american	american	PROPN
aji-153	481	20	journal	journal	PROPN
aji-153	481	21	of	of	ADP
aji-153	481	22	kidney	kidney	NOUN
aji-153	481	23	diseases	disease	NOUN
aji-153	481	24	.	.	PUNCT
aji-153	482	1	2024	2024	NUM
aji-153	482	2	nov	nov	PROPN
aji-153	482	3	7	7	NUM
aji-153	482	4	.	.	NOUN
aji-153	482	5	26	26	NUM
aji-153	482	6	.	.	PUNCT
aji-153	482	7	imai	imai	PROPN
aji-153	482	8	e	e	PROPN
aji-153	482	9	,	,	PUNCT
aji-153	482	10	imai	imai	PROPN
aji-153	482	11	a.	a.	NOUN
aji-153	482	12	the	the	DET
aji-153	482	13	comparison	comparison	NOUN
aji-153	482	14	between	between	ADP
aji-153	482	15	vadadustat	vadadustat	NOUN
aji-153	482	16	and	and	CCONJ
aji-153	482	17	daprodustat	daprodustat	PROPN
aji-153	482	18	regarding	regard	VERB
aji-153	482	19	dose	dose	NOUN
aji-153	482	20	,	,	PUNCT
aji-153	482	21	cost	cost	NOUN
aji-153	482	22	,	,	PUNCT
aji-153	482	23	and	and	CCONJ
aji-153	482	24	safety	safety	NOUN
aji-153	482	25	of	of	ADP
aji-153	482	26	treatment	treatment	NOUN
aji-153	482	27	for	for	ADP
aji-153	482	28	renal	renal	ADJ
aji-153	482	29	anemia	anemia	NOUN
aji-153	482	30	in	in	ADP
aji-153	482	31	non	non	ADJ
aji-153	482	32	-	-	ADJ
aji-153	482	33	dialysis	dialysis	ADJ
aji-153	482	34	patients	patient	NOUN
aji-153	482	35	with	with	ADP
aji-153	482	36	chronic	chronic	ADJ
aji-153	482	37	kidney	kidney	NOUN
aji-153	482	38	diseases	disease	NOUN
aji-153	482	39	.	.	PUNCT
aji-153	483	1	internal	internal	ADJ
aji-153	483	2	medicine	medicine	NOUN
aji-153	483	3	.	.	PUNCT
aji-153	484	1	2024:2501	2024:2501	NUM
aji-153	484	2	-	-	SYM
aji-153	484	3	3	3	NUM
aji-153	484	4	.	.	NOUN
aji-153	484	5	27	27	NUM
aji-153	484	6	.	.	PUNCT
aji-153	485	1	locatelli	locatelli	PROPN
aji-153	485	2	f	f	PROPN
aji-153	485	3	,	,	PUNCT
aji-153	485	4	del	del	PROPN
aji-153	485	5	vecchio	vecchio	PROPN
aji-153	485	6	l.	l.	PROPN
aji-153	485	7	expert	expert	PROPN
aji-153	485	8	guidance	guidance	NOUN
aji-153	485	9	for	for	ADP
aji-153	485	10	treating	treat	VERB
aji-153	485	11	anemia	anemia	NOUN
aji-153	485	12	in	in	ADP
aji-153	485	13	chronic	chronic	ADJ
aji-153	485	14	kidney	kidney	NOUN
aji-153	485	15	disease	disease	NOUN
aji-153	485	16	:	:	PUNCT
aji-153	485	17	what	what	PRON
aji-153	485	18	is	be	AUX
aji-153	485	19	the	the	DET
aji-153	485	20	appropriate	appropriate	ADJ
aji-153	485	21	drug	drug	NOUN
aji-153	485	22	treatment	treatment	NOUN
aji-153	485	23	strategy	strategy	NOUN
aji-153	485	24	?	?	PUNCT
aji-153	485	25	.	.	PUNCT
aji-153	486	1	expert	expert	ADJ
aji-153	486	2	opinion	opinion	NOUN
aji-153	486	3	on	on	ADP
aji-153	486	4	pharmacotherapy	pharmacotherapy	NOUN
aji-153	486	5	.	.	PUNCT
aji-153	487	1	2023	2023	NUM
aji-153	487	2	feb	feb	NOUN
aji-153	487	3	11;24(3):287	11;24(3):287	NUM
aji-153	487	4	-	-	SYM
aji-153	487	5	90	90	NUM
aji-153	487	6	.	.	PUNCT
aji-153	487	7	28	28	NUM
aji-153	487	8	.	.	PUNCT
aji-153	488	1	kontoghiorghes	kontoghiorghes	PROPN
aji-153	488	2	gj	gj	PROPN
aji-153	488	3	.	.	PUNCT
aji-153	489	1	new	new	ADJ
aji-153	489	2	iron	iron	NOUN
aji-153	489	3	metabolic	metabolic	NOUN
aji-153	489	4	pathways	pathway	NOUN
aji-153	489	5	and	and	CCONJ
aji-153	489	6	chelation	chelation	NOUN
aji-153	489	7	targeting	targeting	NOUN
aji-153	489	8	strategies	strategy	NOUN
aji-153	489	9	affecting	affect	VERB
aji-153	489	10	the	the	DET
aji-153	489	11	treatment	treatment	NOUN
aji-153	489	12	of	of	ADP
aji-153	489	13	all	all	DET
aji-153	489	14	types	type	NOUN
aji-153	489	15	and	and	CCONJ
aji-153	489	16	stages	stage	NOUN
aji-153	489	17	of	of	ADP
aji-153	489	18	cancer	cancer	NOUN
aji-153	489	19	.	.	PUNCT
aji-153	490	1	international	international	ADJ
aji-153	490	2	journal	journal	NOUN
aji-153	490	3	of	of	ADP
aji-153	490	4	molecular	molecular	ADJ
aji-153	490	5	sciences	science	NOUN
aji-153	490	6	.	.	PUNCT
aji-153	491	1	2022	2022	NUM
aji-153	491	2	nov	nov	NOUN
aji-153	491	3	13;23(22):13990	13;23(22):13990	NUM
aji-153	491	4	.	.	PUNCT
aji-153	492	1	gupta	gupta	PROPN
aji-153	492	2	et	et	PROPN
aji-153	492	3	al	al	PROPN
aji-153	492	4	.	.	PROPN
aji-153	492	5	;	;	PUNCT
aji-153	492	6	asian	asian	PROPN
aji-153	492	7	j.	j.	PROPN
aji-153	492	8	immunol	immunol	PROPN
aji-153	492	9	.	.	PROPN
aji-153	492	10	,	,	PUNCT
aji-153	492	11	vol	vol	NOUN
aji-153	492	12	.	.	PROPN
aji-153	492	13	7	7	NUM
aji-153	492	14	,	,	PUNCT
aji-153	492	15	no	no	INTJ
aji-153	492	16	.	.	NOUN
aji-153	492	17	1	1	NUM
aji-153	492	18	,	,	PUNCT
aji-153	492	19	pp	pp	ADJ
aji-153	492	20	.	.	PUNCT
aji-153	493	1	302	302	NUM
aji-153	493	2	-	-	SYM
aji-153	493	3	315	315	NUM
aji-153	493	4	,	,	PUNCT
aji-153	493	5	2024	2024	NUM
aji-153	494	1	;	;	PUNCT
aji-153	494	2	article	article	NOUN
aji-153	494	3	no.aji.127402	no.aji.127402	VERB
aji-153	494	4	314	314	NUM
aji-153	494	5	29	29	NUM
aji-153	494	6	.	.	PUNCT
aji-153	495	1	minutolo	minutolo	PROPN
aji-153	495	2	r	r	NOUN
aji-153	495	3	,	,	PUNCT
aji-153	495	4	liberti	liberti	VERB
aji-153	495	5	me	i	PRON
aji-153	495	6	,	,	PUNCT
aji-153	495	7	simeon	simeon	PROPN
aji-153	495	8	v	v	NOUN
aji-153	495	9	,	,	PUNCT
aji-153	495	10	sasso	sasso	PROPN
aji-153	495	11	fc	fc	PROPN
aji-153	495	12	,	,	PUNCT
aji-153	495	13	borrelli	borrelli	PROPN
aji-153	495	14	s	s	PROPN
aji-153	495	15	,	,	PUNCT
aji-153	495	16	de	de	X
aji-153	495	17	nicola	nicola	PROPN
aji-153	495	18	l	l	PROPN
aji-153	495	19	,	,	PUNCT
aji-153	495	20	garofalo	garofalo	PROPN
aji-153	495	21	c.	c.	PROPN
aji-153	495	22	efficacy	efficacy	PROPN
aji-153	495	23	and	and	CCONJ
aji-153	495	24	safety	safety	NOUN
aji-153	495	25	of	of	ADP
aji-153	495	26	hypoxia	hypoxia	NOUN
aji-153	495	27	-	-	PUNCT
aji-153	495	28	inducible	inducible	ADJ
aji-153	495	29	factor	factor	NOUN
aji-153	495	30	prolyl	prolyl	NOUN
aji-153	495	31	hydroxylase	hydroxylase	VERB
aji-153	495	32	inhibitors	inhibitor	NOUN
aji-153	495	33	in	in	ADP
aji-153	495	34	patients	patient	NOUN
aji-153	495	35	with	with	ADP
aji-153	495	36	chronic	chronic	ADJ
aji-153	495	37	kidney	kidney	NOUN
aji-153	495	38	disease	disease	NOUN
aji-153	495	39	:	:	PUNCT
aji-153	495	40	meta	meta	ADJ
aji-153	495	41	-	-	PUNCT
aji-153	495	42	analysis	analysis	NOUN
aji-153	495	43	of	of	ADP
aji-153	495	44	phase	phase	NOUN
aji-153	495	45	3	3	NUM
aji-153	495	46	randomized	randomize	VERB
aji-153	495	47	controlled	control	VERB
aji-153	495	48	trials	trial	NOUN
aji-153	495	49	.	.	PUNCT
aji-153	496	1	clinical	clinical	ADJ
aji-153	496	2	kidney	kidney	NOUN
aji-153	496	3	journal	journal	NOUN
aji-153	496	4	.	.	PUNCT
aji-153	497	1	2024	2024	NUM
aji-153	497	2	jan;17(1):sfad143	jan;17(1):sfad143	NOUN
aji-153	497	3	.	.	PUNCT
aji-153	498	1	30	30	NUM
aji-153	498	2	.	.	PUNCT
aji-153	499	1	sackeyfio	sackeyfio	PROPN
aji-153	499	2	a	a	PROPN
aji-153	499	3	,	,	PUNCT
aji-153	499	4	lopes	lopes	PROPN
aji-153	499	5	rd	rd	PROPN
aji-153	499	6	,	,	PUNCT
aji-153	499	7	kovesdy	kovesdy	VERB
aji-153	499	8	cp	cp	PROPN
aji-153	499	9	,	,	PUNCT
aji-153	499	10	cases	case	VERB
aji-153	499	11	a	a	DET
aji-153	499	12	,	,	PUNCT
aji-153	499	13	mallett	mallett	PROPN
aji-153	499	14	sa	sa	PROPN
aji-153	499	15	,	,	PUNCT
aji-153	499	16	ballew	ballew	PROPN
aji-153	499	17	n	n	PROPN
aji-153	499	18	,	,	PUNCT
aji-153	499	19	keeley	keeley	PROPN
aji-153	499	20	tj	tj	PROPN
aji-153	499	21	,	,	PUNCT
aji-153	499	22	garcia	garcia	PROPN
aji-153	499	23	-	-	PUNCT
aji-153	499	24	horton	horton	PROPN
aji-153	499	25	v	v	PROPN
aji-153	499	26	,	,	PUNCT
aji-153	499	27	ayyagari	ayyagari	ADJ
aji-153	499	28	r	r	NOUN
aji-153	499	29	,	,	PUNCT
aji-153	499	30	camejo	camejo	PROPN
aji-153	499	31	rr	rr	PROPN
aji-153	499	32	,	,	PUNCT
aji-153	499	33	johansen	johansen	PROPN
aji-153	499	34	kl	kl	PROPN
aji-153	499	35	.	.	PROPN
aji-153	499	36	comparison	comparison	NOUN
aji-153	499	37	of	of	ADP
aji-153	499	38	outcomes	outcome	NOUN
aji-153	499	39	on	on	ADP
aji-153	499	40	hypoxia	hypoxia	NOUN
aji-153	499	41	-	-	PUNCT
aji-153	499	42	inducible	inducible	ADJ
aji-153	499	43	factor	factor	NOUN
aji-153	499	44	prolyl	prolyl	NOUN
aji-153	499	45	hydroxylase	hydroxylase	NOUN
aji-153	499	46	inhibitors	inhibitor	NOUN
aji-153	499	47	(	(	PUNCT
aji-153	499	48	hif	hif	PROPN
aji-153	499	49	-	-	PUNCT
aji-153	499	50	phis	phis	NOUN
aji-153	499	51	)	)	PUNCT
aji-153	499	52	in	in	ADP
aji-153	499	53	anaemia	anaemia	NOUN
aji-153	499	54	associated	associate	VERB
aji-153	499	55	with	with	ADP
aji-153	499	56	chronic	chronic	ADJ
aji-153	499	57	kidney	kidney	NOUN
aji-153	499	58	disease	disease	NOUN
aji-153	499	59	:	:	PUNCT
aji-153	499	60	network	network	NOUN
aji-153	499	61	meta	meta	NOUN
aji-153	499	62	-	-	PUNCT
aji-153	499	63	analyses	analysis	NOUN
aji-153	499	64	in	in	ADP
aji-153	499	65	dialysis	dialysis	NOUN
aji-153	499	66	and	and	CCONJ
aji-153	499	67	non	non	ADJ
aji-153	499	68	-	-	ADJ
aji-153	499	69	dialysis	dialysis	ADJ
aji-153	499	70	dependent	dependent	ADJ
aji-153	499	71	populations	population	NOUN
aji-153	499	72	.	.	PUNCT
aji-153	500	1	clinical	clinical	ADJ
aji-153	500	2	kidney	kidney	NOUN
aji-153	500	3	journal	journal	NOUN
aji-153	500	4	.	.	PUNCT
aji-153	501	1	2024	2024	NUM
aji-153	501	2	jan;17(1):sfad298	jan;17(1):sfad298	NOUN
aji-153	501	3	.	.	PUNCT
aji-153	502	1	31	31	NUM
aji-153	502	2	.	.	PUNCT
aji-153	502	3	damarlapally	damarlapally	ADV
aji-153	502	4	n	n	CCONJ
aji-153	502	5	,	,	PUNCT
aji-153	502	6	thimmappa	thimmappa	NOUN
aji-153	502	7	v	v	NOUN
aji-153	502	8	,	,	PUNCT
aji-153	502	9	irfan	irfan	PROPN
aji-153	502	10	h	h	PROPN
aji-153	502	11	,	,	PUNCT
aji-153	502	12	sikandari	sikandari	PROPN
aji-153	502	13	m	m	PROPN
aji-153	502	14	,	,	PUNCT
aji-153	502	15	madhu	madhu	PROPN
aji-153	502	16	k	k	PROPN
aji-153	502	17	,	,	PUNCT
aji-153	502	18	desai	desai	PROPN
aji-153	502	19	a	a	X
aji-153	502	20	,	,	PUNCT
aji-153	502	21	pavani	pavani	PROPN
aji-153	502	22	p	p	X
aji-153	502	23	,	,	PUNCT
aji-153	502	24	zakir	zakir	PROPN
aji-153	502	25	s	s	PROPN
aji-153	502	26	,	,	PUNCT
aji-153	502	27	gupta	gupta	PROPN
aji-153	502	28	m	m	PROPN
aji-153	502	29	,	,	PUNCT
aji-153	502	30	khosa	khosa	PROPN
aji-153	502	31	mm	mm	PROPN
aji-153	502	32	,	,	PUNCT
aji-153	502	33	kotak	kotak	PROPN
aji-153	502	34	s.	s.	PROPN
aji-153	502	35	safety	safety	PROPN
aji-153	502	36	and	and	CCONJ
aji-153	502	37	efficacy	efficacy	NOUN
aji-153	502	38	of	of	ADP
aji-153	502	39	hypoxia	hypoxia	NOUN
aji-153	502	40	-	-	PUNCT
aji-153	502	41	inducible	inducible	ADJ
aji-153	502	42	factor	factor	NOUN
aji-153	502	43	-	-	PUNCT
aji-153	502	44	prolyl	prolyl	NOUN
aji-153	502	45	hydroxylase	hydroxylase	NOUN
aji-153	502	46	inhibitors	inhibitor	NOUN
aji-153	502	47	vs.	vs.	ADP
aji-153	502	48	erythropoietin	erythropoietin	NOUN
aji-153	502	49	-	-	PUNCT
aji-153	502	50	stimulating	stimulate	VERB
aji-153	502	51	agents	agent	NOUN
aji-153	502	52	in	in	ADP
aji-153	502	53	treating	treat	VERB
aji-153	502	54	anemia	anemia	NOUN
aji-153	502	55	in	in	ADP
aji-153	502	56	renal	renal	ADJ
aji-153	502	57	patients	patient	NOUN
aji-153	502	58	(	(	PUNCT
aji-153	502	59	with	with	ADP
aji-153	502	60	or	or	CCONJ
aji-153	502	61	without	without	ADP
aji-153	502	62	dialysis	dialysis	NOUN
aji-153	502	63	):	):	PUNCT
aji-153	502	64	a	a	DET
aji-153	502	65	meta	meta	ADJ
aji-153	502	66	-	-	PUNCT
aji-153	502	67	analysis	analysis	NOUN
aji-153	502	68	and	and	CCONJ
aji-153	502	69	systematic	systematic	ADJ
aji-153	502	70	review	review	NOUN
aji-153	502	71	.	.	PUNCT
aji-153	503	1	cureus	cureus	NOUN
aji-153	503	2	.	.	PUNCT
aji-153	504	1	2023	2023	NUM
aji-153	504	2	oct;15(10	oct;15(10	NOUN
aji-153	504	3	)	)	PUNCT
aji-153	504	4	.	.	PUNCT
aji-153	505	1	32	32	NUM
aji-153	505	2	.	.	PUNCT
aji-153	505	3	hanna	hanna	PROPN
aji-153	505	4	rm	rm	PROPN
aji-153	505	5	,	,	PUNCT
aji-153	505	6	streja	streja	PROPN
aji-153	505	7	e	e	PROPN
aji-153	505	8	,	,	PUNCT
aji-153	505	9	kalantar	kalantar	NOUN
aji-153	505	10	-	-	PUNCT
aji-153	505	11	zadeh	zadeh	PROPN
aji-153	505	12	k.	k.	PROPN
aji-153	505	13	burden	burden	PROPN
aji-153	505	14	of	of	ADP
aji-153	505	15	anemia	anemia	NOUN
aji-153	505	16	in	in	ADP
aji-153	505	17	chronic	chronic	ADJ
aji-153	505	18	kidney	kidney	NOUN
aji-153	505	19	disease	disease	NOUN
aji-153	505	20	:	:	PUNCT
aji-153	505	21	beyond	beyond	ADP
aji-153	505	22	erythropoietin	erythropoietin	NOUN
aji-153	505	23	.	.	PUNCT
aji-153	506	1	advances	advance	NOUN
aji-153	506	2	in	in	ADP
aji-153	506	3	therapy	therapy	NOUN
aji-153	506	4	.	.	PUNCT
aji-153	507	1	2021	2021	NUM
aji-153	507	2	jan;38(1):52	jan;38(1):52	PROPN
aji-153	507	3	-	-	PUNCT
aji-153	507	4	75	75	NUM
aji-153	507	5	.	.	PUNCT
aji-153	508	1	33	33	NUM
aji-153	508	2	.	.	PUNCT
aji-153	508	3	haase	haase	PROPN
aji-153	508	4	vh	vh	PROPN
aji-153	508	5	.	.	PUNCT
aji-153	508	6	hypoxia	hypoxia	NOUN
aji-153	508	7	-	-	PUNCT
aji-153	508	8	inducible	inducible	ADJ
aji-153	508	9	factor	factor	NOUN
aji-153	508	10	–	–	PUNCT
aji-153	508	11	prolyl	prolyl	NOUN
aji-153	508	12	hydroxylase	hydroxylase	NOUN
aji-153	508	13	inhibitors	inhibitor	NOUN
aji-153	508	14	in	in	ADP
aji-153	508	15	the	the	DET
aji-153	508	16	treatment	treatment	NOUN
aji-153	508	17	of	of	ADP
aji-153	508	18	anemia	anemia	NOUN
aji-153	508	19	of	of	ADP
aji-153	508	20	chronic	chronic	ADJ
aji-153	508	21	kidney	kidney	NOUN
aji-153	508	22	disease	disease	NOUN
aji-153	508	23	.	.	PUNCT
aji-153	509	1	kidney	kidney	PROPN
aji-153	509	2	international	international	ADJ
aji-153	509	3	supplements	supplement	NOUN
aji-153	509	4	.	.	PUNCT
aji-153	510	1	2021	2021	NUM
aji-153	510	2	apr	apr	NOUN
aji-153	510	3	1;11(1):8	1;11(1):8	NUM
aji-153	510	4	-	-	SYM
aji-153	510	5	25	25	NUM
aji-153	510	6	.	.	PUNCT
aji-153	511	1	34	34	NUM
aji-153	511	2	.	.	PUNCT
aji-153	512	1	ueda	ueda	PROPN
aji-153	512	2	n	n	CCONJ
aji-153	512	3	,	,	PUNCT
aji-153	512	4	takasawa	takasawa	PROPN
aji-153	512	5	k.	k.	PROPN
aji-153	512	6	impact	impact	PROPN
aji-153	512	7	of	of	ADP
aji-153	512	8	inflammation	inflammation	NOUN
aji-153	512	9	on	on	ADP
aji-153	512	10	ferritin	ferritin	ADJ
aji-153	512	11	,	,	PUNCT
aji-153	512	12	hepcidin	hepcidin	ADJ
aji-153	512	13	and	and	CCONJ
aji-153	512	14	the	the	DET
aji-153	512	15	management	management	NOUN
aji-153	512	16	of	of	ADP
aji-153	512	17	iron	iron	NOUN
aji-153	512	18	deficiency	deficiency	NOUN
aji-153	512	19	anemia	anemia	NOUN
aji-153	512	20	in	in	ADP
aji-153	512	21	chronic	chronic	ADJ
aji-153	512	22	kidney	kidney	NOUN
aji-153	512	23	disease	disease	NOUN
aji-153	512	24	.	.	PUNCT
aji-153	513	1	nutrients	nutrient	NOUN
aji-153	513	2	.	.	PUNCT
aji-153	514	1	2018	2018	NUM
aji-153	514	2	aug	aug	PROPN
aji-153	514	3	27;10(9):1173	27;10(9):1173	NUM
aji-153	514	4	.	.	PROPN
aji-153	514	5	35	35	NUM
aji-153	514	6	.	.	PUNCT
aji-153	514	7	semenza	semenza	PROPN
aji-153	514	8	gl	gl	PROPN
aji-153	514	9	.	.	PROPN
aji-153	514	10	regulation	regulation	NOUN
aji-153	514	11	of	of	ADP
aji-153	514	12	erythropoiesis	erythropoiesis	NOUN
aji-153	514	13	by	by	ADP
aji-153	514	14	the	the	DET
aji-153	514	15	hypoxia	hypoxia	NOUN
aji-153	514	16	-	-	PUNCT
aji-153	514	17	inducible	inducible	ADJ
aji-153	514	18	factor	factor	NOUN
aji-153	514	19	pathway	pathway	NOUN
aji-153	514	20	:	:	PUNCT
aji-153	514	21	effects	effect	NOUN
aji-153	514	22	of	of	ADP
aji-153	514	23	genetic	genetic	ADJ
aji-153	514	24	and	and	CCONJ
aji-153	514	25	pharmacological	pharmacological	ADJ
aji-153	514	26	perturbations	perturbation	NOUN
aji-153	514	27	.	.	PUNCT
aji-153	515	1	annual	annual	ADJ
aji-153	515	2	review	review	NOUN
aji-153	515	3	of	of	ADP
aji-153	515	4	medicine	medicine	NOUN
aji-153	515	5	.	.	PUNCT
aji-153	516	1	2023	2023	NUM
aji-153	516	2	jan	jan	PROPN
aji-153	516	3	27;74(1):307	27;74(1):307	NUM
aji-153	516	4	-	-	SYM
aji-153	516	5	19	19	NUM
aji-153	516	6	.	.	NOUN
aji-153	517	1	36	36	NUM
aji-153	517	2	.	.	PUNCT
aji-153	518	1	wing	wing	NOUN
aji-153	518	2	pa	pa	PROPN
aji-153	518	3	,	,	PUNCT
aji-153	518	4	keeley	keeley	PROPN
aji-153	518	5	tp	tp	PROPN
aji-153	518	6	,	,	PUNCT
aji-153	518	7	zhuang	zhuang	PROPN
aji-153	518	8	x	x	PROPN
aji-153	518	9	,	,	PUNCT
aji-153	518	10	lee	lee	PROPN
aji-153	518	11	jy	jy	PROPN
aji-153	518	12	,	,	PUNCT
aji-153	518	13	prange	prange	NOUN
aji-153	518	14	-	-	PUNCT
aji-153	518	15	barczynska	barczynska	PROPN
aji-153	518	16	m	m	PROPN
aji-153	518	17	,	,	PUNCT
aji-153	518	18	tsukuda	tsukuda	PROPN
aji-153	518	19	s	s	PROPN
aji-153	518	20	,	,	PUNCT
aji-153	518	21	morgan	morgan	PROPN
aji-153	518	22	sb	sb	PROPN
aji-153	518	23	,	,	PUNCT
aji-153	518	24	harding	harding	PROPN
aji-153	518	25	ac	ac	PROPN
aji-153	518	26	,	,	PUNCT
aji-153	518	27	argles	argle	NOUN
aji-153	518	28	il	il	PROPN
aji-153	518	29	,	,	PUNCT
aji-153	518	30	kurlekar	kurlekar	PROPN
aji-153	518	31	s	s	PROPN
aji-153	518	32	,	,	PUNCT
aji-153	518	33	noerenberg	noerenberg	PROPN
aji-153	518	34	m.	m.	PROPN
aji-153	518	35	hypoxic	hypoxic	ADJ
aji-153	518	36	and	and	CCONJ
aji-153	518	37	pharmacological	pharmacological	ADJ
aji-153	518	38	activation	activation	NOUN
aji-153	518	39	of	of	ADP
aji-153	518	40	hif	hif	PROPN
aji-153	518	41	inhibits	inhibit	VERB
aji-153	518	42	sars	sar	NOUN
aji-153	518	43	-	-	PUNCT
aji-153	518	44	cov-2	cov-2	PART
aji-153	518	45	infection	infection	NOUN
aji-153	518	46	of	of	ADP
aji-153	518	47	lung	lung	NOUN
aji-153	518	48	epithelial	epithelial	ADJ
aji-153	518	49	cells	cell	NOUN
aji-153	518	50	.	.	PUNCT
aji-153	519	1	cell	cell	NOUN
aji-153	519	2	reports	report	NOUN
aji-153	519	3	.	.	PUNCT
aji-153	520	1	2021	2021	NUM
aji-153	520	2	apr	apr	NOUN
aji-153	520	3	20;35(3	20;35(3	NUM
aji-153	520	4	)	)	PUNCT
aji-153	520	5	.	.	PUNCT
aji-153	521	1	37	37	NUM
aji-153	521	2	.	.	PUNCT
aji-153	522	1	chen	chen	PROPN
aji-153	522	2	h	h	PROPN
aji-153	522	3	,	,	PUNCT
aji-153	522	4	cheng	cheng	PROPN
aji-153	522	5	q	q	PROPN
aji-153	522	6	,	,	PUNCT
aji-153	522	7	wang	wang	PROPN
aji-153	522	8	j	j	PROPN
aji-153	522	9	,	,	PUNCT
aji-153	522	10	zhao	zhao	PROPN
aji-153	522	11	x	x	PROPN
aji-153	522	12	,	,	PUNCT
aji-153	522	13	zhu	zhu	PROPN
aji-153	522	14	s.	s.	PROPN
aji-153	522	15	long‐term	long‐term	PROPN
aji-153	522	16	efficacy	efficacy	NOUN
aji-153	522	17	and	and	CCONJ
aji-153	522	18	safety	safety	NOUN
aji-153	522	19	of	of	ADP
aji-153	522	20	hypoxia‐inducible	hypoxia‐inducible	ADJ
aji-153	522	21	factor	factor	NOUN
aji-153	522	22	prolyl	prolyl	NOUN
aji-153	522	23	hydroxylase	hydroxylase	VERB
aji-153	522	24	inhibitors	inhibitor	NOUN
aji-153	522	25	in	in	ADP
aji-153	522	26	anaemia	anaemia	NOUN
aji-153	522	27	of	of	ADP
aji-153	522	28	chronic	chronic	ADJ
aji-153	522	29	kidney	kidney	NOUN
aji-153	522	30	disease	disease	NOUN
aji-153	522	31	:	:	PUNCT
aji-153	522	32	a	a	DET
aji-153	522	33	meta‐analysis	meta‐analysis	NOUN
aji-153	522	34	including	include	VERB
aji-153	522	35	13,146	13,146	NUM
aji-153	522	36	patients	patient	NOUN
aji-153	522	37	.	.	PUNCT
aji-153	523	1	journal	journal	NOUN
aji-153	523	2	of	of	ADP
aji-153	523	3	clinical	clinical	ADJ
aji-153	523	4	pharmacy	pharmacy	NOUN
aji-153	523	5	and	and	CCONJ
aji-153	523	6	therapeutics	therapeutic	NOUN
aji-153	523	7	.	.	PUNCT
aji-153	524	1	2021	2021	NUM
aji-153	524	2	aug;46(4):999	aug;46(4):999	NOUN
aji-153	524	3	-	-	SYM
aji-153	524	4	1009	1009	NUM
aji-153	524	5	.	.	PUNCT
aji-153	525	1	38	38	NUM
aji-153	525	2	.	.	PUNCT
aji-153	526	1	chertow	chertow	PROPN
aji-153	526	2	gm	gm	PROPN
aji-153	526	3	.	.	PUNCT
aji-153	527	1	global	global	ADJ
aji-153	527	2	phase	phase	NOUN
aji-153	527	3	3	3	NUM
aji-153	527	4	clinical	clinical	ADJ
aji-153	527	5	trials	trial	NOUN
aji-153	527	6	of	of	ADP
aji-153	527	7	vadadustat	vadadustat	NOUN
aji-153	527	8	vs.	vs.	ADP
aji-153	527	9	darbepoetin	darbepoetin	PROPN
aji-153	527	10	alfa	alfa	PROPN
aji-153	527	11	for	for	ADP
aji-153	527	12	treatment	treatment	NOUN
aji-153	527	13	of	of	ADP
aji-153	527	14	anemia	anemia	NOUN
aji-153	527	15	in	in	ADP
aji-153	527	16	patients	patient	NOUN
aji-153	527	17	with	with	ADP
aji-153	527	18	non	non	ADJ
aji-153	527	19	-	-	ADJ
aji-153	527	20	dialysis	dialysis	NOUN
aji-153	527	21	-	-	PUNCT
aji-153	527	22	dependent	dependent	ADJ
aji-153	527	23	ckd	ckd	NOUN
aji-153	527	24	:	:	PUNCT
aji-153	527	25	fr	fr	PROPN
aji-153	527	26	-	-	PUNCT
aji-153	527	27	or54	or54	PROPN
aji-153	527	28	.	.	PUNCT
aji-153	527	29	journal	journal	PROPN
aji-153	527	30	of	of	ADP
aji-153	527	31	the	the	DET
aji-153	527	32	american	american	ADJ
aji-153	527	33	society	society	NOUN
aji-153	527	34	of	of	ADP
aji-153	527	35	nephrology	nephrology	NOUN
aji-153	527	36	.	.	PUNCT
aji-153	528	1	2020	2020	NUM
aji-153	528	2	oct	oct	PROPN
aji-153	528	3	1;31(10s):b2	1;31(10s):b2	NUM
aji-153	528	4	.	.	PROPN
aji-153	529	1	39	39	NUM
aji-153	529	2	.	.	PUNCT
aji-153	530	1	sanghani	sanghani	PROPN
aji-153	530	2	ns	ns	PROPN
aji-153	530	3	,	,	PUNCT
aji-153	530	4	haase	haase	PROPN
aji-153	530	5	vh	vh	PROPN
aji-153	530	6	.	.	PUNCT
aji-153	531	1	hif	hif	PROPN
aji-153	531	2	-	-	PUNCT
aji-153	531	3	prolyl	prolyl	PROPN
aji-153	531	4	hydroxylase	hydroxylase	NOUN
aji-153	531	5	inhibitors	inhibitor	NOUN
aji-153	531	6	in	in	ADP
aji-153	531	7	renal	renal	ADJ
aji-153	531	8	anemia	anemia	NOUN
aji-153	531	9	:	:	PUNCT
aji-153	531	10	current	current	ADJ
aji-153	531	11	clinical	clinical	ADJ
aji-153	531	12	experience	experience	NOUN
aji-153	531	13	.	.	PUNCT
aji-153	532	1	advances	advance	NOUN
aji-153	532	2	in	in	ADP
aji-153	532	3	chronic	chronic	ADJ
aji-153	532	4	kidney	kidney	NOUN
aji-153	532	5	disease	disease	NOUN
aji-153	532	6	.	.	PUNCT
aji-153	533	1	2019	2019	NUM
aji-153	533	2	sssssjul;26(4):253	sssssjul;26(4):253	NUM
aji-153	533	3	.	.	PUNCT
aji-153	534	1	40	40	NUM
aji-153	534	2	.	.	PUNCT
aji-153	535	1	navarro‐gonzales	navarro‐gonzale	NOUN
aji-153	535	2	p	p	X
aji-153	535	3	,	,	PUNCT
aji-153	535	4	ganz	ganz	PROPN
aji-153	535	5	t	t	PROPN
aji-153	535	6	,	,	PUNCT
aji-153	535	7	pergola	pergola	PROPN
aji-153	535	8	pe	pe	PROPN
aji-153	535	9	,	,	PUNCT
aji-153	535	10	zuk	zuk	PROPN
aji-153	535	11	a	a	PROPN
aji-153	535	12	,	,	PUNCT
aji-153	535	13	dykstra	dykstra	PROPN
aji-153	535	14	k.	k.	PROPN
aji-153	535	15	pharmacokinetics	pharmacokinetics	PROPN
aji-153	535	16	,	,	PUNCT
aji-153	535	17	pharmacodynamics	pharmacodynamic	NOUN
aji-153	535	18	,	,	PUNCT
aji-153	535	19	and	and	CCONJ
aji-153	535	20	safety	safety	NOUN
aji-153	535	21	of	of	ADP
aji-153	535	22	vadadustat	vadadustat	NOUN
aji-153	535	23	in	in	ADP
aji-153	535	24	healthy	healthy	ADJ
aji-153	535	25	volunteers	volunteer	NOUN
aji-153	535	26	and	and	CCONJ
aji-153	535	27	patients	patient	NOUN
aji-153	535	28	with	with	ADP
aji-153	535	29	chronic	chronic	ADJ
aji-153	535	30	kidney	kidney	NOUN
aji-153	535	31	disease	disease	NOUN
aji-153	535	32	.	.	PUNCT
aji-153	536	1	clinical	clinical	ADJ
aji-153	536	2	pharmacology	pharmacology	NOUN
aji-153	536	3	&	&	CCONJ
aji-153	536	4	therapeutics	therapeutic	NOUN
aji-153	536	5	.	.	PUNCT
aji-153	537	1	2024	2024	NUM
aji-153	537	2	jun	jun	PROPN
aji-153	537	3	25	25	NUM
aji-153	537	4	.	.	NOUN
aji-153	537	5	41	41	NUM
aji-153	537	6	.	.	PUNCT
aji-153	537	7	zuk	zuk	PROPN
aji-153	538	1	a	a	X
aji-153	538	2	,	,	PUNCT
aji-153	538	3	si	si	PROPN
aji-153	538	4	z	z	PROPN
aji-153	538	5	,	,	PUNCT
aji-153	538	6	loi	loi	PROPN
aji-153	538	7	s	s	PROPN
aji-153	538	8	,	,	PUNCT
aji-153	538	9	bommegowda	bommegowda	PROPN
aji-153	538	10	s	s	PART
aji-153	538	11	,	,	PUNCT
aji-153	538	12	hoivik	hoivik	NOUN
aji-153	538	13	d	d	NOUN
aji-153	538	14	,	,	PUNCT
aji-153	538	15	danthi	danthi	PROPN
aji-153	538	16	s	s	PROPN
aji-153	538	17	,	,	PUNCT
aji-153	538	18	molnar	molnar	PROPN
aji-153	538	19	g	g	PROPN
aji-153	538	20	,	,	PUNCT
aji-153	538	21	csizmadia	csizmadia	PROPN
aji-153	538	22	v	v	PROPN
aji-153	538	23	,	,	PUNCT
aji-153	538	24	rabinowitz	rabinowitz	NOUN
aji-153	538	25	m.	m.	NOUN
aji-153	538	26	preclinical	preclinical	ADJ
aji-153	538	27	characterization	characterization	NOUN
aji-153	538	28	of	of	ADP
aji-153	538	29	vadadustat	vadadustat	NOUN
aji-153	538	30	(	(	PUNCT
aji-153	538	31	akb6548	akb6548	NOUN
aji-153	538	32	)	)	PUNCT
aji-153	538	33	,	,	PUNCT
aji-153	538	34	an	an	DET
aji-153	538	35	oral	oral	ADJ
aji-153	538	36	small	small	ADJ
aji-153	538	37	molecule	molecule	NOUN
aji-153	538	38	hypoxiainducible	hypoxiainducible	ADJ
aji-153	538	39	factor	factor	NOUN
aji-153	538	40	prolyl-4	prolyl-4	NOUN
aji-153	538	41	-	-	PUNCT
aji-153	538	42	hydroxylase	hydroxylase	NOUN
aji-153	538	43	inhibitor	inhibitor	NOUN
aji-153	538	44	,	,	PUNCT
aji-153	538	45	for	for	ADP
aji-153	538	46	the	the	DET
aji-153	538	47	potential	potential	ADJ
aji-153	538	48	treatment	treatment	NOUN
aji-153	538	49	of	of	ADP
aji-153	538	50	renal	renal	ADJ
aji-153	538	51	anemia	anemia	NOUN
aji-153	538	52	.	.	PUNCT
aji-153	539	1	journal	journal	PROPN
aji-153	539	2	of	of	ADP
aji-153	539	3	pharmacology	pharmacology	NOUN
aji-153	539	4	and	and	CCONJ
aji-153	539	5	experimental	experimental	ADJ
aji-153	539	6	therapeutics	therapeutic	NOUN
aji-153	539	7	.	.	PUNCT
aji-153	540	1	2022	2022	NUM
aji-153	540	2	oct	oct	PROPN
aji-153	540	3	1;383(1):11	1;383(1):11	PROPN
aji-153	540	4	-	-	PROPN
aji-153	540	5	24	24	NUM
aji-153	540	6	.	.	PUNCT
aji-153	541	1	42	42	NUM
aji-153	541	2	.	.	PUNCT
aji-153	542	1	chavan	chavan	PROPN
aji-153	542	2	a	a	PRON
aji-153	542	3	,	,	PUNCT
aji-153	542	4	burke	burke	PROPN
aji-153	542	5	l	l	PROPN
aji-153	542	6	,	,	PUNCT
aji-153	542	7	sawant	sawant	PROPN
aji-153	542	8	r	r	PROPN
aji-153	542	9	,	,	PUNCT
aji-153	542	10	navarro‐gonzales	navarro‐gonzale	NOUN
aji-153	542	11	p	p	X
aji-153	542	12	,	,	PUNCT
aji-153	542	13	vargo	vargo	PROPN
aji-153	542	14	d	d	PROPN
aji-153	542	15	,	,	PUNCT
aji-153	542	16	paulson	paulson	PROPN
aji-153	542	17	sk	sk	PROPN
aji-153	542	18	.	.	PROPN
aji-153	542	19	effect	effect	NOUN
aji-153	542	20	of	of	ADP
aji-153	542	21	moderate	moderate	ADJ
aji-153	542	22	hepatic	hepatic	ADJ
aji-153	542	23	impairment	impairment	NOUN
aji-153	542	24	on	on	ADP
aji-153	542	25	the	the	DET
aji-153	542	26	pharmacokinetics	pharmacokinetic	NOUN
aji-153	542	27	of	of	ADP
aji-153	542	28	vadadustat	vadadustat	NOUN
aji-153	542	29	,	,	PUNCT
aji-153	542	30	an	an	DET
aji-153	542	31	oral	oral	ADJ
aji-153	542	32	hypoxia‐inducible	hypoxia‐inducible	ADJ
aji-153	542	33	factor	factor	NOUN
aji-153	542	34	prolyl	prolyl	NOUN
aji-153	542	35	hydroxylase	hydroxylase	NOUN
aji-153	542	36	inhibitor	inhibitor	NOUN
aji-153	542	37	.	.	PUNCT
aji-153	543	1	clinical	clinical	ADJ
aji-153	543	2	pharmacology	pharmacology	NOUN
aji-153	543	3	in	in	ADP
aji-153	543	4	drug	drug	NOUN
aji-153	543	5	development	development	NOUN
aji-153	543	6	.	.	PUNCT
aji-153	544	1	2021	2021	NUM
aji-153	544	2	aug;10(8):950	aug;10(8):950	NOUN
aji-153	544	3	-	-	SYM
aji-153	544	4	8	8	NUM
aji-153	544	5	.	.	NUM
aji-153	544	6	43	43	NUM
aji-153	544	7	.	.	PUNCT
aji-153	545	1	haase	haase	PROPN
aji-153	545	2	vh	vh	PROPN
aji-153	545	3	,	,	PUNCT
aji-153	545	4	chertow	chertow	NOUN
aji-153	545	5	gm	gm	PROPN
aji-153	545	6	,	,	PUNCT
aji-153	545	7	block	block	PROPN
aji-153	545	8	ga	ga	PROPN
aji-153	545	9	,	,	PUNCT
aji-153	545	10	pergola	pergola	PROPN
aji-153	545	11	pe	pe	PROPN
aji-153	545	12	,	,	PUNCT
aji-153	545	13	degoma	degoma	VERB
aji-153	545	14	em	em	PRON
aji-153	545	15	,	,	PUNCT
aji-153	545	16	khawaja	khawaja	PROPN
aji-153	545	17	z	z	PROPN
aji-153	545	18	,	,	PUNCT
aji-153	545	19	sharma	sharma	PROPN
aji-153	545	20	a	a	PROPN
aji-153	545	21	,	,	PUNCT
aji-153	545	22	maroni	maroni	PROPN
aji-153	545	23	bj	bj	PROPN
aji-153	545	24	,	,	PUNCT
aji-153	545	25	mccullough	mccullough	PROPN
aji-153	545	26	pa	pa	PROPN
aji-153	545	27	.	.	PROPN
aji-153	545	28	effects	effect	NOUN
aji-153	545	29	of	of	ADP
aji-153	545	30	vadadustat	vadadustat	NOUN
aji-153	545	31	on	on	ADP
aji-153	545	32	hemoglobin	hemoglobin	NOUN
aji-153	545	33	concentrations	concentration	NOUN
aji-153	545	34	in	in	ADP
aji-153	545	35	patients	patient	NOUN
aji-153	545	36	receiving	receive	VERB
aji-153	545	37	hemodialysis	hemodialysis	NOUN
aji-153	545	38	previously	previously	ADV
aji-153	545	39	treated	treat	VERB
aji-153	545	40	with	with	ADP
aji-153	545	41	erythropoiesis	erythropoiesis	NOUN
aji-153	545	42	-	-	PUNCT
aji-153	545	43	stimulating	stimulate	VERB
aji-153	545	44	agents	agent	NOUN
aji-153	545	45	.	.	PUNCT
aji-153	546	1	nephrology	nephrology	NOUN
aji-153	546	2	dialysis	dialysis	NOUN
aji-153	546	3	transplantation	transplantation	NOUN
aji-153	546	4	.	.	PUNCT
aji-153	547	1	2019	2019	NUM
aji-153	547	2	jan	jan	PROPN
aji-153	547	3	1;34(1):90	1;34(1):90	NUM
aji-153	547	4	-	-	PUNCT
aji-153	547	5	9	9	NUM
aji-153	547	6	.	.	NUM
aji-153	547	7	44	44	NUM
aji-153	547	8	.	.	PUNCT
aji-153	548	1	agarwal	agarwal	PROPN
aji-153	548	2	r	r	PROPN
aji-153	548	3	,	,	PUNCT
aji-153	548	4	anand	anand	PROPN
aji-153	548	5	s	s	PROPN
aji-153	548	6	,	,	PUNCT
aji-153	548	7	eckardt	eckardt	PROPN
aji-153	548	8	ku	ku	PROPN
aji-153	548	9	,	,	PUNCT
aji-153	548	10	luo	luo	PROPN
aji-153	548	11	w	w	PROPN
aji-153	548	12	,	,	PUNCT
aji-153	548	13	parfrey	parfrey	PROPN
aji-153	548	14	ps	ps	PROPN
aji-153	548	15	,	,	PUNCT
aji-153	548	16	sarnak	sarnak	PROPN
aji-153	548	17	mj	mj	PROPN
aji-153	548	18	,	,	PUNCT
aji-153	548	19	solinsky	solinsky	PROPN
aji-153	548	20	cm	cm	PROPN
aji-153	548	21	,	,	PUNCT
aji-153	548	22	vargo	vargo	PROPN
aji-153	548	23	dl	dl	PROPN
aji-153	548	24	,	,	PUNCT
aji-153	548	25	winkelmayer	winkelmayer	PROPN
aji-153	548	26	wc	wc	PROPN
aji-153	548	27	,	,	PUNCT
aji-153	548	28	chertow	chertow	VERB
aji-153	548	29	gm	gm	PROPN
aji-153	548	30	.	.	PUNCT
aji-153	549	1	overall	overall	ADJ
aji-153	549	2	adverse	adverse	ADJ
aji-153	549	3	event	event	NOUN
aji-153	549	4	profile	profile	NOUN
aji-153	549	5	of	of	ADP
aji-153	549	6	vadadustat	vadadustat	NOUN
aji-153	549	7	versus	versus	ADP
aji-153	549	8	darbepoetin	darbepoetin	PROPN
aji-153	549	9	alfa	alfa	PROPN
aji-153	549	10	for	for	ADP
aji-153	549	11	the	the	DET
aji-153	549	12	treatment	treatment	NOUN
aji-153	549	13	of	of	ADP
aji-153	549	14	anemia	anemia	NOUN
aji-153	549	15	associated	associate	VERB
aji-153	549	16	with	with	ADP
aji-153	549	17	chronic	chronic	ADJ
aji-153	549	18	kidney	kidney	NOUN
aji-153	549	19	disease	disease	NOUN
aji-153	549	20	in	in	ADP
aji-153	549	21	phase	phase	NOUN
aji-153	549	22	3	3	NUM
aji-153	549	23	trials	trial	NOUN
aji-153	549	24	.	.	PUNCT
aji-153	550	1	gupta	gupta	PROPN
aji-153	550	2	et	et	PROPN
aji-153	550	3	al	al	PROPN
aji-153	550	4	.	.	PROPN
aji-153	550	5	;	;	PUNCT
aji-153	550	6	asian	asian	PROPN
aji-153	550	7	j.	j.	PROPN
aji-153	550	8	immunol	immunol	PROPN
aji-153	550	9	.	.	PROPN
aji-153	550	10	,	,	PUNCT
aji-153	550	11	vol	vol	NOUN
aji-153	550	12	.	.	PROPN
aji-153	550	13	7	7	NUM
aji-153	550	14	,	,	PUNCT
aji-153	550	15	no	no	INTJ
aji-153	550	16	.	.	NOUN
aji-153	550	17	1	1	NUM
aji-153	550	18	,	,	PUNCT
aji-153	550	19	pp	pp	ADJ
aji-153	550	20	.	.	PUNCT
aji-153	551	1	302	302	NUM
aji-153	551	2	-	-	SYM
aji-153	551	3	315	315	NUM
aji-153	551	4	,	,	PUNCT
aji-153	551	5	2024	2024	NUM
aji-153	551	6	;	;	PUNCT
aji-153	551	7	article	article	NOUN
aji-153	551	8	no.aji.127402	no.aji.127402	VERB
aji-153	551	9	315	315	NUM
aji-153	551	10	american	american	ADJ
aji-153	551	11	journal	journal	PROPN
aji-153	551	12	of	of	ADP
aji-153	551	13	nephrology	nephrology	NOUN
aji-153	551	14	.	.	PUNCT
aji-153	552	1	2023	2023	NUM
aji-153	552	2	jan	jan	NOUN
aji-153	552	3	31;53(10):701	31;53(10):701	NUM
aji-153	552	4	-	-	SYM
aji-153	552	5	10	10	NUM
aji-153	552	6	.	.	PUNCT
aji-153	552	7	45	45	NUM
aji-153	552	8	.	.	PUNCT
aji-153	553	1	ogawa	ogawa	PROPN
aji-153	553	2	c	c	PROPN
aji-153	553	3	,	,	PUNCT
aji-153	553	4	tsuchiya	tsuchiya	PROPN
aji-153	553	5	k	k	PROPN
aji-153	553	6	,	,	PUNCT
aji-153	553	7	maeda	maeda	PROPN
aji-153	553	8	k.	k.	PROPN
aji-153	553	9	hypoxiainducible	hypoxiainducible	PROPN
aji-153	553	10	factor	factor	NOUN
aji-153	553	11	prolyl	prolyl	PROPN
aji-153	553	12	hydroxylase	hydroxylase	NOUN
aji-153	553	13	inhibitors	inhibitor	NOUN
aji-153	553	14	and	and	CCONJ
aji-153	553	15	iron	iron	NOUN
aji-153	553	16	metabolism	metabolism	NOUN
aji-153	553	17	.	.	PUNCT
aji-153	554	1	international	international	ADJ
aji-153	554	2	journal	journal	NOUN
aji-153	554	3	of	of	ADP
aji-153	554	4	molecular	molecular	ADJ
aji-153	554	5	sciences	science	NOUN
aji-153	554	6	.	.	PUNCT
aji-153	555	1	2023	2023	NUM
aji-153	555	2	feb	feb	NOUN
aji-153	555	3	3;24(3):3037	3;24(3):3037	NUM
aji-153	555	4	.	.	PUNCT
aji-153	555	5	46	46	NUM
aji-153	555	6	.	.	PUNCT
aji-153	555	7	zuk	zuk	PROPN
aji-153	556	1	a	a	X
aji-153	556	2	,	,	PUNCT
aji-153	556	3	si	si	PROPN
aji-153	556	4	z	z	PROPN
aji-153	556	5	,	,	PUNCT
aji-153	556	6	loi	loi	PROPN
aji-153	556	7	s	s	PROPN
aji-153	556	8	,	,	PUNCT
aji-153	556	9	bommegowda	bommegowda	PROPN
aji-153	556	10	s	s	PART
aji-153	556	11	,	,	PUNCT
aji-153	556	12	hoivik	hoivik	NOUN
aji-153	556	13	d	d	NOUN
aji-153	556	14	,	,	PUNCT
aji-153	556	15	danthi	danthi	PROPN
aji-153	556	16	s	s	PROPN
aji-153	556	17	,	,	PUNCT
aji-153	556	18	molnar	molnar	PROPN
aji-153	556	19	g	g	PROPN
aji-153	556	20	,	,	PUNCT
aji-153	556	21	csizmadia	csizmadia	PROPN
aji-153	556	22	v	v	PROPN
aji-153	556	23	,	,	PUNCT
aji-153	556	24	rabinowitz	rabinowitz	NOUN
aji-153	556	25	m.	m.	NOUN
aji-153	556	26	preclinical	preclinical	ADJ
aji-153	556	27	characterization	characterization	NOUN
aji-153	556	28	of	of	ADP
aji-153	556	29	vadadustat	vadadustat	NOUN
aji-153	556	30	(	(	PUNCT
aji-153	556	31	akb-6548	akb-6548	NOUN
aji-153	556	32	)	)	PUNCT
aji-153	556	33	,	,	PUNCT
aji-153	556	34	an	an	DET
aji-153	556	35	oral	oral	ADJ
aji-153	556	36	small	small	ADJ
aji-153	556	37	molecule	molecule	NOUN
aji-153	556	38	hypoxia	hypoxia	NOUN
aji-153	556	39	-	-	PUNCT
aji-153	556	40	inducible	inducible	ADJ
aji-153	556	41	factor	factor	NOUN
aji-153	556	42	prolyl-4hydroxylase	prolyl-4hydroxylase	PROPN
aji-153	556	43	inhibitor	inhibitor	NOUN
aji-153	556	44	,	,	PUNCT
aji-153	556	45	for	for	ADP
aji-153	556	46	the	the	DET
aji-153	556	47	potential	potential	ADJ
aji-153	556	48	treatment	treatment	NOUN
aji-153	556	49	of	of	ADP
aji-153	556	50	renal	renal	ADJ
aji-153	556	51	anemia	anemia	NOUN
aji-153	556	52	.	.	PUNCT
aji-153	557	1	journal	journal	PROPN
aji-153	557	2	of	of	ADP
aji-153	557	3	pharmacology	pharmacology	NOUN
aji-153	557	4	and	and	CCONJ
aji-153	557	5	experimental	experimental	ADJ
aji-153	557	6	therapeutics	therapeutic	NOUN
aji-153	557	7	.	.	PUNCT
aji-153	558	1	2022	2022	NUM
aji-153	558	2	oct	oct	PROPN
aji-153	558	3	1;383(1):11	1;383(1):11	PROPN
aji-153	558	4	-	-	PROPN
aji-153	558	5	24	24	NUM
aji-153	558	6	.	.	PUNCT
aji-153	559	1	47	47	NUM
aji-153	559	2	.	.	PUNCT
aji-153	560	1	toka	toka	PROPN
aji-153	560	2	hr	hr	PROPN
aji-153	560	3	,	,	PUNCT
aji-153	560	4	bernardo	bernardo	PROPN
aji-153	560	5	m	m	PROPN
aji-153	560	6	,	,	PUNCT
aji-153	560	7	burke	burke	PROPN
aji-153	560	8	sk	sk	PROPN
aji-153	560	9	,	,	PUNCT
aji-153	560	10	luo	luo	PROPN
aji-153	560	11	w	w	PROPN
aji-153	560	12	,	,	PUNCT
aji-153	560	13	manllo	manllo	PROPN
aji-153	560	14	-	-	PUNCT
aji-153	560	15	karim	karim	PROPN
aji-153	560	16	r	r	PROPN
aji-153	560	17	,	,	PUNCT
aji-153	560	18	ullah	ullah	PROPN
aji-153	560	19	i	i	PROPN
aji-153	560	20	,	,	PUNCT
aji-153	560	21	yang	yang	PROPN
aji-153	560	22	z	z	PROPN
aji-153	560	23	,	,	PUNCT
aji-153	561	1	zhang	zhang	PROPN
aji-153	561	2	z	z	PROPN
aji-153	561	3	,	,	PUNCT
aji-153	561	4	tumlin	tumlin	PROPN
aji-153	561	5	j.	j.	PROPN
aji-153	561	6	vadadustat	vadadustat	PROPN
aji-153	561	7	three	three	NUM
aji-153	561	8	times	time	NOUN
aji-153	561	9	weekly	weekly	ADJ
aji-153	561	10	in	in	ADP
aji-153	561	11	patients	patient	NOUN
aji-153	561	12	with	with	ADP
aji-153	561	13	anemia	anemia	NOUN
aji-153	561	14	due	due	ADP
aji-153	561	15	to	to	ADP
aji-153	561	16	dialysisdependent	dialysisdependent	PROPN
aji-153	561	17	ckd	ckd	PROPN
aji-153	561	18	.	.	PUNCT
aji-153	561	19	american	american	PROPN
aji-153	561	20	journal	journal	PROPN
aji-153	561	21	of	of	ADP
aji-153	561	22	kidney	kidney	NOUN
aji-153	561	23	diseases	disease	NOUN
aji-153	561	24	.	.	PUNCT
aji-153	562	1	2024	2024	NUM
aji-153	562	2	nov	nov	PROPN
aji-153	562	3	7	7	NUM
aji-153	562	4	.	.	SYM
aji-153	562	5	48	48	NUM
aji-153	562	6	.	.	PUNCT
aji-153	562	7	cole	cole	PROPN
aji-153	562	8	p.	p.	PROPN
aji-153	562	9	vadadustat	vadadustat	PROPN
aji-153	562	10	.	.	PUNCT
aji-153	563	1	hypoxia	hypoxia	NOUN
aji-153	563	2	-	-	PUNCT
aji-153	563	3	inducible	inducible	ADJ
aji-153	563	4	factor	factor	NOUN
aji-153	563	5	(	(	PUNCT
aji-153	563	6	hif	hif	PROPN
aji-153	563	7	)	)	PUNCT
aji-153	563	8	prolyl	prolyl	PROPN
aji-153	563	9	hydroxylase	hydroxylase	NOUN
aji-153	563	10	inhibitor	inhibitor	NOUN
aji-153	563	11	,	,	PUNCT
aji-153	563	12	treatment	treatment	NOUN
aji-153	563	13	of	of	ADP
aji-153	563	14	anemia	anemia	NOUN
aji-153	563	15	secondary	secondary	ADJ
aji-153	563	16	to	to	ADP
aji-153	563	17	chronic	chronic	ADJ
aji-153	563	18	kidney	kidney	NOUN
aji-153	563	19	disease	disease	NOUN
aji-153	563	20	.	.	PUNCT
aji-153	564	1	drugs	drug	NOUN
aji-153	564	2	of	of	ADP
aji-153	564	3	the	the	DET
aji-153	564	4	future	future	NOUN
aji-153	564	5	.	.	PUNCT
aji-153	565	1	2016	2016	NUM
aji-153	565	2	oct	oct	PROPN
aji-153	565	3	1;41(10	1;41(10	NUM
aji-153	565	4	)	)	PUNCT
aji-153	565	5	.	.	PUNCT
aji-153	566	1	49	49	NUM
aji-153	566	2	.	.	PUNCT
aji-153	567	1	kuriyama	kuriyama	PROPN
aji-153	567	2	s	s	PROPN
aji-153	567	3	,	,	PUNCT
aji-153	567	4	maruyama	maruyama	PROPN
aji-153	567	5	y	y	PROPN
aji-153	567	6	,	,	PUNCT
aji-153	567	7	honda	honda	PROPN
aji-153	567	8	h.	h.	PROPN
aji-153	568	1	a	a	DET
aji-153	568	2	new	new	ADJ
aji-153	568	3	insight	insight	NOUN
aji-153	568	4	into	into	ADP
aji-153	568	5	the	the	DET
aji-153	568	6	treatment	treatment	NOUN
aji-153	568	7	of	of	ADP
aji-153	568	8	renal	renal	ADJ
aji-153	568	9	anemia	anemia	NOUN
aji-153	568	10	with	with	ADP
aji-153	568	11	hif	hif	PROPN
aji-153	568	12	stabilizer	stabilizer	NOUN
aji-153	568	13	.	.	PUNCT
aji-153	569	1	renal	renal	ADJ
aji-153	569	2	replacement	replacement	NOUN
aji-153	569	3	therapy	therapy	NOUN
aji-153	569	4	.	.	PUNCT
aji-153	570	1	2020	2020	NUM
aji-153	571	1	dec;6:1	dec;6:1	PROPN
aji-153	571	2	-	-	PUNCT
aji-153	571	3	4	4	NUM
aji-153	571	4	.	.	NOUN
aji-153	571	5	50	50	NUM
aji-153	571	6	.	.	PUNCT
aji-153	571	7	del	del	PROPN
aji-153	571	8	vecchio	vecchio	PROPN
aji-153	571	9	l	l	PROPN
aji-153	571	10	,	,	PUNCT
aji-153	571	11	minutolo	minutolo	PROPN
aji-153	571	12	r.	r.	PROPN
aji-153	571	13	esa	esa	PROPN
aji-153	571	14	,	,	PUNCT
aji-153	571	15	iron	iron	NOUN
aji-153	571	16	therapy	therapy	NOUN
aji-153	571	17	and	and	CCONJ
aji-153	571	18	new	new	ADJ
aji-153	571	19	drugs	drug	NOUN
aji-153	571	20	:	:	PUNCT
aji-153	571	21	are	be	AUX
aji-153	571	22	there	there	PRON
aji-153	571	23	new	new	ADJ
aji-153	571	24	perspectives	perspective	NOUN
aji-153	571	25	in	in	ADP
aji-153	571	26	the	the	DET
aji-153	571	27	treatment	treatment	NOUN
aji-153	571	28	of	of	ADP
aji-153	571	29	anaemia	anaemia	NOUN
aji-153	571	30	?	?	PUNCT
aji-153	572	1	journal	journal	NOUN
aji-153	572	2	of	of	ADP
aji-153	572	3	clinical	clinical	ADJ
aji-153	572	4	medicine	medicine	NOUN
aji-153	572	5	.	.	PUNCT
aji-153	573	1	2021	2021	NUM
aji-153	573	2	feb	feb	PROPN
aji-153	573	3	18;10(4):839	18;10(4):839	NUM
aji-153	573	4	.	.	PUNCT
aji-153	574	1	51	51	NUM
aji-153	574	2	.	.	PUNCT
aji-153	575	1	hazin	hazin	PROPN
aji-153	575	2	ma	ma	PROPN
aji-153	575	3	.	.	PROPN
aji-153	575	4	anemia	anemia	NOUN
aji-153	575	5	in	in	ADP
aji-153	575	6	chronic	chronic	ADJ
aji-153	575	7	kidney	kidney	NOUN
aji-153	575	8	disease	disease	NOUN
aji-153	575	9	.	.	PUNCT
aji-153	576	1	revista	revista	PROPN
aji-153	576	2	da	da	PROPN
aji-153	576	3	associação	associação	PROPN
aji-153	576	4	médica	médica	PROPN
aji-153	576	5	brasileira	brasileira	PROPN
aji-153	576	6	.	.	PROPN
aji-153	577	1	2020	2020	NUM
aji-153	577	2	jan	jan	PROPN
aji-153	577	3	13;66(suppl	13;66(suppl	NUM
aji-153	577	4	1	1	NUM
aji-153	577	5	):	):	PUNCT
aji-153	577	6	s55	s55	PROPN
aji-153	577	7	-	-	PUNCT
aji-153	577	8	8	8	NUM
aji-153	577	9	.	.	PUNCT
aji-153	578	1	disclaimer	disclaimer	ADJ
aji-153	578	2	/	/	SYM
aji-153	578	3	publisher	publisher	NOUN
aji-153	578	4	’s	’s	PART
aji-153	578	5	note	note	NOUN
aji-153	578	6	:	:	PUNCT
aji-153	578	7	the	the	DET
aji-153	578	8	statements	statement	NOUN
aji-153	578	9	,	,	PUNCT
aji-153	578	10	opinions	opinion	NOUN
aji-153	578	11	and	and	CCONJ
aji-153	578	12	data	datum	NOUN
aji-153	578	13	contained	contain	VERB
aji-153	578	14	in	in	ADP
aji-153	578	15	all	all	DET
aji-153	578	16	publications	publication	NOUN
aji-153	578	17	are	be	AUX
aji-153	578	18	solely	solely	ADV
aji-153	578	19	those	those	PRON
aji-153	578	20	of	of	ADP
aji-153	578	21	the	the	DET
aji-153	578	22	individual	individual	ADJ
aji-153	578	23	author(s	author(s	PROPN
aji-153	578	24	)	)	PUNCT
aji-153	578	25	and	and	CCONJ
aji-153	578	26	contributor(s	contributor(s	NOUN
aji-153	578	27	)	)	PUNCT
aji-153	578	28	and	and	CCONJ
aji-153	578	29	not	not	PART
aji-153	578	30	of	of	ADP
aji-153	578	31	the	the	DET
aji-153	578	32	publisher	publisher	NOUN
aji-153	578	33	and/or	and/or	CCONJ
aji-153	578	34	the	the	DET
aji-153	578	35	editor(s	editor(s	NOUN
aji-153	578	36	)	)	PUNCT
aji-153	578	37	.	.	PUNCT
aji-153	579	1	this	this	DET
aji-153	579	2	publisher	publisher	NOUN
aji-153	579	3	and/or	and/or	CCONJ
aji-153	579	4	the	the	DET
aji-153	579	5	editor(s	editor(s	NOUN
aji-153	579	6	)	)	PUNCT
aji-153	579	7	disclaim	disclaim	VERB
aji-153	579	8	responsibility	responsibility	NOUN
aji-153	579	9	for	for	ADP
aji-153	579	10	any	any	DET
aji-153	579	11	injury	injury	NOUN
aji-153	579	12	to	to	ADP
aji-153	579	13	people	people	NOUN
aji-153	579	14	or	or	CCONJ
aji-153	579	15	property	property	NOUN
aji-153	579	16	resulting	result	VERB
aji-153	579	17	from	from	ADP
aji-153	579	18	any	any	DET
aji-153	579	19	ideas	idea	NOUN
aji-153	579	20	,	,	PUNCT
aji-153	579	21	methods	method	NOUN
aji-153	579	22	,	,	PUNCT
aji-153	579	23	instructions	instruction	NOUN
aji-153	579	24	or	or	CCONJ
aji-153	579	25	products	product	NOUN
aji-153	579	26	referred	refer	VERB
aji-153	579	27	to	to	ADP
aji-153	579	28	in	in	ADP
aji-153	579	29	the	the	DET
aji-153	579	30	content	content	NOUN
aji-153	579	31	.	.	PUNCT
aji-153	580	1	_	_	PUNCT
aji-153	581	1	_	_	PUNCT
aji-153	582	1	_	_	PUNCT
aji-153	583	1	_	_	PUNCT
aji-153	584	1	_	_	PUNCT
aji-153	585	1	_	_	PUNCT
aji-153	586	1	_	_	PUNCT
aji-153	587	1	_	_	PUNCT
aji-153	588	1	_	_	PUNCT
aji-153	589	1	_	_	PUNCT
aji-153	590	1	_	_	PUNCT
aji-153	591	1	_	_	PUNCT
aji-153	592	1	_	_	PUNCT
aji-153	593	1	_	_	PUNCT
aji-153	594	1	_	_	PUNCT
aji-153	595	1	_	_	PUNCT
aji-153	596	1	_	_	PUNCT
aji-153	597	1	_	_	PUNCT
aji-153	598	1	_	_	PUNCT
aji-153	599	1	_	_	PUNCT
aji-153	600	1	_	_	PUNCT
aji-153	601	1	_	_	PUNCT
aji-153	602	1	_	_	PUNCT
aji-153	603	1	_	_	PUNCT
aji-153	604	1	_	_	PUNCT
aji-153	605	1	_	_	PUNCT
aji-153	606	1	_	_	PUNCT
aji-153	607	1	_	_	PUNCT
aji-153	608	1	_	_	PUNCT
aji-153	609	1	_	_	PUNCT
aji-153	610	1	_	_	PUNCT
aji-153	611	1	_	_	PUNCT
aji-153	612	1	_	_	PUNCT
aji-153	613	1	_	_	PUNCT
aji-153	614	1	_	_	PUNCT
aji-153	615	1	_	_	PUNCT
aji-153	616	1	_	_	PUNCT
aji-153	617	1	_	_	PUNCT
aji-153	618	1	_	_	PUNCT
aji-153	619	1	_	_	PUNCT
aji-153	620	1	_	_	PUNCT
aji-153	621	1	_	_	PUNCT
aji-153	622	1	_	_	PUNCT
aji-153	623	1	_	_	PUNCT
aji-153	624	1	_	_	PUNCT
aji-153	625	1	_	_	PUNCT
aji-153	626	1	_	_	PUNCT
aji-153	627	1	_	_	PUNCT
aji-153	628	1	_	_	PUNCT
aji-153	629	1	_	_	PUNCT
aji-153	630	1	_	_	PUNCT
aji-153	631	1	_	_	PUNCT
aji-153	632	1	_	_	PUNCT
aji-153	633	1	_	_	PUNCT
aji-153	634	1	_	_	PUNCT
aji-153	635	1	_	_	PUNCT
aji-153	636	1	_	_	PUNCT
aji-153	637	1	_	_	PUNCT
aji-153	638	1	_	_	PUNCT
aji-153	639	1	_	_	PUNCT
aji-153	640	1	_	_	PUNCT
aji-153	641	1	_	_	PUNCT
aji-153	642	1	_	_	PUNCT
aji-153	643	1	_	_	PUNCT
aji-153	644	1	_	_	PUNCT
aji-153	645	1	_	_	PUNCT
aji-153	646	1	_	_	PUNCT
aji-153	647	1	_	_	PUNCT
aji-153	648	1	_	_	PUNCT
aji-153	649	1	_	_	PUNCT
aji-153	650	1	_	_	PUNCT
aji-153	651	1	_	_	PUNCT
aji-153	652	1	_	_	PUNCT
aji-153	653	1	_	_	PUNCT
aji-153	654	1	_	_	PUNCT
aji-153	655	1	_	_	PUNCT
aji-153	656	1	_	_	PUNCT
aji-153	657	1	_	_	PUNCT
aji-153	658	1	_	_	PUNCT
aji-153	659	1	_	_	PUNCT
aji-153	660	1	_	_	PUNCT
aji-153	661	1	©	©	PRON
aji-153	661	2	copyright	copyright	NOUN
aji-153	661	3	(	(	PUNCT
aji-153	661	4	2024	2024	NUM
aji-153	661	5	):	):	PUNCT
aji-153	661	6	author(s	author(s	NOUN
aji-153	661	7	)	)	PUNCT
aji-153	661	8	.	.	PUNCT
aji-153	662	1	the	the	DET
aji-153	662	2	licensee	licensee	NOUN
aji-153	662	3	is	be	AUX
aji-153	662	4	the	the	DET
aji-153	662	5	journal	journal	PROPN
aji-153	662	6	publisher	publisher	NOUN
aji-153	662	7	.	.	PUNCT
aji-153	663	1	this	this	PRON
aji-153	663	2	is	be	AUX
aji-153	663	3	an	an	DET
aji-153	663	4	open	open	ADJ
aji-153	663	5	access	access	NOUN
aji-153	663	6	article	article	NOUN
aji-153	663	7	distributed	distribute	VERB
aji-153	663	8	under	under	ADP
aji-153	663	9	the	the	DET
aji-153	663	10	terms	term	NOUN
aji-153	663	11	of	of	ADP
aji-153	663	12	the	the	DET
aji-153	663	13	creative	creative	ADJ
aji-153	663	14	commons	common	NOUN
aji-153	663	15	attribution	attribution	NOUN
aji-153	663	16	license	license	NOUN
aji-153	663	17	(	(	PUNCT
aji-153	663	18	http://creativecommons.org/licenses/by/4.0	http://creativecommons.org/licenses/by/4.0	NOUN
aji-153	663	19	)	)	PUNCT
aji-153	663	20	,	,	PUNCT
aji-153	663	21	which	which	PRON
aji-153	663	22	permits	permit	VERB
aji-153	663	23	unrestricted	unrestricted	ADJ
aji-153	663	24	use	use	NOUN
aji-153	663	25	,	,	PUNCT
aji-153	663	26	distribution	distribution	NOUN
aji-153	663	27	,	,	PUNCT
aji-153	663	28	and	and	CCONJ
aji-153	663	29	reproduction	reproduction	NOUN
aji-153	663	30	in	in	ADP
aji-153	663	31	any	any	DET
aji-153	663	32	medium	medium	NOUN
aji-153	663	33	,	,	PUNCT
aji-153	663	34	provided	provide	VERB
aji-153	663	35	the	the	DET
aji-153	663	36	original	original	ADJ
aji-153	663	37	work	work	NOUN
aji-153	663	38	is	be	AUX
aji-153	663	39	properly	properly	ADV
aji-153	663	40	cited	cite	VERB
aji-153	663	41	.	.	PUNCT
aji-153	664	1	peer	peer	NOUN
aji-153	664	2	-	-	PUNCT
aji-153	664	3	review	review	NOUN
aji-153	664	4	history	history	NOUN
aji-153	664	5	:	:	PUNCT
aji-153	664	6	the	the	DET
aji-153	664	7	peer	peer	NOUN
aji-153	664	8	review	review	NOUN
aji-153	664	9	history	history	NOUN
aji-153	664	10	for	for	ADP
aji-153	664	11	this	this	DET
aji-153	664	12	paper	paper	NOUN
aji-153	664	13	can	can	AUX
aji-153	664	14	be	be	AUX
aji-153	664	15	accessed	access	VERB
aji-153	664	16	here	here	ADV
aji-153	664	17	:	:	PUNCT
aji-153	664	18	https://www.sdiarticle5.com/review-history/127402	https://www.sdiarticle5.com/review-history/127402	NOUN
aji-153	664	19	https://www.sdiarticle5.com/review-history/127402	https://www.sdiarticle5.com/review-history/127402	NOUN